

CZECH UNIVERSITY OF LIFE SCIENCES PRAGUE

FACULTY OF TROPICAL AGRISCIENCES



Assessment of *in vitro* antioxidant and anti-proliferative properties of medicinal and edible plants

DOCTORAL THESIS

Author: Ing. Jan Tauchen

Supervisor: prof. Ing. Ladislav Kokoška, Ph.D.

Co-supervisor: Ing. Přemysl Landa, Ph.D.

Certification

I declare that given Ph.D. thesis is solely my own work unless otherwise referenced or acknowledged.

Prague on

.....

Ing. Jan Tauchen

He who fights with monsters should look to it that he himself does not become a monster. And when you gaze long into an abyss the abyss also gazes into you.

Friedrich Wilhelm Nietzsche

Acknowledgment

Research was supported by Internal Grant Agency of Czech University of Life Sciences Prague and Czech Ministry of Education, Youth and Sports. I would like to express my upmost gratitude to my supervisor prof. Ing. Ladislav Kokoška, Ph.D. (Faculty of Tropical AgriSciences, Czech University of Life Sciences Prague; FTZ, CULS Prague) for his guidance and for conveying his scientific experience. Without these, completion of this dissertation thesis would not be possible. I am also sincerely grateful to my co-supervisor Ing. Přemysl Landa, Ph.D. (Institute of Experimental Botany AV CS; IEB) who likewise provided professional help and advice and therefore contributed significantly to successful completion of my scientific work. I am very thankful to Mgr. Petr Maršík, Ph.D., Ing. Jan Rezek, Ph.D. and Ing. Marie Kvasnicová, Ph.D. (and other colleagues from IEB) who kindly introduced me into extraction and chromatographic techniques or otherwise were of great assistance to me. I must thank to all persons who helped me with plant material collection, including Dr. Landa, Dr. David Maghradze (Institute of Horticulture, Viticulture and Oenology, Agricultural University of Georgia), Ermias Lulekal, Ph.D. (College of Natural Sciences, Debre Berhan University, Ethiopia), and my closest friends Ing. Ludvík Bortl (FTZ, CULS Prague) and Ing. Lukáš Huml (Faculty of Food and Biochemical Technology, University of Chemistry and Technology Prague; FFBT, UCT). I am very indebted to Ing. Ivo Doskočil (Faculty of Agrobiology, Food and Natural Resources, CULS Prague) and PharmDr. Petra Mikšátková (FFBT, UCT) who kindly helped me with cell viability assays and HPLC-MS/MS analysis, respectively. Many thanks also belongs to my colleagues from Laboratory of Ethnobotany and Ethnopharmacology (FTZ, CULS Prague), especially Ing. Johana Rondevaldová, Ph.D., who was always supportive whenever asked. I would like to express gratitude for having the possibility of studying doctorate at my alma mater (FTZ CULS Prague). My appreciations also goes to Restaurace U Klokočníka for offering refuge in the darkest moments. Finally, I am immensely grateful to my parents and to my wife and the rest of my family for their support and never-ending patience.

Summary

Identification and characterization of plant-based products with antioxidant and anti-proliferative effects has received much interest over the past few years as possible therapeutic mean for treatment of diseases likely to be associated to oxidative stress (such as atherosclerosis, diabetes, and cancer). This study provides characterization of *in vitro* antioxidant and/or anti-proliferative potential and phytochemical profile of (i) 39 wine samples of underutilized Georgian grapevine cultivars, (ii) extracts of 22 samples of medicinal plants from Ethiopia and (iii) 23 samples of edible and medicinal plants from Peruvian Amazon. For this purpose, 2,2-diphenyl-1-picrylhydrazyl radical assay (DPPH), oxygen radical absorbance capacity (ORAC) assay, total phenolic content (TPC), and cell viability assay based on metabolization of tetrazolium bromide (MTT) to formazan, together with methods based on high performance liquid chromatography (HPLC-ultra violet/visible spectrometry and HPLC-tandem mass spectrometry) were used. Georgian red wines (particularly Saperavi cultivars) exhibited higher antioxidant capacity (average DPPH and ORAC values at 5.1 and = 10.6 g TE/L wine, respectively) in comparison to Central and West European cultivars [Pinot Noir (DPPH = 3.1 and ORAC = 9.4 g TE/L wine), Cabernet Sauvignon (DPPH = 3.0 and ORAC = 7.3 g TE/L wine) and Cabernet Moravia (DPPH = 2.0 and ORAC = 8.5 g TE/L wine)]. Georgian wines contained significantly greater concentrations of quercetin (14.44 – 1.07 µg/mL), kaempferol (1.68 – 0.03 µg/mL) and syringic acid (12.59 – 4.72 µg/mL), whereas possessed lower quantities of resveratrol (5.11 – 0.32 µg/mL) in comparison to Central and West European wines. Amongst edible and medicinal plants from Ethiopia and Peruvian Amazon, only *Dodonaea angustifolia* (IC₅₀ for DPPH = 22.2 µg/mL, ORAC = 767.6 µg TE/mg extract; IC₅₀ for Hep-G2 = 120.0 µg/mL), *Rumex nepalensis* (IC₅₀ for DPPH = 5.7 µg/mL, ORAC = 1061.4 µg TE/mg extract; IC₅₀ for Hep-G2 = 50.5 µg/mL), *Inga edulis* (DPPH and ORAC = 337.0 and 795.7 µg TE/mg extract; IC₅₀ for Hep-G2 and HT-29 = 36.3 and 57.9 µg/mL) and *Oenocarpus bataua* (DPPH and ORAC = 903.8 and 1024.4 µg TE/mg extract; IC₅₀ for Hep-G2 and HT-29 = 102.6 and 38.8 µg/mL) have demonstrated combinatory antioxidant/anti-proliferative efficacy. Selective anti-proliferative activity was observed for *Verbascum sinaiticum* (IC₅₀ for Hep-G2 = 80.6 µg/mL) and *Annona montana* (IC₅₀ for Hep-G2 and HT-29 = 2.7 and 9.0 µg/mL, respectively). Above-mentioned plant material showed only weak or non-toxic effects towards normal cell line. Despite the fact that extracts of *Jasminum abyssinicum* (IC₅₀ for DPPH = 26.3 µg/mL, ORAC = 1023.7 µg TE/mg extract), *Rumex nepalensis* (IC₅₀ for DPPH = 5.7 µg/mL, ORAC = 1061.4 µg TE/mg extract), *Mauritia flexuosa* (DPPH and

ORAC = 1062.9 and 645.9 $\mu\text{g TE/mg extract}$), *Myrciaria dubia* (DPPH and ORAC = 641.9 and 642.6 $\mu\text{g TE/mg extract}$) and *Theobroma grandiflorum* (DPPH and ORAC = 714.8 and 821.9 $\mu\text{g TE/mg extract}$) have exhibited considerable antioxidant effect, these species were found to possess moderate to low anti-proliferative potential or have shown to be toxic to normal cells line. In all cases it was detected that phenolic compounds content correlated strongly with antioxidant activity, however weakly with anti-proliferative effect. Results suggest above-mentioned species as prospective materials for further development of novel plant-based agents effective against oxidative stress related diseases. However, it is necessary to perform further research which would be focused on detailed characterization of their chemical composition, pharmacological effects and toxicological safety, in order to verify their possible practical use.

Keywords: antioxidant; anticarcinogenic; phenolic compounds; plant extracts; wine

Shrnutí

Identifikace a charakterizace rostlinných produktů s antioxidačními a anti-proliferálními účinky, jakožto potenciálního terapeutického prostředku pro léčbu nemocí spojených s oxidačním stresem (jako např. arterioskleróza, diabetes nebo rakovina), je neustále středem vědeckého zájmu. Tato studie se zabývá charakterizací *in vitro* antioxidační a anti-proliferální aktivity a chemického složení 39 vzorků méně využívaných tradičních gruzínských odrůd vín, extraktů z 23 vzorků etiopských léčivých rostlin a 22 vzorků z jedlých a léčivých rostlin z peruánské Amazonie. Pro stanovení biologických účinků byly použity metody založené na měření inhibice radikálu 2,2-difenyl-1-pikrylhydrazyl (DPPH), kapacity absorpce kyslíkových radikálu (ORAC), celkového obsahu fenolických látek (TPC), a životaschopnosti buněčných linií pomocí metody založené na metabolické přeměně tetrazolium bromidu (MTT) na formazan. Chemické složení bylo stanoveno metodami založenými na vysokotlaké kapalinové chromatografii (HPLC-ultrafialovo-viditelné spektroskopii a HPLC-tandemové hmotnostní spektrometrii). V rámci experimentů s gruzínskými víny bylo prokázáno, že vína červená (zejména odrůdy Saperavi) vykázala silnější antioxidační účinek (průměrné DPPH a ORAC hodnoty na 5.1 a 10.6 g TE/L vína) ve srovnání s běžnými středo- a západoevropskými víny [Pinot Noir (DPPH = 3.1 a ORAC = 9.4 g TE/L vína), Cabernet Sauvignon (DPPH = 3.0 a ORAC = 7.3 g TE/L vína) a Cabernet Moravia (DPPH = 2.0 a ORAC = 8.5 g TE/L vína)]. Gruzínská vína byla oproti středo- a západoevropským vínům výrazně bohatší na kvercetin (14.44 – 1.07 µg/mL), kaempferol (1.68 – 0.03 µg/mL) a syringovou kyselinu (12.59 – 4.72 µg/mL), avšak chudší na resveratrolu (5.11 – 0.32 µg/mL). Mezi jedlými a léčivými rostlinami z Etiopie a Peru jedině extrakty *Dodonaea angustifolia* (IC₅₀ pro DPPH = 22.2 µg/mL, ORAC = 767.6 µg TE/mg extrakt; IC₅₀ pro Hep-G2 = 120.0 µg/mL); *Rumex nepalensis* (IC₅₀ pro DPPH = 5.7 µg/mL, ORAC = 1061.4 µg TE/mg extrakt; IC₅₀ pro Hep-G2 = 50.5 µg/mL); *Inga edulis* (DPPH a ORAC = 337.0 a 795.7 µg TE/mg extrakt; IC₅₀ pro Hep-G2 and HT-29 = 36.3 a 57.9 µg/mL) a *Oenocarpus bataua* (DPPH a ORAC = 903.8 a 1024.4 µg TE/mg extrakt; IC₅₀ pro Hep-G2 a HT-29 = 102.6 a 38.8 µg/mL) projevily kombinovaný antioxidační/anti-proliferální účinek. Selektivní anti-proliferální aktivitu prokázaly pouze extrakty *Verbascum sinaiticum* (IC₅₀ pro Hep-G2 = 80.6 µg/mL) a *Annona montana* (IC₅₀ pro Hep-G2 a HT-29 = 2.7 a 9.0 µg/mL). Výše zmíněný rostlinný materiál vykázal pouze slabou nebo žádnou toxicitu vůči zdravé buněčné linii. Přestože extrakty z *Jasminum abyssinicum* (IC₅₀ pro DPPH = 26.3 µg/mL, ORAC = 1023.7 µg TE/mg extrakt), *Rumex nepalensis* (IC₅₀ pro DPPH = 5.7 µg/mL, ORAC = 1061.4 µg TE/mg extrakt), *Mauritia flexuosa* (DPPH a

ORAC = 1062.9 a 645.9 $\mu\text{g TE/mg}$ extrakt), *Myrciaria dubia* (DPPH a ORAC = 641.9 a 642.6 $\mu\text{g TE/mg}$ extrakt) a *Theobroma grandiflorum* (DPPH a ORAC = 714.8 a 821.9 $\mu\text{g TE/mg}$ extrakt) projevily významný antioxidační účinek, tyto druhy taktéž prokázaly mírnou až velice nízkou anti-proliferaci aktivitu nebo byly toxické pro zdravou buněčnou linii. Ve všech dílčích studiích obsah fenolických látek silně koreloval s antioxidační aktivitou, avšak slabě s anti-proliferacním efektem. Výsledky naznačují, že výše zmíněné druhy by mohly být perspektivní pro vývoj nových rostlinných přípravků, efektivních proti onemocněním souvisejícím s oxidačním stresem. Před jejich možným uvedením do praktického využití však bude nezbytný další výzkum zaměřený na podrobnější stanovení jejich chemického složení, farmakologických účinků a toxikologické bezpečnosti.

Klíčová slova: antioxidant; cytostatikum; fenolické látky; rostlinné extrakty; víno

Contents

1	Introduction.....	17
2	Theoretical background	19
	2.1 Free radicals and antioxidants	19
	2.2 Oxidative stress and human health	20
	2.2.1 Atherosclerosis.....	20
	2.2.2 Diabetes mellitus.....	21
	2.2.3 Cystic fibrosis.....	21
	2.2.4 Inflammatory bowel disease	22
	2.2.5 Cancer	22
	2.2.6 Exposure to ionizing radiation	23
	2.2.7 Stroke/CNS injury.....	23
	2.2.8 Parkinson’s disease	24
	2.2.9 Alzheimer’s disease	24
	2.2.10 Amyotrophic lateral sclerosis.....	25
	2.2.11 Other neurodegenerative diseases.....	25
	2.3 Medicinal and pharmaceutical preparations.....	29
	2.3.1 Drugs with antioxidant action	29
	2.3.2 Anticancer drugs	36
	2.4 Plants as a sources of potential therapeutic agents.....	45
	2.4.1 Compounds with antioxidant activity	45
	2.4.2 Compounds with anti-proliferative activity	51
	2.4.3 Compounds with combined antioxidant/anti-proliferative effect.....	52
	2.5 Plant foods with specified health-promoting properties.....	54

2.6	Traditional uses of plants.....	56
2.7	Underutilized crops and wild plants	58
2.7.1	Wine from Georgia	58
2.7.2	Edible and medicinal plants from Peruvian Amazon.....	60
2.7.3	Wild medicinal plants from Ethiopia	61
3	Hypothesis	63
4	Objectives	65
5	Materials and methods	67
5.1	Plant material.....	67
5.2	Sample preparation.....	67
5.3	Reagents, solvents and standards	68
5.4	Cell culture	68
5.5	Antioxidant activity	68
5.6	Total sulphite content assay.....	68
5.7	Cell viability assay	68
5.8	High performance liquid chromatography	68
5.9	Statistical analysis	68
6	Results and discussion	69
7	Conclusion	73
8	References.....	75
9	Appendices.....	97

List of Figures

Figure 1 Phenolic acids.....	47
Figure 2 Examples of stilbenoid and coumarin structures.....	47
Figure 3 Examples of free and glycosylated flavonoids.....	48
Figure 4 Collection sites of tested plant material (adopted from [478]).....	67

List of Tables

Table 1 Importance of oxidative stress in human diseases (adopted from [1])	27
Table 2 List of antioxidants available for therapeutic use	35
Table 3 Distribution of phenolic compounds in plant kingdom	49
Table 4 Overview of clinically used plant-based anticancer agents	52

List of Abbreviations

5-FU	5-fluorouracil
8OHdG	8-hydroxy-2'-deoxyguanosine
AAPH	2,2'-Azobis(2-methylpropionamidine) dihydrochloride
A β	β -amyloid peptides
AGEs	Advanced glycation end-products
AIDS	Acquired immunodeficiency syndrome
ALS	Amyotrophic lateral sclerosis
ARDS	Acute respiratory distress syndrome
ATP	Adenosine triphosphate
BDNF	Brain-derived neurotrophic factor
BHA	Butylated hydroxyanisole
BHT	Butylated hydroxytoluene
CdK	Cyclin-dependent protein kinases
CLL	Chronic lymphocytic leukaemia
CNS	Central nervous system
DFO	Desferrioxamine
DNA	Deoxyribonucleic acid
DPPH	2,2-diphenyl-1-picrylhydrazyl
FA	Friedreich's ataxia
G6PDH	Glucose-6-phosphate dehydrogenase
GSH	Glutathione
HBED	<i>N,N</i> -bis(2-hydroxybenzyl)ethylenediamine- <i>N,N</i> -diacetic acid
HD	Huntington's disease
HDL	High-density lipoproteins
HIV	Human immunodeficiency virus
HO	Haem oxygenase
HOCl	Hydrochlorous acid
HPLC	High performance liquid chromatography
L1	1,2-dimethyl-3-hydroxypyridin-4-one
LAP	Lipoic acid plus
LDL	Low-density lipoproteins
MAO	Monoamine oxidase
MOG	Myelin oligodendrocyte glycoprotein
MPP+	1-methyl-4-phenylpyridinium
MPTP	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

MS	Mass spectrometry
MTX	Methotrexate
NADH	Reduced nikotinamidadenindinukleotid
NADPH	Nikotinamidadenindinukleotid phosphate
NF- κ B	Nuclear factor kappa-light-chain-enhancer of activated B cells
NSAIDs	Nonsteroidal anti-inflammatory drugs
iNOS	Inducible nitrite oxide synthase
NOX	NADPH oxidase
ORAC	Oxygen radical absorbance capacity
ONOO ⁻	Peroxynitrite radical
OTC	L-2-oxathiazolidine-4-carboxylate
PBN	Phenyl- <i>tert</i> -butylnitronine
PIH	Pyridoxal isonicotinoyl hydrazone
RCS	Reactive chlorine species
RNS	Reactive nitrogen species
ROS	Reactive oxygen species
SOD	Superoxide dismutase
SOR	Superoxide reductase
STAZN	Stilbazulenyl nitronine
TBHQ	<i>Tert</i> -butylhydroquinone
TNF- α	Tumour necrosis factor alpha
TPC	Total phenolic content
TPP	triphenylphosphonium
VLDL	Very low-density lipoproteins
U.S. FDA	Food and drug administration of the United States of America
UV/Vis	Ultra-violet/visible light

List of original publications

- I. Tauchen J**, Maršík P, Kvasnicová M, Maghradze D, Kokoška L, Vaněk T, Landa P. In vitro antioxidant activity and phenolic composition of Georgian, Central and West European wines. *Journal of Food Composition and Analysis*. 2015;41: 113-121.
- II. Tauchen J**, Bortl L, Huml L, Mikšátková P, Doskočil I, Maršík P, Villegas PPP, Flores YB, Van Damme P, Lojka B, Havlík J, Lapčík O, Kokoška L. Phenolic composition, antioxidant and anti-proliferative activities of edible and medicinal plants from the Peruvian Amazon. Manuscript accepted (23. 3. 2016) to *Revista Brasileira de Farmacognosia*.
- III. Tauchen J**, Doskočil I, Caffi C, Lulekal E, Maršík P, Havlík J, Van Damme P, Kokoška L. In vitro antioxidant and anti-proliferative activity of Ethiopian medicinal plant extracts. *Industrial Crops and Products*. 2015;74: 671–679.

These publications are referenced in the text in form of Roman numerals (bold).

Publications are listed in Appendices A-C.

1 Introduction

It is widely believed that free radicals and oxidative stress are responsible for primary onset and secondary pathology in various diseases including atherosclerosis, rheumatoid arthritis, cancer, cystic fibrosis, diabetes, cardiovascular, inflammatory and neurodegenerative (e.g. Alzheimer's disease) disorders. Hence, identification and characterization of products which exhibit antioxidant and/or anti-proliferative activity and might also possess possible therapeutic benefit in above-mentioned diseases has received much interest over the past years [1].

Nowadays, antioxidant activity is primarily examined in common dietary plants such as fruits and vegetables. However, recent studies indicate that other categories of plant material, such as medicinal plants, also possess significant antioxidant efficacy [2]. Health beneficiary effect of plants in oxidative stress-related diseases are mainly attributed to certain types of phenolic compounds, however other plant-derived constituents possess this biological activity as well [3].

It has previously been proposed that progression of cancer might be strongly related to oxidative stress. For this reason, validation of antioxidant effect of tested plant material is nowadays routinely supplemented with analysis of anti-proliferative activity against various types of carcinoma cell lines [4]. Variety of plant-based constituents (such as paclitaxel, podophyllotoxin, and vincristine) has demonstrated significant anti-carcinomatous effect and are used in oncological praxis. However, majority of these also possess adverse toxicity to normal cells [5]. Recent studies have shown that several dietary phenolic compounds (e.g. flavonoids) exerted anti-proliferative activity as well [6]. Despite the fact that medicinal plants are regarded as the main sources of antineoplastic agents, there is now an increased interest in research of edible plants' anti-proliferative effects [7].

Even though plants are generally considered as very important factor for food and health security (mainly in third world countries), their health beneficial properties are not fully verified by modern scientific methods (including antioxidant and anticancer activity). Moreover, with contemporary trend in destruction and ongoing loss of natural habitats by human activities and genetic narrowing of several culturally used crops (e.g. grapevine), there is serious risk of plant diversity being irreversibly lost with interconnected valuable scientific information [8–10]. Despite the well-documented traditional use in treatment of diseases related to the oxidative stress, to my best knowledge, many plants worldwide remains to be examined for antioxidant and/or anti-proliferative efficacy [11–13]. Additionally, phytochemical

profile of compounds likely to be responsible for biological activities of majority of these plants was not properly established [14].

Proceeding from these facts, this dissertation thesis provides detailed information on *in vitro* antioxidant and/or anti-proliferative potential of underutilized plant material with special focus on grapevines traditionally used in Georgia, extracts of medicinal plants from Ethiopia and extracts of edible and medicinal plants from Peruvian Amazon. Additionally total phenolic content and other phytochemical analyses were performed [i.e. high-performance liquid chromatography (HPLC) hyphenated with ultra-violet/visible light (UV/Vis) or tandem mass spectrometry (MS/MS) detector] with the aim to determine the relationship between biological activity and contained compounds.

2 Theoretical background

2.1 Free radicals and antioxidants

Term free radical is applied to any atom or molecule which has one or more unpaired valence electron or has open electron shell. This characteristic makes free radicals highly chemically reactive to other organic compounds, often resulting in chain reaction. Free radicals are also called reactive species and are further divided due the prevalent presence of oxygen (reactive oxygen species – ROS), nitrogen (reactive nitrogen species – RNS) or other atoms (such as carbon, chloride, sulphur) [1,15]. Amongst biologically important free radicals belongs for example hydroxyl radical, carbonate radical, superoxide radical, peroxy and alkoxy radicals, nitric oxide, peroxynitrite (ONOO⁻), hydrogen peroxide, sulphur radicals, hydrochlorous acid (HOCl) etc. [16–20,1]. Singlet oxygen and ozone are also sometimes recognized as free radicals [21,22]. Metals, such as copper, zinc, vanadium, chromium, molybdenum and others are also defined as oxidizing agents. Free radicals and other oxidizing agents are mainly involved in electron transfer reactions referred as oxidation processes [23–26].

It is well known, that oxidation reactions play key role in many biologically important processes, including oxidative phosphorylation (in mitochondria), cell signalling, phagocytosis, formation of enzymes and other important molecules with biological activity (e.g. leukotrienes, prostaglandins, pyruvate, thyroid hormones). This fact is supported by presence of various oxidizing enzymes in biological systems (e.g. cyclooxygenase, lipoxygenase, peroxidase, NADPH oxidase and xanthine oxidase) catalysing free radicals production and realization of above-mentioned biological activities [1,15]. However, free radicals are also involved in degradation of several biologically important molecules, for example lipids, proteins, DNA, and other biomolecules, resulting in development of serious diseases (such as cancer, diabetes, myocardial infarction, stroke and other disorders) [23,27–29]. On the basis of facts noted above, free radicals are important for many vital reactions in biological systems. However, due to their adverse damaging activity, free radical formation should be kept in balance. This function is ascribed to chemical structures called antioxidants [1].

Antioxidants are both low- and high-molecular weight compounds, which are capable of complete inhibition or partial retardation of oxidation processes by one (or more) mechanisms. This includes chelation of metal ions and free radical scavenging ability. In former mechanism of action, antioxidant structures are able to quench metal ions to its own skeleton

and therefore, metal ions are unable to produce radical species. In latter mechanism, antioxidants serve as electron or hydrogen donors to free radicals in order to stabilize them [3]. Although antioxidants lose one or more electrons or hydrogen, by particular chemical nature, they continue to be stable and do not become free radicals themselves [15]. It is important to say that biological systems are capable to produce endogenous antioxidant agents. Such antioxidants are further recognized as either low-molecular [e.g. ascorbic acid (vitamin C), α -keto acids, bilirubin, coenzyme Q, glutathione, lipoic acid, melanins, melatonin, vitamin E, trehalose, and uric acid] [30–38] or high-molecular: [e.g. catalase, histidine-containing dipeptides, glutathione peroxidase and other peroxidases, peroxiredoxins and other sulphur based antioxidants, protein-disulphide isomerase, various superoxide dismutases (SOD), superoxide reductases (SOR), thioredoxin and others]. Nevertheless some low-molecular-mass antioxidant agents could be also acquired in diet, especially plant-based [39–44,1].

2.2 Oxidative stress and human health

It is widely believed that free radicals and their reactive species are involved in human diseases [45]. Oxidative stress have been implicated in over 150 health disorders [46] and some specific diseases are primarily caused by oxidative stress [1]. However, in most cases, oxidative stress is rather consequence raised by particular conditions of the disease (secondary progress). Various studies have reported that administration of large doses of antioxidants have demonstrated little or no preventative or therapeutic effect in human diseases related to oxidative stress. Hence, many authors have raised doubts about effectivity of antioxidants in clinical practice [47]. With aim to summarize critically present data on medicinal potential of antioxidants, only diseases where these compounds have demonstrated positive or limited therapeutic benefit are discussed in this section. Relationship between oxidative damage and human diseases (even those not included in this section), as well as suggested therapeutic benefit of antioxidants is given in Table 1.

2.2.1 Atherosclerosis

Atherosclerosis is a disease characterized by local thickening of the vessel wall which is a result of invasion and accumulation of fatty streak-derived plaque. Increased incidence of plaques in arteries causes limited blood flow to the region of specific organs such as heart or brain. This secondary condition of atherosclerosis develops into diseases known as heart attack (myocardial infarction) and stroke (localized cerebral ischemia) [48]. Specific inflammation, hypertension and other factors are widely recognized as important initiators of atherosclerosis [49]. However, it is believed that impairment of oxidized low-density lipoproteins

(LDL) into vessel wall is a key contribution factor in progress of this disease. LDL are oxidized by endogenously produced factors including metals ions, reactive oxygen species (ROS), reactive nitrogen species (RNS; e.g. ONOO⁻), reactive chlorine species (RCS; e.g. HOCl), lipoxygenases and others [50,51]. Distraction of atherosclerosis development is thus seen in possible avoidance of the LDL peroxidation by antioxidants.

2.2.2 Diabetes mellitus

Diabetes is characterized by elevated blood and urinary glucose levels caused either via defective production of insulin by pancreatic islet cells (type 1) or by faulty response (resistance) of target cells to insulin (type 2). Former type is most often seen in adults as a result of obesity, lack of exercise and poor diet, whereas latter type is appearing in child age and it is believed to be triggered by genetic predisposition [1]. However, there are indications that oxidative stress can contribute to development of diabetes (reactive species-dependent destruction of islet β -cells) [52]. Complication of diabetes is further associated with tissue damage caused by extend exposure to glucose together with plasma lipids such as LDL, very low-density lipoproteins (VLDL) and lipoprotein (a) [53]. Increased levels of glucose further leads to disruption of mitochondrial function via overloaded generation of reduced nikotinamidadenindinukleotid (NADH) [54], and degradation of proteins via reaction with -NH₂ groups and formation of advanced glycation end-products (AGEs). Both of these chemical reactions contributes significantly to increased production of ROS, and therefore to oxidative stress in this disease [1].

2.2.3 Cystic fibrosis

Disease is caused by protein abnormality which is encoded by gene on chromosome 7 (autosomal recessive genetic disorder) [55]. Damaged protein couples ATP hydrolysis with Cl⁻ transport across epithelial surfaces. This consequence further results in uneven distribution of water and electrolytes to various tissue systems such as respiratory tract, but also organs such as liver, bile ducts, pancreas, gastrointestinal tract and skin [1]. Oxidative damage can contribute (both positively and negatively) to injury linked with this disease, however significance is still uncertain [56]. Additionally, it was observed that patients suffering from cystic fibrosis have lowered plasma levels of β -carotene (~ 0.04 μ M; normal levels should be around 0.2 μ M), lutein, zeaxanthin, lycopene, α -carotene and others [1].

2.2.4 Inflammatory bowel disease

Reactive species are believed to be involved in tissue injury of Crohn's disease and ulcerative colitis. Former is a recurrent inflammation and ulceration of whole digestive tract, while latter affects colon and rectum only. In both conditions, autoantibodies to bowel components can be found in plasma [1]. Tissue injury in this disease involves extensive recruitment and activation of neutrophils, monocytes, lymphocytes, production of cytokines (e.g. TNF- α), eicosanoids, proteinases and of course reactive species (such as HOCl and ONOO⁻) [57]. Several studies point that oxidative stress can contribute to development of this disease on mouse models together with progress of cancer (induced by reactive species-mediated DNA damage) [58,59]. However, other studies produce contradictory results, even indicating beneficiary effect of reactive species (e.g. depression of phagocyte recruitment) [57].

2.2.5 Cancer

Tumour may be defined as abnormal mass of tissue with exceeded rate of growth and uncoordinated communication with other cells presented in organism. Tumours are classified according to rate of growth (benign or malignant). Benign forms remain at the site of origin, which later usually become enclosed in layer of fibrous material formed by surrounding tissue. As contrast, malignant forms are very fatal; they are able to travel from their primary site through bloodstream and lymphatic system to form secondary tumours (metastases). Pathogenicity (e.g. rates of growth and metastasis) is related to type of tumour – i.e. skin cancer rarely metastases, whereas melanoma frequently does. Malignant tumours usually lose their resemblance to their tissue of origin [1,60].

The complex process of conversion of a normal cell into the malignant state (cancerogenesis) is chiefly initiated by DNA alteration. Modified DNA is successfully replicated and further cell proliferation allows mutation to be incorporated into DNA of future cells (amitosis). Additional changes and proliferation of DNA (accumulation of defect DNA) leads to progress of cancer [61]. Carcinogenesis is triggered by genetic predisposition as well as by environmental factors, including gene defects (e.g. oncoviruses, faulty tumour-suppressor genes activity etc.) [62,63]. It was previously suggested by battery of studies that oxidative stress and reactive species are intimately involved in carcinogenesis [64]. It was also proposed that malignant tumours alone are capable of ROS production and that this might contribute to additional development of secondary tumours [65]. Despite the existence reports on reactive species impact on cancer development and ongoing pathology, it was previously demonstrated that reactive species in small quantities showed beneficiary effect [66,67].

Finally, treatment of cancer also covers administration of chemotherapeutics which are used as agents suppressing growth of malignant cells (generally) via interference with cell division. Although chemotherapeutics are designed to provide as little damage as possible to normal cells, they possess considerable side effects, among others, also provided by oxidative stress (e.g. doxorubicin [68], bleomycin [69]). Moreover, pathogenicity of tumours is even stressed out by fact that certain types of cancer cell lines possess resistance (intrinsic or acquired) to commonly used anticancer agents (e.g. methotrexate-resistant breast cancer lines) [70–72].

2.2.6 Exposure to ionizing radiation

Modern management of various types of cancer also includes treatment with radiation therapy (ionizing radiation) which possess serious negative impact on human health. Ionizing radiation [γ -and X-rays, high-energy electrons (β -particles) and neutrons, and He^{2+} particles] is characterized as radiation at specific wavelength, which carries enough energy capable of liberating electrons from molecules and transmits them into state of ions. Significant part of the initial damage done to cells by ionizing radiation is due to increased occurrence of hydroxyl radical. DNA is particularly important target, suffering double- and single-stranded breaks, deoxyribose damage and base modification [1]. Double-strand breaks are especially important damaging agents because their repair can be error prone [73]. Subjects which have experienced even relatively small dosage of ionizing radiation are more prone to sterility, specific forms of cancer and cataract [74,1]. In patients undergoing radiotherapy, DNA damage is evidenced by previous reports of increased levels of 8-hydroxy-2'-deoxyguanosine (8OHdG; oxidation product of DNA) in urine [75]. Other mechanism involve increased availability of transition metal ions in plasma as a result of mitochondrial damage caused by radiation [76]. Exposure to ionizing radiation is also secondarily accompanied by significant inflammatory response (e.g. elevated cytokine production induced by reactive species) [77,78].

2.2.7 Stroke/CNS injury

Traumatic injury to the brain or spinal cord involves both direct tissue damage and secondary damage involving many of the events relevant to stroke [79]. Blood vessels which normally support the brain are ruptured and brain suffers from hypoxia. Bloodleak and oedema raise intracranial pressure and further decrease blood flow. Vasospasm that can occur several days after intracranial bleeding seems to involve oxidative damage (production of hydroxyl radical and increased rate of lipid peroxidation) [80,81]. Moreover, during the first 5 days after intracranial bleeding, erythrocytes in cerebrospinal fluid slowly haemolyse, majori-

ty of haemoglobin is further converted to bilirubin by haem oxygenase (HO). However part undergoes non-enzymatic oxidation and degradation [82]. Upon degradation, a potential pro-oxidant agent is released: iron. Moreover, soon after trauma, inflammatory/immune responses begin, involving production of cytokines, activation of transcription factors (e.g. NF- κ B) and microglia and phagocyte recruitment [1].

2.2.8 Parkinson's disease

Disease is characterized by rhythmic tremor in hand or foot and as the disease develops, patients have increasing problems in movement control; movement is slow (bradykinesia), tremor becomes more prominent and initiation of movement is difficult (akinesia). Disease is also accompanied by muscle rigidity. Particularly neurons in locus coeruleus and substantia nigra are affected in Parkinson's disease. Former brain region is responsible for production of noradrenalin; in developed stage of Parkinson's disease levels of this compound are significantly lowered [83,84]. Latter section is rich in granules containing black pigment neuromelanin [85]. Like other melanins, neuromelanin is redox-active and is able to chelate metal ions. In addition, Parkinson's disease is connected with appearance of Lewy bodies in residual neurons of substantia nigra and several other brain regions. These filamentous electron-dense inclusion bodies are composed of abnormal aggregated proteins, namely α -synuclein, ubiquitin and neurofilaments. All of these proteins are prone to oxidation or nitration [86].

Almost all Parkinson's disease cases are sporadic (appearing without obvious genetic cause). However rare inherited variants were previously identified which also appeared in juvenile (before age of 20) and early onset (before age of 40-50) patients [87,88]. To date it is unclear which factors trigger sporadic form of Parkinson's disease; however it is assumed, that toxins play important role. Compounds such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [89], 2,5-hexanedione [90], deguelin, rotenone (both found in *Derris elliptica*) [91] and annonacin (presented in *Annona* species) [92,93] were reported to be significant inhibitors of mitochondrial complex I, resulting in mitochondrial defect and ongoing oxidative stress. Oxidized metabolites of dopamine by monoamine oxidase (MAO), have potential neurotoxic effects *in vivo* too [94].

2.2.9 Alzheimer's disease

In this disease, several brain regions involved in learning and memory, such as basal forebrain and hippocampus, suffer synaptic damage and eventual neuronal loss. This issue results in impairment of cognitive functions, including memory, ability to deal with daily life,

performance of sensimotor and social functions, language communication and control of emotional reactions. It is widely accepted, that genetics play key role in progression of Alzheimer's disease [95]. However, other factors also influence development of this disease, including poor diet (low dietary intake of folic acid), high level of plasma cholesterol (i.e. atherosclerosis) or homocysteine, low intellectual activity and repeated minor brain traumas [96].

Alzheimer's disease is characterized by presence of so called senile plague – i.e. extracellular localized areas of degenerating and frequently swollen axons, neuritis and glia surrounding a core of aggregated β -amyloid peptides ($A\beta$). Senile plagues are to some extent found in normally aging brain. However in Alzheimer's disease brain, levels of soluble and precipitable $A\beta$ are at least 5 and 100 times higher in comparison to controls, respectively [97]. $A\beta$ were accused to be principal cause of secondary neurodegeneration in Alzheimer's disease [98]. It was found out by several studies that $A\beta$ peptides are able to produce reactive species. Resulting oxidative stress causes mitochondrial dysfunction that leads to neurotoxicity and damage to neuronal synapses [99–102]. High levels of 8OHdG and other DNA base oxidation products (both nuclear and mitochondrial) in Alzheimer's disease patients [103] point towards significant contribution of oxidative stress to this disease pathology (apparently stronger than for any other neurodegenerative disease) [1].

2.2.10 Amyotrophic lateral sclerosis

Disease is characterized by degeneration of motor neurons in the motor cortex, brainstem and spinal cord. Mean age of onset of amyotrophic lateral sclerosis (ALS) is 57 years; it begins as painless muscle weakness and impaired muscle tone, leading to atrophy. Problems with speech and swallowing follow. Disease is chronic and progression is rapid, often leading to death within few years of its appearance, usually of pneumonia or respiratory failure secondary to muscle paralysis [86,98,104]. Incidence of ALS cases is of 90% sporadic and of 10% inherited. It was demonstrated, that increased oxidative stress occurs in ALS (increased levels of DNA oxidation products etc.), however its importance to disease pathology is unclear [105].

2.2.11 Other neurodegenerative diseases

Friedreich's ataxia (FA) is the most common type of hereditary ataxia (impaired movement due to loss of motor co-ordination). Onset is usually after age of 15. Disease primarily affects neurons with long axons, which die back from periphery. FA is caused by mutations in gene on chromosome 9 that encodes protein frataxin involved in mitochondrial iron

metabolism. Low frataxin levels delay production of Fe/S clusters in aconitase and in complexes I, II and III. It has also been speculated (but not proven) that low frataxin levels are indirectly involved in free radical production reactions. Apart from brain, heart is also rich in frataxin and premature death of FA patients often involves cardiac problems [1].

Huntington's disease (HD) is inherited disease characterized by psychiatric disorders, dementia and itchings, writhings and other involuntary movements. It is caused by selective degeneration of striatal neurons, accompanied by astrocytosis, leading to atrophy of caudate nucleus and putamen. Disease does not usually appear before age of 30 and can last for 20 years or more with progressively worsening symptoms [106,107]. HD is caused by defect in gene on chromosome 4 encoding protein huntingtin. Its function in human body is unclear, although huntingtin was estimated to be involved in transport of brain-derived neurotrophic factor (BDNF) along microtubules [108]. Degenerated huntingtin possess neurotoxic properties by higher tendency to aggregate and form inclusions bodies containing ubiquitin and proteasome and impairing proteasomase activity [109].

Table 1 Importance of oxidative stress in human diseases (adopted from [1])

Condition	Is oxidative stress primary cause?	If oxidative stress is secondary does it contribute significantly to disease pathology?	Is there evidence that antioxidants have or will have therapeutic benefit?
Atherosclerosis	In specific conditions ^a	Uncertain	Limited
Hypertension	In specific conditions	In specific conditions	Limited
Diabetes	Possibly	Yes	Limited
Rheumatoid arthritis	No ^b	Uncertain ^c	No
Autoimmune diseases	Probably no ^b	Uncertain ^c	Limited
Inflammatory bowel disease	Probably no ^b	Uncertain ^c	Limited
Acute respiratory distress syndrome (ARDS)	Generally no ^d	Possibly	No
Cystic fibrosis	No	Possibly	Limited
Cancer	In specific cases ^e	Probably yes	Limited ^f
Radiation-induced damage	Yes	Yes ^g	Yes
Stroke/Traumatic CNS injury	No	In specific conditions	Limited
Parkinson's disease	Possibly	Probably yes	Limited

Table 1 (continued)

Condition	Is oxidative stress primary cause?	If oxidative stress is secondary does it contribute significantly to disease pathology?	Is there evidence that antioxidants have or will have therapeutic benefit?
Alzheimer's disease	Probably no	Probably yes	Limited
Amyotrophic lateral sclerosis (ALS)	No	Uncertain	Limited
Neuronal ceroid lipofuscinoses	No	N/A ^h	N/A ^h
Multiple sclerosis	No	Possibly	No ⁱ
Drug side-effects	In few cases	In few cases	Limited
Huntington's disease	No	Possibly	Limited
Friedreich's ataxia	No	Probably yes	Limited
HIV infection/AIDS	No	Possibly	No

^a reactive species can damage vascular endothelium to start the process; ^b however, oxidatively-modified proteins/DNA can be antigenic; ^c phagocyte ROS production may be of protective character; ^d but may contribute to phagocyte recruitment; ^e chronic inflammation-related, may contribute to mechanism of carcinogen action; ^f protective against chemotherapeutics side effects; ^g secondary production of reactive species via inflammation; ^h no data are available; ⁱ several studies declare dual beneficial/harmful effects of plant-based antioxidants

2.3 Medicinal and pharmaceutical preparations

2.3.1 Drugs with antioxidant action

Antioxidants have evoked great interest as possible therapeutic agents. This may involve usage of naturally occurring antioxidants (with or without structural modifications) or completely synthetic molecules [110]. Health beneficiary effect of certain drugs already clinically used (which were not primarily designed as antioxidants) may be partially or completely explained by their antioxidant mechanism [111]. Examples can be seen in aminosalicylates in treatment of inflammatory bowel disease [112] or various antibiotics (e.g. neuroprotective effect of some tetracyclines in stroke, ALS or Huntington's disease) [113]. Primarily, any antioxidant proposed for therapeutic use must be non-toxic. However, other important questions should be addressed as well – (i) what biomolecule(s) is the antioxidant designed to protect, (ii) what is the mechanism of action of proposed antioxidant, (iii) degree of damage of antioxidant-derived radicals and (iv) possibility of interference of antioxidants with beneficial effect of reactive species. For reason to declare that therapeutic benefit of antioxidant molecule in particular disease is clearly related to antioxidant activity, clinical trials of antioxidant drug are nowadays accompanied by measurements of oxidative damage biomarkers [1]. Further section provides summary of therapeutic antioxidants which have undergone clinical trials and demonstrated therapeutic benefit in oxidative stress-related diseases.

2.3.1.1 *Superoxide dismutases and catalases*

Antioxidant enzymes available for therapeutic use include recombinant human SODs (CuZnSOD, MnSOD, and EC-SOD) and their conjugates [114]. Studies done on animal models demonstrated reduction of ischaemia-reperfusion injury upon intravenous application of PEG-SOD and PEG-catalase [115]. Another study confirmed anti-cancerogenous effect of galactosylated or PEG-modified catalase by ability to decrease metastasis in mice [116]. However, in other clinical trials, antioxidant enzymes were found ineffective in treatment of several ailments such as chronic anti-inflammatory or autoimmune diseases [1].

2.3.1.2 *SOD/catalase mimetics*

SOD/catalase mimetics are low molecular weight compounds mostly containing transition metal ions. Research is nowadays mainly focused on iron or manganese porphyrins such as FeTMPyP, AEOL 10150 and other manganese complexes, e.g. EUK-8, EUK-134 or M40403. Unlike, enzymatic antioxidants, SOD-mimetics are more prone to undergo redox reactions. On the other hand, these compounds have advantage of easier penetration into host

cells in comparison to SOD enzymes [117]. SOD-mimetics have shown protection ability against oxidative damage in wide range of cell and animal model systems, even though they possess negative side effects as well [118]. Despite the existence of beneficial effects of SOD-mimetics in animal models, these compounds are not used in clinical praxis yet [1].

2.3.1.3 Spin traps/nitroxides

Idea of using spin traps as therapeutic antioxidants arisen from studies showing that α -phenyl-*tert*-butylnitronine (PBN) protects rats against death from shock induced by gut-*ischaemia* reperfusion or endotoxin injection [119]. Nevertheless, *in vitro* antioxidant characterization demonstrated PBN to be poor chain-braking antioxidant and inhibitor of lipid peroxidation [120]. Therefore, there is suggestion that observed therapeutic beneficial is not associated to antioxidant efficacy, but rather to another biological activity. Several derivatives of PBN have been developed as potential therapeutic agents, such as CPI-142 or NXY-059. Latter derivative, also known as Cerovive®, demonstrated significant improvements in primate stroke models and is nowadays under clinical trials in humans [1], Unlike previously mentioned compounds, LPBNAH [121], stilbazulenyl nitron (STAZN) [122], OXANO and TEMPO [123] exerted significant antioxidant potential *in vitro*. Another examples of related compounds with considerable antioxidant efficacy would be hydroxylamines (e.g. *N-tert*-butyl hydroxylamine, derivative formed during spontaneous decomposition of PBN) or hydroxamates (e.g. *N*-methylhexanoylhydroxamate) [124,125]. Above-mentioned nitroxides have radioprotective effects and can decrease tissue damage in some animal model system of shock, *ischaemia*-reperfusion and inflammation [126].

2.3.1.4 Ascorbic acid, α -tocopherol and their derivatives

α -tocopherol (vitamin E) have been found to possess therapeutic benefits in premature babies or other patients suffering from α -tocopherol deficiency [127] or inborn lack of glutathione synthetase [or glucose-6-phosphate dehydrogenase (G6PDH)] [128]. However, attempts to use α -tocopherol in treatment other diseases such as diabetes, anthracycline-induced cardiotoxicity, cancer, Huntington's and Parkinson's disease, were found disappointing, although limited benefit was detected in Alzheimer's disease [129]. Low efficacy is explained by fact that oxidative damage has faster rate than distribution of α -tocopherol into tissue systems. Second reason is that oxidative damage frequently occurs by mechanisms other than lipid peroxidation, where α -tocopherol seems to be ineffective [1].

Several structural analogues of α -tocopherol, some with improved antioxidant activity have been described. However, for most of these compounds, few human studies have been

reported. One of α -tocopherol derivatives is BO-653 which demonstrated anti-atherosclerotic effects in animals [130]. Troglitazone, an antidiabetic agent with antioxidant properties is being used on patients, although relatively serious side effects have been recorded [131]. Raxofelast have been reported to improve endothelial dysfunction in diabetes. α -tocopherol succinate has been claimed to possess anticancer effect [132].

Various esters of ascorbic acid, for example ascorbyl plamitate and 2-octadecylascorbate, have been synthesized as lipophilic versions of ascorbate. These have been used as food preservatives and tested as antioxidants in some animal models, but had not attracted much interest as for therapeutic use. EPC-K1 is a combined phosphate ester of vitamin E and C that has been reported to exert protective effect in rat stroke model [133].

2.3.1.5 Other chain breaking antioxidants

Probucol have demonstrated cardioprotective [134] and anti-atherosclerotic effects *in vivo* as well as significant antioxidant properties *in vitro* [135]. Succinate ester of probucol, AGI-1067 is in clinical trials as anti-atherosclerotic agent and other derivatives are being considered for use in treating transplant rejection and rheumatoid arthritis [136]. Probucol has some side effects though: it tends to decrease plasma high-density lipoprotein (HDL) levels. However, its analogue AGI-1067 seems to lack this negative characteristic [137].

Coenzyme Q has anti-atherosclerotic effects as well. Moreover, it was discovered that this compound also possess mild benefit in human neurodegenerative diseases [138]. Modified coenzyme Q, idebenone has also been used in treatment of various neurodegenerative diseases [139]. By contrast, phenolic antioxidant OPC-14117, although showing limited benefit in animal models with neurodegenerative disease, did not help patients with Huntington's disease [110]. Compound BN82451 increased survival in transgenic mouse model of this disease, but unfortunately, it appears that so far it was not tested in human clinical trials [140].

Chain-breaking antioxidants butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) are widely used in the food industry to prevent rancidity. To present-day, these compounds have not been explored as possible therapeutic agents, also partly due to supposed toxicity [3]. Propofol, active ingredient of the anaesthetic diprivan, resembles BHT and it is thought that propofol has antioxidant activities *in vivo* during anaesthesia [141].

Therapeutic potential of plant-based phenolic compounds is also under investigation; much work has been done on mixtures of *G. biloba* extract (beneficiary effects are mainly attributed to contained flavonoids myricetin and quercetin) [98]. Another thoroughly studied formula is daflon, which is micronized and purified flavonoid mixture of diosmin (90%) and

hesperidin (10%). Daflon increases venous tone and resistance in small blood vessels, for which is recommended in treatment of chronic venous insufficiency, venous ulcers and haemorrhoidal diseases [142]. Other flavonoids and their analogues are being assayed as anti-inflammatory and anticancer agents and for the treatment of vascular diseases. Since these structures are capable of inhibition of protein glycation and aldose reductase activity as well as exhibiting antioxidant activity, flavonoids are nowadays especially examined as potential therapeutic agent in diabetes [143]. Derivatives of curcumin are at present moment surveyed as potential therapeutics in patients suffering from Alzheimer's disease (decrease of IP levels and neuronal damage [144], reduced plaque development [145]). Similarly, green tea extracts or epigallocatechin gallate (EGCG) injected into mice diminished damage caused by administration of 1-methyl-4-phenylpyridinium (MPP⁺; triggering factor in various neurodegenerative diseases) [146].

2.3.1.6 Thiol compounds

Glutathione (GSH) is often suggested as possibly therapeutically useful. Areas of interest include preservation of organs for transplantation [147] and protection against tissue damage by cytotoxic agents such as aflatoxin B1 [5]. Aerosolized GSH solution has been suggested as mean for lowering lung damage by reactive species (e.g. in cystic fibrosis). However, when tested in asthma patients, solution induced bronchoconstriction [148]. Derivatives based on methyl, isopropyl and ethyl monoesters, which are more readily distributed to tissue systems and possess better efficacy, have been described [149]. L-2-oxathiazolidine-4-carboxylate (OTC) is hydrolysed to cysteine *in vivo* (by enzyme 5-oxoprolinase), and was reported to stimulate GSH synthesis in biological systems. [150]. This compound improved allergen-induced airway injury in mouse model of asthma [151].

N-acetylcysteine is used as antioxidant in many laboratory experiments and is effective in treating paracetamol over-dosage [152]. It has been widely used in human subjects for treatment of various diseases such as ARDS [153] or cardiovascular problems [154]. Although *N*-acetylcysteine was found to possess minimum toxicity, various studies had doubt about its therapeutic benefit via antioxidant mechanism [155]. *N*-acetylcysteine amide, which is able to cross blood-brain barrier, showed protective effects against myelin oligodendrocyte glycoprotein (MOG) induced autoimmune encephalomyelitis and towards MPTP (induction factor for Parkinson's disease) toxicity in rats [156].

2.3.1.6.1 Other thiols

Mercaptoethylguanidine is a powerful scavenger of ONOO⁻ [157] and inhibitor of inducible nitrite oxide synthase (iNOS) [158]. Compound was found to have beneficial effects in various animal models of inflammatory conditions [159]. Lipoic acid can act as antioxidant *in vitro* [160] and has been used in treatment of diabetes [37]. In rat model, lipoic acid prevented falls in GSH levels with age [161]. Several structurally modified forms of lipoic acid with improved antioxidant activity have been described, some of which can cross blood-brain barrier [162]. Many thiols have been tested for their ability to protect cells and animals against ionizing radiation, including GSH, cysteine, bucillamine, cysteamine, dimercaprol, penicillamine, mesna (sodium salt of 2-mercaptoethanesulphonic acid) or amifostine [163].

2.3.1.7 Mitochondrially-targeted antioxidants

Since mitochondria are major sources of reactive oxygen species *in vivo* and damage to them contributes to ageing and development of certain diseases, antioxidants selectively targeted to these organelles have been assumed to be especially beneficial. One approach was developed as linking antioxidant (such as thiol, α -tocopherol, coenzyme Q or spin trap) to the phosphorus of lipophilic compound triphenylphosphonium (TPP) [164]. Example of such hyphenated compound is MitoQ₁₀ (Coenzyme Q–TPP) [165]. Mitochondrially targeted antioxidants are able to enter mitochondria where they accumulate and exert protective antioxidant effect. Additionally, it was proposed that these compounds can enter all tissues, even brain (apparently are able to cross blood-brain barrier) [166]. Indeed, MitoQ₁₀ were found more effective in comparison to untargeted antioxidants, such as Coenzyme Q or TPP alone, in treatment of cardiac ischaemia-reperfusion injury [167]. Due to above-mentioned characteristics, mitochondrially-targeted antioxidants have been found to be exceptionally efficient in wide range of conditions, including Alzheimer's [168] and Parkinson's disease [169], hypertension [165] or diabetes [170]. Despite the existence of records on therapeutic benefit in numerous diseases, mitochondrially-targeted antioxidant are still not used in clinical praxis [1].

2.3.1.8 Iron chelators

Several chelating agents have been used in attempts to inhibit iron- or copper- dependent oxidative damage. It is widely known, that antioxidant activity of chelators can be explained by multiple mechanisms, i.e. by scavenging free radicals. The first chelating agent reported to decrease the superoxide-dependent hydroxyl radical generation *in vitro* was DE-TAPAC [171]. However, other agents with better efficacy were described, among them for

example phytic acid or inositol hexaphosphate. These two chemicals have been used as food preservatives and were described as protective mean in colon, by binding iron in faeces [172]. Various plant phenolic compounds are able to bind transition-metals as well, and indeed, this may be the mechanism by which flavonoid derivatives (such as rutilimone) diminishes cardiotoxicity of doxorubicin in mice [173].

One of the very efficient and widely used iron chelator in praxis is desferrioxamine (DFO) produced by *Streptomyces pilosus*. Compound used for prevention and treatment of iron overload in patients who have ingested toxic oral doses of iron salts or who require multiple blood transfusions (i.e. thalassaemia, a form of inherited autosomal recessive blood disorder characterized by abnormal formation of haemoglobin, resulting in improper oxygen transport and destruction of red blood cells) [174,175]. DFO has been added to some organ preservation solutions, especially for heart transplantation [176]. Additionally, this compound have demonstrated anti-proliferative activity at therapeutically relevant concentrations [177]. High-molecular-mass forms of DFO have been developed, including cellulose, dextran or hydroxyethyl conjugates. Such derivatives were reported to exert lowered iron binding-activity, but on the other hand, toxicity of high doses were decreased as well [1]. DFO derivatives were reported to be protective in cases of septic shock and to delay onset of diabetes in animal models [178].

Hydroxypyridones were introduced in attempt to overcome major disadvantages of DFO in treating thalassaemia. Among chemicals substantially tested as alternatives to DFO, *N,N*-bis(2-hydroxybenzyl)ethylenediamine-*N,N*-diacetic acid (HBED) [179], pyridoxal isonicotinoyl hydrazone (PIH) [180], desferrithiocin and 2,3-dihydroxybenzoate [181] have shown promising results. However most attention was focused on the 3-hydroxypyrid-4-ones. For example 3-hydroxy-1,2-dimethylpyridin-4(1*H*)-one (L1) has undergone clinical trials in humans. Sadly, it appears more toxic than DFO, although still clinically useful [182,183].

Few orally active tridentate ligands have been described. One is ICL670 (Exjade®) which was tested in thalassaemia and its use has been approved by the Food and Drug Administration of the United States of America (U.S. FDA) [184]. Some authors have described so called “oxidative stress-activatable” iron chelators; i.e. compounds able to chelate transition metals at site of oxidative stress and not in the body generally (example of such compound is OR10141) [185]. Another interesting compound is lipoic acid plus (LAP; dithiolan-3-yl-pentanoic acid (2-dimethylamino-ethyl)-amide), derivative of lipoamide designed to accumulate within lysosomes. This compound is more efficient than DFO in cell protection against hydrogen peroxide [186]. Antioxidant derived from serine and vitamin B₆, *N*-(4-

pyridoxylmethylene)-L-serine, was found to protect mouse skin against damage by UV light, presumably by chelating iron [187]. Transition metal chelating ability was “added” to another sort of drugs, such as MAO inhibitors. Examples of this kind are compounds M10 and M30, which have been suggested for use in Parkinson’s disease. Both of these compounds were claimed to exert protective action against MPTP neurotoxicity [1,188].

Table 2 List of antioxidants available for therapeutic use

Category of compound	Example
Naturally occurring	antioxidant enzymes (CuZnSOD, MnSOD, EC-SOD, SOR); peptides, proteins and other amino acids derivatives (histidine containing-dipeptides, transferrin, lactoferrin, adenosine, pyrodixamine, cysteine, glutathione); terpenoids (tocopherols, tocotrienols, coenzyme Q, lipoic acid, carotenoids); flavonoids and other phenolic compounds (resveratrol); antibiotics; hormones (melatonin, coelenterazine); carbohydrates (vitamin C); siderophores (desferrioxamine, rhodotorulic acid)
Synthetic	thiols (mercaptopyrionylglycine, <i>N</i> -acetylcysteine); metal ion chelators (ICRF-187, Exjade®, hydroxypyridones); fullerenes; xanthine oxidase inhibitors; inhibitors of superoxide generation by phagocytes, inhibitors of phagocyte adhesion; lipid-soluble chain-breaking antioxidants; glutathione donors; SOD/Catalase mimetics; derivatives of vitamin E or C; coelenterazine derivatives; modified antibiotics
Compounds used in clinical praxis possessing antioxidant activity <i>in vivo</i> ^a	penicillamine ^b , bucillamine ^b ; aminosalicylates ^b ; apomorphine ^b ; selegiline; flupirtine; omeprazole; 4-hydroxytamoxifen ^b ; ACE inhibitors (quinapril; ramipril; captopril) or angiotensin II receptor antagonists (losartan); ketoconazole; tetracyclines; probucol; propofol; various β -blockers (carvedilol, metoprolol) ^{b,c} ; several Ca ²⁺ channel blockers ^{b,c} ; cimetidine; phenylbutazone ^b ; nitecapone ^b ; entacapone ^b ; idebenone, troglitazone ^b ; tacrolimus

^a Agents primarily not developed as antioxidants, however exhibiting significant antioxidant effect; ^b Compounds reacting with reactive species resulting in formation of antioxidant-based radicals inducing further damage; ^c Several β -blockers and Ca²⁺ blockers inhibits peroxidation *in vitro*, however it is uncertain if they do so *in vivo* at therapeutic levels normally achieved.

2.3.2 Anticancer drugs

Anticancer drugs embody a diverse array of chemical structures which are characterized as compounds possessing ability to suppress cell growth and vitality of tumour cells. This biological activity is achieved by various mechanisms of actions. It is estimated, that there are over 50 clinically approved anticancer drugs. In addition there are many new anticancer drugs in various stages of preclinical and clinical development. There is nowadays excess need for novel and more effective antineoplastic agents. This is caused by increased incidence of cancer amongst human population as well as rapid spread of resistance of cancer cells towards commonly used chemotherapeutics (this fact is especially true for paclitaxel). Moreover, despite the fact that commonly used chemotherapeutics are designed to provide as little damage as possible to human health, these possess considerable adverse effects [5,189,190]. Examples of some commonly used anticancer agents (either used in natural, semi-synthetic or complete synthetic form), as well as their mode of action are discussed below.

2.3.2.1 Antimetabolites

Antimetabolites are one of the oldest families of anticancer drugs whose mechanism of action is based on the interaction with essential biosynthesis pathways, such as disruption of synthesis of nucleic acids via incorporation to cell components (e.g. 5-fluorouracil, mercaptopurine) or interference with enzymatic processes of metabolism (for example methotrexate). Most of these compounds are used in treatment of various types of leukaemia [190].

2.3.2.1.1 Pyrimidine analogues

5-fluorouracil (5-FU) is a widely used cytotoxic agent for the treatment of breast tumours and cancers of the gastrointestinal tract, including advanced colorectal cancer [191]. It has also been given topically for treatment of certain types of skin cancers. Main side effects of this drug include myelosuppression and mucositis [192]. Tegafur and capecitabine are metabolised to 5-FU and are given orally for metastatic colorectal cancer. Major side effects of these two analogues are very similar to 5-FU [193]. Cytarabine is still one of the most effective single agents available in oncological praxis for treating acute myeloblastic leukaemia, although myelosuppression is a major side effect [194]. Gemcitabine is a more recently introduced compound of the antimetabolites and it is used intravenously in association with cisplatin for metastatic non-small cell lung, pancreatic, and bladder cancers [195]. It is generally well tolerated but prolonged administration can cause gastrointestinal disturbances, renal impairment, pulmonary toxicity, and influenza-like symptoms [196,197]. Another example of

pyrimidine analogues is azacitidine, in oncological praxis mainly used in treatment of myelodysplastic syndromes [198].

2.3.2.1.2 Purine analogues

Azathioprine was primarily developed as immunosuppressant agent and was administered to patients undergoing organ transplantation [199]. Compound was also used in treatment of various immune system disorders such as rheumatoid arthritis [200] and Crohn's disease [201]. Subsequently it was discovered that azathioprine is also useful antileukaemic drug. Mercaptopurine (6-methylmercaptopurine), a metabolization product of azathioprine displaying similar immunosuppressive activity as azathioprine, is almost exclusively used as maintenance therapy for acute leukaemia [202]. It has also demonstrated some *in vitro* effectiveness against *Mycobacterium paratuberculosis* [203]. Another purine analogue, thioguanine, is used orally to induce remission in acute myeloid leukaemia. Despite their considerable efficacy, all of these compounds possess similar side effects, including myelosuppression [204].

Cladribine is given by intravenous infusion for the first-line treatment of hairy cell leukaemia [205] and the second-line treatment of chronic lymphocytic leukaemia (CLL) in patients who have failed on standard regimens of alkylating agents [206]. Fludarabine, analogue of cladribine, is sometimes used in combinations with other chemotherapeutics (e.g. cyclophosphamide) in first-line treatment of CLL [207]. Another derivative, clofarabine is approved for treating refractory acute lymphoblastic leukaemia in children after failure of at least two other types of chemotherapeutical treatment [208]. As in case of other purine antimetabolites, usefulness is limited by bone marrow suppression [209].

2.3.2.1.3 Other antimetabolites

Methotrexate (MTX) is used as maintenance therapy for childhood acute lymphoblastic leukaemia, choriocarcinoma, non-Hodgkin's lymphoma, and several solid tumours [210]. It is also administered for the treatment of autoimmune diseases like psoriasis [211], rheumatoid arthritis [145], and lupus [212]. Side effects include myelosuppression, mucositis, and gastrointestinal ulceration with potential damage to kidneys and liver that may require careful monitoring [189]. Raltitrexed (Tomudex®) is given intravenously for palliation of advanced colorectal cancer in cases where 5-FU cannot be used. Compound is also sometimes used in combination with other chemotherapeutics (such as oxaliplatin, cisplatin, irinotecan or various anthracyclines) [213]. It is generally well tolerated, but can cause myelosuppression and gastrointestinal toxicity [189,214]. Another intravenously administered antimetabolite is

pentostatin, which regarded as is highly efficient mean for maintenance of hairy cell leukaemia [215]. However, drug is able to induce prolonged remissions [216]. Hydroxycarbamide, also called hydroxyurea, is an antineoplastic drug used mainly in myeloid leukaemia, often in combination with other drugs [217]. It can also be used for the treatment of melanoma and to reduce the rate of painful attacks in sickle-cell disease [190,218].

2.3.2.2 DNA interactive agents

DNA interactive agents are regarded as one of the largest and most important anticancer drug families. Members of this class of antineoplastic drugs are characterized by their ability to form adducts or otherwise interact with DNA molecule, thus preventing replication of target cell and inducing cell death [189].

2.3.2.2.1 Alkylating agents

Dacarbazine is employed as single agent to treat metastatic melanoma and in combination with other drugs for soft tissue sarcomas [219]. Similarly as for antimetabolites, the predominant side effects are myelosuppression and intense nausea and vomiting [220]. Temozolomide is a more-recently introduced compound for the second-line treatment of brain cancers. Drug is structurally similar to dacarbazine and its main advantage is its good oral bioavailability and distribution properties with penetration into the central nervous system [189,221]. Procarbazine has previously demonstrated significant activity in lymphomas and carcinomas of the bronchus and in brain tumours [222,223]. However, its toxic effects include nausea, myelosuppression, and a hypersensitivity rash that disables supplementary use of the drug [224]. Ecteinascidin-743 is a novel DNA-binding agent derived from the marine tunicate *Ecteinascidia turbinata*. This compound was found to be significantly active towards various carcinomas, including melanoma, breast, ovarian, colon, renal, non-small cell lung and prostate cancers *in vitro*, which was subsequently confirmed by various clinical trials [225,226].

2.3.2.2.2 Cross-linking agents

Platinum complexes belong to one of the most widely used class of anticancer drugs and these have previously exhibited pronounced activity in treatment of various types of cancers. Cisplatin was the first platinum complex used with a noticeable activity in testicular and ovarian cancers. Related derivatives carboplatin and oxaliplatin were developed later to reduce the problematic side effects of cisplatin (such as nephrotoxicity, ototoxicity, and peripheral neuropathy). At present, carboplatin is used in treatment of advanced ovarian and lung

cancers, while oxaliplatin is licensed for the treatment of metastatic colorectal cancer in combination with other chemotherapeutics, such as 5-FU, folinic acid or paclitaxel [190,227].

Nitrogen mustards are class of cytotoxic chemotherapy drugs chemically resembling mustard gas which was used in First World War as warfare agent [228]. Representatives of nitrogen mustard-derived compounds used as chemotherapeutical agents include cyclophosphamide, ifosfamide, melphalan, chlorambucil, chlormethine, estramustine. Cyclophosphamide remains one of the most successful and widely utilized antineoplastic drugs mainly due to its broad spectrum of clinical activity (carcinomas of the bronchus, breast, ovary, and various sarcomas, chronic lymphocytic leukaemia, and lymphomas) as well as bioavailability. Moreover, it is also a potent immunosuppressive agent and the most commonly used drug in blood and marrow transplantation. Due to these properties, cyclophosphamide is also sometimes used in treatment of certain autoimmune disorders [189,229]. Careful monitoring of cyclophosphamide administration is needed though, as it has some very serious and life-threatening adverse effects [230]. Its derivative, ifosfamide, has similar anticancer activity as well as spectrum, however needs to be administered intravenously. This compound is often used in conjunction with mesna (section 2.3.1.6.1) to avoid internal bleeding [231]. In comparison to ifosfamide, its analogue trofosfamide is orally active and generally well-tolerated [232]. Chlormethine (also known as mechlorethamine) is used for the treatment of Hodgkin's disease. Due to its chemical reactivity, it must be freshly prepared prior to administration and subsequently delivered via a fast-running intravenous infusion [190,233]. Estramustine phosphate is a conjugate consisting of chlormethine chemically linked to an oestrogen moiety. It is usually orally administered to patients with metastatic prostate cancer [234]. Chlorambucil is useful in the treatment of ovarian cancer, Hodgkin's disease, non-Hodgkin's lymphomas, and chronic lymphocytic leukaemia. Its lower chemical reactivity allows oral dosing. The most commonly occurring side effect of this drug is bone marrow suppression. Additionally, like many other cross-linking agents, chlorambucil has been associated with the development of other forms of cancer [189,190]. Melphalan, analogue of chlorambucil, is indicated for the treatment of myeloma, solid tumours (e.g., breast and ovarian) and lymphomas. As well as chlorambucil, this compound is orally active. Side effects are also very similar [235,236].

Nitrosourea is class of compounds where basic skeleton is composed of nitroso (R-NO) group and urea. Characteristic representatives of this class of antineoplastic agents are: lomustine, carmustine and fotemustine, to name a few [189,190]. Lomustine is characterized by relatively high degree of lipophilicity in comparison to other chemotherapeutics. Since lomustine is able to cross blood-brain barrier, it is considered as a very valuable anticancer

agent. Compound is administered orally and it is mainly prescribed for patients suffering from certain solid tumours (especially of brain) and Hodgkin's disease [237,238]. Activity and toxicity profile of carmustine is comparable to lomustine [239]. Fotemustine is approved for use in the treatment of metastasising melanoma, although some adverse effects have been observed [240].

Thiotepa (*N,N',N''*-triethylenethiophosphoramidate) is long used as an effective anti-cancer drug and appears to be one of the most effective chemotherapeutic agent when used in high dose regimens. Its main indications are the treatment of bladder or ovarian cancers, breast cancer and malignant effusions [241,242]. Main toxic effect of this compound is myelosuppression and bone marrow depression [243]. Treosulfan, related compound to thiotepa, is mainly used to treat ovarian cancer and it has similar major side effects to nitrogen mustards [244]. Busulfan is used for the treatment of chronic myeloid leukaemia and as part of conditioning regimens for patients undergoing bone marrow transplantation. Unfortunately, it can cause excessive myelosuppression, resulting in irreversible bone marrow aplasia and requires careful monitoring [245,246]. Mitomycin-C is a member of a group of naturally occurring antitumor antibiotics produced by *Streptomyces caespitosus* [247]. Mitomycin needs to be administered intravenously and is indicated for patients suffering from upper gastrointestinal and breast cancers. Moreover, administration via bladder instillation allows treatment of superficial bladder tumours. Adverse events of this compound include toxicity to bone marrow [248].

2.3.2.2.3 Intercalating agents

A mechanism of anticancer activity of so called intercalating agents is explained by their ability to attach themselves between the two strands of DNA. These compounds interfere with replication of the host cell. Typical members of this class are anthracyclines, characterized by presence of planar anthraquinone nucleus attached to an amino-containing sugar [249]. Despite the fact that these compounds exert antibacterial activity, high toxicity limits their use to anticancer therapy [250]. Doxorubicin, daunorubicin, and aclarubicin are natural products extracted from *Streptomyces peucetius* or *S. coeruleorubicus*, while epirubicin and idarubicin are semisynthetic analogues. Doxorubicin is widely used as an anticancer drug because of its broad spectrum of activity (acute leukaemia, lymphomas, and a variety of solid tumours). It is administered by intravenous injection and is largely excreted in the bile. Adverse effects include nausea, vomiting, myelosuppression, mucositis, hair loss and cardiotoxicity. Daunorubicin displays significant activity mainly towards acute lymphocytic and myelo-

cytic leukaemia. However, since it has a much less favourable therapeutic index (severe cardiotoxicity) than doxorubicin, daunorubicin is no longer used therapeutically to any extent. Aclarubicin is used as a second-line treatment for acute non-lymphocytic leukaemia. Epirubicin is similar in terms of efficacy for treatment of breast cancer, and produces lower side-effects in comparison to doxorubicin. Idarubicin is mainly used in advanced breast cancer where first-line chemotherapy has failed. Compound is also used in treatment of acute non-lymphocytic leukaemia. As well as epirubicin, idarubicin show increased activity with less cardiotoxicity than their precursor. The principal disadvantage of all of these agents is their severe cardiotoxicity [5,190]. Other examples of intercalating agents are mitoxantrone and actinomycin-D (dactinomycin). Mitoxantrone, synthetic analogue of anthracycline antibiotics, has reduced toxicity compared with doxorubicin and is indicated in cases of metastatic breast cancer, adult non-lymphocytic leukaemia and non-Hodgkin's lymphoma [5]. In addition, it is currently proving useful in multiple sclerosis treatment, where it can reduce the frequency of relapses [251]. Actinomycin-D, polypeptide antibiotic isolated from *Streptomyces parvullus*, is mainly used to treat paediatric cancers, some testicular sarcomas and AIDS-related Kaposi's sarcoma [252]. The side effects of mitoxantrone and actinomycin-D are similar to those of doxorubicin except that the cardiac toxicity is less prominent. However, cardiac examinations and monitoring are still recommended when a certain cumulative dose has been reached [190].

2.3.2.2.4 Topoisomerase inhibitors

Topoisomerases are responsible for cleavage and resealing of the DNA strands during the replication process, and are broadly classified as type I or II according to their ability to cleave one or both strands. Inhibition of both enzymes leads to apoptosis of affected cell [253]. Typical representatives of topo-I and II inhibitors would be alkaloids camptothecin and ellipticine, respectively. Camptothecin is quinoline-based alkaloid with a unique five-ring system and is commercially extracted from the bark of trees belonging to genera *Camptotheca* and *Nothapodytes* (section 2.4.2). In clinical trials, camptothecin showed broad-spectrum anticancer activity, but on the other hand severe toxicity (such as myelosuppression, gastrointestinal disturbances including delayed diarrhoea, asthenia, alopecia, and anorexia) and poor solubility. This lead to development of semi-synthetic derivatives such as topotecan and irinotecan, which are now available for the treatment of ovarian and colorectal cancers, respectively [254–256]. Ellipticine, a terpenoid indole alkaloid, is isolated from bark of *Ochrosia* spp. (section 2.4.2). Clinical trials with ellipticine and 9-methoxyellipticine showed these two

compounds to be potent inhibitors of several cancerous disorders, but preclinical toxicology indicated a number of side-effects, including haemolysis and cardiovascular effects. Again, these compounds had problems with water solubility. Semi-synthetic analogue elliptinium acetate had demonstrated more promising results and it has been suggested to be used clinically in treatment of breast and renal cell cancers [257,258]. Amsacrine, another topoisomerase II inhibitor, has an acridine-based structure. Clinically, amsacrine has an activity and toxicity profile similar to doxorubicin. It is administered intravenously for the treatment of advanced ovarian carcinomas, myelogenous leukaemia, and lymphomas. Its side effects include myelosuppression and mucositis [259,260].

2.3.2.2.5 DNA cleaving agents

Typical example of DNA cleaving agents is bleomycin. Bleomycin is a mixture of glycopeptide antibiotics isolated from cultures of *Streptomyces verticillus*, and is used in oncological praxis for its anticancer activity. The major components of the mixture are bleomycin A₂ and bleomycin B₂. Exact mode of action of this compound is still not fully revealed. However, it is suggested that bleomycin possess significant intercalation and chelation activity (usually towards iron and oxygen ions), which are necessary for the DNA degradation reaction. Bleomycin is used alone, or in combination with other anticancer drugs, to treat squamous cell carcinomas of various organs, lymphomas, and some solid tumours. It is unusual amongst antitumor antibiotics in producing very little bone-marrow suppression, making it particularly useful in combination therapies with other drugs which do cause this response. However, there is some lung toxicity associated with bleomycin treatment [5,190].

2.3.2.3 Antitubulin agents

Antimitotics act by disruption of the normal mitotic spindle apparatus during mitosis, either through (i) microtubule stabilization or (ii) prevention of microtubule polymerization, resulting in condition where cells fail to complete normal mitosis [261]. Examples of former mode of action would be paclitaxel and jatrophone 1, while of latter combretastatin A-4, colchicine, maytansine, podophyllotoxin and vinca alkaloids. It is interesting to note, that compounds with antimitotic activity are almost exclusively acquired from plants [5,262].

2.3.2.3.1 Taxanes

Paclitaxel (Taxol®) is a highly complex tetracyclic diterpene found in the needles and bark of *Taxus brevifolia* and other related species (section 2.4.2). Pure paclitaxel was isolated in 1966 and its structure published in 1971. However, it did not appear in clinical praxis until

the 1990s [263]. Paclitaxel is used clinically in the management of ovarian and breast cancers, non-small-cell lung cancer, small-cell lung cancer, and cancers of the head and neck. Paclitaxel has disadvantage in its low water solubility, and lack of activity in some cancers with resistance. For this reason, side-chain analogues of paclitaxel with better activity as well as solubility were manufactured [264,265]. One of this compound is docetaxel. This drug displays similar therapeutic and toxicological properties as paclitaxel; it is mainly licensed for initial treatment of advanced breast cancer in combination with doxorubicin or alone when adjuvant cytotoxic chemotherapy has failed [266].

2.3.2.3.2 Vinca alkaloids

Vincristine and vinblastine are constituents isolated from *Catharanthus roseus* (section 2.4.2) and have proved to be extremely valuable drugs in the treatment of Hodgkin's disease and childhood leukaemia, respectively. Isolation and structural identification were reported in the 1960s [267]. Sadly, both compounds needs to be administered intravenously and possess some serious side effects (e.g. neurotoxicity, myelosuppression, hair loss). However new orally active derivatives with broader anticancer activity, together with lower neurotoxic side-effects have been developed [268,269]. Vindesin has been introduced for the treatment of acute lymphoid leukaemia in children [270]. Vinorelbine is a newer semi-synthetic modification obtained from anhydrovinblastine. In this structure, the indole C₂N bridge in the catharanthine-derived unit has been shortened by one carbon. Vinorelbine is used for the treatment of advanced breast cancer, small-cell lung cancer and non-small-cell lung cancer [5,252].

2.3.2.3.3 Other antitubulin agents

Colchicine, obtained from *Colchicum autumnale* have shown to be very potent antimetabolic drug, however due to its severe toxicity is unsuitable for clinical use as chemotherapeutic agent [271]. However, it still used as alternative treatment for gout in patients who are intolerant to commonly administered non-steroidal anti-inflammatory drugs (NSAIDs) [272]. Less-toxic variants of colchicine such as *N*-acetylcolchinol are under active development as potent anticancer drug [5]. Rhizomes of *Podophyllum* species (section 2.4.2) are source of phenolic compound podophyllotoxin with antitumor activity. Due to its adverse side-effects this compound is not used in medicine. However semi-synthetic derivatives (such as etoposide and teniposide) have been developed, which provided more promising results [273,274]. Etoposide is a very effective anticancer agent, and is used in the treatment of small-cell lung cancer, testicular cancer, and lymphomas, usually in combination therapies with other anticancer

drugs. It may be given orally or intravenously [275]. Teniposide has similar anticancer properties and, though not as widely used as etoposide, has value in paediatric neuroblastoma [262]. Another compound of medicinal interest as potential antineoplastic drug is combretastatin A-4, produced by bark of *Combretum* spp. (Section 2.4.2). This compound, which structurally resembles colchicine, is currently showing considerable cytotoxic potential in clinical trials against several types of cancer [261,262]. Attracting considerable interest at the present time are the epothilones, a group of macrolides produced by cultures of the myxobacterium *Sorangium cellulosum* [278]. Epothilones display marked antitumor properties with a mode of action paralleling to that of the highly successful anticancer drug taxol (stabilization of microtubules) [279]. However, the epothilones have a much higher potency (2,000–5,000 times) and are active against cell lines which are resistant to taxol and other drugs [280]. There appears to be considerable potential for developing the epothilones or its analogues into valuable anticancer drugs, and several derivatives are undergoing clinical trials. These include epothilone B (patupilone) and its allyl analogue sagopilone. Lactam derivative ixabepilone has recently been approved for drug use in the treatment of breast cancer [5,190].

2.3.2.4 Cdk inhibitors

With the identification of an increasing number of molecular targets associated with particular cancers, high throughput screening of compounds against a range of such targets now forms the basis of anti-cancer drug discovery. Examples are the cyclin-dependent kinases (Cdks), which, together with their cyclin partners, play a key role in the regulation of cell cycle progression, and inhibition of their activity delays or arrests progression at specific stages of the cell cycle. There are over 2,000 kinases so far identified from genomic studies [281]. Anticancer agents with this mode of action are called Cdk inhibitors. Few plant-based compounds (and their analogues) with this activity have been suggested suitable candidates for preclinical development as anticancer agents. Flavopiridol, compound synthesized from flavonoid rohitukine, have demonstrated effect against a series of breast and lung carcinoma cell lines [282]. Another synthetic molecule based on natural model is roscovitine, derived from purine alkaloid olomucine, exhibited anticancer activity towards non-small cell lung cancer and various types of leukaemia [283]. β -lapachone was found out to possess significant activity against a range of tumour cell lines, including breast, leukaemia, prostate, together with several multidrug-resistant lines [284]. Indirubins are chief constituents presented in various herbal preparation used in traditional Chinese medicine and have shown to be effective to-

wards chronic myelogenous leukaemia [281]. Despite their significant activity, none of these compounds are used in oncological praxis yet [262].

2.4 Plants as a sources of potential therapeutic agents

Plants have a long history of use in the treatment of many human diseases [285]. Botanicals are considered as valuable source of wide variety of secondary metabolites which have been found to possess many biological activities affecting human health. Verpoorte [286] have earlier estimated that from approximately 250,000 – 500,000 known higher plant species, only 6% were tested for at least one biological activity and just 15% has been studied phytochemically. As contrast, it is expected that 25 to 50% of commonly used pharmaceutical preparations are derived from plants [287]. Hence, there is still considerable interest in identification and characterization of plant-derived components which would serve as leads for discovery of novel compounds with pharmacologically-important activity. This is also true for compounds with antioxidant and anti-proliferative effect. Especially when we take into consideration the ever-increasing endeavour in improvement of human health and nutrition, aggravated incidence of oxidative stress-related diseases amongst human population and resistance of cancer cells to commonly used chemotherapeutics [14,288]. This section summarizes chemistry and botanical sources of currently used antioxidants and anti-proliferative constituents as well as discovery of novel plant-based compounds and their possible use in medicinal practice.

2.4.1 Compounds with antioxidant activity

Despite the fact that various types of secondary metabolites such as alkaloids (caffeine [289]), diterpenoids (ginkgolides [290]), steroids (glycyrrhizic acid), carotenoids (canthaxanthin [291]), and others contributes to overall antioxidant potential of plants, the phenolic compounds are considered as the main class of low-molecular chemicals responsible for this biological activity [292–296].

Phenolics are generally defined as any organic compound whose basic skeleton is consisted of one or more aromatic ring (simple phenols or polyphenols, respectively) which is substituted by at least one hydroxy group. Presented hydroxy groups may occurs either in free form (these phenolics are sometimes referred to as aglycons) or are engaged in another function: ether, ester or glycosides [297–299]. Phenolic compounds are almost exclusively produced by plants, fungi and microorganisms. Animals are unable to synthesize these constituents [300]. There are few exception however – i.e. terpenoid quinones (such as ubiquinones or plastoquinones) [5]. All other phenolic compounds found in animal tissue probably originate

from dietary intake [300]. Although above-mentioned definition of phenolic compounds could be applied for wide range of plant-based secondary metabolites, these compounds are additionally more strictly characterized by their specific biosynthetic pathway. Two main pathways of synthesis of phenolic compounds are widely accepted:

1. Shikimate pathway (also known as phenylpropanoids pathway). Aromatic amino acids, such as L-tyrosine and L-phenylalanine, are important products/intermediates of this synthesis pathway [301–303].
2. Polyketide pathway, based on sequential building of the phenolic ring from two carbon units originating in decarboxylation of malonyl-coenzyme A [304–307].

Moreover, some phenolic compounds are pure products of above-mentioned pathways (e.g. coumarins and lignans) while others are of mixed origin (e.g. flavonoids). Despite the fact that phenolic compounds may be categorised according to various schemes (such as number of carbon atoms in skeleton or type of basic skeleton) [308,309], following classification based on biosynthesis pathway is nowadays widely accepted [5]:

1. derivatives of cinnamic acid (e.g. coumaric acid, caffeic acid, ferulic acid, chlorogenic acid, sinapic acid)
2. derivatives of benzoic acid (e.g. salicylic acid, vanillic acid, vanillin)
3. phenylpropenes (e.g. anethole, cinnamaldehyde, cinnamyl acetate, estragole, eugenol, myristicin, elemicin)
4. lignans and lignins (e.g. pinoresinol, podophyllotoxin)
5. coumarins (aesculin, scopoletin, umbeliferone, coumarin)
6. styrylpyrones and diarylheptanoids (e.g. yangonin, curcumin)
7. flavonoids and stilbenes (e.g. epigallocatechin gallate, myricetin, naringenin, quercetin, resveratrol)
8. flavonolignans (e.g. taxifolin, silybin)
9. isoflavonoids (e.g. daidzein, genistein, formononetin, biochanin A)
10. terpenoid quinones (e.g. α -tocopherol)




Figure 1 Phenolic acids




Figure 2 Examples of stilbenoid and coumarin structures




Figure 3 Examples of free and glycosylated flavonoids

Several authors agree that phenolic compounds are distributed virtually in all vascular plants (both dicotyledons and monocotyledons). It is estimated, phenolic compounds encompasses more than 10,000 chemical structures, with hundreds of new constituents being discovered every year [310,297]. Generally, phenolics are found in dietary plants, such as fruits, vegetables, legumes, nuts, oilseeds, and cereals [311]. However more recent studies are showing that certain medicinal plants may also be regarded as valuable source of these chemical structures [312,2]. Additionally, distribution of phenolic compounds is not plant-part specific; phenolics are found in leaves, flowers, seeds, stems, roots, and other botanical parts. Some typical examples of phenolic compounds and their distribution in both edible and medicinal plants is given in Table 3.

Table 3 Distribution of phenolic compounds in plant kingdom

Compound	Sources	
	Dietary plants	Medicinal Plants
Benzoic acid derivatives		
anisic acid	<i>Fagopyrum esculentum</i> (Polygonaceae) [313]	<i>Pimpinella anisum</i> (Apiaceae) [314]
gallic acid	<i>Ribes nigrum</i> (Grossulariaceae) [315]	<i>Salvia officinalis</i> (Lamiaceae) [316]
salicylic acid	<i>Vaccinium oxycoccos</i> (Ericaceae) [317]	<i>Salix</i> species (Salicaceae) [318]
syringic acid	<i>Euterpe oleracea</i> (Arecaceae) [319]	<i>Rosmarinus officinalis</i> (Lamiaceae) [320]
vanillic acid	<i>Vanilla planiflora</i> (Orchideaceae) [5]	<i>Aristolochia</i> species (Aristolochiaceae) [321]
Cinnamic acid derivatives		
caffeic acid	<i>Spinacia oleracea</i> (Chenopodiaceae) [311]	<i>Echinacea purpurea</i> (Compositae) [322]
ferulic acid	<i>Beta vulgaris</i> (Amaranthaceae) [323]	<i>Allium sativum</i> (Amaryllidaceae) [324]
chlorogenic acid	<i>Ipomoea batatas</i> (Convolvulaceae) [325]	<i>Coffea arabica</i> (Rubiaceae) [311]
<i>p</i> -coumaric acid	<i>Solanum lycopersicum</i> (Solanaceae) [311]	<i>Cuminum cyminum</i> (Apiaceae) [326]
sinapic acid	<i>Myristica fragrans</i> (Myristicaceae) [327]	<i>Borago officinalis</i> (Boraginaceae) [328]
Stilbenes		
resveratrol	<i>Vitis vinifera</i> (Vitaceae) [5]	<i>Polygonum cuspidatum</i> (Polygonaceae) [5]
pterostilbene	<i>Vaccinium myrtillus</i> (Ericaceae) [329]	<i>Pterocarpus marsupium</i> (Leguminosae) [330]

Table 3 (continued)

Compound	Sources	
	Dietary plants	Medicinal plants
Flavanols		
epicatechin	<i>Theobroma cacao</i> (Malvaceae) [331]	<i>Hypericum perforatum</i> (Hypericaceae) [332]
Flavanones		
hesperetin	<i>Citrus aurantium</i> (Rutaceae) [333]	<i>Cyclopia genistoides</i> (Leguminosae) [334]
liquiritigenin	<i>Cicer arietinum</i> (Leguminosae) [335]	<i>Glycyrrhiza glabra</i> (Leguminosae) [336]
naringenin	<i>Citrus paradisi</i> (Rutaceae) [337]	<i>Satureja hortensis</i> (Lamiaceae) [338]
Flavonols		
kaempferol	<i>A Armoracia rusticana</i> (Brassicaceae) [339]	<i>Syzygium aromaticum</i> (Myrtaceae) [340]
morin	<i>Psidium guajava</i> (Myrtaceae) [341]	<i>Morus alba</i> (Moraceae) [342]
quercetin	<i>Olea europaea</i> (Oleaceae) [343]	<i>Ginkgo biloba</i> (Ginkgoaceae) [344]
myricetin	<i>Vitis vinifera</i> (Vitaceae) [345]	<i>Myrica rubra</i> (Myricaceae) [346]
Flavones		
apigenin	<i>Apium graveolens</i> (Apiaceae) [347]	<i>Achillea millefolium</i> (Compositae) [348]
luteolin	<i>Capsicum annuum</i> (Solanaceae) [349]	<i>Matricaria chamomilla</i> (Compositae) [350]
Condensed tannins		
epigallocatechin gallate	<i>Camellia sinensis</i> (Theaceae) [351]	<i>Cinnamomum verum</i> (Lauraceae) [352]

2.4.2 Compounds with anti-proliferative activity

Anti-proliferative efficacy of plant species is mainly credited to alkaloids, certain phenolic compounds and various terpenoids. Sources of plant-based anticancer agents (or their semisynthetic analogues) which have been suggested for clinical use or are already used in oncological praxis is given in Table 4.

In comparison to antioxidant compounds, plant-based anti-proliferative constituents are more restricted to specific families in plant kingdom. Despite the fact that camptothecin (pyrroloquinoline alkaloid) is chiefly obtained from *Camptotheca acuminata* belonging to Cornaceae family, there are other sources of this alkaloid as well, including Icacinaceae (*Nothapodytes nimmoniana*, *Merilliodendron megacarpum*, *Pyrenacantha klaineana*), Rubiaceae (*Ophiorrhiza pumila*) and Apocynaceae (*Ervatmia heyneana*) families. Other members of Apocynaceae family are important sources of anticancer agents as well. Two extremely valuable terpenoid indole alkaloids with anticancer activity, vincristine and vinblastin, are produced by *Catharanthus roseus*. Bark of *Ochrosia elliptica* and other related *Ochrosia* species are sources of another indole alkaloids ellipticine and its derivative 9-methoxyellipticine. Taxaceae family is also regarded as significant source of plant-based anticancer agents – i.e. diterpenoid paclitaxel along with several key precursors (baccatins), extracted from the leaves and bark of *Taxus brevifolia*, and alkaloid homoharringtonine found in the *Cephalotaxus harringtonii*. Podophyllotoxin and other related lignans (phenolics) are found in the roots of *Podophyllum peltatum* and *P. hexandrum* belonging to Berberidaceae family. Another phenolic compound with significant anticancer activity, combretastatin A-4 is isolated from bark of *Combretum caffrum* (Combretaceae) [252,5].

List of few examples of other plant-based compounds which have evoked interest as potential anticancer agents and are in clinical or pre-clinical development is given below: flavonoid rohitukine (*Dysoxylum gotadhora*, Meliaceae) [282], quinone β -lapachone (*Tabebuia* spp., Bignoniaceae) [284], polyketide maytansine (*Gymnosporia serrata*, Celastraceae) [353], sesquiterpene lactone thapsigargin (*Thapsia garganica*, Apiaceae) [354], diterpenoid bruceanine (*Brucea antidysenterica*, Simaroubaceae) [355], diterpenoic jatrophone esters (*Euphorbia semiperfoliata*, Euphorbiaceae) [356], triterpene betulinic acid (*Betula* spp., Betulaceae) [357], bisindolic alkaloids indirubins (*Indigofera tinctoria*, Fabaceae) [281], tropane alkaloids pervilleines (*Erythroxylum pervillei*, Erythroxylaceae) [358], purine alkaloid olomucine (*Raphanus raphanistrum*, Brassicaceae) [359], protoberberine alkaloids nitidine (*Zanthoxylum* spp., Rutaceae) [360]. This list encompasses only few examples of plant-derived anti-proliferative compounds and serves only as illustrational. Approximately 3,000 plant species

are till present moment reported to be traditionally used in the treatment of cancer and are waiting to be properly screened for active constituents [262]. New plant-based antineoplastic agents based on selective activity against cancer-related molecular targets are discovered from these plants each year. Some of these are regarded as promising candidates for use in clinical praxis.

Table 4 Overview of clinically used plant-based anticancer agents

Compound	Source		
	Mode of anti-proliferative action	Plant	Family
Alkaloids			
camptothecin ^a	topoisomerase I inhibition	<i>Camptotheca acuminata</i>	Cornaceae
ellipticine ^a	topoisomerase II inhibition	<i>Ochrosia elliptica</i>	Apocynaceae
colchicin ^a	antimitotic	<i>Colchicum autumnale</i>	Colchicaceae
homoharringtonine	Cdk inhibitor	<i>Cephalotaxus harringtonii</i>	Taxaceae
vinca alkaloids	antimitotic	<i>Catharanthus roseus</i>	Apocynaceae
Phenolic compounds			
combretastatin A-4	antimitotic	<i>Combretum caffrum</i>	Combretaceae
podophyllotoxin ^a	antimitotic	<i>Podophyllum peltatum</i>	Berberidaceae
Terpenoids			
paclitaxel	antimitotic	<i>Taxus brevifolia</i>	Taxaceae

^a due to severe toxicity is not used in clinical praxis, however semi-synthetic derivatives with lowered adverse-effects were developed or are subjected to development

2.4.3 Compounds with combined antioxidant/anti-proliferative effect

Clinically used antioxidants as well as chemotherapeutics should be designed to provide as little damage to human health. However, the majority of these possess serious adverse and in some cases even life-threatening effects (as noted in previous sections). Additionally, there are more and more indications, that development of cancer might be strongly connected to oxidative stress [1]. For these reason there is nowadays interest in search for compounds which would potentially possess combined antioxidant and anticancer activity, providing pre-

ventive as well as therapeutic benefit in oxidative stress-related diseases, particular cancer [361,362]. More recently, phenolic compounds (mainly flavonoids and their derivatives) have evoked interest as promising compounds with above-mentioned combinatorial biological activity [6].

Antioxidant mechanism of phenolic compounds is relatively well-understood – i.e. mainly scavenging of free radicals or sequestration of metal ions (e.g. section 2.1.) [363]. However, the mechanism underlying anti-proliferative action of phenolic compounds (especially flavonoids) is not completely understood and still remains to be properly clarified. Tangeretin and nobiletin, flavonoids produced by citrus species, are among phenolics regarded as one of the most effective inhibitors of cancer cell growth *in vitro* and *in vivo* [364]. In one study where these flavonoids were tested towards several human breast cancer cell lines, cytostatic activity by induction of cell cycle arrest have been observed [365]. It was suggested that this effect is mediated by ability of tangeretin and nobiletin to influence expression of various cell cycle-controlling proteins and enzymes [366].

Various studies described other mechanism of anti-proliferative activity of phenolic compounds – i.e. through interference with apoptosis by their ability to promote formation of various apoptosis-inducing proteins and enzymes (such as caspase-3). This effect was for example described for apigenin and kaempferol. Moreover, increased levels of antioxidant compounds (e.g. catalase and SOD) were detected in treated cancer cells, suggesting that apigenin and kaempferol-mediated apoptosis might be facilitated by pro-oxidant activity of these flavonoids (generation of reactive species) [367,368]. Some compounds, such as quercetin, were even reported to possess both mechanisms of above-mentioned anti-proliferative activity (through cell-cycle arrest and induction of apoptosis), e.g. quercetin [369]. Antitumor activity of various phenolic compounds was also evidenced in clinical trials [370]. As contrast to antimitotics and topoisomerase inhibitors (section 2.3.2), above-mentioned compounds were claimed to be ineffective towards non-cancer cells, representing less-toxic alternative to commonly used chemotherapeutics. With regard to given information, it seems that anti-proliferative potential is not mediated via antioxidant-related manner. Though various studies declare partial contribution [371,372].

In view of above-mentioned information, it seems that phenolic compounds are nowadays regarded as important class of chemicals that would potentially serve as leads for discovery of novel compounds with sole or combined antioxidant and anticancer effect. Further sections will be focused on brief overview of traditional and modern use of edible and medic-

inal plants in connection with prevention and/or therapeutic benefit towards oxidative stress-related diseases. Special emphasis will be placed on reference of phenolic compounds.

2.5 Plant foods with specified health-promoting properties

It is widely believed, that nutrition is closely related to human health and that poor diet may play crucial role in progress of various chronic diseases. In the last few decades, scientific disciplines such as food science and preventive medicine had undergone great progress. This has led to development of foods, which, apart from their nutritional value, contain components and/or artificially added ingredients with specific medical (preventive or therapeutic) or other physiological benefit [373]. Several types of modified food products are given below:

1. Fortified foods and beverages. These were especially developed to lower micronutrients deficiencies within population (e.g. fortification of food with niacin) [374].
2. Medical food. Specifically formulated foods to treat diseases with distinctive nutritional needs (inability to metabolize a common molecule such as lactose or food containing slowly digestible carbohydrates in diabetes patients) [375].
3. Dietary supplements. Chiefly characterized as liquid or encapsulated product containing food derived ingredients (often used as complex mixtures such as herbs and other botanicals however may occur as sole components, including enzymes, vitamins, minerals etc.) [376].
4. Foods containing food additives. Constituents added to food products with aim to reduce natural decomposition. Few of these have also been suggested as agents with therapeutic benefit in various diseases [377]. However, this option is nowadays acknowledged only at theoretical/experimental level.

Definition of functional food and other modified food products are occasionally not clearly stated, which is also apparent from fact that above-mentioned terms are overlapped in some cases. As functional food is also considered as food product in which functional component have been lost due to processing and was afterwards artificially added back [378].

Despite the existence of relatively diverse types of functional foods, special emphasis was also placed to development of modified foods which could be helpful in prevention and treatment of diseases related to oxidative stress. Examples of these would be fruits, vegetables and other plant products which possess natural antioxidant potential and/or are subsequently

enriched with antioxidant molecules (plant-based compounds or their derivatives) [379]. These include primarily enriched foods with antioxidants or foods designed to treat other diseases (such as certain types of malnutrition) which later on demonstrated mechanism via antioxidant effect [380]. It is accepted that anticancer properties of plant foods is only restricted to preventive (not therapeutic) potential [381]. Few foodstuffs that are suggested to be helpful in oxidative stress-related diseases are listed below.

It has been previously revealed that tomatoes (*Solanum lycopersicum*) and watermelons (*Citrullus lanatus* var. *lanatus*) are relatively rich on triterpenoid lycopene. Consumption of these two plant species have been found to be associated with lowered risk of prostate cancer both *in vitro* and *in vivo* [382,383]. Broccoli (*B. oleracea* var. *italica*) had demonstrated relatively high levels of lutein [384] (another compound belonging to chemical class of triterpenoids) and there are reports of regular intake of this vegetable to decrease cognitive impairment in Alzheimer disease's patients [385]. Generally, various species of citrus (*Citrus* spp.) are regarded as rich source of flavonoids, namely naringin and quercetin. One study shows that administration of citrus fruits to patients suffering from lung cancer brought clinical benefit [386]. It was numerously proved that various anthocyanins (such as cyanidin, peonidin) are responsible for colouration of cranberries (*Vaccinium macrocarpon*) [387]. Cranberries and its products (e.g. jams, juices) were found to significantly reduce proinflammatory cytokines and alleviated oxidative stress-dependent mitochondrial dysfunction in human model [388]. Various foodstuffs containing isoflavonoids, such as soybean (*Glycine max*), were observed to reduce levels of LDL and total cholesterol in randomized controlled trials [389]. Soy extracts are sold as dietary supplement in some countries [390]. Stilbene resveratrol, which is mainly found in grapevine (*V. vinifera*) is also nowadays available as dietary supplement [5]. In pre-clinical findings it was discovered that resveratrol possess protective effect against various types of cancer and in cardiovascular disease [391]. Several plant-derived compounds, such as isoquercitrin (flavonoid found in *Mangifera indica* and *Rheum nobile*) [392] or bixin (apocarotenoid from *Bixa orellana*) [393], are added to certain foodstuff as colouring agent. Former compound was effective in experimental treatment of liver cancer [394], while latter demonstrated positive results in animal model of diabetes [395]. Hence, various food additives, apart from their preservative function, also might exhibit health beneficiary properties. Phytosterol-enriched foods and dietary supplements have been marketed for decades (e.g. sitosterol, stigmasterol, ergosterol) and vegetables are considered as rich source of these compounds. These include *Solanum surattense*, specific species of potatoes containing high levels of β -sitosterol, which demonstrated significant antidiabetic effect

in animal model [396]. Additionally, phytosterols are also regarded as cholesterol lowering agents [397], however their beneficial impact in cardiovascular problems was never proved [398]. Food products with artificially added folic acid (e.g. grains or flour) were developed primarily to be consumed by pregnant woman, in order to reduce neural tube defects in newborns [399]. However, clinical benefit of folic acid-fortified food was also evidenced in other conditions such as prevention of age-related macular degeneration, especially in patients with increased risk of cardiovascular disease [400]. Other groups of chemicals, such as thiols, isothiocyanates, fatty acids, polyols of various vitamins or phenolic compounds are regarded as functional constituents as well.

2.6 Traditional uses of plants

Plant products have always played an important role in human live. At present, there is considerable interest in detailed identification and characterization of antioxidant and anti-proliferative potential of plant-based natural products and their possible use in various branches of industry (including the use as foods and pharmaceuticals). For this reason, many ethnobotanists gather information on plant material in which traditional use could be explained by antioxidant and anti-proliferative mechanism [401,402]. Various ethnomedicinal indications for antioxidant and/or anti-proliferative activity are generally accepted, which serves as selection criteria for plant material collection. For antioxidant activity reference is made to conditions such as arthritis, diabetes, cardiovascular, inflammatory and neurodegenerative disorders, rheumatism, snakebite and wound-healing properties [1,403]. In case of anticancer effect, following examples of descriptions are taken into consideration: abscesses, calluses, cancer, corns, hard swellings, polyps, stomach-ache, tumours, and warts [285,262]. It should be noted that many of the traditional claims for efficacy should be viewed with some scepticism because anticancer and (especially) antioxidant activity, is likely to be poorly defined in terms of folklore and traditional medicine. Few cases of traditional use of plants in conditions or diseases likely to be related to oxidative stress are listed below.

Curcuma longa, plant traditionally used in Indian continent as mean for food colorant and as natural remedy (by Ayurvedic medicine) in treatment of various illnesses, including those of the skin, pulmonary, and gastrointestinal systems, aches, pains, sprains, tumours, wounds and liver disorders [404]. These activities were credited to phenolic compound curcumin. Lower incidence of neurodegenerative diseases in Indian continent is explained by long tradition of consumption of foods containing *C. longa* (such as curry spice) by local population. Indeed, curcumin was found to prevent and delay brain pathology in Alzheimer's

disease [405]. Consistent with claims to be traditionally used in treatment of tumours, curcumin have demonstrated anticancer activity in animal models [406]. Extract of the leaves of *Ginkgo biloba* has been used to improve memory for thousands of years. This tree was found to produce ginkgolides, which exhibits antioxidant and neuroprotective activities [407]. Since this discovery, many other plants traditionally used to treat brain disorders (such as Alzheimer's and other neurodegenerative diseases) have been described [408]. Ginger (*Zingiber officinale*) was considered by indigenous Asian and Arabic cultures as important component of diet, however was used as medicinal plant, especially in treatment of arthritis [409]. Beneficial effect of ginger extract in this disease was later on affirmed by clinical studies [410]. Kampo medicines are traditionally practiced in Japan, above all also used in treatment of certain types of cancer [411,412]. Extracts used in Kampo are composed of multiple herbs and it was found out to contain a complex mixture of phenolic compounds, but also glycyrrhizic acid, the chief sweet-tasting constituent of *Glycyrrhiza glabra* root [413]. This compound has evoked interest as possible anticancer drug [414]. Extracts of propolis, plant-originated resinous substance used by bees in hive construction, have often been used in herbal medicine in treatment of different disorders, including cancer [415]. Propolis contains high levels of phenolic and other plant-derived compounds (such as caffeic acid phenethyl ether), which are believed to be responsible for its health beneficiary properties [416]. Roots of *Polygonum cuspidatum*, used extensively in traditional Chinese medicine to treat cancer [321], are rich in stilbene resveratrol [5]. Various fruit-producing plants, including *Euterpe oleracea*, were reported to be traditionally used by indigenous cultures in South America to treat diabetes, but also cancer and cardiovascular problems. These therapeutic effect have been attributed to phenolic compounds and vitamin C [417]. In Madagascar, *Catharanthus roseus* was primarily used in management of diabetes [418]. Apart from antimetabolic alkaloids (see section 2.4.2), this plant was demonstrated to be rich in phenolic compounds, namely derivatives of 2,3-dihydroxybenzoate and phenylpropanoids [419], which are believed to be responsible for observed antidiabetic effect.

Even though plant-based natural products with high levels of phenolic compounds are generally considered as safe and to possess health-promoting properties, few have been reported to possess adverse toxicological effects. This include nordihydroguaiaretic acid isolated from *Larrea divaricata* [420], extract of *Cratogeomys cochinchinense* [421] and also various flavonoids (e.g. hesperitin) [422].

2.7 Underutilized crops and wild plants

Despite the fact that there are many records throughout ethnobotanical studies aimed on traditional usage of plants in treatment of various illnesses connected to oxidative stress, relatively large proportion of these stays scientifically undiscovered (especially true for plant material originated in third world countries). Antioxidant and anti-proliferative assays were primarily examined in relatively well-known plant material (e.g. spices; as noted above). However, there is nowadays increased interest in characterization of above-mentioned biological activities together with analysis of related secondary metabolites in plant-material generally recognized as underutilized or wild. Underutilized crops are described as plant species with strong linkage to cultural heritage of their places of origin and which have been traditionally used for various purposes (drink, food, medicinal etc.); however their importance and public awareness over time have been reduced due to biological and/or socioeconomic reasons [423]. Special emphasis is nowadays placed on examining following categories of underutilized crops and wild plants: (i) food-derived beverages, (ii) edible plants and (iii) medicinal plants [424,425]. Brief summary of these categories and their examples is given below.

2.7.1 Wine from Georgia

Grapevine and its products are considered to be one of the richest natural sources of antioxidant compounds such as phenolic acids, stilbenes, flavonoids, and anthocyanidins [426]. Accordingly, the moderate wine consumption is nowadays recognized as risk-reducing factor in several human diseases related to oxidative-stress such as cancer, type 2 diabetes, inflammation and especially myocardial infarction [427–430]. Paradoxical epidemiological phenomena, also known as “French paradox”, was observed among French population, who had relatively low incidence of coronary heart disease, while consuming diet rich on saturated fats (such as cheese). It was suggested that adverse side-effects of inappropriate food intake is compensated by consumption of relatively large amounts of wine [431,432]. It is widely believed, that these health-promoting properties of wine are ascribed to antioxidant potential of above-mentioned compounds. Composition of health-beneficiary chemicals (e.g. phenolics) presented in wine varies markedly depending mainly on the grape cultivar. However other factors, such as soil, nutrition, climatic conditions, weather, winemaking procedure, conditions of maturation and storage, are also considered to be important [433–435]. Approximately 1,400 cultivars are registered and used for commercial production of wine [436]. Large proportion of these (mainly the lesser known cultivars) remains undiscovered by means of

detailed phytochemical composition, biological activities and herewith connected health-promoting properties.

Wine grapes are chiefly grown between the 30th and the 50th degree of latitude, in both the Northern and Southern hemispheres. France, Italy, Spain, USA, Argentina, China, Australia, Chile, South Africa and Germany are considered as top 10 wine producing countries in the world. Georgia is listed on position 22 among top 40 wine producing countries [437]. Yet, Georgia, which is considered to be cradle of the world's winemaking [438], is one of the countries where many underutilized (or less known) local grapevine varieties are cultivated. It is believed that viticulture and winemaking first began in the South Caucasus region around 6,000 years ago, and this fact is supported by several archaeological findings [439]. At present, the Georgian vine gene pool contains up to 525 underutilized white and red varieties (e.g. Aladasturi, Budeshuri Titseli, Chinuri, Dzvelshavi Obchuri, Goruli Mtsvane, Mtsvane Kakhuri, Ojaleshi, Shavkapito, Tavkveri, Usakhelouri) [10]. Moreover, some of the Georgian wines are reported to be prepared by so called Kakhetian method. This winemaking technique, which is believed to be elaborated in Kakhetian region, is characterized by long period (up to 5 month) of maceration and fermentation of must with usage of 100% of grape pomace (mixture of skin, seeds, stems) in clay vessel called "kvevri" buried under ground. Despite the above-mentioned information, to the best of my knowledge, only scarce data about phytochemical profile and antioxidant activity of Georgian wines, especially prepared by Kakhetian methods, is available [440]. Accessible studies done on traditional grape cultivars originated in Georgia are given below.

Chkhikvishvili et al. [441] compared antioxidant activity and the content of *trans*- and *cis*-resveratrol in Georgian (from cultivars Saperavi, Kakhuri Tsarchinebuli), European, and South and North American red wines. A comparison among several red and white wines produced by Kakhetian and commonly used "European method" in total content of phenolics, catechins, proanthocyanidins, anthocyanins and antioxidant activity was published by Shalashvili et al. [442]. Recently, another study done by Shalashvili et al. [12] was aimed at investigation of the content of some flavonoids, phenolic acids and resveratrol in Georgian wines prepared from local cultivars Saperavi (red) and Rkatsiteli (white). The content of catechins, hydroxycinnamic acids, volatile compounds and their glycosides in wines prepared by Kakhetian and European wine making processes (juice fermented without stems for 7–30 days; white wines fermented without the presence of pomace) has been compared by two studies of Mikiashvili et al. [443,444]. The content of total catechins, proanthocyanidins, flavanols, and some phenolic acids in wines produced from white cultivars Kakhuri Mtsvivani,

Rkatsiteli, Kakhuri Mtsvane, and Khikhvi prepared by Kakhetian and European wine making method was investigated by Glonti [445]. Glonti and Glonti [446] also published extensive study where total phenolics, sulphur, various volatile compounds, amino acids, and minerals were quantified in wines fermented in kvevri and by standard process.

2.7.2 Edible and medicinal plants from Peruvian Amazon

As indicated above, common dietary plants (such as fruits, vegetables, nuts) are recognized as main source of antioxidant compounds, and indeed, antioxidant potential is primarily examined in these categories of plant material [3]. However, recent studies indicate that other categories of plants (e.g. medicinal plants) possess this biological activity as well [312,2]. On the other hand, medicinal plants are considered as valuable source of pharmacologically active substituents, among other those that exert antineoplastic activity. Previously it was proposed that progression and secondary complications of cancer is strongly related to oxidative stress. Anticancer activity of medicinal plants is chiefly credited to alkaloids, diterpenoids but also various phenolic compounds (section 2.4.2) [262]. Despite the beneficial effect in cancer treatment, majority of these compounds also provide damage to normal cells. More recent studies are showing that dietary phenolics (e.g. flavonoids) may exert anti-proliferative effect as well [6], and also less side-effects in comparison to commonly used plant-based chemotherapeutics. Even though medicinal plants are regarded as the main sources of antineoplastic agents, there is now an increased interest in research of edible plants' anti-proliferative effect [7]. For reasons given-above, newly introduced edible and medicinal plants are nowadays routinely supplemented by validation of antioxidant effect as well as analysis of anti-proliferative activity against various types of carcinoma cell lines [4].

Even though wild plants used for dietary and medicinal purposes are generally considered as very important factor for maintaining food and health security (mainly in third world countries), till present-day health-promoting properties of majority of these plants have not been properly verified via modern scientific methods [447]. Moreover, with current trends in destruction and ever-increasing loss of natural habitats by human activities (such as agriculture practices, logging), there is serious risk of plant diversity being irreversibly lost with interconnected valuable scientific information. One of the world's regions where the above-mentioned phenomena occur quite intensively is, among others, Peruvian Amazon [448]. In the same time, this area is considered as genetic centre for huge array of plant species and as a biodiversity hotspot. Since many unexplored areas in Amazon still exists, it is nearly impossible to determine exact plant diversity of this region. However, it is estimated by various au-

thors that Amazon Basin shelters more than 50,000 species of higher plants [449]. Among commercially and pharmaceutically interesting plants with edible and medicinal purpose, Amazon basin encompasses species such as brazil nut (*Bertholletia excels*), cassava (*Manihot esculenta*), cocoa (*Theobroma cacao*), crown cinchona (*Cinchona officinalis*), ipecac (*Carapichea ipecacuanha*), maize (*Zea mays*), pineapple (*Ananas comosus*), and papaya (*Carica papaya*) to name a few [450]. Despite the fact that traditional use of edible and medicinal plants from Peruvian Amazon in treatment of diseases related to oxidative stress (such as cancer, diabetes, chronic inflammatory, cardiovascular and neurodegenerative diseases) is relatively well documented, as far as I know, in only a very small proportion of these plants antioxidant and anti-proliferative profiles were assessed [451].

Brief summary of ethnomedicinal data as well as research done on these species with relevance to antioxidant and anti-proliferative activity is given below. *Annona montana* is an edible fruit and medicinal plant traditionally used mainly in treatment of cancer [451]. There are numerous records on anti-proliferative efficacy of various Annonaceous species (such as *A. montana*, *A. squamosa* or *A. reticulata*), and sometimes are referred to as cancer-killers [452]. Acetogenins are believed to be chiefly responsible for anti-proliferative effect of *Annona* species [453]. However, up till now the cytotoxicity and the respective compounds for this biological activity were never described for *A. montana*. *Inga edulis* is widely grown by indigenous Amazonian inhabitants for various purposes, including as dietary and medicinal plant. Records in literature indicates that *I. edulis* has been especially used in treatment of rheumatoid arthritis [454]. Pompeu et al. [455] have earlier assessed anti-proliferative effect of *Inga edulis* towards various carcinoma cell lines including multidrug resistant variants. Only moderate to weak activity was observed though. Souza et al. [456] detected gallic acid, catechin, epicatechin and derivatives of myricetin and quercetin in leaves of in *I. edulis*. *Oenocarpus bataua* is considered locally as highly nutritious fruit, and is widely consumed throughout the Amazon basin [457]. Moreover it has been widely used by Amazonian healers in treatment of cancer [458]. Rezaire et al. [459] have assayed *O. bataua* for antioxidant activity and analysed 11 phenolic compounds (derivatives of chlorogenic acid, syringic acid, resveratrol and various anthocyanidins) in fruit. Records on anti-proliferative activity of this palm species are unavailable.

2.7.3 Wild medicinal plants from Ethiopia

Similarly as in Peruvian Amazon, at this moment majority of plant species originated in Ethiopia have not been subjected to modern scientific evaluation of their proposed biologi-

cal activities. In the same time, local flora is in danger of being irretrievably lost by present-day tendencies in natural habitat devastation, mainly achieved by above-mentioned human activities [9,460]. Moreover, Ethiopia is also recognized as genetic centre for wide range of plant species. It is predictable, that Ethiopian flora covers approximately up to 8,000 vascular plant species [461]. Medicinal plants with commercial and pharmaceutical interest originated in Ethiopia are for example Abyssinian hard wheat (*Triticum aethiopicum*), castor (*Ricinus communis*), coffee (*Coffea arabica*), grain sorghum (*Sorghum bicolor*), cowpea (*Vigna unguiculata*), niger seed (*Guizotia abyssinica*), okra (*Abelmoschus esculentus*), sesame (*Sesamum indicum*) [462]. Indeed, as in case of plants originated in Peruvian Amazon, many of these plants from Ethiopia were comprehensively documented to be traditionally used in treatment of various conditions (these are mentioned above) likely to be mediated by oxidative stress. Yet, to my very best knowledge, only a very small percentage of these species were assayed for their antioxidant and anti-proliferative properties [463].

Although research with regard to antioxidant and anti-proliferative activity of Ethiopian medicinal plants (including *Dodonaea angustifolia*, *Rumex nepalensis* and *Verbascum sinaiticum*) is very limited (in some cases unavailable), there are at least some records on phytochemical analyses. Brief summary of ethnomedicinal information together with available phytochemical data of these species is given below. *D. angustifolia* was previously reported to be traditionally used as medicine in treatment of lymphatic swelling [464]. Omosa et al. [465] investigated leaf extract of *D. angustifolia* for presence of secondary compounds and discovered various chemicals belonging to neo-clerodane diterpenoids. Some members of this chemical class have previously demonstrated antioxidant and anti-proliferative effect [466–468]. Traditional medicinal knowledge describes *R. nepalensis* to be used in treatment of rheumatism [469] and stomach-ache [470]. Various derivatives of anthraquinones were previously isolated and analysed from *R. nepalensis* [471]. These have subsequently demonstrated antioxidant and anti-proliferative effect [472,473]. *V. sinaiticum* has relatively long tradition in treatment of cancer [474]. This plant have also been reported to be used by African medicine-men in treatment of various conditions referred to as stomach-ache [475]. *V. sinaiticum* was previously described to possess significant anti-proliferative activity against towards various carcinoma cells (Hep-2, MCF-7, and Vero lines) [476] and moderate antioxidant activity in DPPH assay [477]. Furthermore, various compounds such as two flavonolignans hydrocarpin and sinaiticin, and two flavones chrysoeriol and luteolin were identified in *V. sinaiticum*. All constituents exhibited dose-dependent cytotoxicity when tested against P-388 (lymphoma) cells [478].

3 Hypothesis

Since human population is nowadays facing to an increased incidence of oxidative-stress related diseases with additional rapid spread of resistance of cancer cells towards commonly used chemotherapeutics, there is an urgent need of new effective agents. One option to overcome above-mentioned phenomena is seen in use of novel plant-derived preparations (including food products) or sole compounds with combinatorial antioxidant/anti-proliferative efficacy, which would serve either as prevention or as active therapeutics. Selection of plant material (underutilized Georgian wine cultivars, extracts of edible and medicinal plants from Peruvian Amazon and extracts of Ethiopian medicinal plants) tested in this study was based on their previous report on traditional usage for treatment of diseases likely to be associated with oxidative stress. Even though, some of these plants have been indicted to possess significant antioxidant and/or anti-proliferative potential, to our best knowledge, (i) many of these were not tested with ORAC assay (which is considered as the most biologically relevant method to measure *in vitro* antioxidant activity), (ii) assayed towards specific combination of carcinoma/normal cell lines and (iii) detailed phytochemical profile was not established. Therefore, there is a high probability that systematic screening of these plants can lead to discovery of extracts and novel compounds with potent antioxidant/anticancer activity.

4 Objectives

Objective of this study was to investigate antioxidant and anti-proliferative effects and chemical composition of wines, food and medicinal plants from Georgia, Ethiopia and Peru.

The specific aims of this study were:

1. To determine *in vitro* antioxidant activity with use of specific combination of assays based on measurement of different antioxidant mechanisms, in order to ensure the maximal biological relevancy of gained results.
2. To assess *in vitro* anti-proliferative effect where special emphasis was payed to detect selective cytotoxic activity towards carcinoma and normal cell lines.
3. To identify relationship between tested biological activity and chemical composition with use of analytical techniques and statistical methods.

5 Materials and methods

5.1 Plant material

Based on previously reported data on traditional use for treatment of diseases likely to be associated with oxidative stress, following plant material was selected for further testing: (i) 39 wine samples of underutilized Georgian grapevine cultivars, (ii) 23 samples of edible and medicinal plants from Peruvian Amazon and (iii) extracts of 22 samples of Ethiopian medicinal plants. Detailed description of selection, collection/purchasing and other essential information (e.g. ethnomedicinal data, voucher specimen numbers) of each category of collected plant material is properly given in **I**, **II** and **III**. Map of the study area is given in Figure 4.




Figure 4 Collection sites of tested plant material (adopted from [479])

5.2 Sample preparation

Bottled samples of wines were tested unprocessed. Ethiopian medicinal plants and edible and medicinal plants from Peruvian amazon were dried and extracted. Exact process of preparation is described in **II** and **III**, respectively.

5.3 Reagents, solvents and standards

Complete list of reagents, solvents, standards and other chemicals used in this study is given in **I**, **II** and **III**.

5.4 Cell culture

Human liver carcinoma cell line (Hep-G2), human colon carcinoma cell line (HT-29) and normal cell line (MRC-5) were used in this study for assessment of cell viability assay. Proper description of maintenance of cell cultures is described in **II** and **III**.

5.5 Antioxidant activity

DPPH (2,2-diphenyl-1-picrylhydrazyl) radical-scavenging [480], oxygen radical absorbance capacity (ORAC) [481] and total phenolic content (TPC) [482] assays have been used for determination of antioxidant properties of samples tested. Specific conditions of each assay are properly described in **I**, **II** and **III**.

5.6 Total sulphite content assay

In order to evaluate influence of sulphites added to wine on samples' antioxidant efficacy (via free radical scavenging ability), wines were submitted to analysis of total sulphite content. For this purpose, commercially available kit Enzytec™ Colour SO₂-Total kit (R-BiopharmAG, Darmstadt, Germany) was used. Detailed description is given in **I**.

5.7 Cell viability assay

Determination of anti-proliferative effect of samples were performed using modified MTT (tetrazolium bromide) cell proliferation assay [483]. Method is properly stated in **II** and **III**.

5.8 High performance liquid chromatography

For better understanding of relationship between tested biological activity and chemical composition, analytical techniques based on high performance liquid chromatography (HPLC) hyphenated to ultraviolet/visible light (UV/Vis) or tandem mass spectrometer (MS/MS) detectors were used. HPLC methods are described in detail in **I** and **III**. Structures of some analysed phenolic compounds tested in this study are given in Figures 1 – 3.

5.9 Statistical analysis

Gained results were analysed using various statistical tests. Detailed description of statistical analyses is given in each original publication (**I**, **II** and **III**).

6 Results and discussion

In this study, the *in vitro* antioxidant and/or anti-proliferative activity and chemical composition of wines, food and medicinal plants from Georgia, Ethiopia and Peru were examined. The results showed that Georgian wines possessed significantly higher antioxidant potential in DPPH ($p = 0.01$), ORAC ($p = 0.05$) and TPC ($p = 0.01$) assays in comparison to Central- and West-European wines. The highest antioxidant effect was recorded in red wines, particularly Saperavi cultivars (range of DPPH, ORAC and TPC values: 8.59 – 2.08 g TE/L wine; 12.14 – 7.29 g TE/L wine and 4.46 – 1.59 g GAE/L wine, respectively), followed by European cultivars (Pinot Noir and Cabernet Sauvignon). Similar results were also observed elsewhere [441]. White wines were significantly less effective in antioxidant assays than the red wines. Only exception was sample RK 4 (cuvée of Rkatsiteli), which was fermented by Kakhetian method. Wine RK 4 exhibited antioxidant efficacy comparable to red wines (DPPH, ORAC and TPC values 2.90 g TE/ L wine; 4.01 g TE/ L wine and 1.88 g GAE/ L wine, respectively). Stronger antioxidant effect of white wines prepared by traditional Kakhetian technology (in comparison to wines prepared by European method) was also recorded by Shalashvili et al. [442]. Results of HPLC-UV/Vis analysis revealed that Georgian wine samples contained significantly higher concentrations of quercetin ($p = 0.01$), kaempferol ($p = 0.05$), and syringic acid ($p = 0.05$), while West and Central European samples were considerably richer in *trans*-resveratrol ($p = 0.01$). The highest quantities of quercetin, kaempferol and syringic acid were recorded in wines prepared from Saperavi cultivar (quercetin = 14.44 – 1.07 $\mu\text{g/mL}$; kaempferol = 1.68 – 0.03 $\mu\text{g/mL}$ and syringic acid 12.59 – 4.72 $\mu\text{g/mL}$), whereas Pinot Noir was the richest sample in resveratrol content, followed by representatives of Cabernet Sauvignon (concentration range 8.71 – 2.43 and 7.41 – 1.13 $\mu\text{g/mL}$, respectively). These results are in accordance with several comparative studies dealing with differences in phenolic composition across wine cultivars, vintage and production area [484–486]. None statistical differences between white wines grouped according to their origin were revealed. In view of these results, it is suggested that that oenological techniques and cultivar have higher impact than climatic factors on the content of phenolic compounds and therefore antioxidant potential red and white of wines, which is in agreement with studies of Goldberg et al. [487,488]. Additionally, results from correlation demonstrated that content of sulphites had negligible impact on the antioxidant capacity (in ORAC and DPPH models) of tested wines which is in the agreement with study of Zúñiga et al. [489].

Combined antioxidant/anti-proliferative effect was observed for extracts of *D. angustifolia*, *R. nepalensis* (Ethiopian medicinal plants), *I. edulis* and *O. bataua* (edible and medicinal plants from the Peruvian Amazon). Values for antioxidant and anti-proliferative activity were recorded as follows: *D. angustifolia* (IC₅₀ for DPPH = 22.2 µg/mL, ORAC = 767.6 µg TE/mg extract, TPC = 531.7 µg GAE/mg extract; IC₅₀ for Hep-G2 = 120.0 µg/mL); *R. nepalensis* (IC₅₀ for DPPH = 5.7 µg/mL, ORAC = 1061.4 µg TE/mg extract, TPC = 1101.5 µg GAE/mg extract; IC₅₀ for Hep-G2 = 50.5 µg/mL); *I. edulis* (DPPH and ORAC = 337.0 and 795.7 µg TE/mg extract, TPC = 262.3 µg GAE/mg extract; IC₅₀ for Hep-G2 and HT-29 = 36.3 and 57.9 µg/mL) and *O. bataua* (DPPH and ORAC = 903.8 and 1024.4 µg TE/mg extract, TPC = 672.3 µg GAE/mg extract; IC₅₀ for Hep-G2 and HT-29 = 102.6 and 38.8 µg/mL). Despite the fact that extracts of *Jasminum abyssinicum* (IC₅₀ for DPPH = 26.3 µg/mL, ORAC = 1023.7 µg TE/mg extract), *Rubus steudneri* (IC₅₀ for DPPH = 5.8 µg/mL, ORAC = 1019.2 µg TE/mg extract), *Mauritia flexuosa* (DPPH and ORAC = 1062.9 and 645.9 µg TE/mg extract), *Myrciaria dubia* (DPPH and ORAC = 641.9 and 642.6 µg TE/mg extract) and *Theobroma grandiflorum* (DPPH and ORAC = 714.8 and 821.9 µg TE/mg extract) have exhibited considerable antioxidant effect, these species were found to possess moderate to low anti-proliferative potential or have shown to be toxic to normal cells line. Antioxidant profiles of *D. angustifolia*, *R. nepalensis*, *I. edulis* and *O. bataua* have previously been reported [490,472,491,459], whereas these results are with correspondence with our study. Except of *I. edulis*, this is the first report on anti-proliferative activity of above-mentioned plant species. Despite the fact that *I. edulis* have earlier demonstrated relatively low cytotoxic efficacy towards various carcinoma cell lines including multidrug resistant variants [455], in our study leaves of *I. edulis* exhibited moderate anti-proliferative activity against Hep-G2 and HT-29 cells. Based on the literature reports on secondary metabolites so far detected in these plant species [472,459,473,465,492–494] together with results in this study from statistical analysis (correlation between TPC and antioxidant and anti-proliferative activity) and results from HPLC-MS/MS analysis, it is suggested that phenolic compounds and their derivatives might completely or partially be responsible for observed combinatory antioxidant/anti-proliferative effect.

Among Ethiopian medicinal plants and edible and medicinal plants from the Peruvian Amazon, *V. sinaiticum* and *A. montana* demonstrated significant anti-proliferative potential. Values for anti-proliferative efficacy were recorded as follows: *V. sinaiticum* (IC₅₀ for Hep-G2 = 80.6 µg/mL) and *A. montana* (IC₅₀ for Hep-G2 and HT-29 = 2.7 and 9.0 µg/mL, respectively). Moreover, these plant extracts also proved to be nontoxic to normal MRC-5 cells

(IC₅₀'s for both samples were detected at levels higher than 500 µg/mL). Anti-proliferative efficacy of *V. sinaiticum* is relatively well established and our results are in accordance with cytotoxic properties of this plant observed in other studies [476]. Despite the existence of records on anti-proliferative efficacy of various Annonaceous species (such as *A. muricata*, *A. squamosa* or *A. reticulata*) [452], up till now the cytotoxicity and the respective compounds for this biological activity were never described for *A. montana*. Even though extracts of *V. sinaiticum* and *A. montana* demonstrated considerable selective cytotoxic effect, their antioxidant potential was recognized as moderate to low. With regard to results observed in this study as well as information from the literature [453,478,495], phenolic compounds are considered to be only partially responsible for anti-proliferative efficacy of these plant species. Results and discussion for Georgian, Central- and West-European wines, Ethiopian medicinal plants and edible and medicinal plants from the Peruvian Amazon are described in detail and summarized in **I**, **II** and **III**, respectively.

7 Conclusion

In summary, the current study proved *in vitro* antioxidant and anti-proliferative activity of various underutilized wines, food and medicinal plants of Georgian, Ethiopian, and Peruvian origin. Especially antioxidant potential of Georgian grapevine varieties Saperavi and Rkatsiteli, combinatory antioxidant/anti-proliferative efficacy of extracts of *Dodonaea angustifolia*, *Rumex nepalensis*, *Inga edulis* and *Oenocarpus bataua*, and selective anti-proliferative effect of *Verbascum sinaiticum* and *Annona montana* extracts deserve deeper research attention. Despite the fact that other plant species demonstrated substantial activity, such as *Jasminum abyssinicum* and *Rubus steudneri* (Ethiopian medicinal plants), *Mauritia flexuosa*, *Myrciaria dubia*, and *Theobroma grandiflorum* (edible and medicinal plants from Peruvian Amazon), some of these have also exerted toxicity to normal cells and/or significant efficacy in only one of the performed assays. Results indicate that phenolic compounds might be fully responsible for observed combinatory antioxidant/anti-proliferative effect, whilst only partially in case of selective anti-proliferative activity. Above-mentioned plant species might potentially serve as prospective material for further development of plant-derived antioxidant and/or anti-proliferative agents. However, further research which would be focused on detailed characterization of their chemical composition, pharmacological effects and toxicological safety is required, in order to verify possible practical use of these plant species.

8 References

- Halliwell B, Gutteridge JM. Free radicals in biology and medicine. 4th ed. Oxford, UK: Oxford University Press; 2007.
- Jaberian H, Piri K, Nazari J. Phytochemical composition and in vitro antimicrobial and antioxidant activities of some medicinal plants. *Food Chem.* 2013;136: 237–244.
- Brewer MS. Natural antioxidants: Sources, compounds, mechanisms of action, and potential applications. *Compr Rev Food Sci Food Saf.* 2011;10: 221–247.
- Loizzo MR, Rashed K, Said A, Bonesi M, Menichini F, Tundis R. Antiproliferative and antioxidant properties of *Alhagi maurorum* Boiss (Leguminosae) aerial parts. *Ind Crops Prod.* 2014;53: 289–295.
- Dewick PM. Medicinal natural products: A biosynthetic approach. 3rd ed. Chichester, UK: Wiley & Sons; 2009.
- De la Rosa LA, Vazquez-Flores AA, Alvarez-Parrilla E, Rodrigo-García J, Medina-Campos ON, Ávila-Nava A, et al. Content of major classes of polyphenolic compounds, antioxidant, antiproliferative, and cell protective activity of pecan crude extracts and their fractions. *J Funct Foods.* 2014;7: 219–228.
- Ruiz-Montañez G, Burgos-Hernández A, Calderón-Santoyo M, López-Saiz CM, Velázquez-Contreras CA, Navarro-Ocaña A, et al. Screening antimutagenic and antiproliferative properties of extracts isolated from Jackfruit pulp (*Artocarpus heterophyllus* Lam). *Food Chem.* 2015;175: 409–416.
- Malhi Y, Roberts JT, Betts RA, Killeen TJ, Li W, Nobre CA. Climate change, deforestation, and the fate of the Amazon. *Science.* 2008;319: 169–172.
- Teklehaymanot T, Giday M. Ethnobotanical study of wild edible plants of Kara and Kwegu semi-pastoralist people in Lower Omo River Valley, Debub Omo Zone, SNNPR, Ethiopia. *J Ethnobiol Ethnomedicine.* 2010;6. Available: <http://www.scopus.com/inward/record.url?eid=2-s2.0-77955542649&partnerID=40&md5=54b30a5797bf7c6b7223eb5ca22335cb>
- Maghradze D, Rustioni L, Scienza A, Turok J, Failla O. Caucasus and northern black sea region ampelography. Special Issue: *Vitis*; 2012.
- Amoo SO, Finnie JF, Van Staden J. Acetylcholinesterase inhibition, antioxidant, antiinflammatory, antimicrobial and phytochemical properties of *huernia hystrix*. *Phytother Res.* 2012;26: 639–645.
- Shalashvili A, Ugrekhelidze D, Mitaishvili T, Targamadze I, Zambakhidze N. Phenolic compounds of wines from georgian autochthonous grapes, rkatsiteli and saperavi, prepared by georgian (kakhétian) technology. *Bull Georgian Natl Acad Sci.* 2012;6: 99–103.
- Neri-Numa IA, Carvalho-Silva LB, Morales JP, Malta LG, Muramoto MT, Ferreira JEM, et al. Evaluation of the antioxidant, antiproliferative and antimutagenic potential of araçá-boi fruit (*Eugenia stipitata* Mc Vaugh - Myrtaceae) of the Brazilian Amazon Forest. *Food Res Int.* 2013;50: 70–76.
- Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. *J Nat Prod.* 2012;75: 311–335.
- Denisov ET, Afanas'ev IB. Oxidation and antioxidants in organic chemistry and biology. London, UK: Taylor & Francis Group; 2005.
- Griller D, Ingold KU. Persistent carbon-centered radicals. *Acc Chem Res.* 1976;9: 13–19.
- Folkes LK, Candeias LP, Wardman P. Kinetics and mechanisms of hypochlorous acid reactions. *Arch Biochem Biophys.* 1995;323: 120–126.
- Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and the ugly. *Am J Physiol - Cell Physiol.* 1996;271: C1424–C1437.
- Pogocki D, Schöneich C. Thiyl radicals abstract hydrogen atoms from carbohydrates: Reactivity and selectivity. *Free Radic Biol Med.* 2001;31: 98–107.
- Giles GI, Jacob C. Reactive sulfur species: An emerging concept in oxidative stress. *Biol Chem.* 2002;383: 375–388.
- Schmut O, Gruber E, El-Shabrawi Y, Faulborn J. Destruction of human tear proteins by ozone. *Free Radic Biol Med.* 1994;17: 165–169.
- Davies MJ. Singlet oxygen-mediated damage to proteins and its consequences. *Biochem Biophys Res Commun.* 2003;305: 761–770.
- Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human disease: An overview. *Methods Enzymol.* 1990;186: 1–85.

24. Quinlan GJ, Coudray C, Hubbard A, Gutteridge JMC. Vanadium and copper in clinical solutions of albumin and their potential to damage protein structure. *J Pharm Sci.* 1992;81: 611–614.
25. Shimon MB, Goldshleger R, Karlsh SJD. Specific Cu²⁺-catalyzed oxidative cleavage of Na,K-ATPase at the extracellular surface. *J Biol Chem.* 1998;273: 34190–34195.
26. Mylonas M, Malandrinos G, Plakatouras J, Hadjiliadis N, Kasprzak KS, Kręzel A, et al. Stray Cu(II) may cause oxidative damage when coordinated to the -TESHHK- sequence derived from the C-terminal tail of histone H2A. *Chem Res Toxicol.* 2001;14: 1177–1183.
27. Imlay JA. Pathways of Oxidative Damage. *Annu Rev Microbiol.* 2003;57: 395–418.
28. Finkel T. Radical medicine: Treating ageing to cure disease. *Nat Rev Mol Cell Biol.* 2005;6: 971–976.
29. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. *Physiol Rev.* 2007;87: 315–424.
30. Cantoni O, Sestili P, Brandi G, Cattabeni F. The l-histidine-mediated enhancement of hydrogen peroxide-induced cytotoxicity is a general response in cultured mammalian cell lines and is always associated with the formation of DNA double strand breaks. *FEBS Lett.* 1994;353: 75–78.
31. Nath KA, Ngo EO, Hebbel RP, Croatt AJ, Zhou B, Nutter LM. α -Ketoacids scavenge H₂O₂ in vitro and in vivo and reduce menadione-induced DNA injury and cytotoxicity. *Am J Physiol - Cell Physiol.* 1995;268: C227–C236.
32. Salvemini F, Franzé A, Iervolino A, Filosa S, Salzano S, Ursini MV. Enhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression. *J Biol Chem.* 1999;274: 2750–2757.
33. Benaroudj N, Lee DH, Goldberg AL. Trehalose Accumulation during Cellular Stress Protects Cells and Cellular Proteins from Damage by Oxygen Radicals. *J Biol Chem.* 2001;276: 24261–24267.
34. Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V. Coenzyme Q10 improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. *Diabetologia.* 2002;45: 420–426.
35. Liu Y, Zhu B, Wang X, Luo L, Li P, Paty DW, et al. Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: Implications for the role of oxidative stress in the development of multiple sclerosis. *J Neuroimmunol.* 2003;139: 27–35.
36. Reiter RJ, Tan D-X. Melatonin: A novel protective agent against oxidative injury of the ischemic/reperfused heart. *Cardiovasc Res.* 2003;58: 10–19.
37. Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. *Curr Med Chem.* 2004;11: 1135–1146.
38. Žitňanová I, Korytár P, Aruoma OI, Šustrová M, Garaiová I, Muchová J, et al. Uric acid and allantoin levels in Down syndrome: Antioxidant and oxidative stress mechanisms? *Clin Chim Acta.* 2004;341: 139–146.
39. Touati D, Jacques M, Tardat B, Bouchard L, Despied S. Lethal oxidative damage and mutagenesis are generated by iron in Δ fur mutants of *Escherichia coli*: Protective role of superoxide dismutase. *J Bacteriol.* 1995;177: 2305–2314.
40. Bertini I, Manganl S, Viezzoli MS. Structure and Properties of Copper-Zinc Superoxide Dismutases. *Adv Inorg Chem.* 1998;45: 127–250.
41. Antunes F, Han D, Cadenas E. Relative contributions of heart mitochondria glutathione peroxidase and catalase to H₂O₂ detoxification in vivo conditions. *Free Radic Biol Med.* 2002;33: 1260–1267.
42. Poeggeler B, Thuermann S, Dose A, Schoenke M, Burkhardt S, Hardeland R. Melatonin's unique radical scavenging properties - Roles of its functional substituents as revealed by a comparison with its structural analogs. *J Pineal Res.* 2002;33: 20–30.
43. Wong C-M, Siu K-L, Jin D-Y. Peroxiredoxin-null yeast cells are hypersensitive to oxidative stress and are genomically unstable. *J Biol Chem.* 2004;279: 23207–23213.
44. Passardi F, Cosio C, Penel C, Dunand C. Peroxidases have more functions than a Swiss army knife. *Plant Cell Rep.* 2005;24: 255–265.
45. Southorn PA, Powis G. Free radicals in medicine. II. Involvement in human disease. *Mayo Clin Proc.* 1988;63: 390–408.
46. Halliwell B, Gutteridge JMC, Cross CE. Free radicals, antioxidants, and human disease: Where are we now? *J Lab Clin Med.* 1992;119: 598–620.
47. Halliwell B. The antioxidant paradox: Less paradoxical now? *Br J Clin Pharmacol.* 2013;75: 637–644.

48. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. *Nature*. 1993;362: 801–809.
49. Steinberg D. Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. *Nat Med*. 2002;8: 1211–1217.
50. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, et al. The oxidation hypothesis of atherogenesis: The role of oxidized phospholipids and HDL. *J Lipid Res*. 2004;45: 993–1007.
51. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. *Arterioscler Thromb Vasc Biol*. 2005;25: 1102–1111.
52. Piganelli JD, Flores SC, Cruz C, Koepf J, Batinic-Haberle I, Crapo J, et al. A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. *Diabetes*. 2002;51: 347–355.
53. Davi G, Falco A, Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. *Chem Phys Lipids*. 2004;128: 149–163.
54. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. *Diabetes*. 2005;54: 1615–1625.
55. Collins FS, Riordan JR, Tsui L-C. The cystic fibrosis gene: Isolation and significance. *Hosp Pract*. 1990;25: 47–57.
56. Van Der Vliet A, Eiserich JP, Marelich GP, Halliwell B, Cross CE. Oxidative stress in cystic fibrosis: Does it occur and does it matter? *Adv Pharmacol*. 1996;38: 491–513.
57. Pavlick KP, Laroux FS, Fuseler J, Wolf RE, Gray L, Hoffman J, et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. *Free Radic Biol Med*. 2002;33: 311–322.
58. Chu F-F, Esworthy RS, Chu PG, Longmate JA, Huycke MM, Wilczynski S, et al. Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. *Cancer Res*. 2004;64: 962–968.
59. D'Inca R, Cardin R, Benazzato L, Angriman I, Martines D, Sturniolo GC. Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. *Inflamm Bowel Dis*. 2004;10: 23–27.
60. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. *Nature*. 1980;283: 139–146.
61. Barnes DE, Lindahl T. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. *Annu Rev Genet*. 2004;38: 445–476.
62. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. *Nat Med*. 2004;10: 789–799.
63. Bensaad K, Vusden KH. Savior and slayer: The two faces of p53. *Nat Med*. 2005;11: 1278–1279.
64. Jackson JH. Potential molecular mechanisms of oxidant-induced carcinogenesis. *Environ Health Perspect*. 1994;102: 155–157.
65. Arbiser JL, Petros J, Klafter R, Govindajaran B, McLaughlin ER, Brown LF, et al. Reactive oxygen generated by Nox1 triggers the angiogenic switch. *Proc Natl Acad Sci U S A*. 2002;99: 715–720.
66. Hofseth LJ, Saito S, Perwez Hussain S, Espey MG, Miranda KM, Araki Y, et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. *Proc Natl Acad Sci U S A*. 2003;100: 143–148.
67. Pervaiz S, Clément M-V. Tumor intracellular redox status and drug resistance-serendipity or a causal relationship? *Curr Pharm Des*. 2004;10: 1969–1977.
68. Doroshow JH, Synold TW, Somlo G, Akman SA, Gajewski E. Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. *Blood*. 2001;97: 2839–2845.
69. Chen J, Stubbe J. Bleomycins: Towards better therapeutics. *Nat Rev Cancer*. 2005;5: 102–112.
70. Fox BW, Fox M, editors. Antitumor drug resistance. Berlin, Germany: Springer Verlag; 1984.
71. Bertino JR, Göker E, Gorlick R, Li WW, Banerjee D. Resistance mechanisms to methotrexate in tumors. *Oncologist*. 1996;1: 223–226.
72. Lindgren M, Rosenthal-Aizman K, Saar K, Eiríksdóttir E, Jiang Y, Sassian M, et al. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. *Biochem Pharmacol*. 2006;71: 416–425.
73. Khanna KK, Jackson SP. DNA double-strand breaks: Signaling, repair and the cancer connection. *Nat Genet*. 2001;27: 247–254.
74. Stone R. Epidemiology - Russian cancer study adds to the indictment of low-dose radiation. *Science*. 2005;310: 959–959.
75. Tondel M, Arynchyn A, Jönsson P, Persson B, Tagesson C. Urinary 8-hydroxydeoxyguanosine in Belarussian children relates to urban living ra-

- ther than radiation dose after the Chernobyl accident: A pilot study. *Arch Environ Contam Toxicol*. 2005;48: 515–519.
76. Dürken M, Herrnring C, Finckh B, Nagel S, Nielsen P, Fischer R, et al. Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation. *Free Radic Biol Med*. 2000;28: 887–894.
 77. Persson HL, Kurz T, Eaton JW, Brunk UT. Radiation-induced cell death: importance of lysosomal destabilization. *Biochem J*. 2005;389: 877–884.
 78. Epperly MW, Sikora CA, Defilippi SJ, Gretton JE, Greenberger JS. Irradiation-induced inflammatory mRNA levels differ between bone marrow stromal cells compared to hematopoietic progenitor cells. *Blood*. 2000;96: 132B–132B.
 79. Phillis JW, O'Regan MH. A potentially critical role of phospholipases in central nervous system ischemic, traumatic, and neurodegenerative disorders. *Brain Res Rev*. 2004;44: 13–47.
 80. Liu D, Liu J, Sun D, Alcock NW, Wen J. Spinal cord injury increases iron levels: Catalytic production of hydroxyl radicals. *Free Radic Biol Med*. 2003;34: 64–71.
 81. Asaeda M, Sakamoto M, Kurosaki M, Tabuchi S, Kamitani H, Yokota M, et al. A non-enzymatic derived arachidonyl peroxide, 8-iso-prostaglandin F 2 α , in cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage participates in the pathogenesis of delayed cerebral vasospasm. *Neurosci Lett*. 2005;373: 222–225.
 82. Wagner KR, Sharp FR, Ardizzone TD, Lu A, Clark JF. Heme and iron metabolism: Role in cerebral hemorrhage. *J Cereb Blood Flow Metab*. 2003;23: 629–652.
 83. von Bohlen und Halbach O, Schober A, Kriegstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. *Prog Neurobiol*. 2004;73: 151–177.
 84. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. *Annu Rev Neurosci*. 2005;28: 57–87.
 85. Zecca L, Zucca FA, Wilms H, Sulzer D. Neuro-melanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. *Trends Neurosci*. 2003;26: 578–580.
 86. Ischiropoulos H, Beckman JS. Oxidative stress and nitration in neurodegeneration: Cause, effect, or association? *J Clin Invest*. 2003;111: 163–169.
 87. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. *J Biol Chem*. 2004;279: 13256–13264.
 88. Houlden H, Singleton AB. The genetics and neuropathology of Parkinson's disease. *Acta Neuropathol (Berl)*. 2012;124: 325–338.
 89. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. *J Neurochem*. 2001;76: 1265–1274.
 90. Pezzoli G, Antonini A, Barbieri S, Canesi M, Perbellini L, Zecchinelli A, et al. n-Hexane-induced parkinsonism: pathogenetic hypotheses. *Mov Disord*. 1995;10: 279–282.
 91. Caboni P, Sherer TB, Zhang NJ, Taylor G, Na HM, Greenamyre JT, et al. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. *Chem Res Toxicol*. 2004;17: 1540–1548.
 92. Champy P, Hoglinger GU, Feger J, Gleye C, Hocquemiller R, Laurens A, et al. Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. *J Neurochem*. 2004;88: 63–69.
 93. Potts LF, Luzzio FA, Smith SC, Hetman M, Champy P, Litvan I. Annonacin in Asimina triloba fruit: Implication for neurotoxicity. *Neuro-Toxicology*. 2012;33: 53–58.
 94. Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS. 3,4-dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. *Brain Res*. 2003;989: 205–213.
 95. Mattson MP. Pathways towards and away from Alzheimer's disease. *Nature*. 2004;430: 631–639.
 96. Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. *Am J Clin Nutr*. 2005;82: 636–643.
 97. Piccini A, Russo C, Gliozzi A, Relini A, Vitali A, Borghi R, et al. β -amyloid is different in normal aging and in Alzheimer disease. *J Biol Chem*. 2005;280: 34186–34192.
 98. Halliwell B. Oxidative stress and neurodegeneration: Where are we now? *J Neurochem*. 2006;97: 1634–1658.

99. Abramov AY, Canevari L, Duchen MR. β -amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. *J Neurosci*. 2004;24: 565–575.
100. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. *Nat Rev Drug Discov*. 2004;3: 205–214.
101. Puglielli L, Friedlich AL, Setchell KDR, Nagano S, Opazo C, Cherny RA, et al. Alzheimer disease β -amyloid activity mimics cholesterol oxidase. *J Clin Invest*. 2005;115: 2556–2563.
102. Yan SD, Stern DM. Mitochondrial dysfunction and Alzheimer's disease: Role of amyloid- β peptide alcohol dehydrogenase (ABAD). *Int J Exp Pathol*. 2005;86: 161–171.
103. Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. *J Neurochem*. 2005;93: 953–962.
104. Dib M. Amyotrophic lateral sclerosis: Progress and prospects for treatment. *Drugs*. 2003;63: 289–310.
105. Casoni F, Basso M, Massignan T, Gianazzail E, Cheroni C, Salmona M, et al. Protein nitration in a mouse model of familial amyotrophic lateral sclerosis: Possible multifunctional role in the pathogenesis. *J Biol Chem*. 2005;280: 16295–16304.
106. Huntington G. On chorea. George Huntington, M.D. *J Neuropsychiatry Clin Neurosci*. 2003;15: 109–112.
107. Brouillet E, Jacquard C, Bizat N, Blum D. 3-Nitropropionic acid: A mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. *J Neurochem*. 2005;95: 1521–1540.
108. Marx J. Huntington's research points to possible new therapies. *Science*. 2005;310: 43–45.
109. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. *Science*. 2001;292: 1552–1555.
110. Moosmann B, Behl C. Antioxidants as treatment for neurodegenerative disorders. *Expert Opin Investig Drugs*. 2002;11: 1407–1435.
111. Halliwell B. Drug antioxidant effects: A basis for drug selection? *Drugs*. 1991;42: 569–605.
112. Ahnfelt-Rønne I, Nielsen OH, Christensen A, Langholz E, Binder V, Riis P. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. *Gastroenterology*. 1990;98: 1162–1169.
113. Koistinaho M, Malm TM, Kettunen MI, Goldsteins G, Starckx S, Kauppinen RA, et al. Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. *J Cereb Blood Flow Metab*. 2005;25: 460–467.
114. Somack R, Saifer MG, Williams LD. Preparation of long-acting superoxide dismutase using high molecular weight polyethylene glycol (41,000–72,000 daltons). *Free Radic Res Commun*. 1991;12-13: 553–562.
115. Luo J, Borgens R, Shi R. Polyethylene glycol immediately repairs neuronal membranes and inhibits free radical production after acute spinal cord injury. *J Neurochem*. 2002;83: 471–480.
116. Nishikawa M, Hyoudou K, Kobayashi Y, Umeyama Y, Takakura Y, Hashida M. Inhibition of metastatic tumor growth by targeted delivery of antioxidant enzymes. *J Controlled Release*. 2005;109: 101–107.
117. Day BJ. Catalytic antioxidants: A radical approach to new therapeutics. *Drug Discov Today*. 2004;9: 557–566.
118. Konorev EA, Kotamraju S, Zhao H, Kalivendi S, Joseph J, Kalyanaraman B. Paradoxical effects of metalloporphyrins on doxorubicin-induced apoptosis: Scavenging of reactive oxygen species versus induction of heme oxygenase-1. *Free Radic Biol Med*. 2002;33: 988–997.
119. Maples KR, Green AR, Floyd RA. Nitron-related therapeutics: Potential of NXY-059 for the treatment of acute ischaemic stroke. *CNS Drugs*. 2004;18: 1071–1084.
120. Maples KR, Ma F, Zhang Y-K. Comparison of the radical trapping ability of PBN, S-PBN and NXY-059. *Free Radic Res*. 2001;34: 417–426.
121. Poeggeler B, Durand G, Polidori A, Pappolla MA, Vega-Naredo I, Coto-Montes A, et al. Mitochondrial medicine: Neuroprotection and life extension by the new amphiphilic nitron LPB-NAH acting as a highly potent antioxidant agent. *J Neurochem*. 2005;95: 962–973.
122. Ley JJ, Vigdorichik A, Belayev L, Zhao W, Busto R, Khoutorova L, et al. Stilbazulenyl nitron, a second-generation azulenyl nitron antioxidant, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat: Neurobehavior, histopathology, and pharmacokinetics. *J Pharmacol Exp Ther*. 2005;313: 1090–1100.
123. Goldstein S, Merenyi G, Russo A, Samuni A. The role of oxoammonium cation in the SOD-mimic activity of cyclic nitroxides. *J Am Chem Soc*. 2003;125: 789–795.

124. Collis CS, Davies MJ, Rice-Evans C. Comparison of N-methyl hexanoylhydroxamic acid, a novel antioxidant, with desferrioxamine and N-acetyl cysteine against reperfusion-induced dysfunctions in isolated rat heart. *J Cardiovasc Pharmacol.* 1993;22: 336–342.
125. Atamna H, Robinson C, Ingersoll R, Elliott H, Ames BN. N-t-butyl hydroxylamine is an antioxidant that reverses age-related changes in mitochondria in vivo and in vitro. *FASEB J.* 2001;15: 2196–2204.
126. Cuzzocrea S, Thiemermann C, Salvemini D. Potential therapeutic effect of antioxidant therapy in shock and inflammation. *Curr Med Chem.* 2004;11: 1147–1162.
127. Debier C. Vitamin E During Pre- and Postnatal Periods. *Vitam Horm.* 2007;76: 357–373.
128. Ristoff E, Larsson A. Patients with genetic defects in the γ -glutamyl cycle. *Chem Biol Interact.* 1998;111-112: 113–121.
129. Montine TJ, Montine KS, McMahan W, Markesbery WR, Quinn JF, Morrow JD. F2-isoprostanes in Alzheimer and other neurodegenerative diseases. *Antioxid Redox Signal.* 2005;7: 269–275.
130. Takabe W, Matsukawa N, Kodama T, Tanaka K, Noguchi N. Chemical structure-dependent gene expression of proteasome subunits via regulation of the antioxidant response element. *Free Radic Res.* 2006;40: 21–30.
131. Goldberg RB. The new clinical trials with thiazolidinediones - DREAM, ADOPT, and CHICAGO: Promises fulfilled? *Curr Opin Lipidol.* 2007;18: 435–442.
132. Shiau C-W, Huang J-W, Wang D-S, Weng J-R, Yang C-C, Lin C-H, et al. α -tocopheryl succinate induces apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 function. *J Biol Chem.* 2006;281: 11819–11825.
133. Zhang WR, Hayashi T, Sasaki C, Sato K, Nagano I, Manabe Y, et al. Attenuation of oxidative DNA damage with a novel antioxidant EPC-K1 in rat brain neuronal cells after transient middle cerebral artery occlusion. *Neurol Res.* 2001;23: 676–680.
134. Kumar D, Kirshenbaum LA, Li T, Danelisen I, Singal PK. Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. *Antioxid Redox Signal.* 2001;3: 135–145.
135. Keyamura Y, Nagano C, Kohashi M, Niimi M, Nozako M, Koyama T, et al. Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin. *PLoS ONE.* 2014;9. Available: <http://www.scopus.com/inward/record.url?eid=2-s2.0-84901045045&partnerID=40&md5=218175dd2c2b954b52fd611ada2b9126>
136. Meng CQ, Somers PK, Hoong LK, Zheng XS, Ye Z, Worsencroft KJ, et al. Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases. *J Med Chem.* 2004;47: 6420–6432.
137. Andersson C-M, Hallberg A, Högberg T. Advances in the development of pharmaceutical antioxidants. *Adv Drug Res.* 1996;28: 65–180.
138. Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q 10 as a potential treatment. *J Bioenerg Biomembr.* 2004;36: 381–386.
139. Schulz JB, Dehmer T, Schöls L, Mende H, Hardt C, Vorgerd M, et al. Oxidative stress in patients with Friedreich ataxia. *Neurology.* 2000;55: 1719–1721.
140. Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier P-E, Beal MF. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. *J Neurochem.* 2003;86: 267–272.
141. Runzer TD, Ansley DM, Godin DV, Chambers GK. Tissue antioxidant capacity during anesthesia: Propofol enhances in vivo red cell and tissue antioxidant capacity in a rat model. *Anesth Analg.* 2002;94: 89–93.
142. Lyseng-Williamson KA, Perry CM. Micronised purified flavonoid fraction: A review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. *Drugs.* 2003;63: 71–100.
143. Wu C-H, Yen G-C. Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts. *J Agric Food Chem.* 2005;53: 3167–3173.
144. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, et al. Phenolic anti-inflammatory antioxidant reversal of A β -induced cognitive deficits and neuropathology. *Neurobiol Aging.* 2001;22: 993–1005.
145. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. *J Biol Chem.* 2005;280: 5892–5901.
146. Mandel S, Weinreb O, Amit T, Youdim MBH. Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: Implications for neu-

- rodegenerative diseases. *J Neurochem.* 2004;88: 1555–1569.
147. Parsons RF, Guarrera JV. Preservation solutions for static cold storage of abdominal allografts: Which is best? *Curr Opin Organ Transplant.* 2014;19: 100–107.
 148. Marrades RM, Roca J, Barberà JA, De Jover L, Macnee W, Rodriguez-Roisin R. Nebulized glutathione induces bronchoconstriction in patients with mild asthma. *Am J Respir Crit Care Med.* 1997;156: 425–430.
 149. Packer L, Cadenas E. *Handbook of synthetic antioxidants (Antioxidants in health and disease)*. 1st ed. New York, USA: Marcel Dekker, Inc.; 1997.
 150. Fukagawa NK, Hercules E, Ajami AM. L-2-[13C]oxothiazolidine-4-carboxylic acid: A probe for precursor mobilization for glutathione synthesis. *Am J Physiol - Endocrinol Metab.* 2000;278: E171–E176.
 151. Lee KS, Hee SP, Seoung JP, So RK, Kyung HM, Sun MJ, et al. A prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid, regulates vascular permeability by reducing vascular endothelial growth factor expression in asthma. *Mol Pharmacol.* 2005;68: 1281–1290.
 152. Jaeschke H, Knight TR, Bajt ML. The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity. *Toxicol Lett.* 2003;144: 279–288.
 153. Jain R, DalNogare A. Pharmacological therapy for acute respiratory distress syndrome. *Mayo Clin Proc.* 2006;81: 205–212.
 154. Decramer M, Rutten-Van Mölken M, Dekhuijzen PNR, Troosters T, Van Herwaarden C, Pellegrino R, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomised placebo-controlled trial. *Lancet.* 2005;365: 1552–1560.
 155. Efrati S, Dishy V, Averbukh M, Blatt A, Krakover R, Weisgarten J, et al. The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. *Kidney Int.* 2003;64: 2182–2187.
 156. Bahat-Stroomza M, Gilgun-Sherki Y, Offen D, Panet H, Saada A, Krool-Galron N, et al. A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease. *Eur J Neurosci.* 2005;21: 637–646.
 157. Guven A, Uysal B, Caliskan B, Oztas E, Ozturk H, Korkmaz A. Mercaptoethylguanidine attenuates caustic esophageal injury in rats: A role for scavenging of peroxynitrite. *J Pediatr Surg.* 2011;46: 1746–1752.
 158. Wolfárd A, Kaszaki J, Szabó C, Szalay L, Nagy S, Boros M. Prevention of early myocardial depression in hyperdynamic endotoxemia in dogs. *Shock.* 2000;13: 46–51.
 159. Wilmott RW, Kitzmiller JA, Szabó C, Southan GJ, Salzman AL. Mercaptoethylguanidine inhibits the inflammatory response in a murine model of chronic infection with *Pseudomonas aeruginosa*. *J Pharmacol Exp Ther.* 2000;292: 88–95.
 160. Dorozhko EV, Korotkova EI. Antioxidant properties of sulfur-containing biologically active substances studied by voltammetric and spectrophotometric techniques. *Pharm Chem J.* 2011;44: 581–584.
 161. Suh JH, Shenvi SV, Dixon BM, Liu H, Jaiswal AK, Liu R-M, et al. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. *Proc Natl Acad Sci U S A.* 2004;101: 3381–3386.
 162. Guillonneau C, Charton Y, Ginot Y-M, Fouquier-D'Hérouël M-V, Bertrand M, Lockhart B, et al. Synthesis and pharmacological evaluation of new 1,2-dithiolane based antioxidants. *Eur J Med Chem.* 2003;38: 1–11.
 163. Nair CKK, Parida DK, Nomura T. Radioprotectors in radiotherapy. *J Radiat Res (Tokyo).* 2001;42: 21–37.
 164. Smith RA, Murphy MP. Mitochondria-targeted antioxidants as therapies. *Discov Med.* 2011;11: 106–114.
 165. Graham D, Huynh NN, Hamilton CA, Beattie E, Smith RAJ, Cochemé HM, et al. Mitochondria-targeted antioxidant mitoq10 improves endothelial function and attenuates cardiac hypertrophy. *Hypertension.* 2009;54: 322–328.
 166. Smith RAJ, Kelso GF, Blaikie FH, Porteous CM, Ledgerwood EC, Hughes G, et al. Using mitochondria-targeted molecules to study mitochondrial radical production and its consequences. *Biochem Soc Trans.* 2003;31: 1295–1299.
 167. Adlam VJ, Harrison JC, Porteous CM, James AM, Smith RAJ, Murphy MP, et al. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. *FASEB J.* 2005;19: 1088–1095.
 168. Mcmanus MJ, Murphy MP, Franklin JL. The mitochondria-targeted antioxidant mitoq prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of

- Alzheimer's disease. *J Neurosci.* 2011;31: 15703–15715.
169. Ghosh A, Chandran K, Kalivendi SV, Joseph J, Antholine WE, Hillard CJ, et al. Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. *Free Radic Biol Med.* 2010;49: 1674–1684.
 170. Chacko BK, Reily C, Srivastava A, Johnson MS, Ye Y, Ulasova E, et al. Prevention of diabetic nephropathy in Ins2^{+/-}AkitaJ mice by the mitochondria-targeted therapy MitoQ. *Biochem J.* 2010;432: 9–19.
 171. Fukuda S. Chelating agents used for plutonium and uranium removal in radiation emergency medicine. *Curr Med Chem.* 2005;12: 2765–2770.
 172. Cowieson AJ, Acamovic T, Bedford MR. The effects of phytase and phytic acid on the loss of endogenous amino acids and minerals from broiler chickens. *Br Poult Sci.* 2004;45: 101–108.
 173. Van Acker FAA, Van Acker SABE, Kramer K, Haenen GRMM, Bast A, Van Der Vijgh WJF. 7-Monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week. *Clin Cancer Res.* 2000;6: 1337–1341.
 174. Lucarelli G, Clift R, Angelucci E. Deferoxamine in thalassemia major. *N Engl J Med.* 1995;332: 271; discussion 272–273.
 175. Cunningham MJ. Update on thalassemia: Clinical care and complications. *Hematol Oncol Clin North Am.* 2010;24: 215–227.
 176. Eicher JC, Gabrielle F, Abadie C, Maupoil V, Wolf JE, David M, et al. Experimental preservation of the heart transplant: Effects of deferoxamine on functional recovery and lipid peroxidation of the isolated-perfused rat heart subjected to ischemia and reperfusion. *Transplant Proc.* 1995;27: 1654.
 177. Le NTV, Richardson DR. Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21^{CIP1}/WAF1, but paradoxically inhibit its translation: A potential mechanism of cell cycle dysregulation. *Carcinogenesis.* 2003;24: 1045–1058.
 178. Moch D, Schröppel B, Schoenberg MH, Schulz HJ, Thorab FC, Marzinzag M, et al. Protective effects of hydroxyethyl starch-deferoxamine in early sepsis. *Shock Augusta Ga.* 1995;4: 425–432.
 179. Bergeron RJ, Wiegand J, Brittenham GM. HBED: The continuing development of a potential alternative to deferoxamine for iron-chelating therapy. *Blood.* 1999;93: 370–375.
 180. Richardson DR. Orally effective iron chelators for the treatment of iron overload disease: The case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs. *J Lab Clin Med.* 1998;132: 351–352.
 181. Grady RW, Graziano JH, Peterson CM, Cerami A. The identification of 2,3 dihydroxybenzoic acid as a potentially useful iron chelating drug. *Bull N Y Acad Med J Urban Health.* 1975;51: 1162.
 182. Heli H, Mirtorabi S, Karimian K. Advances in iron chelation: An update. *Expert Opin Ther Pat.* 2011;21: 819–856.
 183. Sheth S. Iron chelation: An update. *Curr Opin Hematol.* 2014;21: 179–185.
 184. Cappellini MD. Iron-chelating therapy with the new oral agent ICL670 (Exjade®). *Best Pract Res Clin Haematol.* 2005;18: 289–298.
 185. Galey J-B, Dumats J, Genard S, Destree O, Pichaud P, Cctroux P, et al. N,N'-bis-(3,4,5-trimethoxybenzyl) ethylenediamine N,N'-diacetic acid as a new iron chelator with potential medicinal applications against oxidative stress. *Biochem Pharmacol.* 1996;51: 103–115.
 186. Persson HL, Richardson DR. Iron-binding drugs targeted to lysosomes: A potential strategy to treat inflammatory lung disorders. *Expert Opin Investig Drugs.* 2005;14: 997–1008.
 187. Kitazawa M, Ishitsuka Y, Kobayashi M, Nakano T, Iwasaki K, Sakamoto K, et al. Protective effects of an antioxidant derived from serine and vitamin B 6 on skin photoaging in hairless mice ¶. *Photochem Photobiol.* 2005;81: 970–974.
 188. Gal S, Zheng H, Fridkin M, Youdim MBH. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. *J Neurochem.* 2005;95: 79–88.
 189. Thurston DE. *Chemistry and pharmacology of anticancer drugs.* 1st ed. Boca Raton, USA: CRC Press; 2006.
 190. Nussbaumer S, Bonnabry P, Veuthey J-L, Fleury-Souverain S. Analysis of anticancer drugs: A review. *Talanta.* 2011;85: 2265–2289.
 191. Middleton G, Cunningham D. Current options in the management of gastrointestinal cancer. *Ann Oncol.* 1995;6: S17–S26.

192. Johnson PWM, Thompson PI, Seymour MT, Deasy NP, Thuraisingham Slevin RCML, Wrigley PFM. A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. *Br J Cancer*. 1991;64: 603–605.
193. Kelly C, Cassidy J. Chemotherapy in metastatic colorectal cancer. *Surg Oncol*. 2007;16: 65–70.
194. Pommier Y, Pochat L, Marie JP, Zittoun RA. High-dose cytarabine in acute leukemia: Toxicity and pharmacokinetics. *Cancer Treat Rep*. 1983;67: 371–373.
195. Shrum KJP, Gill SE, Thompson LK, Blackhurst DW, Puls LE. New-onset congestive heart failure with gemcitabine in ovarian and other solid cancers. *Am J Clin Oncol Cancer Clin Trials*. 2014;37: 364–368.
196. Aapro MS, Martin C, Hatty S. Gemcitabine - A safety review. *Anticancer Drugs*. 1998;9: 191–201.
197. Sheyman AT, Wald KJ, Pakh PJ, Freund KB. Gemcitabine associated retinopathy and nephropathy. *Retin Cases Brief Rep*. 2014;8: 107–109.
198. Kaminskas E, Farrell AT, Wang Y-C, Sridhara R, Pazdur R. FDA drug approval summary: Azacitidine (5-azacytidine, Vidaza™) for injectable suspension. *Oncologist*. 2005;10: 176–182.
199. Remuzzi G, Lesti M, Gotti E, Ganeva M, Dimitrov BD, Ene-Iordache B, et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): A randomised trial. *Lancet*. 2004;364: 503–512.
200. Cronstein BN. Pharmacogenetics in the rheumatic diseases. *Ann Rheum Dis*. 2004;63: ii25–ii27.
201. Biancone L, Tosti C, Fina D, Fantini M, De Nigris F, Geremia A, et al. Review article: Maintenance treatment of Crohn's disease. *Aliment Pharmacol Ther Suppl*. 2003;17: 31–37.
202. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. *Eur J Clin Pharmacol*. 2008;64: 753–767.
203. Sung JS, Collins MT. Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. *Antimicrob Agents Chemother*. 2008;52: 418–426.
204. de Boer NKH, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJJ. Drug Insight: Pharmacology and toxicity of thiopurine therapy in patients with IBD. *Nat Clin Pract Gastroenterol Hepatol*. 2007;4: 686–694.
205. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. *Blood*. 2003;102: 810–813.
206. Robak T. Cladribine in the treatment of chronic lymphocytic leukemia. *Leuk Lymphoma*. 2001;40: 551–564.
207. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. *Blood*. 2006;107: 885–891.
208. Dinner S, Lee D, Liedtke M. Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. *Leuk Lymphoma*. 2014;55: 1715–1724.
209. Bagley RG, Roth S, Kurtzberg LS, Rouleau C, Yao M, Crawford J, et al. Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs. *Int J Oncol*. 2009;34: 1329–1340.
210. Goodsell DS. The molecular perspective: Methotrexate. *Oncologist*. 1999;4: 340–341.
211. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: Consensus conference. *J Am Acad Dermatol*. 2012;66: 689–690.
212. Gansauge S, Breitbart A, Rinaldi N, Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). *Ann Rheum Dis*. 1997;56: 382–385.
213. Van Cutsem E. Raltitrexed (Tomudex(TM)) in combination treatment for colorectal cancer: New perspectives. *Eur J Cancer*. 1999;35: S1–S2.
214. Sato A, Kurihara M, Horikoshi N, Aiba K, Kikawa N, Shirouzu K, et al. Phase II study of raltitrexed (Tomudex®) in chemotherapy-pretreated patients with advanced colorectal cancer. *Anticancer Drugs*. 1999;10: 741–748.
215. Cannon T, Mobarek D, Wegge J, Tabbara IA. Hairy cell leukemia: Current concepts. *Cancer Invest*. 2008;26: 860–865.
216. Cassileth PA, Chevart B, Spiers ASD, Harrington DP, Cummings FJ, Neiman RS, et al. Pentostatin induces durable remissions in hairy cell leukemia. *J Clin Oncol*. 1991;9: 243–246.
217. Dalziel K, Round A, Stein K, Garside R, Price A. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukemia in chronic phase: A systematic review and economic analysis. *Health Technol Assess*. 2004;8: iii–67.

218. Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, et al. Hydroxyurea for sickle cell disease: A systematic review for efficacy and toxicity in children. *Pediatrics*. 2008;122: 1332–1342.
219. Poklepovic A, Youseffian L, Winning M, Birdsell CA, Crosby NA, Ramakrishnan V, et al. Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. *Invest New Drugs*. 2013;31: 937–942.
220. Barton-Burke M, Wilkes GM, Ingwersen KC, Bean CK, Berg D. *Cancer chemotherapy: A nursing process approach*. 2nd ed. Burlington, USA: Jones & Bartlett Pub; 1996.
221. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. *Cancer Treat Rev*. 1997;23: 35–61.
222. Okines A, Thomson CS, Radstone CR, Horsman JM, Hancock BW. Second primary malignancies after treatment for malignant lymphoma. *Br J Cancer*. 2005;93: 418–424.
223. Armand J-P, Ribrag V, Harrousseau J-L, Abrey L. Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. *Ther Clin Risk Manag*. 2007;3: 213–224.
224. Samandouras G. *The neurosurgeon's handbook*. 1st ed. Oxford, UK: Oxford University Press; 2010.
225. Izbicka E, Lawrence R, Raymond E, Eckhardt G, Faircloth G, Jimeno J, et al. In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. *Ann Oncol*. 1998;9: 981–987.
226. Hendriks HR, Fiebig HH, Giavazzi R, Langdon SP, Jimeno JM, Faircloth GT. High antitumor activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. *Ann Oncol*. 1999;10: 1233–1240.
227. Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: An historical perspective and an update. *Eur J Cancer*. 1998;34: 1522–1534.
228. Keyes DC, Burstein JL, Schwartz RB, Swienton RE. *Medical response to terrorism: Preparedness and clinical practice*. 1st ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2004.
229. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: Golden anniversary. *Nat Rev Clin Oncol*. 2009;6: 638–647.
230. Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. *J Rheumatol*. 1991;18: 188–194.
231. Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. *Oncologist*. 2007;12: 1351–1360.
232. Reichardt P, Pink D, Tilgner J, Kretzschmar A, Thuss-Patience PC, Dörken B. Oral trofosfamide: An active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis. *Onkologie*. 2002;25: 541–546.
233. Bunn Jr. PA, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). *Ann Intern Med*. 1994;121: 592–602.
234. Ravery V, Fizazi K, Oudard S, Drouet L, Eymard J-C, Culine S, et al. The use of estramustine phosphate in the modern management of advanced prostate cancer. *BJU Int*. 2011;108: 1782–1786.
235. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. *Lancet*. 2007;370: 1209–1218.
236. Piver MS. Treatment of ovarian cancer at the crossroads: 50 Years after single-agent melphalan chemotherapy. *Onology*. 2006;20: 1156–1158.
237. Cervantes F, Reverte J-C, Montserrat E, Rozman C. Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide, and prednimustine. *Cancer Treat Rep*. 1986;70: 665–667.
238. Laquintana V, Trapani A, Denora N, Wang F, Gallo JM, Trapani G. New strategies to deliver anticancer drugs to brain tumors. *Expert Opin Drug Deliv*. 2009;6: 1017–1032.
239. Ewend MG, Brem S, Gilbert M, Goodkin R, Penar PL, Varia M, et al. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. *Clin Cancer Res*. 2007;13: 3637–3641.
240. Quéreux G, Dréno B. Fotemustine for the treatment of melanoma. *Expert Opin Pharmacother*. 2011;12: 2891–2904.
241. Cohen BE, Egorin MJ, Kohlhepp EA, Aisner J, Gutierrez PL. Human plasma pharmacokinetics

- and urinary excretion of thiotepa and its metabolites. *Cancer Treat Rep.* 1986;70: 859–864.
242. Maanen MJV, Smeets CJM, Beijnen JH. Chemistry, pharmacology and pharmacokinetics of N,N',N''-triethylenethiophosphoramidate (Thio-TEPA). *Cancer Treat Rev.* 2000;26: 257–268.
 243. Agnelli G, Gresele P, Cunto MD, Favero AD. Early onset life-threatening myelosuppression after low dose of intravesical thiotepa. *Postgrad Med J.* 1982;58: 380–381.
 244. Schmittel A, Schmidt-Hieber M, Martus P, Bechrakis NE, Schuster R, Siehl JM, et al. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. *Ann Oncol.* 2006;17: 1826–1829.
 245. Bishop JB, Wassom JS. Toxicological review of busulfan (Myleran). *Mutat Res Genet Toxicol.* 1986;168: 15–45.
 246. Eberly AL, Anderson GD, Bubalo JS, McCune JS. Optimal prevention of seizures induced by high-dose busulfan. *Pharmacotherapy.* 2008;28: 1502–1510.
 247. Tomasz M. Mitomycin C: small, fast and deadly (but very selective). *Chem Biol.* 1995;2: 575–579.
 248. Bradner WT. Mitomycin C: A clinical update. *Cancer Treat Rev.* 2001;27: 35–50.
 249. Lee TS, Khosla C, Tang Y. Engineered biosynthesis of aklanonic acid analogues. *J Am Chem Soc.* 2005;127: 12254–12262.
 250. Braña MF, Cacho M, Gradillas A, De Pascual-Teresa B, Ramos A. Intercalators as anticancer drugs. *Curr Pharm Des.* 2001;7: 1745–1780.
 251. Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: A review. *Clin Ther.* 2006;28: 461–474.
 252. Cragg GM, Kingston DGI, Newman DJ. *Anticancer agents from natural products.* 1st ed. Boca Raton, USA: Taylor & Francis Group; 2005.
 253. Malonne H, Atassi G. DNA topoisomerase targeting drugs: Mechanisms of action and perspectives. *Anticancer Drugs.* 1997;8: 811–822.
 254. Du W. Towards new anticancer drugs: A decade of advances in synthesis of camptothecins and related alkaloids. *Tetrahedron.* 2003;59: 8649–8687.
 255. Lorence A, Nessler CL. Camptothecin, over four decades of surprising findings. *Phytochemistry.* 2004;65: 2735–2749.
 256. Thomas CJ, Rahier NJ, Hecht SM. Camptothecin: Current perspectives. *Bioorg Med Chem.* 2004;12: 1585–1604.
 257. Sternberg CN, Yagoda A, Casper E, Scoppetuolo M, Scher HI. Phase II trial of elliptinium in advanced renal cell carcinoma and carcinoma of the breast. *Anticancer Res.* 1985;5: 415–418.
 258. Garbett NC, Graves DE. Extending nature's leads: The anticancer agent ellipticine. *Curr Med Chem - Anti-Cancer Agents.* 2004;4: 149–172.
 259. Grove WR, Fortner CL, Wiernik PH. Review of amsacrine, an investigational antineoplastic agent. *Clin Pharm.* 1982;1: 320–326.
 260. Cassileth PA, Gale RP. Amsacrine: A review. *Leuk Res.* 1986;10: 1257–1265.
 261. Gascoigne KE, Taylor SS. How do anti-mitotic drugs kill cancer cells? *J Cell Sci.* 2009;122: 2579–2585.
 262. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. *J Ethnopharmacol.* 2005;100: 72–79.
 263. Goodman J, Walsh V. *The story of Taxol: Nature and politics in the pursuit of an anti-cancer drug.* 1st ed. Cambridge, UK: Cambridge University Press; 2001.
 264. Kingston DGI. Taxol, a molecule for all seasons. *Chem Commun.* 2001; 867–880.
 265. Fang W-S, Liang X-T. Recent progress in structure activity relationship and mechanistic studies of taxol analogues. *Mini-Rev Med Chem.* 2005;5: 1–12.
 266. Crown J, O'Leary M, Ooi W-S. Docetaxel and paclitaxel in the treatment of breast cancer: A review of clinical experience. *Oncologist.* 2004;9: 24–32.
 267. Noble RL. The discovery of the vinca alkaloids - Chemotherapeutic agents against cancer. *Biochem Cell Biol.* 1990;68: 1344–1351.
 268. van der Heijden R, Jacobs DI, Snoeijer W, Hallard D, Verpoorte R. The Catharanthus alkaloids: Pharmacognosy and biotechnology. *Curr Med Chem.* 2004;11: 607–628.
 269. El-Sayed M, Verpoorte R. Catharanthus terpenoid indole alkaloids: Biosynthesis and regulation. *Phytochem Rev.* 2007;6: 277–305.
 270. Schrey D, Boos J. Inadvertent intrathecal administration of vincristine/vindesine in polychemotherapy. *Monatsschr Kinderheilkd.* 2008;156: 902–904.

271. Graening T, Schmalz H-G. Total syntheses of colchicine in comparison: A journey through 50 years of synthetic organic chemistry. *Angew Chem - Int Ed.* 2004;43: 3230–3256.
272. Chen LX, Schumacher HR. Gout: an evidence-based review. *J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis.* 2008;14: S55–62.
273. Castro MA, Del Corral JMM, Gordaliza M, Gómez-Zurita MA, García PA, San Feliciano A. Chemoinduction of cytotoxic selectivity in Podophyllotoxin-related lignans. *Phytochem Rev.* 2003;2: 219–233.
274. Lee K-H, Xiao Z. Lignans in treatment of cancer and other diseases. *Phytochem Rev.* 2003;2: 341–362.
275. Meresse P, Dechaux E, Monneret C, Bertounesque E. Etoposide: Discovery and medicinal chemistry. *Curr Med Chem.* 2004;11: 2443–2466.
276. Cirila A, Mann J. Combretastatins: From natural products to drug discovery. *Nat Prod Rep.* 2003;20: 558–564.
277. Tron GC, Piralí T, Sorba G, Pagliai F, Busacca S, Genazzani AA. Medicinal chemistry of combretastatin A4: Present and future directions. *J Med Chem.* 2006;49: 3033–3044.
278. Altmann K-H. The merger of natural product synthesis and medicinal chemistry: On the chemistry and chemical biology of epothilones. *Org Biomol Chem.* 2004;2: 2137–2152.
279. Feyen F, Cachoux F, Gertsch J, Wartmann M, Altmann K-H. Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization. *Acc Chem Res.* 2008;41: 21–31.
280. Nicolaou KC, Ritzén A, Namoto K. Recent developments in the chemistry, biology and medicine of the epothilones. *Chem Commun.* 2001; 1523–1535.
281. Newman DJ, Cragg GM, Holbeck S, Sausville EA. Natural products and derivatives as leads to cell cycle pathway targets in cancer chemotherapy. *Curr Cancer Drug Targets.* 2002;2: 279–308.
282. Sausville EA, Zaharevitz D, Gussio R, Meijer L, Louarn-Leost M, Kunick C, et al. Cyclin-dependent kinases initial approaches to exploit a novel therapeutic target. *Pharmacol Ther.* 1999;82: 285–292.
283. Young-Tae C, Gray NS, Rosania GR, Sutherlin DP, Kwon S, Norman TC, et al. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. *Chem Biol.* 1999;6: 361–375.
284. Ravelo ÁG, Estévez-Braun A, Chávez-Orellana H, Pérez-Sacau E, Mesa-Siverio D. Recent studies on natural products as anticancer agents. *Curr Top Med Chem.* 2004;4: 241–265.
285. Graham JG, Quinn ML, Fabricant DS, Farnsworth NR. Plants used against cancer - An extension of the work of Jonathan Hartwell. *J Ethnopharmacol.* 2000;73: 347–377.
286. Verpoorte R. Pharmacognosy in the new millennium: leadfinding and biotechnology. *J Pharm Pharmacol.* 2000;52: 253–262.
287. Cowan MM. Plant products as antimicrobial agents. *Clin Microbiol Rev.* 1999;12: 564–582.
288. Dubey NK. Plants as a source of natural antioxidants. 1st ed. Wallingford, UK: CAB International; 2015.
289. Seeram NP, Henning SM, Niu Y, Lee R, Scheuller HS, Heber D. Catechin and caffeine content of green tea dietary supplements and correlation with antioxidant capacity. *J Agric Food Chem.* 2006;54: 1599–1603.
290. Diamond BJ, Bailey MR. Ginkgo biloba. Indications, Mechanisms, and Safety. *Psychiatr Clin North Am.* 2013;36: 73–83.
291. Polyakov NE, Leshina TV, Salakhutdinov NF, Kononova TA, Kispert LD. Antioxidant and redox properties of supramolecular complexes of carotenoids with β -glycyrrhizic acid. *Free Radic Biol Med.* 2006;40: 1804–1809.
292. Frankel EN, Waterhouse AL, Teissedre PL. Principal phenolic phytochemicals in selected California wines and their antioxidant activity in inhibiting oxidation of human low-density lipoproteins. *J Agric Food Chem.* 1995;43: 890–894.
293. Krinsky NI. Carotenoids as antioxidants. *Nutrition.* 2001;17: 815–817.
294. Meagher EA, Barry OP, Lawson JA, Rokach J, FitzGerald GA. Effects of vitamin E on lipid peroxidation in healthy persons. *J Am Med Assoc.* 2001;285: 1178–1182.
295. Hodgson JM, Puddey IB. Dietary flavonoids and cardiovascular disease: Does the emperor have any clothes? *J Hypertens.* 2005;23: 1461–1463.
296. Sagun KC, Cárcamo JM, Golde DW. Vitamin C enters mitochondria via facilitative glucose transporter 1 (Glut1) and confers mitochondrial protection against oxidative injury. *FASEB J.* 2005;19: 1657–1667.
297. Robbins RJ. Phenolic acids in foods: An overview of analytical methodology. *J Agric Food Chem.* 2003;51: 2866–2887.

298. Amorati R, Valgimigli L. Modulation of the antioxidant activity of phenols by non-covalent interactions. *Org Biomol Chem*. 2012;10: 4147–4158.
299. Khoddami A, Wilkes MA, Roberts TH. Techniques for analysis of plant phenolic compounds. *Molecules*. 2013;18: 2328–2375.
300. Salunkhe DK, Chavan JK, Pashev I. Dietary tannins: Consequences and remedies. 1st ed. Boca Raton, USA: CRC Press; 1990.
301. Dewick PM. The biosynthesis of shikimate metabolites. *Nat Prod Rep*. 1995;12: 579–607.
302. Knaggs AR. The biosynthesis of shikimate metabolites. *Nat Prod Rep*. 2003;20: 119–136.
303. Mustafa NR, Verpoorte R. Chorismate derived C6C1 compounds in plants. *Planta*. 2005;222: 1–5.
304. Xie D-Y, Dixon RA. Proanthocyanidin biosynthesis - Still more questions than answers? *Phytochemistry*. 2005;66: 2127–2144.
305. Martens S, Mithöfer A. Flavones and flavone synthases. *Phytochemistry*. 2005;66: 2399–2407.
306. Grotewold E. The genetics and biochemistry of floral pigments. *Annu Rev Plant Biol*. 2006;57: 761–780.
307. Ayabe S-I, Akashi T. Cytochrome P450s in flavonoid metabolism. *Phytochem Rev*. 2006;5: 271–282.
308. Harborne JB. Plant phenolics. *Encyclopedia of plant physiology, volume 8: Secondary plant products*. New York, USA: Springer; 1980. pp. 329–395.
309. Vermerris W, Nicholson R. Phenolic compound biochemistry. 1st ed. New York, USA: Springer; 2009.
310. Miller AL. Antioxidant flavonoids: Structure, function and clinical usage. *Altern Med Rev*. 1996;1: 103–111.
311. Shahidi F, Chandrasekara A. Hydroxycinnamates and their in vitro and in vivo antioxidant activities. *Phytochem Rev*. 2010;9: 147–170.
312. Inayatullah S, Prenzler PD, Obied HK, Rehman A-U, Mirza B. Bioprospecting traditional Pakistani medicinal plants for potent antioxidants. *Food Chem*. 2012;132: 222–229.
313. Gabr AMM, Sytar O, Ahmed AR, Smetanska I. Production of phenolic acid and antioxidant activity in transformed hairy root cultures of common buckwheat (*Fagopyrum esculentum* M.). *Aust J Basic Appl Sci*. 2012;6: 577–586.
314. Kubo I, Chen Q-X, Nihei K-I, Calderón JS, Céspedes CL. Tyrosinase inhibition kinetics of anisic acid. *Z Naturforschung - Sect C J Biosci*. 2003;58: 713–718.
315. Tomás-Barberán FA, Clifford MN. Dietary hydroxybenzoic acid derivatives - Nature, occurrence and dietary burden. *J Sci Food Agric*. 2000;80: 1024–1032.
316. Santos-Gomes PC, Seabra RM, Andrade PB, Fernandes-Ferreira M. Phenolic antioxidant compounds produced by in vitro shoots of sage (*Salvia officinalis* L.). *Plant Sci*. 2002;162: 981–987.
317. Duthie CG, Kyle JAM, Jenkinson AM, Duthie SJ, Baxter GJ, Paterson JR. Increased salicylate concentrations in urine of human volunteers after consumption of cranberry juice. *J Agric Food Chem*. 2005;53: 2897–2900.
318. Kammerer B, Kahlich R, Biegert C, Gleiter CH, Heide L. HPLC-MS/MS analysis of willow bark extracts contained in pharmaceutical preparations. *Phytochem Anal*. 2005;16: 470–478.
319. Pacheco-Palencia LA, Mertens-Talcott S, Talcott ST. Chemical composition, antioxidant properties, and thermal stability of a phytochemical enriched oil from Açai (*Euterpe oleracea* Mart.). *J Agric Food Chem*. 2008;56: 4631–4636.
320. Vallverdú-Queralt A, Regueiro J, Martínez-Huélamo M, Rinaldi Alvarenga JF, Leal LN, Lamuela-Raventos RM. A comprehensive study on the phenolic profile of widely used culinary herbs and spices: Rosemary, thyme, oregano, cinnamon, cumin and bay. *Food Chem*. 2014;154: 299–307.
321. Cai Y, Luo Q, Sun M, Corke H. Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer. *Life Sci*. 2004;74: 2157–2184.
322. Bergeron C, Gafner S, Batcha LL, Angerhofer CK. Stabilization of caffeic acid derivatives in *Echinacea purpurea* L. glycerin extract. *J Agric Food Chem*. 2002;50: 3967–3970.
323. Zhao Z, Moghadasian MH. Chemistry, natural sources, dietary intake and pharmacokinetic properties of ferulic acid: A review. *Food Chem*. 2008;109: 691–702.
324. Kallel F, Driss D, Chaari F, Belghith L, Bouaziz F, Ghorbel R, et al. Garlic (*Allium sativum* L.) husk waste as a potential source of phenolic compounds: Influence of extracting solvents on its antimicrobial and antioxidant properties. *Ind Crops Prod*. 2014;62: 34–41.
325. Harrison Jr. HF, Mitchell TR, Peterson JK, Wechter WP, Majetich GF, Snook ME. Contents

- of caffeoylquinic acid compounds in the storage roots of sixteen sweetpotato genotypes and their potential biological activity. *J Am Soc Hortic Sci.* 2008;133: 492–500.
326. Bettaieb Rebey I, Bourgou S, Ben Slimen Debez I, Jabri Karoui I, Hamrouni Sellami I, Msaada K, et al. Effects of extraction solvents and provenances on phenolic contents and antioxidant activities of Cumin (*Cuminum cyminum* L.) seeds. *Food Bioprocess Technol.* 2012;5: 2827–2836.
327. Herrmann K. Occurrence and content of hydroxycinnamic and hydroxybenzoic acid compounds in foods. *Crit Rev Food Sci Nutr.* 1989;28: 315–347.
328. Wettasinghe M, Shahidi F, Amarowicz R, Abou-Zaid MM. Phenolic acids in defatted seeds of borage (*Borago officinalis* L.). *Food Chem.* 2001;75: 49–56.
329. Rimando AM, Kalt W, Magee JB, Dewey J, Ballington JR. Resveratrol, pterostilbene, and piceatannol in *Vaccinium* berries. *J Agric Food Chem.* 2004;52: 4713–4719.
330. Devgun M, Nanda A, Ansari SH. *Pterocarpus marsupium* Roxb. - A comprehensive review. *Pharmacogn Rev.* 2009;3: 359–363.
331. Cordero-Herrera I, Martín MT, Goya L, Ramos S. Cocoa flavonoids attenuate high glucose-induced insulin signalling blockade and modulate glucose uptake and production in human HepG2 cells. *Food Chem Toxicol.* 2014;64: 10–19.
332. Ploss O, Peterleit F, Nahrstedt A. Procyanidins from the herb of *Hypericum perforatum*. *Pharmazie.* 2001;56: 509–511.
333. Pellati F, Benvenuti S, Melegari M. High-performance liquid chromatography methods for the analysis of adrenergic amines and flavanones in *Citrus aurantium* L. var. *amara*. *Phytochem Anal.* 2004;15: 220–225.
334. Verhoog NJD, Joubert E, Louw A. Screening of four *Cyclopia* (honeybush) species for putative phyto-oestrogenic activity by oestrogen receptor binding assays. *South Afr J Sci.* 2007;103: 13–21.
335. Arman M. LC-ESI-MS characterisation of phytoalexins induced in chickpea and pea tissues in response to a biotic elicitor of *Hypnea musciformis* (red algae). *Nat Prod Res.* 2011;25: 1352–1360.
336. Fukai T, Marumo A, Kaitou K, Kanda T, Terada S, Nomura T. Antimicrobial activity of licorice flavonoids against methicillin-resistant *Staphylococcus aureus*. *Fitoterapia.* 2002;73: 536–539.
337. Shirasaka Y, Shichiri M, Mori T, Nakanishi T, Tamai I. Major active components in grapefruit, orange, and apple juices responsible for OATP2B1-mediated drug interactions. *J Pharm Sci.* 2013;102: 280–288.
338. Lung I, Soran ML, Tudoran C, Măruțoiu C. Effect of microwave irradiation on polyphenolic compounds from *Satureja hortensis* L. *Cent Eur J Chem.* 2013;11: 535–541.
339. Gafrikova M, Galova E, Sevcovicova A, Imreova P, Mucaji P, Miadokova E. Extract from *Armoracia rusticana* and its flavonoid components protect human lymphocytes against oxidative damage induced by hydrogen peroxide. *Molecules.* 2014;19: 3160–3172.
340. Cai L, Wu CD. Compounds from *Syzygium aromaticum* possessing growth inhibitory activity against oral pathogens. *J Nat Prod.* 1996;59: 987–990.
341. Eidenberger T, Selg M, Krennhuber K. Inhibition of dipeptidyl peptidase activity by flavonol glycosides of guava (*Psidium guajava* L.): A key to the beneficial effects of guava in type II diabetes mellitus. *Fitoterapia.* 2013;89: 74–79.
342. Yang J-Y, Lee H-S. Evaluation of antioxidant and antibacterial activities of morin isolated from mulberry fruits (*Morus alba* L.). *J Korean Soc Appl Biol Chem.* 2012;55: 485–489.
343. de Bock M, Derraik JGB, Brennan CM, Biggs JB, Morgan PE, Hodgkinson SC, et al. Olive (*Olea europaea* L.) Leaf polyphenols improve insulin sensitivity in middle-Aged overweight men: A randomized, placebo-controlled, crossover trial. *PLoS ONE.* 2013;8. Available: <http://www.scopus.com/inward/record.url?eid=2-s2.0-84874848268&partnerID=40&md5=3dc7e553b59b425784adbf8d609ba2a>
344. Wei T, Xiong F-F, Wang S-D, Wang K, Zhang Y-Y, Zhang Q-H. Flavonoid ingredients of *Ginkgo biloba* leaf extract regulate lipid metabolism through Sp1-mediated carnitine palmitoyltransferase 1A up-regulation. *J Biomed Sci.* 2014;21. Available: <http://www.scopus.com/inward/record.url?eid=2-s2.0-84907428186&partnerID=40&md5=5bc006620799b302fd118c06142ce0d1>
345. Roberts MF. The flavonoids advances in research since 1986.: edited by J. B. Harborne (1994) Chapman and Hall, London. 675 pp. £195. ISBN 0-412-28070-0. *Phytochemistry.* 1994;37: 913.
346. Kim HH, Kim DH, Kim MH, Oh MH, Kim SR, Park KJ, et al. Flavonoid constituents in the leaves of *Myrica rubra* sieb. et zucc. with anti-

- inflammatory activity. *Arch Pharm Res.* 2013;36: 1533–1540.
347. Liu B-G, Yang J-G, Qiu X-B, Zhang R-T, Ning Z-X. Preparation, identification and purification of apigenin. *Mod Food Sci Technol.* 2013;29: 2947–2952.
348. Pedneault K, Dorais M, Léonhart S, Angers P, Gosselin A. Time-course accumulation of flavonoids in hydroponically grown *Achillea millefolium* L. *Can J Plant Sci.* 2014;94: 383–395.
349. Lee Y, Howard L., Villalón B. Flavonoids and antioxidant activity of fresh pepper (*Capsicum annum*) cultivars. *J Food Sci.* 1995;60: 473–476.
350. McKay DL, Blumberg JB. A review of the bioactivity and potential health benefits of chamomile tea (*Matricaria recutita* L.). *Phyther Res.* 2006;20: 519–530.
351. Nagle DG, Ferreira D, Zhou Y-D. Epigallocatechin-3-gallate (EGCG): Chemical and biomedical perspectives. *Phytochemistry.* 2006;67: 1849–1855.
352. Lv J, Huang H, Yu L, Whent M, Niu Y, Shi H, et al. Phenolic composition and nutraceutical properties of organic and conventional cinnamon and peppermint. *Food Chem.* 2012;132: 1442–1450.
353. Cassady JM, Chan KK, Floss HG, Leistner E. Recent developments in the maytansinoid anti-tumor agents. *Chem Pharm Bull (Tokyo).* 2004;52: 1–26.
354. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. *J Natl Cancer Inst.* 2003;95: 990–1000.
355. Cuendet M, Pezzuto JM. Antitumor activity of bruceantin: An old drug with new promise. *J Nat Prod.* 2004;67: 269–272.
356. Miglietta A, Gabriel L, Appendino G, Bocca C. Biological properties of jatrophone polyesters, new microtubule-interacting agents. *Cancer Chemother Pharmacol.* 2003;51: 67–74.
357. Cichewicz RH, Kouzi SA. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. *Med Res Rev.* 2004;24: 90–114.
358. Mi Q, Cui B, Lantvit D, Reyes-Lim E, Chai H, Pezzuto JM, et al. Pervilleine F, a new tropane alkaloid aromatic ester that reverses multidrug resistance. *Anticancer Res.* 2003;23: 3607–3615.
359. Meijer L, Raymond E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. *Acc Chem Res.* 2003;36: 417–425.
360. Cragg GM, Newman DJ. A tale of two tumor targets: Topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. *J Nat Prod.* 2004;67: 232–244.
361. Ghali W, Vaudry D, Jouenne T, Marzouki MN. Assessment of cyto-protective, antiproliferative and antioxidant potential of a medicinal plant *Jatropha podagrica*. *Ind Crops Prod.* 2013;44: 111–118.
362. Znati M, Ben Jannet H, Cazaux S, Souchard JP, Harzallah Skhiri F, Bouajila J. Antioxidant, 5-Lipoxygenase inhibitory and cytotoxic activities of compounds isolated from the *Ferula lutea* flowers. *Molecules.* 2014;19: 16959–16975.
363. Lü J, Lin PH, Yao Q, Chen C. Chemical and molecular mechanisms of antioxidants: Experimental approaches and model systems. *J Cell Mol Med.* 2010;14: 840–860.
364. Manthey JA, Guthrie N. Antiproliferative activities of citrus flavonoids against six human cancer cell lines. *J Agric Food Chem.* 2002;50: 5837–5843.
365. Morley KL, Ferguson PJ, Koropatnick J. Tangeletin and nobiletin induce G1 cell cycle arrest but not apoptosis in human breast and colon cancer cells. *Cancer Lett.* 2007;251: 168–178.
366. Park KI, Park HS, Nagappan A, Hong GE, Lee DH, Kang SR, et al. Induction of the cell cycle arrest and apoptosis by flavonoids isolated from Korean *Citrus aurantium* L. in non-small-cell lung cancer cells. *Food Chem.* 2012;135: 2728–2735.
367. Leung HW-C, Lin C-J, Hour M-J, Yang W-H, Wang M-Y, Lee H-Z. Kaempferol induces apoptosis in human lung non-small carcinoma cells accompanied by an induction of antioxidant enzymes. *Food Chem Toxicol.* 2007;45: 2005–2013.
368. Valdameri G, Trombetta-Lima M, Worfel PR, Pires ARA, Martinez GR, Noletto GR, et al. Involvement of catalase in the apoptotic mechanism induced by apigenin in HepG2 human hepatoma cells. *Chem Biol Interact.* 2011;193: 180–189.
369. Vidya Priyadarsini R, Senthil Murugan R, Maitreyi S, Ramalingam K, Karunakaran D, Nagini S. The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF- κ B inhibition. *Eur J Pharmacol.* 2010;649: 84–91.

370. Ferry DR, Smith A, Malkhandi J, Fyfe DW, DeTakats PG, Anderson D, et al. Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. *Clin Cancer Res*. 1996;2: 659–668.
371. Seelinger G, Merfort I, Wölfle U, Schempp CM. Anti-carcinogenic effects of the flavonoid luteolin. *Molecules*. 2008;13: 2628–2651.
372. Anter J, Romero-Jiménez M, Fernández-Bedmar Z, Villatoro-Pulido M, Analla M, Alonso-Moraga Á, et al. Antigenotoxicity, cytotoxicity, and apoptosis induction by apigenin, bisabolol, and protocatechuic acid. *J Med Food*. 2011;14: 276–283.
373. Ghosh D, Bagchi D, Konishi T, editors. *Clinical aspects of functional foods and nutraceuticals*. 1st ed. Boca Raton, USA: CRC Press; 2015.
374. Park YK, Sempos CT, Barton CN, Vanderveen JE, Yetley EA. Effectiveness of food fortification in the United States: The case of Pellagra. *Am J Public Health*. 2000;90: 727–738.
375. Barham JB, Edens MB, Fonteh AN, Johnson MM, Easter L, Chilton FH. Addition of eicosapentaenoic acid to γ -linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans. *J Nutr*. 2000;130: 1925–1931.
376. Starr RR. Too little, too late: Ineffective regulation of dietary supplements in the United States. *Am J Public Health*. 2015;105: 478–485.
377. McCann D, Barrett A, Cooper A, Crumpler D, Dalen L, Grimshaw K, et al. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial. *Lancet*. 2007;370: 1560–1567.
378. Allen L, de Benoist B, Dary O, Hurrell R, editors. *Guidelines on food fortification with micronutrients*. Geneva, Switzerland: World Health Organization and Food and Agriculture Organization of the United Nations; 2006.
379. Kähkönen MP, Hopia AI, Vuorela HJ, Rauha J-P, Pihlaja K, Kujala TS, et al. Antioxidant activity of plant extracts containing phenolic compounds. *J Agric Food Chem*. 1999;47: 3954–3962.
380. Smith AD. Folic acid fortification: The good, the bad, and the puzzle of vitamin B-12. *Am J Clin Nutr*. 2007;85: 3–5.
381. Manson MM, Foreman BE, Howells LM, Moiseeva EP. Determining the efficacy of dietary phytochemicals in cancer prevention. *Biochem Soc Trans*. 2007;35: 1358–1363.
382. van Breemen RB, Pajkovic N. Multitargeted therapy of cancer by lycopene. *Cancer Lett*. 2008;269: 339–351.
383. Lee LK, Foo KY. An appraisal of the therapeutic value of lycopene for the chemoprevention of prostate cancer: A nutrigenomic approach. *Food Res Int*. 2013;54: 1217–1228.
384. Perry A, Rasmussen H, Johnson EJ. Xanthophyll (lutein, zeaxanthin) content in fruits, vegetables and corn and egg products. *J Food Compos Anal*. 2009;22: 9–15.
385. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. *Neurobiol Aging*. 2003;24: 915–919.
386. Le Marchand L, Murphy SP, Hankin JH, Wilkens LR, Kolonel LN. Intake of flavonoids and lung cancer. *J Natl Cancer Inst*. 2000;92: 154–160.
387. Brown PN, Shipley PR. Determination of anthocyanins in cranberry fruit and cranberry fruit products by high-performance liquid chromatography with ultraviolet detection: Single-laboratory validation. *J AOAC Int*. 2011;94: 459–466.
388. Denis M-C, Delvin E, Marette A, Levy E. Prevention of oxidative stress, inflammation and mitochondrial dysfunction in the intestine by different cranberry phenolic fractions. *Clin Sci Lond Engl* 1979. 2015;128: 197–212.
389. Taku K, Umegaki K, Sato Y, Taki Y, Endoh K, Watanabe S. Soy isoflavones lower serum total and LDL cholesterol in humans: A meta-analysis of 11 randomized controlled trials. *Am J Clin Nutr*. 2007;85: 1148–1156.
390. Erdman J.W. J. Soy protein and cardiovascular disease: A statement for healthcare professionals from the nutrition committee of the AHA. *Circulation*. 2000;102: 2555–2559.
391. Novelle MG, Wahl D, Diéguez C, Bernier M, De Cabo R. Resveratrol supplementation: Where are we now and where should we go? *Ageing Res Rev*. 2015;21: 1–15.
392. Sakakibara H, Honda Y, Nakagawa S, Ashida H, Kanazawa K. Simultaneous determination of all polyphenols in vegetables, fruits, and teas. *J Agric Food Chem*. 2003;51: 571–581.
393. Santos LF, Dias VM, Pilla V, Andrade AA, Alves LP, Munin E, et al. Spectroscopic and photothermal characterization of annatto: Applications in functional foods. *Dyes Pigments*. 2014;110: 72–79.

394. Yokohira M, Yamakawa K, Saoo K, Matsuda Y, Hosokawa K, Hashimoto N, et al. Antioxidant effects of flavonoids used as food additives (purple corn color, enzymatically modified isoquercitrin, and isoquercitrin) on liver carcinogenesis in a rat medium-term bioassay. *J Food Sci.* 2008;73: C561–C568.
395. Roehrs M, Figueiredo CG, Zanchi MM, Bochi GV, Moresco RN, Quatrin A, et al. Bixin and norbixin have opposite effects on glycemia, lipidemia, and oxidative stress in streptozotocin-induced diabetic rats. *Int J Endocrinol.* 2014;2014. Available: <http://www.scopus.com/inward/record.url?eid=2-s2.0-84895085752&partnerID=40&md5=332e5be9c29e6e264c925d7dbf73cb22>
396. Gupta R, Sharma AK, Dobhal MP, Sharma MC, Gupta RS. Antidiabetic and antioxidant potential of β -sitosterol in streptozotocin-induced experimental hyperglycemia. *J Diabetes.* 2011;3: 29–37.
397. Tilvis RS, Miettinen TA. Serum plant sterols and their relation to cholesterol absorption. *Am J Clin Nutr.* 1986;43: 92–97.
398. Weingärtner O, Böhm M, Laufs U. Controversial role of plant sterol esters in the management of hypercholesterolaemia. *Eur Heart J.* 2009;30: 404–409.
399. Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong L-YC. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. *J Am Med Assoc.* 2001;285: 2981–2986.
400. Christen WG, Glynn RJ, Chew EY, Albert CM, Manson JE. Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: The women's antioxidant and folic acid cardiovascular study. *Arch Intern Med.* 2009;169: 335–341.
401. Cox PA. *The ethnobotanical approach to drug discovery: Strengths and limitations.* Ethnobotany and the search for new drugs. 1st ed. Chichester, UK: John Wiley & Sons; 1994.
402. Balick MJ, Cox PA. Ethnobotanical research and traditional health care in developing countries. In: Bodeker G, Bhat KKS, Burley J, Vantomme P, editors. *Non-wood forest products 11: Medicinal plants for forest conservation and health care.* 3rd ed. Rome, Italy: Food and Agriculture Organization of the United Nations; 2003.
403. Houghton PJ, Howes M-J, Lee CC, Steventon G. Uses and abuses of in vitro tests in ethnopharmacology: Visualizing an elephant. *J Ethnopharmacol.* 2007;110: 391–400.
404. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: The Indian solid gold. *Adv Exp Med Biol.* 2007;595: 1–75.
405. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. *J Neurosci.* 2001;21: 8370–8377.
406. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, et al. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. *Clin Cancer Res.* 2004;10: 6847–6854.
407. Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NSL. Medicinal plants and Alzheimer's disease: From ethnobotany to phytotherapy. *J Pharm Pharmacol.* 1999;51: 527–534.
408. Adams M, Gmünder F, Hamburger M. Plants traditionally used in age related brain disorders—A survey of ethnobotanical literature. *J Ethnopharmacol.* 2007;113: 363–381.
409. Zhang P, Li J, Han Y, Yu XW, Qin L. Traditional Chinese medicine in the treatment of rheumatoid arthritis: A general review. *Rheumatol Int.* 2010;30: 713–718.
410. Altman RD, Marcussen KC. Effects of a ginger extract on knee pain in patients with osteoarthritis. *Arthritis Rheum.* 2001;44: 2531–2538.
411. Okuda T. Antioxidant phenolics in oriental medicine. In: Yagi, K, editor. *Active oxygens, lipid peroxides and antioxidants.* Tokyo, Japan: The Japan Science Society Press; 1993. p. 333.
412. Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, et al. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. *J Clin Oncol.* 2005;23: 2645–2654.
413. Vaya J, Belinky PA, Aviram M. Antioxidant constituents from licorice roots: Isolation, structure elucidation and antioxidative capacity toward LDL oxidation. *Free Radic Biol Med.* 1997;23: 302–313.
414. Kinghorn AD, Pan L, Fletcher JN, Chai H. The relevance of higher plants in lead compound discovery programs. *J Nat Prod.* 2011;74: 1539–1555.
415. Fearnley J. *Bee propolis: Natural healing from the hive (nature's remedies).* 1st ed. London, UK: Souvenir Press Ltd.; 2001.
416. Irmak MK, Koltuksuz U, Kutlu NO, Yağmurca M, Özyurt H, Karaman A, et al. The effect of caffeic acid phenethyl ester on ischemia-reperfusion injury in comparison with α -

- tocopherol in rat kidneys. *Urol Res.* 2001;29: 190–193.
417. Schreckinger ME, Lotton J, Lila MA, de Mejia EG. Berries from South America: a comprehensive review on chemistry, health potential, and commercialization. *J Med Food.* 2010;13: 233–246.
418. Afolayan AJ, Sunmonu TO. In vivo studies on antidiabetic plants used in South African herbal medicine. *J Clin Biochem Nutr.* 2010;47: 98–106.
419. Mustafa NR, Verpoorte R. Phenolic compounds in *Catharanthus roseus*. *Phytochem Rev.* 2007;6: 243–258.
420. Sahu SC, Ruggles DI, O'Donnell MW. Prooxidant activity and toxicity of nordihydroguaiaretic acid in clone-9 rat hepatocyte cultures. *Food Chem Toxicol.* 2006;44: 1751–1757.
421. Tang SY, Whiteman M, Jenner A, Peng ZF, Halliwell B. Mechanism of cell death induced by an antioxidant extract of *Cratogeomys cochinchinense* (YCT) in Jurkat T cells: The role of reactive oxygen species and calcium. *Free Radic Biol Med.* 2004;36: 1588–1611.
422. Verbeek R, Van Tol EAF, Van Noort JM. Oral flavonoids delay recovery from experimental autoimmune encephalomyelitis in SJL mice. *Biochem Pharmacol.* 2005;70: 220–228.
423. Williams JT, Haq N. Global research on underutilized crops: An assessment of current activities and proposals for enhanced cooperation. Southampton, UK: International Centre for Underutilized Crops, University of Southampton; 2002.
424. Duke JA, Bogenschutz-Godwin MJ, Ottesen AR. Duke's handbook of medicinal plants of Latin America. 1st ed. Boca Raton, USA: CRC Press; 2009.
425. Lim TK. Edible medicinal and non medicinal plants: Volume 9, Modified stems, roots, bulbs. Dordrecht, Netherlands: Springer Verlag; 2015.
426. Teixeira A, Baenas N, Dominguez-Perles R, Barros A, Rosa E, Moreno DA, et al. Natural bioactive compounds from winery by-products as health promoters: A review. *Int J Mol Sci.* 2014;15: 15638–15678.
427. Fagherazzi G, Vilier A, Lajous M, Boutron-Ruault M-C, Balkau B, Clavel-Chapelon F, et al. Wine consumption throughout life is inversely associated with type 2 diabetes risk, but only in overweight individuals: results from a large female French cohort study. *Eur J Epidemiol.* 2014;29: 831–839.
428. Kutil Z, Temml V, Maghradze D, Pribylova M, Dvorakova M, Schuster D, et al. Impact of wines and wine constituents on cyclooxygenase-1, cyclooxygenase-2, and 5-lipoxygenase catalytic activity. *Mediators Inflamm.* 2014; Article ID 178931: 8.
429. Rossi M, Praud D, Monzio Compagnoni M, Bellocco R, Serafini M, Parpinel M, et al. Dietary non-enzymatic antioxidant capacity and the risk of myocardial infarction: A case-control study in Italy. *Nutr Metab Cardiovasc Dis.* 2014;24: 1246–1251.
430. Russo M, Spagnuolo C, Bilotto S, Tedesco I, Maiani G, Russo GL. Inhibition of protein kinase CK2 by quercetin enhances CD95-mediated apoptosis in a human thymus-derived T cell line. *Food Res Int.* 2014;63: 244–251.
431. Law M, Wald N. Why heart disease mortality is low in France: The time lag explanation. *Br Med J.* 1999;318: 1471–1480.
432. Ferrières J. The French paradox: Lessons for other countries. *Heart.* 2004;90: 107–111.
433. Singleton VL. Grape and wine phenolics; background and prospects. *Wine Centennial Symposium* (p 215-227). Davis, USA: Proceedings of the University of California; 1982.
434. Alén-Ruiz F, García-Falcón MS, Pérez-Lamela MC, Martínez-Carballo E, Simal-Gándara J. Influence of major polyphenols on antioxidant activity in Mencía and Brancellao red wines. *Food Chem.* 2009;113: 53–60.
435. García-Falcón MS, Pérez-Lamela C, Martínez-Carballo E, Simal-Gándara J. Determination of phenolic compounds in wines: Influence of bottle storage of young red wines on their evolution. *Food Chem.* 2007;105: 248–259.
436. Robinson J, Harding J, Vouillamoz J. *Wine grapes: A complete guide to 1,368 vine varieties, including their origins and flavours.* London, UK: Penguin Group; 2012.
437. (OIV) International Organisation of Vine and Wine. Statistical report on world vitiviniculture. Castelluci F, editor. Paris, France: Statistics department of the International Organisation of Vine and Wine; 2012.
438. This P, Lacombe T, Thomas MR. Historical origins and genetic diversity of wine grapes. *Trends Genet.* 2006;22: 511–519.
439. Imazio S, Maghradze D, de Lorenzis G, Bacilieri R, Laucou V, This P, et al. From the cradle of grapevine domestication: Molecular overview and description of Georgian grapevine (*Vitis vinifera* L.) germplasm. *Tree Genet Genomes.* 2013;9: 641–658.

440. Gagunashvili B. La Géorgie, berceau de la vigne et du vin. *Rev Oenologues Tech Vitivinic Oenologiques*. 2006;120: 55–56.
441. Chkhikvishvili I, Gogia N, Sirbiladze G. Study of resveratrol and antioxidant activity in Georgian brand red wines and a number of foreign red wines. *Georgian Med News*. 2008; 53–57.
442. Shalashvili A, Targamadze I, Zambakhidze N, Chichua D, Nareklshvili V, Ugrekheldze D. Comparison of wines of Kakhetian and European types according to quantitative content of flavonoids and antiradical efficiency. *Bull Georgian Natl Acad Sci*. 2007;175: 102–104.
443. Mikiashvili M, Kiknavelidze Z, Khositashvili M, Nakhucrishvili B, Favale B, Ciolfi G. The hard part of grape cluster influence on the quality of kakhetian wine type. In: http://www.oiv2010.ge/POSTER/POST_OENOLOGY/P.II.47-No%20175%20P%20Kiknavelidze.pdf. 2010.
444. Mikiashvili M, Kiknavelidze Z, Khositashvili M, Khositashvili T, Favale S, Ciolfi G. The varietal effect of Georgian red grape cultivar Saperavi (*Vitis vinifera* L.) and Cabernet Sauvignon (*Vitis vinifera* L.) on consistence of phenolic compounds and aromatic components. In: http://www.oiv2010.ge/POSTER/POST_OENOLOGY/P.II.48-No%20178%20P%20Mikiashvili.pdf. 2010.
445. Glonti T. Phenolic sources of wine made from grapes of “Kakhuri Mtsvivani” and some other vine (*V. vinifera* L.) breeds. In: http://www.oiv2010.ge/POSTER/POST_OENOLOGY/P.II.18-No%2085%20P%20Glonti%20Teimuraz%20Phenolicsources%20corr%20Volatile%20aroma-forming%20compounds.pdf. 2010.
446. Glonti T, Glonti Z. The remarkable qvevri wine. Tbilisi, Georgia: Qvevri foundation; 2011.
447. Addis G, Urga K, Dikasso D. Ethnobotanical study of edible wild plants in some selected districts of Ethiopia. *Hum Ecol*. 2005;33: 83–118.
448. Hecht SB, Cockburn A. The Fate of the forest: Developers, destroyers, and defenders of the Amazon, Updated Edition. Chigaco, USA: University of Chicago Press; 2010.
449. Feeley KJ, Silman MR. Extinction risks of Amazonian plant species. *Proc Natl Acad Sci U S A*. 2009;106: 12382–12387.
450. Smith NP, Henderson A, Stevenson DW. Flowering plants of the Neotropics. New Jersey, USA: Princeton University Press; 2003.
451. Duke JA, Vásquez R. Amazonian ethnobotanical dictionary. 1st ed. Boca Raton, USA: CRC Press; 1994.
452. Barbalho SM, de Alvares Goulart R, Farinazzi-Machado FMV, de Souza MSS, dos Santos Bueno PC, Guiguer ÉL, et al. *Annona* sp: Plants with multiple applications as alternative medicine - a review. *Curr Bioact Compd*. 2012;8: 277–286.
453. Smith RE, Tran K, Richards KM. Bioactive annonaceous acetogenins. *Stud Nat Prod Chem*. 2014;41: 95–117.
454. Lim TK. Edible medicinal and non medicinal plants: Fruits. Dordrecht, Netherlands: Springer; 2012.
455. Pompeu DR, Rogez H, Monteiro KM, Tinti SV, Carvalho JE. Antioxidant capacity and pharmacologic screening of crude extracts of *Byrsonima crassifolia* and *Inga edulis* leaves. *Acta Amaz*. 2012;42: 165–172.
456. Souza JNS, Silva EM, Da Silva MN, Arruda MSP, Larondellea Y, Rogez H. Identification and antioxidant activity of several flavonoids of *Inga edulis* leaves. *J Braz Chem Soc*. 2007;18: 1276–1280.
457. Zambrana NYP, Byg A, Svenning J-C. Diversity of palm uses in the western Amazon. *Biodivers Conserv*. 16: 2771–2787.
458. Sosnowska J, Balslev H. American palm ethnobotany: A meta-analysis. *J Ethnobiol Ethnomedicine*. 2009;5.
459. Rezaire A, Robinson J-C, Bereau D, Verbaere A, Sommerer N, Khan MK, et al. Amazonian palm *Oenocarpus bataua* (“patawa”): Chemical and biological antioxidant activity – Phytochemical composition. *Food Chem*. 2014;149: 62–70.
460. Mengistu F, Hager H. Wild edible fruit species cultural domain, informant species competence and preference in three districts of Amhara region, Ethiopia. *Ethnobot Res Appl*. 2008;6: 487–502.
461. Hedberg I, Edwards S, Nemomissa S. Flora of Ethiopia and Eritrea, Volume 4, Part 1: Apiaceae to Dipsacaceae. Uppsala, Sweden: Uppsala University; 2003.
462. Engels JMM. Plant genetic resources of Ethiopia. 1st ed. Cambridge, UK: Cambridge University Press; 2008.
463. Eyob S, Martinsen BK, Tsegaye A, Appelgren M, Skrede G. Antioxidant and antimicrobial activities of extract and essential oil of korarima (*Aframomum corrorima* (Braun) P.C.M. Jansen). *Afr J Biotechnol*. 2008;7: 2585–2592.


464. Mesfin F, Demissew S, Teklehaymanot T. An ethnobotanical study of medicinal plants in Wonago Woreda, SNNPR, Ethiopia. *J Ethnobiol Ethnomedicine*. 2009;5: 28. 34250811364&partnerID=40&md5=bfec577c6341d7afa177c10a8eb43c40
465. Omosa LK, Midiwo JO, Derese S, Yenesew A, Peter MG, Heydenreich M. Neo-Clerodane diterpenoids from the leaf exudate of *Dodonaea angustifolia*. *Phytochem Lett*. 2010;3: 217–220.
466. Huang D-M, Shen Y-C, Wu C, Huang Y-T, Kung F-L, Teng C-M, et al. Investigation of extrinsic and intrinsic apoptosis pathways of new clerodane diterpenoids in human prostate cancer PC-3 cells. *Eur J Pharmacol*. 2004;503: 17–24.
467. Van Nguyen H, Van Pham C, Nguyen TTH, Van Tran H, Doan TMH. Novel antioxidant neo-clerodane diterpenoids from *scutellaria barbata*. *Eur J Org Chem*. 2009; 5810–5815.
468. Ma M, Jiang Z, Ruan J, Tan X, Liu J, Wang C, et al. The furano norclerodane diterpenoid disobulbin-D induces apoptosis in normal human liver L-02 cells. *Exp Toxicol Pathol*. 2012;64: 611–618.
469. Singh KN, Lal B. Ethnomedicines used against four common ailments by the tribal communities of Lahaul-Spiti in western Himalaya. *J Ethnopharmacol*. 2008;115: 147–159.
470. Giday M, Asfaw Z, Woldu Z. Medicinal plants of the Meinit ethnic group of Ethiopia: An ethnobotanical study. *J Ethnopharmacol*. 2009;124: 513–521.
471. Yang Y, Yan Y-M, Wei W, Luo J, Zhang L-S, Zhou X-J, et al. Anthraquinone derivatives from *Rumex* plants and endophytic *Aspergillus fumigatus* and their effects on diabetic nephropathy. *Bioorg Med Chem Lett*. 2013;23: 3905–3909.
472. Gautam R, Karkhile KV, Bhutani KK, Jachak SM. Anti-inflammatory, cyclooxygenase (COX)-2, COX-1 inhibitory, and free radical scavenging effects of *Rumex nepalensis*. *Planta Med*. 2010;76: 1564–1569.
473. Liang H-X, Dai H-Q, Fu H-A, Dong X-P, Adebayo AH, Zhang L-X, et al. Bioactive compounds from *Rumex* plants. *Phytochem Lett*. 2010;3: 181–184.
474. Teklehaymanot T. Ethnobotanical study of knowledge and medicinal plants use by the people in Dek Island in Ethiopia. *J Ethnopharmacol*. 2009;124: 69–78.
475. Teklehaymanot T, Giday M. Ethnobotanical study of medicinal plants used by people in Zegie Peninsula, Northwestern Ethiopia. *J Ethnobiol Ethnomedicine*. 2007;3. Available: [http://www.scopus.com/inward/record.url?eid=2-s2.0-](http://www.scopus.com/inward/record.url?eid=2-s2.0-34250811364&partnerID=40&md5=bfec577c6341d7afa177c10a8eb43c40)
476. Talib WH, Mahasneh AM. Antiproliferative activity of plant extracts used against cancer in traditional medicine. *Sci Pharm*. 2010;78: 33–45.
477. Umer S, Asres K, Veeresham C. Hepatoprotective activities of two Ethiopian medicinal plants. *Pharm Biol*. 2010;48: 461–468.
478. Afifi MSA, Ahmed MM, Pezzuto JM, Douglas Kinghorn A. Cytotoxic flavonolignans and flavones from *Verbascum sinaiticum* leaves. *Phytochemistry*. 1993;34: 839–841.
479. Wikipedia Commons, SVG locator maps. https://commons.wikimedia.org/wiki/Category:SVG_locator_maps_%28location_map_scheme%29 [Internet]. 23 Jul 2015.
480. Sharma OP, Bhat TK. DPPH antioxidant assay revisited. *Food Chem*. 2009;113: 1202–1205.
481. Ou B, Hampsch-Woodill M, Prior RL. Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe. *J Agric Food Chem*. 2001;49: 4619–4626.
482. Cao G, Prior RL. Measurement of oxygen radical absorbance capacity in biological samples. *Methods Enzymol*. 1998;299: 50–62.
483. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J Immunol Methods*. 1983;65: 55–63.
484. McDonald MS, Hughes M, Burns J, Lean MEJ, Matthews D, Crozier A. Survey of the free and conjugated myricetin and quercetin content of red wines of different geographical origins. *J Agric Food Chem*. 1998;46: 368–375.
485. Landrault N, Pouchet P, Ravel P, Gasc F, Cros G, Teissedre P-L. Antioxidant capacities and phenolics levels of French wines from different varieties and vintages. *J Agric Food Chem*. 2001;49: 3341–3348.
486. Atanacković M, Petrović A, Jović S, Bukarica LG-, Bursać M, Cvejić J. Influence of winemaking techniques on the resveratrol content, total phenolic content and antioxidant potential of red wines. *Food Chem*. 2012;131: 513–518.
487. Goldberg DM, Tsang E, Karumanchiri A, Soleas GJ. Quercetin and p-coumaric acid concentrations in commercial wines. *Am J Enol Vitic*. 1998;49: 142–151.
488. Goldberg DM, Karumanchiri A, Soleas GJ, Tsang E. Concentrations of selected polyphenols

- in white commercial wines. *Am J Enol Vitic.* 1999;50: 185–193.
489. Zúñiga MC, Pérez-Roa RE, Olea-Azar C, Laurie VF, Agosin E. Contribution of metals, sulfur-dioxide and phenolic compounds to the antioxidant capacity of Carménère wines. *J Food Compos Anal.* 2014;35: 37–43.
490. Souza JNS, Silva EM, Loir A, Rees J-F, Rogez H, Larondelle Y. Antioxidant capacity of four polyphenol-rich Amazonian plant extracts: A correlation study using chemical and biological in vitro assays. *Food Chem.* 2008;106: 331–339.
491. Anusuya N, Gomathi R, Manian S, Sivaram V, Menon A. Evaluation of *Basella rubra* L., *Rumex nepalensis* Spreng. and *Commelina benghalensis* L. for antioxidant activity. *Int J Pharm Pharm Sci.* 2012;4: 714–720.
492. Koolen HH, da Silva F, Gozzo FC, de Souza AQ, de Souza AD. Antioxidant, antimicrobial activities and characterization of phenolic compounds from Buriti (*Mauritia flexuosa* L. f.) by UPLC-ESI-MS/MS. *Food Res Int.* 2013;51: 467–473.
493. Tchuenmogne AM, Donfack EV, Kongue MD, Lenta BN, Ngouela S, Tsamo E, et al. Ingacameroul, a new flavonol and other chemical constituents from leaves and stem bark of *Inga edulis* Mart. *Bull Korean Chem Soc.* 2013;34: 3859–3862.
494. Omosa LK, Amugune B, Ndunda B, Milugo TK, Heydenreich M, Yenesew A, et al. Antimicrobial flavonoids and diterpenoids from *Dodonaea angustifolia*. *South Afr J Bot.* 2014;91: 58–62.
495. Mahmoud SM, Abdel-Azim NS, Shahat AA, Ismail SI, Hammouda FM. Phytochemical and biological studies on *Verbascum sinaiticum* growing in Egypt. *Nat Prod Sci.* 2007;13: 186–189.

9 Appendices

Appendix A:

Tauchen J, Maršík P, Kvasnicová M, Maghradze D, Kokoška L, Vaněk T, Landa P. In vitro antioxidant activity and phenolic composition of Georgian, Central and West European wines. *Journal of Food Composition and Analysis*. 2015;41: 113-121.



Original Research Article

In vitro antioxidant activity and phenolic composition of Georgian, Central and West European wines



Jan Tauchen^{a,b}, Petr Marsik^b, Marie Kvasnicova^b, David Maghradze^c, Ladislav Kokoska^a, Tomas Vanek^{b,*}, Premysl Landa^{b,*}

^a Department of Crop Science and Agroforestry, Faculty of Tropical AgriSciences, Czech University of Life Sciences Prague, Kamycka 129, 165 21 Praha 6 – Suchbát, Czech Republic

^b Laboratory of Plant Biotechnologies, Institute of Experimental Botany AS CR, v.v.i., Rozvojova 263, 165 02 Prague 6 – Lysolaje, Czech Republic

^c Institute of Horticulture, Viticulture and Oenology, Agricultural University of Georgia, David Aghmashenebeli Alley, 13th km, 0159 Tbilisi, Georgia

ARTICLE INFO

Article history:

Received 15 August 2014

Received in revised form 22 December 2014

Accepted 30 December 2014

Available online 5 March 2015

Chemical compounds studied in this article:

Gallic acid (PubChem CID: 370)

Syringic acid (PubChem CID: 10742)

Epigallocatechin gallate (PubChem CID: 65064)

p-Coumaric acid (PubChem CID: 637542)

Ferulic acid (PubChem CID: 445858)

Rutin (PubChem CID: 5280805)

Myricetin (PubChem CID: 5281672)

Resveratrol (PubChem CID: 445154)

Quercetin (PubChem CID: 5280343)

Kaempferol (PubChem CID: 5280863)

Keywords:

Red wine

White wine

Antioxidant activity

HPLC

Kakhetian fermentation method

Phenolic compounds

Rkatsiteli

Saperavi

Food composition

ABSTRACT

Georgia is a traditional country of viticulture and winemaking but only a few studies have been focused on wines originating from this area. In this study, we compared antioxidant effect, total sulfite content and concentration of 14 phenolic compounds of some native Georgian red and white wines with wines commonly produced in Central and Western Europe. Georgian red wines exhibited higher antioxidant capacity in DPPH, ORAC and total phenolic content assay. Further, Georgian red wines were richer in quercetin, kaempferol and syringic acid content, while the concentration of *trans*-resveratrol was lower than in Central and West European red wines. While differences among red wines from different origins and cultivars were observed, winemaking technology was the most important factor in the case of white wines. Kakhetian method increased antioxidant effect and levels of some phenolic compounds in comparison with white wines prepared by common European method. Our findings suggest that Georgian wines deserve further attention because of their high content of phenolics and high antioxidant capacity.

© 2015 Elsevier Inc. All rights reserved.

1. Introduction

Antioxidant activity of natural products has received much interest over the past few years, both in public and scientific community. Generally, it is believed that consumption of plant phenolics decreases the risk of occurrence of diseases related to

oxidative stress (Georgiev et al., 2014). This biological effect is explained by the ability of these compounds to act as antioxidant agents; i.e. act as regulators of unwanted damaging oxidative processes (Liang et al., 2014; Gris et al., 2013). Therefore, the identification of foodstuff rich in phenolic compounds is still important.

Grapevine and its products are considered to be one of the richest natural sources of phenolic compounds such as phenolic acids, stilbenes, flavonoids, and anthocyanidins (Teixeira et al., 2014). Accordingly, the moderate wine consumption is nowadays

* Corresponding authors. Tel.: +420 225 106 832; fax: +420 225 106 456.

E-mail addresses: vaneke@ueb.cas.cz (T. Vanek), landa@ueb.cas.cz (P. Landa).

recognized as risk-reducing factor in several human diseases related to oxidative-stress such as cancer, type 2 diabetes, inflammation and myocardial infarction (Fagherazzi et al., 2014; Kutil et al., 2014; Rossi et al., 2014; Russo et al., 2014). Composition of health-promoting chemicals (e.g. phenolics) presented in wine is influenced by many factors such as winemaking procedure, conditions of maturation and storage, grape cultivar, soil, nutrition, climatic conditions and weather (Singleton, 1982; de Pascali et al., 2014; King et al., 2014; Ivanova-Petropulos et al., 2015). Large proportion of nearly 1400 cultivars used for commercial production of wine (Robinson et al., 2012), stays still undiscovered by means of phytochemical composition, biological activities and herewith connected health-promoting properties.

Georgia, which is considered to be cradle of the world's winemaking (This et al., 2006), is one of the countries where many local grapevine varieties are cultivated. It is believed that viticulture and winemaking first began in the South Caucasus region around 6000 years ago, and this fact is supported by several archeological findings (Imazio et al., 2013). At present, the Georgian vine gene pool contains up to 525 white and red varieties (Maghradze et al., 2012). However, to the best of our knowledge, only scarce information about phytochemical profile and antioxidant activity of Georgian wines is available. Chkhikvishvili et al. (2008) compared antioxidant activity and the content of *trans*- and *cis*-resveratrol in Georgian (from cultivars Saperavi, Kakhuri Tsarchinebuli), European, and South and North American red wines. A comparison among several red and white wines produced by Kakhetian and European method in total content of phenolics, catechins, proanthocyanidins, anthocyanins and antioxidant activity was published by Shalashvili et al. (2007). Recently Shalashvili et al. (2012) investigated the content of some flavonoids, phenolic acids and resveratrol in Georgian wines prepared from local cultivars Saperavi (red) and Rkatsiteli (white). The content of catechins, hydroxycinnamic acids, volatile compounds and their glycosides in wines prepared by Kakhetian (juice fermented with skins, seeds, and bunch stems in clay vessel [kvevri] dug into the ground for three to five months) and European wine making processes (juice fermented without stems for 7–30 days; white wines fermented without the presence of pomace) has been compared by Mikiashvili et al. (2010a,b). The content of total catechins, proanthocyanidins, flavanols, and some phenolic acids in wines produced from white cultivars Kakhuri Mtsvivani, Rkatsiteli, Kakhuri Mtsvane, and Khikhvi prepared by Kakhetian and European wine making method was investigated by Glonti (2010a). Glonti and Glonti (2013) also published extensive study where total phenolics, sulfur, various volatile compounds, amino acids, and minerals were quantified in wines fermented in kvevri and by standard process.

In our study, we investigated antioxidant activity (using ORAC and DPPH method), total phenolic content, total sulfite content and quantified 14 phenolic compounds (by HPLC-UV/Vis method) including phenolic acids, flavonoids and stilbenes in Georgian red (Alexandrouli, Saperavi and cuvee of Saperavi and Saperavi Budeshuriseburi) and white wines (Rkatsiteli, and cuvee of Rkatsiteli and other local cultivars). Central and West European red (Cabernet Moravia, Cabernet Sauvignon, Pinot Noir) and white wines (Chardonnay, Sauvignon Blanc) were assayed with the aim to compare the differences between regions and cultivars.

2. Materials and methods

2.1. Wines

Red and white wine samples were acquired from different regions of Georgia, Czech Republic, France, Italy, and Austria, and were provided by local producers or purchased from supermarkets

or wine stores. A total of 26 red wines of the cultivars Pinot Noir ($n = 5$), Cabernet Sauvignon ($n = 7$), Cabernet Moravia ($n = 2$), Seperavi ($n = 9$), cuvee of Saperavi and Saperavi Budeshuriseburi ($n = 2$), and Alexandrouli ($n = 1$) and 13 white wine samples of the cultivars Chardonnay ($n = 6$), Sauvignon Blanc ($n = 3$), Rkatsiteli ($n = 2$), and cuvee of Rkatsiteli and other local cultivars ($n = 2$) were assayed. Detailed information about tested wines (cultivar, vintage, producer, origin and wine type) is given in Table 1.

2.2. Winemaking methods

The majority of red and white wines included in this study were made based on the common "European methods". However, white wine samples RK 1 and RK 4 from Georgia, were made by the Kakhetian method, which is one of method elaborated in Georgia. This style of wine is based on long period (up to 5 month) maceration and fermentation of must with usage of 100% of grape pomace (skin, seeds, stems) in clay vessel called "kvevri" buried under ground (Gagunashvili, 2006; Glonti, 2010a,b).

2.3. Reagents, solvents and standards

2,2'-azobis(2-methylpropionamide) dihydrochloride (AAPH, purity 97.0%), 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,6-di-*tert*-butyl-4-methylphenol (BHT, $\geq 99.0\%$), (\pm)-6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (trolox, 97.0%), analytical grade quality solvents, Folin-Ciocalteu reagent, fluorescein sodium salt (FL, 93.3%), fluorosalicylic acid (97.0%), standards of phenolic acids: 3,4-dihydroxybenzoic (purity $\geq 97\%$), caffeic ($\geq 98\%$), chlorogenic (94.9%), gallic (97.9%), ferulic (99.0%), *p*-coumaric ($\geq 98\%$), syringic ($\geq 95\%$) and vanillic acid ($\geq 97\%$); flavonoids: epigallocatechin gallate ($\geq 95\%$), kaempferol ($\geq 97\%$), myricetin ($\geq 96\%$), quercetin ($\geq 95\%$) and rutin ($\geq 95\%$), and stilbene resveratrol (99.0%) were obtained from Sigma-Aldrich (Prague, Czech Republic). Inorganic salts of p.a. grade used for buffer preparation and total phenolic content assessment were purchased from Lach-ner (Brno, Czech Republic).

2.4. Antioxidant activity

2.4.1. DPPH radical-scavenging assay

The antioxidant effect of wine and positive control (trolox) was tested using DPPH assay according to the slightly modified method previously described by Sharma and Bhat (2009). Two-fold serial dilution of each sample was prepared in absolute methanol (175 μL) in 96-well microtiter plate. Subsequently, 25 μL of freshly prepared 0.4 mM DPPH solution in methanol was added to each well (final volume 200 μL), creating a range of concentration 50–0.78125 $\mu\text{L mL}^{-1}$ for red wines and 500–7.8125 $\mu\text{L mL}^{-1}$ for white wines. Range of concentration for trolox (used as a reference antioxidant) was settled at 80–1.25 $\mu\text{g mL}^{-1}$ and calibration curve was thereafter established. Mixture was kept in dark at room temperature for 30 min. Absorbance was measured at 517 nm using Infinite 200 reader (Tecan, Männedorf, Switzerland). Results were expressed as trolox equivalents (g TE L⁻¹ wine).

2.4.2. Oxygen radical absorbance capacity (ORAC) assay

Slightly modified method previously described by Ou et al. (2001) was used. Firstly, outer wells of black 96-well microtiter plates were filled with 200 μL of distilled water, in order to provide better thermal mass stability. Stock solution of AAPH radical and FL were prepared in 75 mM phosphate buffer (pH 7.0). Each sample (25 μL) was diluted in 150 μL FL (48 nM) and incubated in 37 °C for 10 min. Reaction was started by application of 25 μL AAPH (153 mM) yielding final volume of 200 μL and final dilution at 1:4000 for red wines and 1:800 for white wines (in phosphate

Table 1
Information on variety, producer, origin and type of studied wines.

Wine code	Cultivar and vintage	Producer	Origin	Wine type
PN 1	Pinot Noir, 2008	VINIUM Velké Popovice	Moravia, Czech Republic	Red dry
PN 2	Pinot noir, 2010	Augustinian cellar Neoklas	Moravia, Czech Republic	Red dry
PN 3	Pinot noir, 2007	Gsellmann & Hans	Burgenland, Austria	Red dry
PN 4	Pinot noir, 2008	Virely Arcelain	Bourgogne, France	Red dry
PN 5	Pinot noir, 2007	André Goichot	Bourgogne, France	Red dry
CS 1	Cabernet Sauvignon, 2010	Famiglia Cielo	Venetia, Italy	Red dry
CS 2	Cabernet Sauvignon, 2010	Folonari	Venetia, Italy	Red dry
CS 3	Cabernet Sauvignon, 2010	Brise de France	N/A ^a , France	Red dry
CS 4	Cabernet Sauvignon, 2011	Jean D'Aosque	Languedoc, France	Red dry
CS 5	Cabernet Sauvignon, N/A ^a	Vino Mikulov	Moravia, Czech Republic	Red dry
CS 6	Cabernet Sauvignon, 2008	Templar cellars Čejkovice	Moravia, Czech Republic	Red dry
CS 7	Cabernet Sauvignon, 2005	Teliani valley PLC	Teliani, Georgia	Red dry
CM 1	Cabernet Moravia, N/A ^a	Templar cellars Čejkovice	Moravia, Czech Republic	Red dry
CM 2	Cabernet Moravia, 2007	Vinselekt Michlovský	Moravia, Czech Republic	Red dry
SA 1	Saperavi, 2008	P.E. Givi Nikolashvili	Gurjaani, Georgia	Red dry
SA 2	Saperavi, 2007	Teliani valley PLC	Tsinandali, Georgia	Red dry (aged in oak, unfiltered)
SA 3	Saperavi, 2005	Teliani valley PLC	Napareuli, Georgia	Red dry
SA 4	Saperavi, 2006	Teliani valley PLC	Mukuzani, Georgia	Red dry
SA 5	Saperavi, 2004	Teliani valley PLC	Kidzmarauli, Georgia	Red semi-sweet
SA 6	Saperavi, 2006	Geovan Wine	Kakheti, Georgia	Red dry
SA 7	Saperavi, 2010	Tbilvino	Kakheti, Georgia	Red dry
SA 8	Saperavi, 2009	Kindzmarauli Marani	Kakheti, Georgia	Red dry
SA 9	Saperavi, 2007	Kindzmarauli Marani	Kakheti, Georgia	Red dry (barrel aged)
SA 10	Kvareli (Saperavi + Saperavi Budeshuriseburi), 2005	Kindzmarauli Marani	Kakheti, Georgia	Red dry
SA 11	Saperavi (95%) + Saperavi Budeshuriseburi (5%), N/A ^a	Kindzmarauli Marani	Kakheti, Georgia	Red dry (fermented 25–30 days)
AL 1	Alexandrouli, 2007	Chrebalo Wine Factory	Ambrolauri district, Georgia	Red dry
CH 1	Chardonnay, 2011	VINIUM Velké Pavlovice	Moravia, Czech Republic	White dry
CH 2	Chardonnay, N/A ^a	Chateau Valtice	Moravia, Czech Republic	White dry
CH 3	Chardonnay, 2010	Folonari	Venetia, Italy	White dry
CH 4	Chardonnay, 2010	Delibori	Venetia, Italy	White dry
CH 5	Chardonnay, 2011	Joseph Castalan	Pays d'oc, France	White dry
CH 6	Chardonnay, 2010	André Goichot	Bourgogne, France	White dry
SB 1	Sauvignon Blanc, 2010	Famiglia Cielo	Venetia, Italy	White dry
SB 2	Sauvignon Blanc, 2011	Brise de France	N/A ^a , France	White dry
SB 3	Sauvignon Blanc, 2008	VINIUM Velké Pavlovice	Moravia, Czech Republic	White dry
RK 1	Rkatsiteli, 2010	Institute of Horticulture, Viticulture and Oenology (IHVO)	Kakheti, Georgia	White dry (fermented by Kakhetian method)
RK 2	Rkatsiteli, 2009	Tbilvino	Kakheti, Georgia	White
RK 3	Rkatsiteli + Mtsvane, 2008	Geovan Wine	Kakheti, Georgia	White dry
RK 4	Rkatsiteli (50%) + Mtsvane Kakhuri (20%) + Khikhvi (15%) + Kisi (15%), N/A ^a	Kindzmarauli Marani	Kakheti, Georgia	Amber (fermented by Kakhetian method)

^a Information not available.

buffer). Trolox was tested at range of concentration 4–0.5 $\mu\text{g mL}^{-1}$ and calibration curve was thereafter established. Fluorescence changes were measured in one minute intervals for 120 min with emission and absorbance wavelengths were set at 494 nm and 518 nm, respectively. Antioxidant capacity was calculated as area under the calibration curve as proposed by (Cao and Prior, 1998). Results were expressed as trolox equivalents (g TE L⁻¹ wine).

2.4.3. Total phenolic content (TPC) assay

Total phenolic compounds were measured using modified method previously described by Singleton et al. (1998). Sample in volume of 100 μL (dilution: red wine:water 1:19; white wine:water 1:1) was added to 96-well microtiter plate. Range of concentration of gallic acid (used as a reference compound) was settled at 16.7–0.008 $\mu\text{g mL}^{-1}$. Thereafter, 25 μL of pure Folin-Ciocalteu reagent was added. Plate was inserted in orbital shaker at 100 rpm for 10 min. Reaction was started by addition of 75 μL 20% Na_2CO_3 . Mixture was kept in dark at 37 °C for 2 h and then absorbance was measured at 700 nm. Results were expressed as gallic acid equivalents (g GAE L⁻¹ wine).

2.4.4. Total sulfite content assay

Commercially available kit Enzytec™ Color SO₂-Total kit (R-Biopharm AG, Darmstadt, Germany) was used for the quantification

of total sulfites in wine samples. The test was performed according to manufacturer's instructions with slight modifications. Briefly, sample solutions were prepared by mixing 950 μL of buffer with 50 μL of each sample. Sample solution (200 μL) was added to 96-well microtiter plate and measured using Infinite 200 reader with absorbance set at 340 nm. Thereafter, 40 μL of chromogen was added and 200 μL of this solution was transferred to new 96-well microtiter plate and measured at 340 nm again. Calibration curve was constructed by using calibrator (SO₂) in concentration range between 300 and 0 mg L⁻¹. Difference in optical densities (ΔA) was calculated as $\Delta A = (A_2 - R_f \times A_1)_{\text{sample or calibrator}} - (A_2 - R_f \times A_1)_{\text{blank}}$, where A_2 is the absorbance value acquired from the second measurement and A_1 absorbance value of samples before application of the chromogen. R_f refer to diffraction factor which was settled at 0.952 according to manufacturer's instructions. Total sulfite content was further calculated according to following equation: $C_{\text{sample}} = C_{\text{calibrator}} / \Delta A_{\text{calibrator}} \times \Delta A_{\text{sample}}$. Results were expressed as mg SO₂ mL⁻¹ wine.

2.5. High performance liquid chromatography (HPLC) analysis

2.5.1. Extraction procedure

Each wine sample (4.75 mL) was treated by addition of 150 μL BHT (200 μg dissolved in 1 mL of methanol) to prevent oxidation

of phenolic compounds. As inner standard 100 μL of fluorosalicylic acid (200 μg dissolved in 1 mL of methanol) was used. Each sample was acidified to pH 2.8 by adding 10 μL of 35% HCl. Remaining alcohol (ethanol and methanol) presented in each wine was further evaporated by inserting sample to refrigerated CentriVap concentrator (Labconco, Kansas City, MO, USA) for 2 h under 50 $^{\circ}\text{C}$. Extraction procedure was performed by liquid–liquid extraction using 5 mL of diethylether. Wine:diethylether solution was vortexed for 60 s. Separation of the ether layer was facilitated by centrifugation at 3500 rpm for 5 min. Extraction procedure was repeated three times and provided about 15 mL of ether extract which was further evaporated to dryness on rotary evaporator R210 (Büchi, Flawil, Switzerland). Residue was dissolved in 500 μL acetonitrile:water (50:50) solution and poured into HPLC vial glass for further analysis.

2.5.2. HPLC-UV/Vis

Apparatus consisted of autosampler Midas (Spark, Emmen, Netherlands), thermostat (Midas, Spark, Emmen, Netherlands) and pump (Q-Grad, Watrex, Prague, Czech Republic). System was coupled on-line to UV6000 LP detector (SpectraSystem, ThermoFinnigan, Waltham, MA, USA) and was controlled by software Clarity (DataApex, Prague, Czech Republic) and EZ-Chrom Elite (ThermoFinnigan, Waltham, MA, USA). For identification of simple phenolic acids, stilbenes and flavonoids, Kinetex (2.6 μm) PFP, 100 A (150 \times 4.6 mm) column was used (Phenomenex, Torrance, CA, USA). Gradient elution was carried out employing mobile phase

A (water with 0.5% acetic acid) and B (acetonitrile with 0.5% acetic acid) as follows: 0 min, 96:4 (A:B); 10 min, 85:15; 14 min, 79:21; 25 min, 78:22; 34 min, 59:41; 38 min, 0:100; 48 min, 0:100; 51 min, 96:4; 61 min, 96:4. Injection volume was settled at 10 μL , flow rate at 1 mL/min and thermostat temperature at 33 $^{\circ}\text{C}$.

2.5.3. Quantitative analysis

UV absorption was monitored at wavelengths between 194 and 500 nm. Quantification was done under 260 and 300 nm (chromatogram of wine sample SA 8 and chromatogram of standard solution is shown in Fig. 1). Evaluation of acquired data was performed in software Clarity (DataApex, Prague, Czech Republic) and EZ-Chrom Elite (ThermoFinnigan, Waltham, MA, USA). Standard calibration curves were obtained in a concentration range of 100–0.2 $\mu\text{g mL}^{-1}$ with nine concentrations levels (100, 50, 20, 10, 5, 2, 1, 0.5, 0.2 $\mu\text{g mL}^{-1}$). UV peak areas of the external standards (at each concentration) were plotted against the corresponding standard concentrations ($\mu\text{g mL}^{-1}$) using weighed linear regression to generate standard curve. Retentions times and linear equations for each standard are given in Supplementary Table S1. Amount of compounds were finally expressed as $\mu\text{g mL}^{-1}$ wine.

2.5.4. Method validation

Linearity of calibration based on regression analysis was obtained at all measured concentration levels. The coefficients of determination (R^2) for particular compounds are shown in Supplementary Table S1.




Fig. 1. Chromatogram of wine sample SA 8 (A) in comparison to standard solution (B) at concentration of 50 $\mu\text{g mL}^{-1}$. 1 = gallic acid; 2 = 3,4-dihydroxybenzoic acid; 3 = chlorogenic acid; 4 = vanillic acid; 5 = caffeic acid; 6 = syringic acid; 7 = epigallocatechin gallate; 8 = *p*-coumaric acid; 9 = rutin; 10 = ferulic acid; 11 = myricetin; 12 = resveratrol; 13 = quercetin; 14 = kaempferol.

Limit of detection (LOD) as well as limit of quantification (LOQ) were calculated from the standard additional curves as a 1:3 and 1:10 signal-to-noise ratio, respectively. For the measured compounds, LOD and LOQ ranged between 0.010–0.398 and 0.012–0.790 $\mu\text{g mL}^{-1}$, respectively (for details see Supplementary Table S1).

The precision of the HPLC measurement expressed as relative standard deviation (RSD, %) was evaluated by five replicate injections of standard solution and randomly selected wine sample during the same day. The precision for the standards and samples ranged between 2.1–9.7% and 1.3–14.7%, respectively. The detailed data for all analyzed compounds are listed in Supplementary Table S1.

Accuracy of measurement was determined as the average deviation between computed and obtained concentrations of standards in spiked samples. The recovery for the measured compounds varied from 2.6 to 10.9% (for details see Supplementary Table S1).

Repeatability of the extraction method was determined as recovery of spiked standards solved in freshly prepared wine samples. Recoveries of gallic acid, 3,4-hydroxybenzoic acid, chlorogenic acid, vanillic acid, caffeic acid, syringic acid, epigallocatechin gallate, *p*-coumaric, rutin, ferulic acid, myricetin, resveratrol, quercetin and kaempferol were determined at 50 $\mu\text{g mL}^{-1}$. The recovery was expressed as percentage of corresponding determined concentration of pure standards. The value was computed as an average of five technical replicates. Recovery values of analyzed compounds ranged from 82.7 to 105.7% (Supplementary Table S2).

2.6. Statistical analysis

In vitro antioxidant experiments were performed in three separate experiments, each in duplicate. Results were expressed as mean values with standard deviations (mean \pm SD). Extraction and HPLC/UV-Vis analyses were performed two times for each sample. HPLC data (concentration of studied compounds) were expressed as mean.

For further statistical analyses, wine samples were grouped according to color (red and white) and further into three groups according to their production area: Georgia, Central Europe and Western Europe. Georgian group consisted, up to one exception (CS 7 – Cabernet Sauvignon), of Georgian autochthonous cultivars Saperavi, Alexandrouli, and Saperavi Budeshuriseburi only (present only in the cuvee with Saperavi) in the case of red wines and Rkatsiteli, Mtsvane, Khikhvi, and Kisi (last three cultivars present only in the cuvee with Rkatsiteli). Central European group consisted from Cabernet Sauvignon, Pinot Noir, Cabernet Moravia cultivars from Czech Republic and Austria in the case of red wines and Chardonnay and Sauvignon Blanc from Czech Republic in the case of white wines. West European group consisted from Cabernet Sauvignon and Pinot Noir cultivars from France and Italy in the case of red wines and Chardonnay and Sauvignon Blanc from France and Italy in the case of white wines.

Values recorded in DPPH, ORAC, TPC, and SO_2 assay and concentrations of 14 compounds were analyzed using one way analysis of variance (ANOVA) followed by Tukey's test in order to ascertain possible significant differences between groups. Linear correlation coefficients (*r*) between total sulfite content and antioxidant assays DPPH and ORAC were established using Pearson product moment correlation. For all statistical tests STATISTICA 8.0 (StatSoft Inc., Tulsa, OK, USA) software was used.

3. Results and discussion

3.1. Antioxidant activity

Georgian red wines possessed significantly higher antioxidant activity (complete results for each sample are summarized in Table 2; average values for samples separated according to

Table 2

Antioxidant activity measured by DPPH and ORAC, total phenolic content (TPC) and total sulfite content of tested wines (mean \pm standard deviation).

Wine code	DPPH [g TE ^a L ⁻¹ wine]	ORAC [g TE L ⁻¹ wine]	TPC [g GAE ^b L ⁻¹ wine]	Total SO ₂ [mg SO ₂ L ⁻¹ wine]
PN 1	3.06 \pm 0.41	8.59 \pm 1.01	1.56 \pm 0.02	24.63 \pm 2.14
PN 2	3.12 \pm 0.34	10.49 \pm 1.55	2.08 \pm 0.03	56.73 \pm 4.44
PN 3	1.88 \pm 0.24	8.67 \pm 1.55	1.57 \pm 0.05	11.35 \pm 1.14
PN 4	4.22 \pm 0.38	10.01 \pm 1.48	3.31 \pm 0.13	2.44 \pm 0.33
PN 5	3.38 \pm 0.46	9.19 \pm 1.73	2.46 \pm 0.04	73.18 \pm 4.09
CS 1	2.37 \pm 0.26	6.93 \pm 1.45	1.55 \pm 0.04	59.60 \pm 4.47
CS 2	2.95 \pm 0.39	6.70 \pm 1.37	1.89 \pm 0.05	58.43 \pm 3.99
CS 3	3.31 \pm 0.41	7.11 \pm 1.33	2.03 \pm 0.07	59.60 \pm 4.47
CS 4	2.82 \pm 0.29	7.09 \pm 1.1	1.86 \pm 0.06	36.06 \pm 4.52
CS 5	2.78 \pm 0.22	7.61 \pm 1.54	1.69 \pm 0.04	25.23 \pm 0.29
CS 6	1.97 \pm 0.42	7.02 \pm 0.76	1.11 \pm 0.01	93.85 \pm 4.49
CS 7	4.58 \pm 0.33	8.42 \pm 1.39	2.49 \pm 0.07	18.17 \pm 4.13
CM 1	1.97 \pm 0.31	8.29 \pm 0.91	1.40 \pm 0.04	34.65 \pm 3.80
CM 2	2.12 \pm 0.20	8.77 \pm 1.63	1.50 \pm 0.03	32.46 \pm 1.73
SA 1	5.89 \pm 0.63	10.39 \pm 1.31	2.78 \pm 0.08	18.22 \pm 1.59
SA 2	5.27 \pm 0.46	10.81 \pm 1.68	2.74 \pm 0.07	10.79 \pm 0.37
SA 3	5.03 \pm 0.72	11.16 \pm 1.75	2.42 \pm 0.05	8.38 \pm 0.49
SA 4	4.79 \pm 0.32	10.56 \pm 2.11	2.61 \pm 0.08	9.13 \pm 2.06
SA 5	2.08 \pm 0.14	7.29 \pm 0.81	1.59 \pm 0.03	60.69 \pm 2.94
SA 6	4.50 \pm 0.43	9.99 \pm 2.14	2.67 \pm 0.07	25.59 \pm 5.34
SA 7	4.70 \pm 0.34	10.92 \pm 2.00	3.05 \pm 0.07	26.68 \pm 2.77
SA 8	8.59 \pm 0.50	11.37 \pm 2.01	4.46 \pm 0.18	39.45 \pm 3.80
SA 9	5.21 \pm 0.45	9.82 \pm 1.48	3.22 \pm 0.13	21.36 \pm 2.38
SA 10	5.01 \pm 0.47	11.71 \pm 1.65	3.87 \pm 0.10	29.28 \pm 1.89
SA 11	5.43 \pm 0.48	12.14 \pm 2.15	3.39 \pm 0.08	20.95 \pm 5.78
AL 1	1.91 \pm 0.18	5.87 \pm 0.66	1.36 \pm 0.04	0.00
CH 1	0.10 \pm 0.02	0.48 \pm 0.07	0.21 \pm 0.01	103.61 \pm 6.98
CH 2	0.24 \pm 0.03	1.12 \pm 0.19	0.29 \pm 0.01	91.81 \pm 2.80
CH 3	0.14 \pm 0.02	0.84 \pm 0.12	0.22 \pm 0.01	98.24 \pm 2.54
CH 4	0.13 \pm 0.01	0.85 \pm 0.14	0.22 \pm 0.001	91.09 \pm 2.26
CH 5	0.34 \pm 0.04	1.12 \pm 0.21	0.28 \pm 0.01	121.57 \pm 9.47
CH 6	0.12 \pm 0.01	0.73 \pm 0.05	0.23 \pm 0.01	108.2 \pm 3.54
SB 1	0.12 \pm 0.01	0.74 \pm 0.14	0.22 \pm 0.01	92.94 \pm 2.88
SB 2	0.15 \pm 0.01	1.04 \pm 0.2	0.23 \pm 0.01	115.14 \pm 2.34
SB 3	0.06 \pm 0.01	1.27 \pm 0.11	0.20 \pm 0.01	202.19 \pm 18.68
RK 1	0.51 \pm 0.04	1.67 \pm 0.25	0.40 \pm 0.01	2.66 \pm 0.10
RK 2	0.17 \pm 0.02	0.99 \pm 0.13	0.24 \pm 0.01	86.96 \pm 2.15
RK 3	0.29 \pm 0.02	1.64 \pm 0.24	0.29 \pm 0.01	95.39 \pm 2.65
RK 4	2.90 \pm 0.27	4.01 \pm 0.70	1.88 \pm 0.04	38.21 \pm 4.48

^a Trolox equivalency.

^b Gallic acid equivalency.

geographical regions are shown in Table 3) than West and Central European samples in DPPH ($p = 0.01$), ORAC ($p = 0.05$) as well as in TPC ($p = 0.01$) assay. The highest antioxidant effect in all three assays was recorded in wines from Georgian cultivar Saperavi and cuvee Saperavi + Saperavi Budeshuriseburi (range of DPPH, ORAC and TPC values: 8.59–2.08 g TE L⁻¹ wine; 12.14–7.29 g TE L⁻¹ wine and 4.46–1.59 g GAE L⁻¹ wine, respectively), followed by Pinot Noir (4.22–1.88 g TE L⁻¹ wine; 10.49–8.59 g TE L⁻¹ wine and 3.31–1.56 g GAE L⁻¹ wine) and Cabernet Sauvignon (4.58–1.97 g TE L⁻¹ wine; 8.42–6.70 g TE L⁻¹ wine and 2.49–1.11 g GAE L⁻¹ wine). In contrast to our results, Chkhikvishvili et al. (2008) recorded

Table 3

Antioxidant activity of red wine samples grouped according to their origin (mean \pm SD).

Region	DPPH (g TE/L wine)**	ORAC (g TE/L wine) *	TPC (g GAE/L wine)**
Georgia (n = 13)	4.84 \pm 1.64 ^a	10.04 \pm 1.82 ^a	2.82 \pm 0.83 ^a
Western Europe (n = 6)	3.18 \pm 0.63 ^{ab}	7.84 \pm 1.40 ^b	2.18 \pm 0.62 ^{ab}
Central Europe (n = 7)	2.42 \pm 0.55 ^b	8.50 \pm 1.09 ^{ab}	1.56 \pm 0.29 ^b

Different letters within each column showed significant differences (ANOVA with Tukey post hoc test; * $p \leq 0.05$, ** $p \leq 0.01$).

comparable or lower antioxidant activity of Georgian Saperavi wines prepared by European method in comparison with French wine. However, in mentioned study was only one sample of French wine for comparison. Higher antioxidant effect of Pinot Noir than antioxidant activity of Cabernet Sauvignon wines is in the agreement with the study of [Hosu et al. \(2011\)](#) and [Landrault et al. \(2001\)](#). Other representatives of red wines (Alexandrouli, Cabernet Moravia) were regarded as samples with moderate antioxidant efficacy (values ranging as follows: DPPH = 2.13–1.92 g TE L⁻¹ wine; ORAC = 8.77–5.87 g TE L⁻¹ wine and TPC = 1.50–1.36 g GAE L⁻¹ wine).

Comparison of antioxidant activity among regions in the frame of one cultivar (Cabernet Sauvignon and Pinot Noir) indicates that red wines produced in Western Europe were more effective than those from Central Europe. The activity of Cabernet Sauvignon from Western Europe ranged from 3.31 to 2.37 TE L⁻¹ while samples from Central Europe ranged from 2.79 to 1.97 TE L⁻¹. Similarly, the activity of West European Pinot Noir ranged from 4.22 to 3.39 TE L⁻¹ while Central European samples ranged from 3.12 to 1.87 TE L⁻¹ in DPPH. However, for statistical analyses and reliable conclusions more samples for each cultivar and geographical region would be needed.

White wines were significantly less effective in antioxidant assays than the red wines. Only exception was sample RK 4 (cuvée of Rkatsiteli), which was fermented by Kakhetian method. Wine RK 4 exhibited antioxidant efficacy comparable to some red wines (DPPH, ORAC and TPC values 2.90 g TE L⁻¹ wine; 4.01 g TE L⁻¹ wine and 1.88 g GAE L⁻¹ wine, respectively). Also another representative of white wine (RK 1) prepared by Kakhetian method showed higher antioxidant effect in comparison to the rest of tested white wines. However, its antioxidant activity (values ranging as follows: DPPH = 0.51 g TE L⁻¹ wine; ORAC = 1.67 g TE L⁻¹ wine and TPC = 0.40 g GAE L⁻¹ wine) was not as strong as in case of RK 4 sample. Positive effect of Kakhetian technology (more than two times better than in case of European method) on antioxidant activity of white wines was recorded also by [Shalashvili et al. \(2007\)](#). This could be explained by the higher content of phenolics in wines fermented with pomace. Rest of tested white wines (Chardonnay, Sauvignon Blanc and Rkatsiteli made by common method used in Europe) were regarded as weak antioxidants (range of values for DPPH, ORAC and TPC were 0.34–0.07 g TE L⁻¹ wine; 1.64–0.48 g TE L⁻¹ wine and 0.29–0.20 g GAE L⁻¹ wine, respectively) without significant differences between regions of origin.

3.2. Total sulfite content

In the framework of this study the content of total sulfite was measured in wine samples. Generally, white wines contained higher quantities of mg SO₂ L⁻¹ (sulfite content in all samples is shown in [Table 2](#)). Two Sauvignon Blanc SB 3 (202.19 mg SO₂ L⁻¹ wine) and SB 2 (115.14 mg SO₂ L⁻¹ wine) samples and one Chardonnay sample CH 5 (121.57 mg SO₂ L⁻¹ wine) were most abundant samples on total SO₂ level. Sulfites in red wines ranged from 73.18 to 0 mg SO₂ L⁻¹ wine. Wines with strongest antioxidant activity (SA 8, SA 10 and SA 11) contained low sulfite levels 39.45, 29.28 and 20.95 mg SO₂ L⁻¹ wine, respectively. Total sulfite content in tested wines was similar to values recorded by [Zúñiga et al. \(2014\)](#) and [Comuzzo et al. \(2013\)](#). We also ascertained if artificially added sulfites could possibly alter the antioxidant potential of wine in ORAC and DPPH assay. SO₂ possessed EC₅₀ = 289 mg L⁻¹ in DPPH assay. Since the highest concentration of SO₂ in wine samples was 202 mg L⁻¹ and highest tested concentration of white wine was 0.5 mL mL⁻¹, the maximal concentration of SO₂ in sample was 101 mg L⁻¹. It means that in the sulfite most rich sample SO₂ level does not reach its EC₅₀. In the case of red wines the highest tested concentration was

0.05 mL mL⁻¹ which means that concentration and impact of SO₂ was negligible. In ORAC assay the effect of SO₂ was even lower. While 1 mL of weakest white wine was equal to activity of 0.48 mg trolox, the activity of 200 µg SO₂ (contained in 1 mL of most SO₂ rich wine) was equal only to 1.5 µg of trolox in ORAC assay. According to recorded results, no positive correlation between SO₂ and antioxidant potential ($r = -0.77$ for ORAC and $r = -0.82$ for DPPH) was revealed. These results demonstrate that content of sulfites had negligible impact on the antioxidant capacity of wines tested using ORAC and DPPH assays which is in the agreement with study of [Zúñiga et al. \(2014\)](#). In white wines, three times higher average concentration of total sulfites was observed in comparison to red wines (97.0 and 32.5 mg SO₂ L⁻¹ for white and red wines, respectively). Since white wines do not contain as much quantities of phenolic compounds as red wines, higher concentrations of sulfites must be added in order to prevent degradation ([Comuzzo and Zironi, 2013](#)).

3.3. HPLC analysis

Individual concentrations of 14 phenolic compounds presented in each wine sample were quantified by HPLC-UV/Vis analysis with the aim to find differences between wines produced in Georgia, Central and Western Europe (concentrations of compounds in all wine samples is shown in [Table 4](#)). Order of mean content of presented compounds in all investigated samples were as follows: gallic acid > epigallocatechin gallate > caffeic acid > *p*-coumaric acid > myricetin > syringic acid > vanillic acid > 3,4-dihydroxybenzoic acid > quercetin > chlorogenic acid > resveratrol > rutin > ferulic acid > kaempferol.

Georgian wine samples contained significantly higher concentrations of quercetin ($p = 0.01$), kaempferol ($p = 0.05$), and syringic acid ($p = 0.05$), while content of *trans*-resveratrol was considerably lower ($p = 0.01$) in Georgian wines than in West and Central European samples ([Table 5](#)). The highest quantities of quercetin, kaempferol and syringic acid were recorded in wines prepared from Saperavi cultivar (quercetin = 14.44–1.07 µg mL⁻¹; kaempferol = 1.68–0.03 µg mL⁻¹ and syringic acid 12.59–4.72 µg mL⁻¹), followed by Pinot Noir (quercetin = 9.64–0.00 µg mL⁻¹; kaempferol = 0.60–0.00 µg mL⁻¹ and syringic acid = 12.02–5.17 µg mL⁻¹) and Cabernet Sauvignon cultivars (quercetin = 8.51–0.00 µg mL⁻¹; kaempferol = 0.63–0.00 µg mL⁻¹ and syringic acid = 8.00–4.28 µg mL⁻¹). On the contrary, Pinot Noir was the richest samples in resveratrol content, followed by representatives of Cabernet Sauvignon (concentration range 8.71–2.43 and 7.41–1.13 µg mL⁻¹, respectively). In contrast to our results, [McDonald et al. \(1998\)](#) recorded higher content of quercetin in Cabernet Sauvignon (2.6–4.6 µg mL⁻¹) than in Pinot Noir (0.9–2.6 µg mL⁻¹) wines from France. However, our results are in the agreement with the study of [Nikfardjam et al. \(2006\)](#) where Hungarian Pinot Noir wine samples contained higher concentrations of quercetin and resveratrol (7.5 and 3.2 µg mL⁻¹, respectively) than Cabernet Sauvignon samples (5.5 and 2.8 µg mL⁻¹, respectively). Our data recorded for *trans*-resveratrol in Czech Pinot Noir samples (2.43 and 8.71 µg mL⁻¹) are similar or slightly higher than those of [Kolouchova-Hanzlikova et al. \(2004\)](#) which were in range from 1.322 to 6.253 µg mL⁻¹. Wines belonging to Saperavi cultivar contained only moderate to low concentration of resveratrol, ranging from 5.11 to 0.32 µg mL⁻¹. In comparison, [Chkhikvishvili et al. \(2008\)](#) recorded values in range 0.69–1.17 µg mL⁻¹ for Saperavi wines.

Although the differences were observed in red wines grouped according to geographical origin, it seems possible that cultivar played also important role because Georgian group included only two wines from different cultivars than Saperavi (one Cabernet Sauvignon and one Alexandrouli sample). Several comparative studies dealing with differences in phenolic composition across wine cultivars, vintage, and production area revealed elevated

Table 4
Concentration of phenolic compounds in studied wines (expressed as mean of two measurements).

Wine code	Compound ^a /($\mu\text{g mL}^{-1}$)													
	3,4-DB	CAF	COUM	CHL	FER	GAL	SYR	VAN	RESV	EGCG	KAEM	MYR	QUER	RUT
PN 1	7.15	13.84	9.32	2.11	1.45	117.84	9.16	7.06	8.71	52.25	ND ^{b,f}	5.95	0.97	ND ^{b,i}
PN 2	1.43	10.39	3.27	ND ^{b,c}	1.53	64.08	5.17	5.06	2.43	36.31	ND ^{b,f}	3.34	ND ^{b,h}	0.89
PN 3	10.62	6.77	4.45	3.77	0.58	38.00	12.02	9.12	7.66	19.89	ND ^{b,f}	6.94	0.32	ND ^{b,i}
PN 4	2.60	26.40	4.65	2.53	1.33	104.65	5.69	5.17	3.50	58.87	0.47	3.17	7.95	3.26
PN 5	3.19	15.46	5.40	3.98	ND ^{b,d}	99.59	5.48	4.51	5.75	54.83	0.60	6.66	9.64	1.99
CS 1	4.40	5.69	5.04	2.43	ND ^{b,d}	70.48	5.33	3.73	1.95	31.97	0.17	5.31	1.12	1.52
CS 2	5.40	3.62	2.92	1.98	0.77	85.44	5.46	3.12	1.13	49.16	0.07	7.46	3.48	1.50
CS 3	3.25	9.15	6.18	2.24	1.31	43.77	5.54	2.58	2.05	24.13	0.22	14.50	8.51	4.46
CS 4	6.27	8.39	7.45	1.93	0.65	51.32	5.57	3.07	2.93	26.80	ND ^{b,f}	11.34	0.58	2.94
CS 5	3.49	27.05	14.06	1.38	1.31	63.09	6.67	4.88	7.41	30.36	ND ^{b,f}	7.64	0.45	ND ^{b,i}
CS 6	5.23	6.31	7.34	2.97	1.06	47.38	4.28	3.39	2.50	19.42	ND ^{b,f}	4.04	ND ^{b,h}	ND ^{b,i}
CS 7	4.28	12.55	7.87	1.91	0.59	96.74	8.00	3.82	1.17	50.19	0.63	9.21	7.62	ND ^{b,i}
CM 1	0.68	11.02	11.14	1.67	1.12	24.79	8.57	5.64	4.50	17.89	ND ^{b,f}	8.90	0.69	ND ^{b,i}
CM 2	1.80	6.42	9.23	1.90	0.36	39.65	8.85	4.14	3.35	14.21	ND ^{b,f}	7.09	1.58	ND ^{b,i}
SA 1	6.87	15.51	13.89	2.01	1.74	85.72	8.42	8.52	3.79	44.59	0.36	13.39	12.57	2.73
SA 2	3.25	8.10	15.93	2.04	1.28	61.81	9.09	4.81	5.11	30.57	1.19	18.67	14.44	2.61
SA 3	3.28	4.98	9.56	2.20	0.88	74.03	8.44	3.97	1.36	32.59	0.54	11.27	8.71	ND ^{b,i}
SA 4	1.86	19.29	16.53	2.01	1.77	43.27	8.14	4.46	3.29	27.40	0.80	15.30	9.70	2.45
SA 5	3.75	7.59	10.94	2.41	0.76	34.68	6.12	3.16	0.34	15.04	0.03	7.04	3.48	ND ^{b,i}
SA 6	3.62	6.32	14.40	3.04	1.01	52.00	12.37	5.11	1.14	29.12	0.38	10.94	6.19	2.96
SA 7	2.13	3.94	5.24	3.92	0.52	41.50	4.72	2.83	1.24	24.12	1.68	14.46	12.18	2.37
SA 8	1.86	3.15	2.79	3.34	0.29	43.65	4.73	3.06	0.32	26.91	0.76	9.92	7.56	4.13
SA 9	9.06	7.99	9.08	2.82	0.65	101.38	12.59	6.89	0.85	52.60	0.27	8.79	3.53	ND ^{b,i}
SA 10	7.15	6.63	12.70	3.49	1.79	91.70	12.59	9.63	1.12	56.28	0.24	3.98	1.28	ND ^{b,i}
SA 11	6.72	4.81	3.62	1.79	0.45	97.57	10.24	8.05	0.43	53.18	0.22	2.63	1.07	1.82
AL 1	8.93	9.10	4.57	1.40	0.95	60.40	11.53	8.52	0.13	26.94	ND ^{b,f}	ND ^{b,g}	ND ^{b,h}	ND ^{b,i}
CH 1	0.32	1.11	0.84	0.79	0.32	4.10	0.10	0.15	ND ^{b,e}	0.61	ND ^{b,f}	ND ^{b,g}	ND ^{b,h}	ND ^{b,i}
CH 2	1.00	2.77	0.99	1.82	0.17	7.22	0.25	0.25	ND ^{b,e}	2.24	ND ^{b,f}	ND ^{b,g}	ND ^{b,h}	ND ^{b,i}
CH 3	1.21	2.40	1.13	1.50	0.37	8.24	0.40	0.37	ND ^{b,e}	1.93	ND ^{b,f}	ND ^{b,g}	ND ^{b,h}	ND ^{b,i}
CH 4	1.28	3.38	1.35	1.57	0.48	15.66	0.25	0.62	ND ^{b,e}	3.74	ND ^{b,f}	ND ^{b,g}	ND ^{b,h}	ND ^{b,i}
CH 5	1.44	8.24	3.47	1.55	0.52	3.23	0.37	0.33	ND ^{b,e}	1.23	ND ^{b,f}	ND ^{b,g}	ND ^{b,h}	ND ^{b,i}
CH 6	1.59	6.77	2.43	1.64	0.32	2.11	0.25	0.23	ND ^{b,e}	0.99	ND ^{b,f}	ND ^{b,g}	ND ^{b,h}	ND ^{b,i}
SB 1	0.81	1.41	0.76	1.94	0.25	15.02	0.27	0.33	ND ^{b,e}	3.38	ND ^{b,f}	ND ^{b,g}	ND ^{b,h}	ND ^{b,i}
SB 2	0.94	4.09	2.43	1.47	0.46	1.99	0.17	0.20	ND ^{b,e}	1.02	ND ^{b,f}	ND ^{b,g}	ND ^{b,h}	ND ^{b,i}
SB 3	1.06	1.33	1.76	1.35	0.30	5.77	0.22	0.28	ND ^{b,e}	1.36	ND ^{b,f}	ND ^{b,g}	ND ^{b,h}	ND ^{b,i}
RK 1	1.29	7.41	0.84	3.22	0.21	9.93	0.21	0.35	0.32	1.68	ND ^{b,f}	ND ^{b,g}	ND ^{b,h}	ND ^{b,i}
RK 2	0.76	5.25	0.96	2.84	0.30	7.14	0.16	0.18	ND ^{b,e}	1.39	ND ^{b,f}	ND ^{b,g}	ND ^{b,h}	ND ^{b,i}
RK 3	2.70	7.34	3.32	2.49	0.57	10.31	0.51	0.55	ND ^{b,e}	2.00	ND ^{b,f}	ND ^{b,g}	ND ^{b,h}	ND ^{b,i}
RK 4	3.21	0.91	0.73	2.04	0.17	38.48	0.25	0.46	ND ^{b,e}	22.91	ND ^{b,f}	ND ^{b,g}	ND ^{b,h}	ND ^{b,i}

^a 3,4-DB=3,4-hydroxybenzoic acid; CAF=caffeic acid; COUM=*p*-coumaric acid; CHL=chlorogenic acid; FER=ferulic acid; GAL=gallic acid; SYR=syringic acid; VAN=vanillic acid; RESV=resveratrol; EGCG=epigallocatechin gallate; KAEM=kaempferol; MYR=myricetin; QUER=quercetin; RUT=rutin.

^b Compound not detected.

^c Limit of detection (LOD)=0.398 $\mu\text{g mL}^{-1}$.

^d LOD=0.070 $\mu\text{g mL}^{-1}$.

^e LOD=0.072 $\mu\text{g mL}^{-1}$.

^f LOD=0.010 $\mu\text{g mL}^{-1}$.

^g LOD=0.220 $\mu\text{g mL}^{-1}$.

^h LOD=0.074 $\mu\text{g mL}^{-1}$.

ⁱ LOD=0.042 $\mu\text{g mL}^{-1}$.

content of flavonoids (especially quercetin, myricetin, and kaempferol), whereas decreased levels of *trans*-resveratrol in local grape varieties in comparison to commonly cultivated (Pinot noir, Cabernet Sauvignon) (McDonald et al., 1998; Landrault et al., 2001; Atanacković et al., 2012).

Cabernet Moravia were relatively rich in resveratrol and syringic acid content (concentration ranging between 4.50–3.35 $\mu\text{g mL}^{-1}$ and 8.85–8.57 $\mu\text{g mL}^{-1}$, respectively). Nevertheless, representatives of Cabernet Moravia had low quantities of

quercetin (range of concentrations were 1.58–0.69 $\mu\text{g mL}^{-1}$). Kaempferol was not detected in Cabernet Moravia samples. Cabernet Sauvignon and Pinot Noir samples from Western Europe contained higher levels of kaempferol, quercetin and rutin than those from Central Europe. For example, quercetin concentrations reached from 0.58 to 9.64 $\mu\text{g mL}^{-1}$ in West European samples while in Central European samples quercetin reached from 0.00 to 0.97 $\mu\text{g mL}^{-1}$. Also Goldberg et al. (1998) observed higher levels of quercetin in samples from warmer climates.

Table 5
Content of syringic acid, *trans*-resveratrol, quercetin, and kaempferol in red wine samples grouped according to their origin (mean \pm SD).

Region	Syringic acid [†]	Resveratrol ^{**}	Quercetin ^{**}	Kaempferol [†]
Georgia (n = 13)	9.00 \pm 2.77 ^a	1.56 \pm 1.53 ^a	7.36 \pm 4.43 ^a	0.59 \pm 0.47 ^a
Western Europe (n = 6)	5.51 \pm 0.12 ^b	2.88 \pm 1.63 ^{ab}	5.21 \pm 3.98 ^{ab}	0.31 \pm 0.22 ^{ab}
Central Europe (n = 7)	7.82 \pm 2.64 ^{ab}	5.22 \pm 2.65 ^b	0.80 \pm 0.50 ^b	0.00 \pm 0.00 ^b

Different letters within each column showed significant differences (ANOVA with Tukey post hoc test; [†] $p \leq 0.05$, ^{**} $p \leq 0.01$).

None statistical differences between white wines grouped according to their origin were revealed. Quercetin and kaempferol were under detection limits in representatives of white wines. Resveratrol was only detected in sample RK 1 ($0.32 \mu\text{g mL}^{-1}$). In comparison to other white wines, RK 4 differed in high gallic acid and epigallocatechin gallate content (38.48 and $22.91 \mu\text{g mL}^{-1}$, respectively). Both RK 1 and RK 4 wine samples were prepared by Kakhetian method. Higher content ($5.82 \mu\text{g mL}^{-1}$) of resveratrol in Saperavi wine prepared by Kakhetian method than in Saperavi wines prepared by European method (0.69 – $1.17 \mu\text{g mL}^{-1}$) was recorded also by Chkhikvishvili et al. (2008). Also the higher content of epigallocatechin gallate is in concordance with study of Shalashvili et al. (2007) where the white wines manufactured by Kakhetian method were significantly richer in total catechins. Further, our observations are in the agreement with conclusions made by Goldberg et al. (1999) that enological techniques have higher impact than climatic factors on the content of phenolic compounds in the case of white wine.

4. Conclusion

In summary, Georgian red wines showed higher antioxidant potential than red wines from Central and Western Europe. Red wines prepared from Georgian native cultivar Saperavi and cuvee Saperavi + Saperavi Budeshuriseburi showed highest antioxidant effect followed by Pinot Noir and Cabernet Sauvignon. Further, Georgian red wines differed from Central and West European red wines by higher content of quercetin, kaempferol, and syringic acid and by lower content of *trans*-resveratrol. No statistical differences among cultivars and regions were revealed in the case of white wines. However, white wines prepared by Kakhetian winemaking method possessed increased antioxidant activity and contained higher amounts of phenolic compounds. Our results indicate that antioxidant effect and content of phenolics in red wines was influenced by geographical origin and by cultivar while winemaking technology was the main factor influencing antioxidant activity and concentration of phenolic compounds in studied white wines. This study showed interesting potential of Georgian wines and therefore we suggest further detailed research of grapevine cultivars originated from Caucasus region because it could bring interesting results regarding chemical composition and biological activity connected with health-promoting effects.

Acknowledgement

The authors are grateful to Dr Temur Gonjilashvili from the winery “Kindzmaraulis Marani” and Dr Vasil Gurasashvili from the winery “Tbilvino” from Georgia for donation of wine samples. This study was financed by Czech Ministry of Education, Youth and Sports project no. LD11005 and by project CIGA no. 20142012. Our research was also supported by Czech COST Action FA1003 “East-West Collaboration for Grapevine Diversity Exploration and Mobilization of Adaptive Traits for Breeding” and by OPVK project no. CZ.2.16/3.1.00/24014.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.jfca.2014.12.029>.

References

Atanacković, M., Petrović, A., Jović, S., Gojković-Bukarica, L., Bursać, M., Cvejić, J., 2012. Influence of winemaking techniques on the resveratrol content, total phenolic content and antioxidant potential of red wines. *Food Chemistry* 131, 513–518.

- Cao, G., Prior, R.L., 1998. Measurement of oxygen radical absorbance capacity in biological samples. *Methods in Enzymology* 299, 50–62.
- Chkhikvishvili, I., Gogia, N., Sirbiladze, G., 2008. Study of resveratrol and antioxidant activity in Georgian brand red wines and a number of foreign red wines. *Georgian Medical News* 159, 53–57.
- Comuzzo, P., Zironi, R., 2013. Biotechnological strategies for controlling wine oxidation. *Food Engineering Reviews* 5, 217–229.
- Comuzzo, P., Rauhut, D., Werner, M., Lagazio, C., Zironi, R., 2013. A survey on wines from organic viticulture from different European countries. *Food Control* 34, 274–282.
- de Pascali, S.A., Coletta, A., Del Coco, L., Basile, T., Gambacorta, G., Fanizzi, F.P., 2014. Viticultural practice and winemaking effects on metabolic profile of Negroamaro. *Food Chemistry* 161, 112–119.
- Fagherazzi, G., Vilier, A., Lajous, M., Boutron-Ruault, M.C., Balkau, B., Clavel-Chapelon, F., Bonnet, F., 2014. Wine consumption throughout life is inversely associated with type 2 diabetes risk, but only in overweight individuals: results from a large female French cohort study. *European Journal of Epidemiology* 29, 831–839.
- Gagunashvili, B., 2006. La Géorgie, berceau de la vigne et du vin. *Revue des oenologues et des techniques vitivinicoles et oenologues* 120, 55–56.
- Georgiev, V., Ananga, A., Tsoleva, V., 2014. Recent advances and uses of grape flavonoids as nutraceuticals. *Nutrients* 6, 391–415.
- Glonti, T., 2010a. Phenolic sources of wine made from grapes of Kakhuri Mtsvivani and some other vine (*V. vinifera* L.) breeds. In: OIV 33rd Congress. Tbilisi, Georgia. Retrieved from: http://www.oiv2010.ge/POSTER/POST_OENOLOGY/P.II.18-No%2085%20P%20Glonti%20Teimuraz%20Phenolicsources%20corr%20Volatile%20aroma-forming%20compounds.pdf (07.03.14).
- Glonti, T., 2010b. Traditional technologies and history of Georgian wine. In: OIV 33rd Congress. Tbilisi, Georgia. Retrieved from: <http://www.oiv2010.ge/> (12.12.14).
- Glonti, T., Glonti, Z., 2013. The Remarkable Qvevri Wine. Qvevri foundation, Tbilisi, Georgia.
- Goldberg, D.M., Karumanchiri, A., Soleas, G.J., Tsang, E., 1999. Concentrations of selected polyphenols in white commercial wines. *American Journal of Enology and Viticulture* 50, 185–193.
- Goldberg, D.M., Tsang, E., Karumanchiri, A., Soleas, G.J., 1998. Quercetin and *p*-coumaric acid concentrations in commercial wines. *American Journal of Enology and Viticulture* 149, 142–151.
- Gris, E.F., Mattivi, F., Ferreira, E.A., Vrhovsek, U., Filho, D.W., Pedrosa, R.C., Bordignon-Luiz, M.T., 2013. Phenolic profile and effect of regular consumption of Brazilian red wines on *in vivo* antioxidant activity. *Journal of Food Composition and Analysis* 31, 31–40.
- Hosu, D., Cimpoi, C., Miclaus, V., Jantschi, V., 2011. Antioxidant content of three different varieties of wine grapes. *Biotechnology and Biotechnological Equipment* 25, 2217–2221.
- Imazio, S., Maghradze, D., de Lorenzis, G., Bacilieri, R., Laucou, V., This, P., Scienza, A., Failla, O., 2013. From the cradle of grapevine domestication: molecular overview and description of Georgian grapevine (*Vitis vinifera* L.) germplasm. *Tree Genetics and Genomes* 9, 641–658.
- Ivanova-Petropoulos, V., Ricci, A., Nedelkovski, D., Dimovska, V., Parpinello, G.P., Versari, A., 2015. Targeted analysis of bioactive phenolic compounds and antioxidant activity of Macedonian red wines. *Food Chemistry* 171, 412–420.
- King, E.S., Stoumen, M., Buscema, F., Hjelmeland, A.K., Ebeler, S.E., Heymann, H., Boulton, R.B., 2014. Regional sensory and chemical characteristics of Malbec wines from Mendoza and California. *Food Chemistry* 143, 256–267.
- Kolouchova-Hanzlikova, I., Melzoch, K., Filip, V., Smidrkal, J., 2004. Rapid method for resveratrol determination by HPLC with electrochemical and UV detections in wines. *Food Chemistry* 87, 151–158.
- Kutil, Z., Temml, V., Maghradze, D., Pribylova, M., Dvorakova, M., Schuster, D., Vanek, T., Landa, P., 2014. Impact of wines and wine constituents on cyclooxygenase-1, cyclooxygenase-2, and 5-lipoxygenase catalytic activity. *Mediators of Inflammation* 2014, 178931.
- Landraut, N., Poucheret, P., Ravel, P., Gasc, F., Cros, G., Teissedre, P.-L., 2001. Antioxidant capacities and phenolics levels of French wines from different varieties and vintages. *Journal of Agricultural and Food Chemistry* 49, 3341–3348.
- Liang, Z.C., Cheng, L.L., Zhong, G.Y., Liu, R.H., 2014. Antioxidant and antiproliferative activities of twenty-four *Vitis vinifera* grapes. *PLOS ONE* 9, e105146.
- Maghradze, D., Rustioni, L., Scienza, A., Turok, J., Failla, O., 2012. Caucasus and Northern Black Sea Region Ampelography. *Vitis (Special issue)*.
- McDonald, M.S., Hughes, M., Burns, J., Lean, M.E.J., Matthews, D., Crozier, A., 1998. Survey of the free and conjugated Myricetin and Quercetin content of red wines of different geographical origins. *Journal of Agricultural and Food Chemistry* 46, 368–375.
- Mikashvili, M., Kiknavelidze, Z., Khositashvili, M., Khositashvili, T., Favale, S., Cioffi, G., 2010a. The varietal effect of Georgian red grape cultivar Saperavi (*vitis vinifera* L.) and Cabernet Sauvignon (*vitis vinifera* L.) on consistence of phenolic compounds and aromatic components. In: OIV 33rd congress. Tbilisi, Georgia. Retrieved from: http://www.oiv2010.ge/POSTER/POST_OENOLOGY/P.II.48-No%20178%20P%20Mikashvili.pdf (15.06.14).
- Mikashvili, M., Kiknavelidze, Z., Khositashvili, M., Nakhchrishvili, B., Favale, B., Cioffi, G., 2010b. The hard part of grape cluster influence on the quality of kakhetian wine type. In: OIV 33rd congress. Tbilisi, Georgia. Retrieved from: http://www.oiv2010.ge/POSTER/POST_OENOLOGY/P.II.47-No%20175%20P%20Kiknavelidze.pdf (15.06.14).
- Nikfardjam, M.S.P., Mark, L., Avar, P., Figler, M., Ohmacht, R., 2006. Polyphenols, anthocyanins, and *trans*-resveratrol in red wines from the Hungarian Villany region. *Food Chemistry* 98, 453–462.

- Ou, B., Hampsch-Woodill, M., Prior, R.L., 2001. Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe. *Journal of Agricultural and Food Chemistry* 49, 4619–4626.
- Robinson, J., Harding, J., Vouillamoz, J., 2012. *Wine Grapes: A Complete Guide to 1,368 Vine Varieties, Including Their Origins and Flavours*. Penguin Group, London, UK.
- Rossi, M., Praud, D., Compagnoni, M.M., Bellocco, R., Serafini, M., Parpinel, M., La Vecchia, C., Tavani, A., 2014. Dietary non-enzymatic antioxidant capacity and the risk of myocardial infarction: a case-control study in Italy. *Nutrition, Metabolism and Cardiovascular Diseases* 24, 1246–1251.
- Russo, M., Spagnuolo, C., Bilotto, S., Tedesco, I., Maiani, G., Russo, G.L., 2014. Inhibition of protein kinase CK2 by quercetin enhances CD95-mediated apoptosis in a human thymus-derived T cell line. *Food Research International* 63, 244–251.
- Shalashvili, A., Targamadze, I., Zambakhidze, N., Chichua, D., Nareklishvili, V., Ugrehelidze, D., 2007. Comparison of wines of Kakhetian and European types according to quantitative content of flavonoids and antiradical efficiency. *Bulletin of the Georgian National Academy of Sciences* 175, 102–104.
- Shalashvili, A., Ugrehelidze, D., Mitaishvili, T., Targamadze, I., Zambakhidze, N., 2012. Phenolic compounds of wines from Georgian autochthonous grapes, rkatsiteli and saperavi, prepared by Georgian (kakhétian) technology. *Bulletin of the Georgian National Academy of Sciences* 6, 99–103.
- Sharma, O.P., Bhat, T.K., 2009. DPPH antioxidant assay revisited. *Food Chemistry* 113, 1202–1205.
- Singleton, V.L., 1982. Grape and wine phenolics; background and prospects. In: *Wine Centennial Symposium, Proceedings of the University of California, Davis, USA*, pp. 215–227.
- Singleton, V.L., Orthofer, R., Lamuela-Raventos, R.M., 1998. Analysis of total phenols and other oxidation substrates and antioxidants by means of folin-ciocalteu reagent. *Methods in Enzymology* 299, 152–178.
- Teixeira, A., Baenas, N., Dominguez-Perles, R., Barros, A., Rosa, E., Moreno, D.A., García-Viguera, C., 2014. Natural bioactive compounds from winery by-products as health promoters: a review. *International Journal of Molecular Sciences* 15, 15638–15678.
- This, P., Lacombe, T., Thomas, M.R., 2006. Historical origins and genetic diversity of wine grapes. *Trends in Genetics* 22, 511–519.
- Zúñiga, M.C., Pérez-Roa, R.E., Olea-Azar, C., Laurie, V.F., Agosin, E., 2014. Contribution of metals, sulfur-dioxide and phenolic compounds to the antioxidant capacity of Carménère wines. *Journal of Food Composition and Analysis* 35, 37–43.

Appendix B:

Tauchen J, Bortl L, Huml L, Mikšátková P, Doskočil I, Maršík P, Villegas PPP, Flores YB, Van Damme P, Lojka B, Havlík J, Lapčík O, Kokoška L. Phenolic composition, antioxidant and anti-proliferative activities of edible and medicinal plants from the Peruvian Amazon. Manuscript accepted (23. 3. 2016) to Revista Brasileira de Farmacognosia.

Date: Mar 23, 2016
To: "Ladislav Kokoska" kokoska@ftz.czu.cz
cc: sgleitao@pharma.ufrj.br;sgleitao@superig.com.br;revista@sbfgnosia.org.br
From: "Revista Brasileira de Farmacognosia" esubmissionsupport@elsevier.com
Subject: Your Submission - BJP-D-15-00415R2
Ms. Ref. No.: BJP-D-15-00415R2
Title: Phenolic composition, antioxidant and anti-proliferative activities of edible and medicinal plants from the Peruvian Amazon
Revista Brasileira de Farmacognosia - Brazilian Journal of Pharmacognosy

Dear Prof. Kokoska,

I am pleased to inform you that your paper "Phenolic composition, antioxidant and anti-proliferative activities of edible and medicinal plants from the Peruvian Amazon" has been accepted for publication in Revista Brasileira de Farmacognosia - Brazilian Journal of Pharmacognosy.

Below are comments from the editor and reviewers.

Thank you for submitting your work to Revista Brasileira de Farmacognosia - Brazilian Journal of Pharmacognosy.

Yours sincerely,

Suzana Guimaraes Leitao, Ph.D.
(Associate editor)
Revista Brasileira de Farmacognosia - Brazilian Journal of Pharmacognosy

Comments from the editors and reviewers:

The answers can be acceptable and corrected manuscript is now suitable for publication.

For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EES via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

Manuscript Number: BJP-D-15-00415R2

Title: Phenolic composition, antioxidant and anti-proliferative activities of edible and medicinal plants from the Peruvian Amazon

Article Type: Original Article

Keywords: antioxidant, anticarcinogenic, phenolic compounds, plant extracts

Corresponding Author: Prof. Ladislav Kokoska,

Corresponding Author's Institution: Czech University of Life Sciences Prague

First Author: Jan Tauchen

Order of Authors: Jan Tauchen; Ludvik Bortl; Lukas Huml; Petra Miksatkova; Ivo Duskocil; Petr Marsik; Pablo Villegas; Ymber B Flores; Patrick Van Damme; Bohdan Lojka; Jaroslav Havlik; Oldrich Lapcik; Ladislav Kokoska

Abstract: Among 23 extracts of medicinal and edible plants tested, *Mauritia flexuosa* showed significant antioxidant ability (DPPH and ORAC = 1062.9 and 645.9 ± 51.4 µg TE/ mg extract, respectively), while *Annona montana* demonstrated the most promising anti-proliferative effect (IC50 for Hep-G2 and HT-29 = 2.7 and 9.0 µg/ml, respectively). However, combinatory antioxidant/anti-proliferative effect was only detected in *Oenocarpus bataua* (DPPH = 903.8 and ORAC = 1024 µg TE/ mg extract; IC50 for Hep-G2 and HT-29 at 102.6 and 38.8 µg/ml, respectively) and *Inga edulis* (DPPH = 337.0 and ORAC = 795.7 µg TE/ mg extract; IC50 for Hep-G2 and HT-29 at 36.3 and 57.9 µg/ml, respectively). Phenolic content was positively correlated with antioxidant potential, however not with anti-proliferative effect. None of these extracts possessed toxicity towards normal foetal lung cells, suggesting their possible use in development of novel plant-based agents with preventive and/or therapeutic action against oxidative stress-related diseases.

Suggested Reviewers:

Opposed Reviewers:

Response to Reviewers: ITEMIZED RESPONSE TO THE REVIEWER'S COMMENTS

Ms. Ref. No.: BJP-D-15-00415

Authors: Jan Tauchen, Ludvik Bortl, Lukas Huml, Petra Miksatkova, Ivo Duskocil, Petr Marsik, Pablo Pedro Panduro Villegas, Ymber Bendezu Flores, Patrick Van Damme, Bohdan Lojka, Jaroslav Havlik, Oldrich Lapcik, Ladislav Kokoska

Title: Phenolic composition, antioxidant and anti-proliferative activities of edible and medicinal plants from the Peruvian Amazon

Editor's comments

Query: DPPH and ORAC tests are said to have been modified - which were those changes? Inform the concentrations of the stock solutions. Which are the concentrations of the samples on the serial dilution? No blank, no control?

Response: Following changes were made in the text:

Modifications performed in DPPH and ORAC methods were described:
Lines 124 - 125: Concentrations and volumes of samples, standard and reagent were adjusted in order to be used in a microplate format.
Lines 136 - 138: Outer wells of black absorbance 96-well microtiter plates were filled with 200 μ l of distilled water, in order to provide better thermal mass stability, as suggested by Held (2005).

Concentrations of the stock solutions were added:
Line 139: Stock solutions of AAPH radical (153 mM) and FL (540 μ M) were prepared in 75 mM phosphate buffer (pH 7.0).

Final concentrations at which extracts were tested were added:
Lines 125 - 127: Two-fold serial dilution of each sample (final concentration range: 1.25 - 5120 μ g/ml) was prepared in absolute methanol (175 μ l) in 96-well microtiter plates.
Lines 140 - 141: Afterwards, 25 μ l of each sample at final concentration range of 6.4 - 32 μ g/ml were diluted in 150 μ l FL (54 nM) and incubated at 37°C for 10 min.

Positive and negative controls are mentioned:
Lines 131 - 132: Trolox (at concentrations 0.5, 1, 2, 4, 8, 16, 32, 64, 128, 254 and 512 μ g/mL) was used as positive control and methanol as blank.
Lines 142 - 143: Standard calibration curves of positive control Trolox were acquired at five concentration levels (0.5, 1, 2, 4, 8 μ g/ml).
Line 143: The 75 mM phosphate buffer was used as a blank.

Query: Which were the concentrations used to build the calibration curve and express the results as Trolox equivalents? revise trolox x Trolox
Response: Concentrations of Trolox were added to DPPH and ORAC methodologies at lines 131 - 132 and 142 - 143, respectively, as mentioned in the previous paragraph.
Moreover, Trolox now appears in the whole manuscript with upper case character at the beginning of the word: e.g. Lines 106, 131, 132, 142, 146, 208, and 213.

Query: r.149 Which were the concentrations used to build the calibration curve and express the results gallic acid equivalents? How did you prepare the sample for TPC determination?
Response: Following sentences were added:
Lines 153 - 155: Nine concentration levels of gallic acid (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64 μ g/ml) were used to create the standard calibration curve.
Lines 148 - 149: Firstly, each sample (diluted in water; final concentration ranging from 16 to 80 μ g/ml)

Query: Characterization of phenolic compounds by UHPLC-MS/MS - authors inform that eleven concentration levels ranging from 0.1 to 1000 ng/ml were used to generate calibration curves. Specify which were these concentrations.

Response: Concentrations of standards used to generate calibration curves for UHPLC-MS/MS analysis were added to the text:

Lines 183 - 185: Peak areas of standards (eleven concentration levels ranging from 0.1 to 1000 ng/ml - i.e. 0.1, 0.5, 1, 2.5, 5, 10, 25, 50, 100, 500 and 1000 ng/ml).

Query: Check the conditions of the gradient elution - 15 min, 60:40, 19 min, 60:40 ??? Is that correct?

Response: Yes, the given gradient is correct. Four minutes of starting mobile phases are used to prepare the conditions for the next analysis. For better understanding, "to reach starting conditions" was positioned at the end of the sentence at lines 175 - 177.

Query: Which was the collision gas? Cone voltage?

Response: Nozzle voltage and type of collision gas was added to the text at line 181 (nozzle voltage 2.0 kV and 1.8 kV) and line 182 (Nitrogen was used as collision gas), respectively.

Query: Linear correlation coefficients should read r², not r

Response: The symbol for correlation coefficient was rewritten from r to r² (line 192).

Query: check the spelling of isoquercitrin (not isoqercitrin) along the text.

Response: The misspelled word isoqercitrin was corrected to isoquercitrin throughout the text: e.g. lines 250, 252 and in Table 6.

Other changes:

The following reference was added to the list of references:

Held, P., 2005. Performing oxygen radical absorbance capacity assays with synergyTM HT: ORAC antioxidant tests. Application Note. Biotek Instruments, Winooski, USA.

Combined
antioxidant and
anti-proliferative
activity



Inga edulis Mart.



Oenocarpus bataua Mart.


Selective anti-
proliferative effect




Annona montana Macfad.





UHPLC-ESI-MS/MS analysis



chlorogenic acid



(-)-epicatechin



salicylic acid

	R ¹	R ²
myricetin	OH	H
isoquercitrin	H	glucose
quercetin-3-arabinoside	H	arabinose
rutin	H	rutinose

1 **Phenolic composition, antioxidant and anti-proliferative activities of edible**
2 **and medicinal plants from the Peruvian Amazon**

3 *Jan Tauchen,^{1,2} Ludvik Bortl,¹ Lukas Huml,³ Petra Miksatkova,^{3,4} Ivo Dorskocil,⁵ Petr*
4 *Marsik,² Pablo Pedro Panduro Villegas,⁶ Ymber Bendezu Flores,⁷ Patrick Van Damme,^{1,8}*
5 *Bohdan Lojka,¹ Jaroslav Havlik,⁵ Oldrich Lapcik,³ Ladislav Kokoska,^{*,1}*

6 *¹Department of Crop Sciences and Agroforestry, Faculty of Tropical AgriSciences, Czech*
7 *University of Life Sciences Prague, Kamýcka 129, 165 21 Prague 6 – Suchdol, Czech*
8 *Republic*

9 *²Department of Quality of Agricultural Products, Faculty of Agrobiology, Food and Natural*
10 *Resources, Czech University of Life Sciences Prague, Kamýcka 129, Prague 6 – Suchdol, 165*
11 *21, Czech Republic*

12 *³Department of Chemistry of Natural Compounds, Faculty of Food and Biochemical*
13 *Technology, University of Chemistry and Technology Prague, Technická 5, Prague 6 –*
14 *Dejvice, Czech Republic*

15 *⁴Forensic Laboratory of Biologically Active Substances, University of Chemistry and*
16 *Technology, Prague, Technická 5, Prague 6 - Dejvice, Czech Republic*

17 *⁵Department of Microbiology, Nutrition and Dietetics, Faculty of Agrobiology, Food and*
18 *Natural Resources, Czech University of Life Sciences Prague, Kamýcka 129, 165 21 Prague 6*
19 *– Suchdol, Czech Republic*

20 *⁶Escuela de Ingenieria Agroforestal Acuicola, Facultad de Ingenieria y Ciencias*
21 *Ambientales, Universidad Nacional Intercultural de la Amazonia, Carretera San Jose km 0.5,*
22 *Pucallpa, Peru*

23 *⁷Instituto Nacional de Investigacion Agraria, Avenida La Molina 1981, 2791 Lima, Peru*

24 *⁸Laboratory for Tropical and Subtropical Agriculture and Ethnobotany, Department of Plant*
25 *Production, Faculty of Bio-Science Engineering, Ghent University, Coupure links 653, 9000*
26 *Gent, Belgium*

27 **Running head:** Chemistry and biological activity of Peruvian plants

28 Correspondence: Ladislav Kokoska, Tel.: +420 224 382 180; E-mail: kokoska@ftz.czu.cz

29

30 **Abstract**

31 Among 23 extracts of medicinal and edible plants tested, *Mauritia flexuosa* showed
32 significant antioxidant ability (DPPH and ORAC = 1062.9 and 645.9 ± 51.4 µg TE/ mg
33 extract, respectively), while *Annona montana* demonstrated the most promising anti-
34 proliferative effect (IC₅₀ for Hep-G2 and HT-29 = 2.7 and 9.0 µg/ml, respectively). However,
35 combinatory antioxidant/anti-proliferative effect was only detected in *Oenocarpus bataua*
36 (DPPH = 903.8 and ORAC = 1024 µg TE/ mg extract; IC₅₀ for Hep-G2 and HT-29 at 102.6
37 and 38.8 µg/ml, respectively) and *Inga edulis* (DPPH = 337.0 and ORAC = 795.7 µg TE/ mg
38 extract; IC₅₀ for Hep-G2 and HT-29 at 36.3 and 57.9 µg/ml, respectively). Phenolic content
39 was positively correlated with antioxidant potential, however not with anti-proliferative
40 effect. None of these extracts possessed toxicity towards normal foetal lung cells, suggesting
41 their possible use in development of novel plant-based agents with preventive and/or
42 therapeutic action against oxidative stress-related diseases.

43 **Keywords:** antioxidant, anticarcinogenic, phenolic compounds, plant extracts

44

45 Conflict of interest: The authors declare no conflicts of interest.

46

47 **1 Introduction**

48 It is widely accepted that oxidative stress is involved in the development and/or
49 secondary pathology of various human diseases (Halliwell and Gutteridge, 2007). Several
50 studies show evidence that regular consumption of plant foods is associated with lowered risk
51 of incidence of these (Alasalvar and Shahidi, 2013). It is believed that health beneficial effect
52 of plants foodstuffs can mainly be credited to number of phenolic compounds and their ability
53 to promote antioxidant effect (Brewer, 2011). Currently, antioxidant activity is primarily
54 examined in common food plants such as fruits and vegetables. However, recent studies
55 indicate that other plant categories, such as medicinal plants, also possess significant
56 antioxidant efficacy (Jaberian et al., 2013).

57 Previously it was proposed that progression of cancer is strongly related to oxidative
58 stress. Thus, validation of antioxidant effect of tested plant material is nowadays routinely
59 supplemented with analysis of anti-proliferative activity against various types of carcinoma
60 cell lines (Loizzo et al., 2014; da Costa et al., 2015). In case of phenylporpanoids, the
61 compounds toxic to normal cells (e.g. podophyllotoxin) may be responsible for this anti-
62 carcinomatous effect (Dewick, 2009). However, more recent studies are showing that dietary
63 phenolics (e.g. flavonoids) may exert anti-proliferative effect as well (Ferry et al., 1996; Anter
64 et al., 2011). Despite the fact that medicinal plants are regarded as the main sources of
65 antineoplastic agents, there is now an increased interest in research of edible plants' anti-
66 proliferative effects (De la Rosa et al., 2014).

67 Even though plants are generally considered as very important factor for maintaining
68 food and health security (mainly in third world countries), health-promoting properties of
69 majority of these plants have not been properly verified via modern scientific methods.
70 Despite the well-documented traditional use of plants from that region for treatment of
71 diseases related to oxidative stress such as cancer, diabetes, cardiovascular, inflammatory and

72 neurodegenerative diseases (Duke and Vásquez, 1994; Duke et al., 2009), to our best
73 knowledge, only a very small proportion of edible and medicinal plants from the Peruvian
74 Amazon have ever been assessed for their combinatory antioxidant/anti-proliferative
75 properties (Neri-Numa et al., 2013). In addition, for a majority of these plants, the
76 phytochemical profile was never fully characterized (Newman and Cragg, 2012).

77 Proceeding from these facts, this study provides detailed information on *in vitro*
78 antioxidant and anti-proliferative potential of 23 methanol extracts from 12 Peruvian
79 medicinal and edible plant species which were additionally analysed by UHPLC-MS/MS with
80 the aim to determine the relationship between biological activity and phenolic compound
81 content.

82 **2 Materials and methods**

83 **2.1 Plant material**

84 Selection of plant material was based on previously reported data on traditional use for
85 treatment of diseases likely to be associated with oxidative stress (Table 1). Plants were
86 collected from farms in areas surrounding Pucallpa city in the Peruvian Amazon, between
87 March and June 2013. Voucher specimens were authenticated by Ymber Bendezu Flores and
88 deposited at herbarium of IVITA-Pucallpa, Universidad Nacional Mayor de San Marcos
89 (UNMSM).

90 **2.2 Sample preparation**

91 Fresh plant samples were frozen and lyophilized in Free-Zone 1 freeze dry system
92 (Labconco, Kansas City, USA). Samples were finely grounded in IKA A 11 electric mill
93 (IKA Werke GMBH&Co.KG, Staufen, Germany). Subsequently, 2 g of plant material were
94 extracted in a Soxhlet-like IKA 50 extractor (IKA Werke GMBH&Co.KG, Staufen,
95 Germany) in 70% ethanol in a 1/20 (w/v) proportion during three 7-mins cycles at 130°C
96 followed by cooling to 50°C. Extracts were subsequently filtered through a Teflon (PTFE)

97 syringe filter (17 x 0.45 mm) and evaporated to dryness using a rotary evaporator R-3000
98 (Büchi, Flawil, Switzerland) *in vacuo* at 40°C. Dry residues were dissolved in 80% methanol
99 to create 50 mg/ml stock solutions and subsequently stored at -20°C. Extracts for UHPLC-
100 MS/MS analysis were evaporated to dryness and re-dissolved at a concentration of 0.4 g dry
101 weight per ml.

102 **2.3 Chemicals and reagents**

103 The following chemicals and reagents, purchased from Sigma-Aldrich (Prague, Czech
104 Republic), were used in this study: 2,2'-azobis(2-methylpropionamidine) dihydrochloride
105 (AAPH), 2,2-diphenyl-1-picrylhydrazyl (DPPH), thiazolyl blue tetrazolium bromide (MTT),
106 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (Trolox), Dulbecco's modified
107 Eagle's medium (DMEM), Eagle's minimum essential medium (EMEM), fluorescein (FL),
108 Folin-Ciocalteu reagent, Griess reagent and penicillin–streptomycin solution. Analytical
109 standards (given in Table 2) were purchased from Indofine Chemical Company
110 (Hillsborough, USA) or Sigma-Aldrich. Formic acid, methanol and water of HPLC-grade
111 were purchased from Merck (Darmstadt, Germany); ethanol and dimethyl sulfoxide (DMSO)
112 from Penta (Prague, Czech Republic).

113 **2.4 Cell culture**

114 Liver carcinoma cell line Hep-G2 and normal foetal lung cells MRC-5 (ATCC,
115 Rockville, USA) were maintained in EMEM supplemented with foetal bovine serum (10%),
116 penicillin–streptomycin solution (1%), non-essential amino acids (1%) and glutamine (4 mM
117 and 2 mM for Hep-G2 and MRC-5, respectively). Colon carcinoma cell line HT-29 (ATCC,
118 Rockville, USA) was maintained in DMEM solution and otherwise were treated identically as
119 Hep-G2 and MRC-5. Cultures were incubated in 5% CO₂ atmosphere at 37°C using MCO
120 170AIC-PE CO₂ incubator (Panasonic Corporation, Osaka, Japan).

121 **2.5 *In vitro* antioxidant activity**

122 **2.5.1 *DPPH radical-scavenging assay***

123 Slightly modified method described by Sharma and Bhat (2009) was used for
124 evaluation of samples' ability to inhibit DPPH radical. Concentrations and volumes of
125 samples, standard and reagent were adjusted in order to be used in a microplate format. Two-
126 fold serial dilution of each sample (final concentration range: 1.25 – 5120 µg/ml) was
127 prepared in absolute methanol (175 µl) in 96-well microtiter plates. Subsequently, 25 µl of
128 freshly prepared 1 mM DPPH in methanol was added to each well in order to start the radical-
129 antioxidant reaction. Mixture was kept in the dark at room temperature for 30 min.
130 Absorbance was measured at 517 nm using Infinite 200 reader (Tecan, Männedorf,
131 Switzerland). Trolox (at concentrations 0.5, 1, 2, 4, 8, 16, 32, 64, 128, 254 and 512 µg/mL)
132 was used as a positive control and methanol as a blank. Results were expressed as Trolox
133 equivalents (µg TE/ mg extract).

134 **2.5.2 *Oxygen radical absorbance capacity (ORAC) assay***

135 Adjusted ORAC method was used for determination of samples' ability to protect FL
136 from AAPH-induced damage (Cao and Prior, 1998; Ou et al., 2001). Outer wells of black
137 absorbance 96-wellmicrotiter plates were filled with 200 µl of distilled water, in order to
138 provide better thermal mass stability, as suggested by Held (2005). Stock solutions of AAPH
139 radical (153 mM) and FL (540 µM) were prepared in 75 mM phosphate buffer (pH 7.0).
140 Afterwards, 25 µl of each sample at final concentration range of 6.4 – 32 µg/ml were diluted
141 in 150 µl FL (54 nM) and incubated at 37°C for 10 min. Reaction was started by adding 25 µl
142 AAPH Standard calibration curves of positive control Trolox were acquired at five
143 concentration levels (0.5, 1, 2, 4, 8 µg/ml). The 75 mM phosphate buffer was used as a blank.
144 Fluorescence changes were measured in 1-min intervals for 120 min using an Infinite 200

145 reader with emission and absorbance wavelengths set at 494 nm and 518 nm, respectively.
146 Results were expressed as Trolox equivalents ($\mu\text{g TE/ mg extract}$).

147 **2.5.3 Total phenolic content (TPC)**

148 TPC was measured using the method developed by Singleton et al. (1998). Firstly,
149 each sample (diluted in water; final concentration ranging from 16 to 80 $\mu\text{g/ml}$) with a
150 volume of 100 μl was added to 96-well microtiter plates. Thereafter, 25 μl of pure Folin-
151 Ciocalteu reagent was added. Plate was inserted in an orbital shaker at 40 rpm for 10 min.
152 Reaction was started by adding 75 μl of 12% Na_2CO_3 (w/v). Mixture was kept in dark at 37°C
153 for 2 h. Absorbance was measured at 700 nm (Infinite 200 reader). Nine concentration levels
154 of gallic acid (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64 $\mu\text{g/ml}$) were used to create the standard
155 calibration curve. Results were expressed as gallic acid equivalents ($\mu\text{g GAE/ mg extract}$).

156 **2.6 Cell viability assay**

157 Modified method based on metabolization of MTT to blue formazan by mitochondrial
158 dehydrogenases in living cells previously described by Mosmann (1983) was used to test cell
159 viability. Cells were pre-incubated (24 h) in a 96-well plate at a density of 2.5×10^3 cells per
160 well and afterwards treated with two-fold serial dilutions of plant extracts in range of 0.24 –
161 500 $\mu\text{g/ml}$ for 72 h. After addition of MTT reagent (1 mg/ml) in EMEM or DMEM solution,
162 plates were incubated for an additional 2 h. Media were then removed, and the intracellular
163 formazan product was dissolved in 100 μl of DMSO. Absorbance was measured at 555 nm
164 (Infinite 200 reader) and percentage of viability calculated when compared to untreated
165 control. Results were expressed as 50% inhibitory concentration (IC_{50}) in $\mu\text{g/ml}$.

166 **2.7 Characterization of phenolic compounds by UHPLC-MS/MS**

167 UHPLC-MS/MS analysis of 30 phenolic acids, flavonoids and related compounds was
168 carried out using previously developed and validated method (Prokudina et al., 2012).
169 Instrument was composed of Agilent 1290 Infinity instrument (Agilent, Santa Clara, USA)

170 equipped with a binary pump (G4220B), autosampler (G4226A), autosampler thermostat
171 (G1330B), column compartment thermostat (G1316C), coupled to an Agilent triple
172 quadrupole mass spectrometer (6460A) with a Jet Stream ESI ion source. A Kinetex PFP
173 column (2.6 μm , 100 Å, 150.0 x 3.0 mm) from Phenomenex (Torrance, USA) was used for
174 the chromatographic separation of extracts. Column temperature was set at 35°C and injection
175 volume at 3 μl . Gradient elution was carried out employing mobile phase A (10 mM formic
176 acid) and B (100% methanol) as follows: 0 min, 60:40 (A:B); 10 min, 0:100; 14 min, 0:100;
177 15 min, 60:40, 19 min, 60:40 to reach starting conditions. Flow rate was set at 0.3 ml/min.
178 The MS/MS apparatus was operating in positive and negative mode in the same analysis.
179 Conditions of Jet Stream Ion Source were: drying gas temperature 290°C; drying gas flow 4
180 l/min; sheath gas temperature 380°C; sheath gas flow 10 l/min; nebulizer pressure 35 psi;
181 nozzle voltage 2.0 kV and 1.8 kV; and capillary voltage was set at 3.5 and 5.0 kV in positive
182 and negative acquisitions, respectively. Nitrogen was used as collision gas. Multiple reaction
183 monitoring (MRM) mode was used for the detection. Peak areas of standards (eleven
184 concentration levels ranging from 0.1 to 1000 ng/ml – i.e. 0.1, 0.5, 1, 2.5, 5, 10, 25, 50, 100,
185 500 and 1000 ng/ml) were plotted against the corresponding response using weighed linear
186 regression to generate calibration curves. Specific parameters of MS/MS method are given in
187 Table 2. Agilent Mass Hunter (Agilent, Santa Clara, USA) was used for data acquisition and
188 quantification of samples.

189 **2.8 Statistical analysis**

190 All *in vitro* assays were performed in three separated experiments, each in duplicate.
191 UHPLC-MS/MS data were acquired in two separate experimental measurements. Results
192 were expressed as mean values with standard deviations. Linear correlation coefficients (r^2)
193 were established using Pearson product moment correlation between TPC and (i) antioxidant
194 assay (plotted against DPPH and ORAC values) and (ii) anti-proliferative assay (plotted

195 against IC₅₀ values for Hep-G2 and HT-29). Statistical analysis was performed in
196 STATISTICA 7.1 (StatSoft Inc., Tulsa, USA) software.

197 **3 Results**

198 Six plant extracts out of total 23 tested, namely leaves of *Annona montana*, *Inga*
199 *edulis*, *Myrciaria dubia* and *Theobroma grandiflorum*; exocarp of *Mauritia flexuosa* and fruit
200 without seed of *Oenocarpus bataua* showed significant antioxidant and/or anti-proliferative
201 activity (Table 3). None of the tested plants exhibited toxicity to normal cells. Gallic,
202 chlorogenic, salicylic and vanillic acids, (-)-epicatechin, myricetin, quercetin and its
203 derivatives (isoquercitrin, quercetin-3-arabinoside and rutin) were the most predominant
204 constituents in all analysed extracts. Complete results for antioxidant efficacy and cytotoxicity
205 are given in Table 3, whereas for UHPLC-MS/MS analysis in Tables 4 – 6.

206 **3.1 Antioxidant activity**

207 In DPPH assay, *M. flexuosa* (exocarp) extract possessed higher antioxidant potential
208 than positive control Trolox (1062.9 µg TE/mg). The promising antioxidant efficacy was also
209 detected for *O. bataua* fruit, *T. grandiflorum* leaves, *M. dubia* leaves and pericarp (903.8,
210 714.8, 641.9, and 440.9 µg TE/mg, respectively). Other extracts showed only weak to
211 moderate free radical scavenging ability (range 0.2 - 337.0 µg TE/mg). In ORAC assay, *O.*
212 *bataua* fruits showed highest antioxidant activity (1024.4 µg TE/mg), being stronger than
213 Trolox. Leaf extracts of *T. grandiflorum*, *I. edulis* and *M. dubia*; extracts of *M. flexuosa*
214 exocarp and *I. edulis* pericarp, also showed promising results with µg TE/mg values at 821.9,
215 795.7, 642.6, 645.9 and 645.7, respectively. The rest of the tested plants showed weak to
216 moderate efficacy (from 10.7 to 613.3 µg TE/mg). Highest content of phenolic compounds
217 (TPC assay) was observed in *O. bataua* fruit, *M. flexuosa* (exocarp), *T. grandiflorum* (leaves)
218 and *M. dubia* (leaves and pericarp) with values at 672.3, 461.5, 400.6 and 342.0 µg GAE/mg,
219 respectively (Table 3). The rest of plant extracts tested exhibited only low to moderate

220 quantities of phenolic compounds (range 3.6 - 266.4 μg GAE/mg). Strong correlation was
221 found between TPC and both antioxidant assays used: DPPH ($r = 0.946$) and ORAC ($r =$
222 0.899).

223 3.2 Cell viability assay

224 *A. montana* (leaves) demonstrated to be the plant extract with the most-promising anti-
225 proliferative effect to Hep-G2 cell line ($\text{IC}_{50} = 2.7 \mu\text{g/ml}$), followed by extracts of *I. edulis*
226 (leaves), *O. bataua* (fruit), *M. dubia* (pericarp, leaves), *T. grandiflorum* (leaves) and *I. edulis*
227 (seed) (IC_{50} 's at 36.3, 102.6, 124.0, 149.5, 140.4 and 179.1 $\mu\text{g/ml}$, respectively). The other
228 samples exhibited very low anti-proliferative activity to carcinoma cells with IC_{50} values
229 higher than 500 $\mu\text{g/ml}$. In tests performed on HT-29 cell line, leaves of *A. montana* proved
230 again to be the most-effective plant extract, with IC_{50} value at 9.0 $\mu\text{g/ml}$, followed by extracts
231 of *O. bataua* fruit, leaves of *Bertholletia excelsa*, *T. grandiflorum*, *I. edulis*, *Theobroma cacao*
232 and pericarp of *T. grandiflorum*: IC_{50} 's at 38.8, 41.3, 46.5, 57.9, 82.6, and 83.9 $\mu\text{g/ml}$,
233 respectively. The other plants possessed IC_{50} values in a range of 137.6 - 294.0 $\mu\text{g/ml}$ or
234 exhibited non-toxic effect ($\text{IC}_{50} > 500 \mu\text{g/ml}$). Toxicity assessment on normal MRC-5 cells
235 revealed all plant extracts to be non-toxic ($\text{IC}_{50} > 500 \mu\text{g/ml}$) (Table 3). Weak correlation was
236 found between phenolic content and cell viability assays, whereas correlation coefficients of
237 TPC vs. IC_{50} 's for Hep-G2 and HT-29 were 0.050 and 0.230, respectively.

238 3.3 UHPLC-MS/MS analysis

239 With regard to quantity of phenolic compounds identified by UHPLC-MS/MS in
240 individual species, the highest amount was evidenced in *M. flexuosa* (exocarp) and *Solanum*
241 *sessiliflorum* with values of 0.003% of dry weight. Noticeable results were also observed for
242 *M. flexuosa* (mesocarp), pericarps of *T. bicolor* and *T. grandiflorum*, *O. bataua* (fruit without
243 seed), and leaves of *I. edulis*, whose phenolic compound content in dry weight was detected at

244 0.002%. Remaining species had 0.001% or lower percentages of phenolic compounds on a
245 dry weight basis.

246 Predominant constituents identified in *M. flexuosa* (exocarp) and *S. sessiliflorum*,
247 which are expressed as percentage of phenolic compounds quantity, were chlorogenic acid,
248 rutin and isoquercitrin (36%, 23%, 23.0% for *M. flexuosa* and 50%, 12%, 16.0% for *S.*
249 *sessiliflorum*, respectively). Similar to the exocarp of *M. flexuosa*, its mesocarp predominantly
250 contained chlorogenic acid, rutin and isoquercitrin, although in slightly different ratios (48%,
251 19% and 27%, respectively); (-)-epicatechin (31%) and chlorogenic acid (27%) were regarded
252 as principal constituents in pericarp of *T. bicolor*, while isoquercitrin (42%), quercetin-3-*O*-
253 arabinoside (22%), (-)-epicatechin (15%) and vanillic acid (14%) were most in evidence in
254 pericarp of *T. grandiflorum*. Fruit without seed of *O. bataua* showed relatively high levels of
255 epicatechin (45%), chlorogenic acid (12%) and isoquercitrin (11%). Leaves of *I. edulis* were
256 shown to be mostly composed of myricetin (21%), isoquercitrin (21%) and salicylic acid
257 (13%) (Tables 4 – 6).

258 **4 Discussion**

259 In this study, we investigated potential of Peruvian edible and medicinal plants for
260 elimination of oxidative stress-related diseases using innovative approach based on
261 determination of their combinatory antioxidant and anti-proliferative effects (Tauchen et al.,
262 2015). As a result of our experiments, *O. bataua* and *I. edulis* possessed the best
263 antioxidant/anti-proliferative properties. Although previous studies on chemistry of *O. bataua*
264 have suggested high contents of anthocyanins (Rezaire et al., 2014), a compounds known to
265 produce antioxidant and anticancer activity (Prior and Wu, 2006; Wang and Stoner, 2008),
266 this is the first report on combined antioxidant and anti-proliferative effects of this plant. In
267 contrast to earlier demonstrated relatively low cytotoxic efficacy of *I. edulis* towards various
268 carcinoma cell lines (UACC-62, MCF-7, 786-O, NCI-460, PCO-3, OVCAR-03, HT-29 and

269 K-562) including multidrug-resistant variants (NCI-ADR) (Pompeu et al., 2012), we recorded
270 moderate anti-proliferative activity against Hep-G2 and HT-29 cells of this plant. Differences
271 between results of these experiments can be caused by dissimilar response of cancer cells to
272 active compounds present in *I. edulis* as it has previously been observed for various classes of
273 natural compounds (Sak, 2014). Since the kojic acid, recently found in leaves of *I. edulis*
274 (Tchuenmogne et al., 2013), have exerted significant antioxidant as well as anti-proliferative
275 activities (Novotny et al., 1999; Kusumawati and Indrayanto, 2013) it might considerably
276 contribute to combined biological effect of the plant.

277 The most-interesting results regarding selectivity of anti-proliferative effect towards
278 carcinoma and normal cells were observed for *A. montana*. Despite the existence of records
279 on anti-proliferative efficacy of various Annonaceous species (such as *A. muricata*, *A.*
280 *squamosa* or *A. reticulata*) (Barbalho et al., 2012), the cytotoxicity have not previously been
281 recorded for *A. montana*. Acetogenins are regarded as being chiefly responsible for prominent
282 anticancer effect of Annonaceous species (Smith et al., 2014). Hence, supposedly these
283 constituents are also responsible for the cytotoxic effect of *A. montana* observed in this study.
284 Contrary to the fact that our results suggests *A. montana* extract to be safe, a study of Potts et
285 al. (2012) describes present acetogenins (e.g. annonaine) as the induction factor for
286 neurotoxicity. Additional studies regarding toxicological profile of this plant and its
287 constituents are thus required. Low correlation between TPC and anti-proliferative activity in
288 the rest of tested plant extracts, as well as similar findings in literature (Yang et al., 2009),
289 suggest only partial responsibility of phenolic compounds for anticancer effect.

290 Among the plant species tested in this study, *I. edulis*, *M. dubia*, *M. flexuosa*, *O.*
291 *bataua* and *T. grandiflorum* have been found to be the most effective antioxidants. Despite the
292 existence of previous records on antioxidant effect of these species (Souza et al., 2008;
293 Fracassetti et al., 2013; Koolen et al., 2013; Pugliese et al., 2013; Rezaire et al., 2014), to our

294 best knowledge, majority of these were not using ORAC assay, regarded as one of the most
295 biological relevant methods to determine antioxidant activity *in vitro* (MacDonald-Wicks et
296 al., 2006). Our results from phytochemical and statistical analyses suggested phenolics to be
297 major constituents responsible for the observed antioxidant effect of all five above-mentioned
298 species that is corresponding with earlier published studies (De Sousa Dias et al., 2010;
299 Fracassetti et al., 2013; Pugliese et al., 2013; Bataglion et al., 2014; Rezaire et al., 2014).

300 **5 Conclusion**

301 The current study provides novel information on *in vitro* antioxidant activity and/or
302 anti-proliferative activity of six plant species, namely *A. montana*, *I. edulis*, *M. dubia*, *M.*
303 *flexuosa*, *O. bataua* and *T. grandiflorum*. None of the tested extracts exerted significant
304 toxicity towards normal MRC-5 cells, pointing their relative safety. We conclude that the
305 above-noted plant extracts could serve as prospective material for further development of
306 novel plant-based antioxidant and/or anti-proliferative agents. Particularly *O. bataua* and *I.*
307 *edulis*, the only extracts exhibiting combinatory antioxidant and anti-proliferative efficacy in
308 this study, deserve deeper research attention. Detailed analysis of their chemical composition
309 and *in vivo* antioxidant/anti-proliferative activity should be carried out in order to verify their
310 potential practical use.

311 **Acknowledgements**

312 This research was supported by the Internal Grant Agency of the Czech University of
313 Life Sciences Prague (project no. CIGA 20142012, CIGA 20132035 and IGA 20155021).
314 Study was also supported by a grant of Czech Ministry of Education, Youth and Sports
315 (MSMT n. 20/2015). Authors are very grateful to Mirella Zoyla Clavo (UNMSM) for
316 deposition of herbarium specimens of plant species tested in this study.

317 **Authors' contribution**

318 LB, PPPV and YBF collected the plant samples and organized the botanical
319 identification and confection of herbarium specimens. JT performed the antioxidant assays
320 and drafted the paper. ID organized the anti-proliferative test. LH and PMik did the UHPLC-
321 MS/MS analysis. PMar provided statistical analysis of gained data. PVD, BL, JH and OL
322 contributed to critical reading of the manuscript. LK designed the study, supervised the
323 laboratory work and revised the final version of the paper. All the authors have read the final
324 manuscript and approved the submission.

325

- 327 Alasalvar, C., Shahidi, F., 2013. Dried fruits: Phytochemicals and health effects, 1st ed, Dried
328 fruits: Phytochemicals and health effects. Wiley-Blackwell, Hoboken, USA.
- 329 Anter, J., Romero-Jiménez, M., Fernández-Bedmar, Z., Villatoro-Pulido, M., Analla, M.,
330 Alonso-Moraga, Á., Muñoz-Serrano, A., 2011. Antigenotoxicity, cytotoxicity, and
331 apoptosis induction by apigenin, bisabolol, and protocatechuic acid. *J. Med. Food* 14,
332 276–283. doi:10.1089/jmf.2010.0139
- 333 Barbalho, S.M., de Alvares Goulart, R., Farinazzi-Machado, F.M.V., de Souza, M.S.S., dos
334 Santos Bueno, P.C., Guiguer, É.L., Araújo, A.C., Groppo, M., 2012. *Annona* sp:
335 Plants with multiple applications as alternative medicine - a review. *Curr. Bioact.*
336 *Compd.* 8, 277–286.
- 337 Bataglion, G.A., da Silva, F.M.A., Eberlin, M.N., Koolen, H.H.F., 2014. Simultaneous
338 quantification of phenolic compounds in buriti fruit (*Mauritia flexuosa* L.f.) by ultra-
339 high performance liquid chromatography coupled to tandem mass spectrometry. *Food*
340 *Res. Int.* 66, 396–400. doi:10.1016/j.foodres.2014.09.035
- 341 Brewer, M.S., 2011. Natural antioxidants: Sources, compounds, mechanisms of action, and
342 potential applications. *Compr. Rev. Food Sci. Food Saf.* 10, 221–247.
- 343 Cao, G., Prior, R.L., 1998. Measurement of oxygen radical absorbance capacity in biological
344 samples. *Methods Enzymol.* 299, 50–62.
- 345 da Costa, L.S., Andreazza, N.L., Correa, W.R., Cunha, I.B.S., Ruiz, A.L.T.G., de Carvalho,
346 J.E., Schinor, E.C., Dias, D.A., Salvador, M.J., 2015. Antiproliferative activity,
347 antioxidant capacity and chemical composition of extracts from the leaves and stem of
348 *Chresta sphaerocephala*. *Braz. J. Pharmacogn.* 25, 369–374.
349 doi:10.1016/j.bjp.2015.04.005
- 350 De la Rosa, L.A., Vazquez-Flores, A.A., Alvarez-Parrilla, E., Rodrigo-García, J., Medina-
351 Campos, O.N., Ávila-Nava, A., González-Reyes, S., Pedraza-Chaverri, J., 2014.
352 Content of major classes of polyphenolic compounds, antioxidant, antiproliferative,
353 and cell protective activity of pecan crude extracts and their fractions. *J. Funct. Foods*
354 7, 219–228.
- 355 De Sousa Dias, A.L., De Souza, J.N.S., Rogez, H., 2010. Purification of phenolic compounds
356 from *ingá edulis* leaves using solid-phase extraction: major compounds quantification
357 and antioxidant capacity evaluation. *Quimica Nova* 33, 38–42.
- 358 Dewick, P.M., 2009. Medicinal natural products: A biosynthetic approach, 3rd ed. Wiley &
359 Sons, Chichester, UK.
- 360 Duke, J.A., Bogenschutz-Godwin, M.J., Ottesen, A.R., 2009. Duke's handbook of medicinal
361 plants of Latin America, 1st ed. CRC Press, Boca Raton, USA.
- 362 Duke, J.A., Vásquez, R., 1994. Amazonian ethnobotanical dictionary, 1st ed. CRC Press,
363 Boca Raton, USA.
- 364 Ferry, D.R., Smith, A., Malkhandi, J., Fyfe, D.W., DeTakats, P.G., Anderson, D., Baker, J.,
365 Kerr, D.J., 1996. Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics
366 and evidence for in vivo tyrosine kinase inhibition. *Clin. Cancer Res.* 2, 659–668.
- 367 Fracassetti, D., Costa, C., Moulay, L., Tomás-Barberán, F.A., 2013. Ellagic acid derivatives,
368 ellagitannins, proanthocyanidins and other phenolics, vitamin C and antioxidant
369 capacity of two powder products from camu-camu fruit (*Myrciaria dubia*). *Food*
370 *Chem.* 139, 578–588.
- 371 Halliwell, B., Gutteridge, J.M., 2007. Free radicals in biology and medicine, 4th ed. Oxford
372 University Press, Oxford, UK.
- 373 Held, P., 2005. Performing oxygen radical absorbance capacity assays with synergyTMHT:
374 ORAC antioxidant tests. Application Note. Biotek Instruments, Winooski, USA.

375 Jaberian, H., Piri, K., Nazari, J., 2013. Phytochemical composition and in vitro antimicrobial
376 and antioxidant activities of some medicinal plants. *Food Chem.* 136, 237–244.

377 Koolen, H.H., da Silva, F., Gozzo, F.C., de Souza, A.Q., de Souza, A.D., 2013. Antioxidant,
378 antimicrobial activities and characterization of phenolic compounds from Buriti
379 (*Mauritia flexuosa* L. f.) by UPLC-ESI-MS/MS. *Food Res. Int.* 51, 467–473.

380 Kusumawati, I., Indrayanto, G., 2013. Natural antioxidants in cosmetics. *Stud. Nat. Prod.*
381 *Chem.* 40, 485–505.

382 Lim, T.K., 2012. *Edible medicinal and non medicinal plants: Fruits.* Springer, Dordrecht,
383 Netherlands.

384 Loizzo, M.R., Rashed, K., Said, A., Bonesi, M., Menichini, F., Tundis, R., 2014.
385 Antiproliferative and antioxidant properties of *Alhagi maurorum* Boiss (Leguminosae)
386 aerial parts. *Ind. Crops Prod.* 53, 289–295.

387 MacDonald-Wicks, L.K., Wood, L.G., Garg, M.L., 2006. Methodology for the determination
388 of biological antioxidant capacity in vitro: A review. *J. Sci. Food Agric.* 86, 2046–
389 2056.

390 Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: Application to
391 proliferation and cytotoxicity assays. *J. Immunol. Methods* 65, 55–63.

392 Neri-Numa, I.A., Carvalho-Silva, L.B., Morales, J.P., Malta, L.G., Muramoto, M.T., Ferreira,
393 J.E.M., de Carvalho, J.E., Ruiz, A.L.T.G., Maróstica Junior, M.R., Pastore, G.M.,
394 2013. Evaluation of the antioxidant, antiproliferative and antimutagenic potential of
395 araçá-boi fruit (*Eugenia stipitata* Mc Vaugh - Myrtaceae) of the Brazilian Amazon
396 Forest. *Food Res. Int.* 50, 70–76.

397 Newman, D.J., Cragg, G.M., 2012. Natural products as sources of new drugs over the 30
398 years from 1981 to 2010. *J. Nat. Prod.* 75, 311–335.

399 Novotny, L., Rauko, P., Abdel-Hamid, M., Vachalková, A., 1999. Kojic acid - A new leading
400 molecule for a preparation of compounds with an anti-neoplastic potential. *Neoplasma*
401 46, 89–92.

402 Ou, B., Hampsch-Woodill, M., Prior, R.L., 2001. Development and validation of an improved
403 oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe. *J.*
404 *Agric. Food Chem.* 49, 4619–4626.

405 Pompeu, D.R., Rogez, H., Monteiro, K.M., Tinti, S.V., Carvalho, J.E., 2012. Antioxidant
406 capacity and pharmacologic screening of crude extracts of *Byrsonima crassifolia* and
407 *Inga edulis* leaves. *Acta Amaz.* 42, 165–172.

408 Potts, L.F., Luzzio, F.A., Smith, S.C., Hetman, M., Champy, P., Litvan, I., 2012. Annonacin
409 in *Asimina triloba* fruit: Implication for neurotoxicity. *NeuroToxicology* 33, 53–58.

410 Prior, R.L., Wu, X., 2006. Anthocyanins: Structural characteristics that result in unique
411 metabolic patterns and biological activities. *Free Radic. Res.* 40, 1014–1028.

412 Prokudina, E.A., Havlíček, L., Al-Maharik, N., Lapčík, O., Strnad, M., Gruz, J., 2012. Rapid
413 UPLC-ESI-MS/MS method for the analysis of isoflavonoids and other
414 phenylpropanoids. *J. Food Compos. Anal.* 26, 36–42. doi:10.1016/j.jfca.2011.12.001

415 Pugliese, A.G., Tomas-Barberan, F.A., Truchado, P., Genovese, M.I., 2013. Flavonoids,
416 proanthocyanidins, vitamin C, and antioxidant activity of *Theobroma grandiflorum*
417 (*Cupuassu*) pulp and seeds. *J. Agric. Food Chem.* 61, 2720–2728.

418 Rezaire, A., Robinson, J.-C., Bereau, D., Verbaere, A., Sommerer, N., Khan, M.K., Durand,
419 P., Prost, E., Fils-Lycaon, B., 2014. Amazonian palm *Oenocarpus bataua* (“patawa”):
420 Chemical and biological antioxidant activity – Phytochemical composition. *Food*
421 *Chem.* 149, 62–70.

422 Sak, K., 2014. Cytotoxicity of dietary flavonoids on different human cancer types.
423 *Pharmacogn. Rev.* 8, 122–146. doi:10.4103/0973-7847.134247

- 424 Sharma, O.P., Bhat, T.K., 2009. DPPH antioxidant assay revisited. *Food Chem.* 113, 1202–
425 1205.
- 426 Singleton, V.L., Orthofer, R., Lamuela-Raventos, R.M., 1998. Analysis of total phenols and
427 other oxidation substrates and antioxidants by means of folin-ciocalteu reagent.
428 *Methods Enzymol.* 299, 152–178.
- 429 Smith, R.E., Tran, K., Richards, K.M., 2014. Bioactive annonaceous acetogenins. *Stud. Nat.*
430 *Prod. Chem.* 41, 95–117.
- 431 Sosnowska, J., Balslev, H., 2009. American palm ethnomedicine: A meta-analysis. *J.*
432 *Ethnobiol. Ethnomedicine* 5. doi:10.1186/1746-4269-5-43
- 433 Souza, J.N.S., Silva, E.M., Loir, A., Rees, J.-F., Rogez, H., Larondelle, Y., 2008. Antioxidant
434 capacity of four polyphenol-rich Amazonian plant extracts: A correlation study using
435 chemical and biological in vitro assays. *Food Chem.* 106, 331–339.
- 436 Tauchen, J., Duskocil, I., Caffi, C., Lulekal, E., Marsik, P., Havlik, J., Damme, P.V.,
437 Kokoska, L., 2015. In vitro antioxidant and anti-proliferative activity of Ethiopian
438 medicinal plant extracts. *Ind. Crops Prod.* 74, 671–679.
439 doi:10.1016/j.indcrop.2015.05.068
- 440 Tchuenmogne, A.M., Donfack, E.V., Kongue, M.D., Lenta, B.N., Ngouela, S., Tsamo, E.,
441 Sidhu, N., Dittrich, B., Laatsch, H., 2013. Ingacamerounol, a new flavonol and other
442 chemical constituents from leaves and stem bark of *Inga edulis* Mart. *Bull. Korean*
443 *Chem. Soc.* 34, 3859–3862.
- 444 Wang, L.-S., Stoner, G.D., 2008. Anthocyanins and their role in cancer prevention. *Cancer*
445 *Lett.* 269, 281–290.
- 446 Yang, J., Liu, R.H., Halim, L., 2009. Antioxidant and antiproliferative activities of common
447 edible nut seeds. *LWT - Food Sci. Technol.* 42, 1–8.
- 448
- 449

450

Table 1. Ethnobotanical data of tested plant species

Botanical name [voucher specimen]	Family	Vernacular name^a	Part(s) tested	Way of consumption	Traditional medicinal use^b	Reference^d
<i>Annona montana</i> Macfad. [LB0037]	Annonaceae	<i>Guanabana</i>	leaf	Infusion/decoction	Cancer	(Duke and Vásquez, 1994; Barbalho et al., 2012)
<i>Bertholletia excelsa</i> Bonpl. [LB0120]	Lecythidaceae	<i>Castaña</i>	leaf	Infusion/decoction	Cancer	(Duke et al., 2009)
<i>Bunchosia armeniaca</i> (Cav.) DC. [LB0044]	Malpighiaceae	<i>Ciruela (china)</i>	seed, pericarp	Fruit eaten fresh or in processed form	n/a ^c	(Lim, 2012)
<i>Genipa americana</i> L. [LB0032]	Rubiaceae	<i>Huito, Lana</i>	whole fruit	Fruit eaten fresh or in processed form	Cancer	(Duke et al., 2009)
<i>Inga edulis</i> Mart. [LB0013]	Fabaceae	<i>Guaba</i>	leaf, pericarp, aril, seed	Pulp eaten fresh or used for flavouring; leaves used as infusion	Rheumatoid arthritis	(Lim, 2012)
<i>Mauritia flexuosa</i> L. f. [LB0084]	Arecaceae	<i>Aguaje</i>	exocarp, mesocarp	Processed into juices	Neurodegenerative diseases	(Duke et al., 2009)
<i>Myrciaria dubia</i> (Kunth) McVaugh [LB0095]	Myrtaceae	<i>Camu camu</i>	leaf, pericarp	Processed into juices; leaves used as infusion	Neurodegenerative diseases	(Duke et al., 2009)
<i>Oenocarpus bataua</i> Mart. [LB0123]	Arecaceae	<i>Ungurahui</i>	exocarp + mesocarp	Fruit eaten fresh or in processed form	Cancer	(Sosnowska and Balslev, 2009)
<i>Solanum sessiliflorum</i> Dunal [LB0046]	Solanaceae	<i>Cocona</i>	whole fruit	Fruit eaten fresh or cooked	Diabetes	(Duke and Vásquez, 1994; Lim, 2012)
<i>Theobroma bicolor</i> Humb. & Bonpl. [LB0073]	Malvaceae	<i>Macambo</i>	pericarp, aril + seed	Pulp is eaten fresh, seeds are consumed roasted	Cardiovascular diseases, cancer, diabetes	(Lim, 2012)
<i>Theobroma cacao</i> L. [LB0016]	Malvaceae	<i>Cacao</i>	leaf, pericarp, aril + seed	Pulp is eaten fresh, seeds are consumed roasted; leaves used as infusion/decoction	Cardiovascular diseases, cancer, diabetes	(Lim, 2012)
<i>Theobroma grandiflorum</i> (Willd. ex Spreng.) K.Schum. [LB0052]	Malvaceae	<i>Copoazú</i>	leaf, pericarp, aril	Pulp is eaten fresh, seeds are consumed roasted; leaves used as infusion/decoction	Cardiovascular diseases, cancer, diabetes	(Lim, 2012)

^a vernacular names apply in the area of collection (Ucayali region, Peruvian Amazon); ^b only diseases or conditions likely to be associated to oxidative stress are recorded; ^c to our best knowledge, documentation on traditional use as remedy in the Amazon region is not available; ^d references are related to plant parts tested in this study

Table 2. Transitions and MS/MS parameters of analysed compounds

Compound	Ionization mode	Retention time (min) ^a	Fragmentor (V)	Precursor ion (m/z)	Product (m/z)				LOD (ng/ml) ^c	LOQ (ng/ml) ^d
					Quantification transition	E (eV) ^b	Confirmation transition	E (eV) ^b		
anistic acid	ESI +	5.35 (0.5)	72	153.06	77.2	5	109.1	9	3.6	11.9
apigenin	ESI -	7.98 (0.6)	108	269.04	117.0	3	151.1	7	0.1	0.3
apigenin-7-glucoside	ESI +	5.54 (0.5)	109	433.12	271.0	3	153.0	60	0.2	0.8
caffeic acid	ESI -	3.60 (0.4)	81	179.00	89.0	30	135.1	3	2.3	7.7
chlorogenic acid	ESI -	3.01(1.0)	81	353.09	191.1	9	*	*	0.6	1.9
<i>p</i> -coumaric acid	ESI +	4.37 (0.5)	60	165.05	147.1	9	*	*	0.9	3.0
(-)- epicatechin	ESI -	3.10 (0.5)	111	289.07	109	3	245.1	5	0.7	2.4
ferulic acid	ESI +	4.65 (0.5)	63	195.07	145.0	3	177.0	5	1.0	3.2
flavone	ESI +	8.80 (0.5)	119	223.10	77.2	1	121.1	25	0.2	0.8
gallic acid	ESI -	2.43 (0.6)	75	169.01	124.9	9	169.0	5	0.7	2.2
hesperetin	ESI -	7.30 (0.5)	108	301.07	164.0	17	286.0	9	0.1	0.3
isoquercitrin	ESI -	4.87 (0.5)	150	463.09	300.3	18	271.0	42	0.4	1.2
kaempferol	EIS +	7.55 (0.6)	161	287.06	153.0	1	69.1	3	1.1	3.6
luteolin	ESI -	7.23 (0.8)	128	285.04	133.0	33	151.0	0	0.4	1.4
luteolin-7-glucoside	ESI -	4.92 (0.6)	151	447.09	285.0	25	133.0	0	1.3	4.4
morin	ESI +	6.22 (0.8)	141	303.05	152.9	0	69.1	4	22.0	73.2
myricetin	ESI -	5.72 (0.8)	113	317.03	151.0	7	137.0	1	30.3	101.0
naringenin	ESI -	7.05 (0.5)	93	271.06	119.0	1	151.0	9	0.1	0.1
naringenin-7-glucoside	ESI -	4.76 (0.5)	117	433.11	271.1	0	119.0	0	0.1	0.4
naringin	ESI -	4.57 (0.5)	166	579.17	271.1	9	151.0	9	3.0	10.0
pterostilbene	ESI -	9.07 (0.5)	102	255.10	240.1	3	197.1	5	0.3	1.0
quercetin	ESI -	6.70 (0.9)	106	301.03	151.0	3	121.1	4	1.3	4.2
quercetin-3-arabinoside	ESI -	5.18 (0.5)	114	433.07	300.0	7	271.0	7	0.3	0.9
resveratrol	ESI -	5.25 (0.5)	102	227.10	143.0	5	185.1	3	0.1	0.2
rutin	ESI -	4.69 (0.5)	163	609.14	271.0	1	300.0	5	0.3	0.9
salicylic acid	ESI -	5.22 (0.6)	72	137.02	93.1	3	65.1	9	0.5	1.8
scopoletin	ESI -	4.84 (0.5)	81	191.03	176.0	0	104.0	2	0.4	1.2

sinapic acid	ESI -	4.80 (0.4)	81	223.06	208.1	9	149.0	7	0.1	0.2
syringic acid	ESI +	3.99 (0.5)	60	199.06	140.1	3	77.2	5	0.5	1.7
vanillic acid	ESI +	3.79 (0.5)	78	169.05	65.2	2	125.1	5	1.4	4.6

^a retention time window (minutes) is given in brackets; ^b collision energy; ^c limits of detection (signal-to-noise ratio of 3); ^d limits of quantification (signal-to-noise ratio of 10); * Only one transition was used for detection.

Table 3. Total phenolic content, antioxidant and anti-proliferative activity of tested plant extracts

Species	Plant part(s) ^a	Antioxidant assay / Mean \pm SD ^b			Cell type / Mean IC ₅₀ \pm SD ^b		
		DPPH ^c	ORAC ^c	TPC ^d	Hep-G2 ^e	HT-29 ^e	MRC-5 ^e
<i>A. montana</i>	L	186.9 \pm 16.7	608.3 \pm 18.8	196.8 \pm 10.7	2.7 \pm 0.2	9.0 \pm 1.3	> 500
<i>B. excelsa</i>	L	258.8 \pm 6.4	613.3 \pm 26.8	266.4 \pm 14.1	> 500	41.3 \pm 3.4	> 500
<i>B. armeniaca</i>	P	1.5 \pm 0.1	10.7 \pm 1.0	6.5 \pm 0.7	> 500	> 500	> 500
	S	> 0.2	27.3 \pm 2.6	3.6 \pm 0.7	> 500	> 500	> 500
<i>G. americana</i>	FW	20.6 \pm 4.7	113.9 \pm 4.7	28.0 \pm 2.2	> 500	> 500	> 500
<i>I. edulis</i>	A	21.2 \pm 3.2	69.9 \pm 3.9	20.8 \pm 1.8	> 500	> 500	> 500
	L	337.0 \pm 26.3	795.7 \pm 25.4	262.3 \pm 11.8	36.3 \pm 15.7	57.9 \pm 2.1	> 500
	P	288.0 \pm 8.8	645.7 \pm 33.9	207.2 \pm 13.8	> 500	190.9 \pm 1.1	> 500
	S	7.9 \pm 0.5	51.5 \pm 2.8	17.2 \pm 3.3	179.1 \pm 13.7	148.5 \pm 41.7	> 500
<i>M. flexuosa</i>	E	1062.9 \pm 163.9	645.9 \pm 51.4	461.5 \pm 32.5	> 500	> 500	> 500
	M	130.8 \pm 15.4	244.5 \pm 7.5	87.0 \pm 3.9	> 500	262.6 \pm 2.2	> 500
<i>M. dubia</i>	L	641.9 \pm 127.9	642.6 \pm 32.7	342.0 \pm 18.7	149.5 \pm 23.8	> 500	> 500
	P	440.9 \pm 62.7	333.0 \pm 21.6	275.8 \pm 13.2	124.0 \pm 12.3	> 500	> 500
<i>O. bataua</i>	FO	903.8 \pm 158.1	1024.4 \pm 69.3	672.3 \pm 46.9	102.6 \pm 4.2	38.8 \pm 5.4	> 500
<i>S. sessiliflorum</i>	FW	8.8 \pm 1.2	88.9 \pm 6.0	18.1 \pm 2.0	> 500	> 500	> 500
<i>T. bicolor</i>	A+S	107.4 \pm 13.6	243.0 \pm 20.7	102.9 \pm 4.3	> 500	294.0 \pm 34.9	> 500
	P	152.4 \pm 3.8	217.9 \pm 16.8	104.9 \pm 4.7	388.5 \pm 22.2	156.8 \pm 11.4	> 500
<i>T. cacao</i>	A+S	329.9 \pm 59.5	587.3 \pm 48.8	217.2 \pm 5.5	407.8 \pm 4.6	137.6 \pm 12.0	> 500
	L	152.2 \pm 7.5	542.7 \pm 23.1	149.8 \pm 4.4	> 500	82.6 \pm 5.5	> 500
	P	51.6 \pm 6.1	179.7 \pm 12.3	49.4 \pm 3.6	> 500	> 500	> 500
	A	25.9 \pm 4.2	145.5 \pm 9.5	57.6 \pm 3.2	> 500	> 500	> 500
<i>T. grandiflorum</i>	L	714.8 \pm 111.3	821.9 \pm 65.6	400.6 \pm 25.9	140.4 \pm 3.0	46.5 \pm 0.2	> 500
	P	188.2 \pm 10.9	434.9 \pm 38.8	163.0 \pm 8.1	218.6 \pm 26.2	83.9 \pm 0.7	> 500

^a abbreviation refers to plant part(s): A = aril, E = exocarp, FO = fruit without seed, FW = whole fruit, M = mesocarp, L = leaves, P = pericarp, S = seed; ^b standard deviation; ^c μ g TE/mg extract; ^d μ g GAE/mg extract; ^e μ g/ml.

Table 4. Concentrations of phenolic acids in tested plant extracts

Species	Plant part(s) ^a	Compound (ng/g DW) ^{bc}									
		anistic a.	caffeic a.	chlorogenic a.	<i>p</i> -coumaric a.	ferulic a.	gallic a.	salicylic a.	sinapic a.	syringic a.	vanillic a.
<i>A. montana</i>	L	116.3 ± 3.0	115.7 ± 4.3	267.1 ± 9.6	153.4 ± 4.2	81.8 ± 2.4	253.2 ± 1.4	64.3 ± 0.6	17.7 ± 0.5	94.2 ± 2.7	317.7 ± 7.2
<i>B. excelsa</i>	L	35.3 ± 0.7	25.5 ± 0.4	45.6 ± 2.3	391.5 ± 7.0	84.5 ± 1.5	3929.8 ± 25.4	665.9 ± 0.1	35.4 ± 1.1	123.9 ± 1.0	183.6 ± 5.4
<i>B. armeniaca</i>	P	ND	<LOQ	65.4 ± 3.1	48.1 ± 0.3	10.6 ± 0.0	ND	37.1 ± 0.4	1.6 ± 0.0	43.9 ± 1.0	37.2 ± 0.5
	S	ND	ND	<LOQ	25.3 ± 0.6	22.7 ± 0.3	ND	16.2 ± 0.3	ND	ND	ND
<i>G. americana</i>	FW	197.5 ± 2.4	46.9 ± 1.1	ND	56.1 ± 1.8	591.2 ± 5.4	ND	104.2 ± 0.1	155.6 ± 3.4	87.7 ± 2.2	6642.9 ± 86.1
<i>I. edulis</i>	A	ND	<LOQ	16.8 ± 0.9	33.6 ± 0.7	19.5 ± 0.5	647.5 ± 11.1	681.7 ± 5.2	26.8 ± 0.6	18.6 ± 0.4	43.9 ± 1.1
	L	ND	46.7 ± 2.0	ND	272.8 ± 0.4	32.1 ± 0.4	829.5 ± 3.5	2158.9 ± 2.5	17.8 ± 0.6	107.1 ± 2.2	1270.1 ± 29.6
	P	ND	<LOQ	5.7 ± 0.3	60.4 ± 1.4	15.0 ± 0.1	789.0 ± 19.3	1985.2 ± 4.1	1.0 ± 0.0	47.9 ± 1.9	456.7 ± 10.3
	S	ND	<LOQ	<LOQ	42.0 ± 1.2	277.8 ± 8.6	62.4 ± 1.1	43.1 ± 0.9	66.1 ± 0.4	16.9 ± 0.5	87.1 ± 2.1
<i>M. flexuosa</i>	E	<LOQ	162.7 ± 4.9	11767.9 ± 75.0	52.3 ± 0.5	98.9 ± 2.9	159.0 ± 0.9	13.9 ± 0.1	188.0 ± 1.4	177.3 ± 6.4	390.5 ± 7.9
	M	ND	53.8 ± 1.8	10354.6 ± 73.5	58.8 ± 1.6	93.4 ± 3.5	61.7 ± 1.0	16.5 ± 0.1	347.3 ± 3.4	48.6 ± 1.5	115.1 ± 2.1
<i>M. dubia</i>	L	37.6 ± 0.3	<LOQ	66.3 ± 0.1	159.9 ± 5.8	<LOQ	4087.7 ± 10.1	111.8 ± 0.8	5.2 ± 0.1	82.9 ± 1.2	108.0 ± 1.4
	P	<LOQ	<LOQ	15.3 ± 0.4	165.2 ± 5.1	19.0 ± 0.1	163.8 ± 4.1	51.3 ± 1.3	ND	10.7 ± 0.1	38.3 ± 3.1
<i>O. bataua</i>	FO	ND	256.3 ± 8.1	2324.7 ± 45.2	501.8 ± 14.7	351.6 ± 1.2	15.4 ± 0.4	39.6 ± 0.1	52.2 ± 0.5	704.2 ± 4.1	980.1 ± 24.0
<i>S. sessiliflorum</i>	FW	ND	235.4 ± 5.3	15066.5 ± 106.2	295.0 ± 7.2	99.6 ± 1.1	ND	432.8 ± 3.6	103.0 ± 2.6	24.1 ± 0.3	59.8 ± 1.2
	A+S	49.1 ± 0.9	23.8 ± 0.3	ND	47.9 ± 1.0	34.7 ± 0.6	ND	153.8 ± 4.3	134.7 ± 3.0	166.7 ± 4.5	261.7 ± 6.8
<i>T. bicolor</i>	P	36.6 ± 0.5	59.1 ± 0.7	5318.4 ± 29.1	100.0 ± 3.3	178.1 ± 2.3	15.3 ± 1.0	51.9 ± 1.2	90.9 ± 1.5	165.7 ± 3.8	1066.3 ± 31.7
<i>T. cacao</i>	A+S	20.9 ± 0.8	42.6 ± 1.0	<LOQ	22.6 ± 0.3	8.5 ± 0.0	<LOQ	13.5 ± 0.1	1.0 ± 0.0	7.2 ± 0.1	121.1 ± 2.0
	L	ND	180.9 ± 4.9	6678.4 ± 38.5	748.0 ± 15.7	198.1 ± 5.1	6.1 ± 0.3	350.6 ± 1.3	274.7 ± 8.2	170.1 ± 3.8	593.6 ± 8.5
	P	ND	66.3 ± 2.0	<LOQ	29.5 ± 1.2	620.0 ± 11.7	<LOQ	53.8 ± 0.2	87.3 ± 2.7	54.7 ± 1.5	307.6 ± 5.9
<i>T. grandiflorum</i>	A	20.2 ± 0.7	<LOQ	9.5 ± 0.8	112.0 ± 2.6	52.5 ± 1.0	8.4 ± 0.9	146.3 ± 1.5	3.7 ± 0.1	240.5 ± 7.9	1179.8 ± 25.5
	L	<LOQ	27.9 ± 0.7	8.7 ± 0.4	142.6 ± 3.3	54.7 ± 0.5	28.2 ± 1.0	1853.9 ± 1.8	102.7 ± 2.3	379.9 ± 6.4	948.1 ± 9.8
	P	ND	<LOQ	16.9 ± 0.8	148.8 ± 3.9	76.8 ± 0.2	6.7 ± 0.2	121.6 ± 0.4	13.1 ± 0.2	497.5 ± 0.7	2723.8 ± 36.9

^a abbreviation refers to plant part(s): A = aril, E = exocarp, FO = fruit without seed, FW = whole fruit, M = mesocarp, L = leaves, P = pericarp, S = seed; ^b ND = compound not detected; ^c <LOQ = compound presented in sample under limit of quantification.

Table 5. Concentrations of flavonoids in tested plant extracts

Species	Plant part(s)	Compound (ng/g DW) ^{bc}									
		apigenin	(-)-epicatechin	flavone	hesperetin	kaempferol	luteolin	morin	myricetin	naringenin	quercetin
<i>A. montana</i>	L	ND	602.2 ± 4.9	ND	ND	54.8 ± 1.1	<LOQ	ND	473.4 ± 0.7	<LOQ	55.3 ± 0.6
<i>B. excelsa</i>	L	<LOQ	137.1 ± 3.9	ND	ND	271.9 ± 7.7	<LOQ	<LOQ	500.0 ± 2.3	5.7 ± 0.0	293.3 ± 0.3
<i>B. armeniaca</i>	P	ND	11.5 ± 0.4	ND	2.0 ± 0.1	<LOQ	<LOQ	ND	ND	1.6 ± 0.0	12.8 ± 0.2
	S	ND	9.8 ± 0.3	ND	ND	ND	ND	ND	ND	ND	ND
<i>G. americana</i>	FW	<LOQ	126.3 ± 3.8	ND	1.5 ± 0.0	34.3 ± 0.1	<LOQ	ND	ND	1.6 ± 0.1	29.2 ± 0.8
<i>I. edulis</i>	A	32.6 ± 0.4	1284.7 ± 24.9	ND	ND	<LOQ	167.6 ± 1.9	ND	ND	0.6 ± 0.0	127.9 ± 2.5
	L	18.4 ± 0.0	298.3 ± 9.9	ND	ND	32.2 ± 0.6	692.1 ± 19.3	ND	3593.1 ± 29.5	1.2 ± 0.0	934.0 ± 8.5
	P	7.7 ± 0.2	2229.3 ± 22.4	ND	1.4 ± 0.0	ND	600.4 ± 5.2	ND	ND	1.6 ± 0.0	153.8 ± 1.6
<i>M. flexuosa</i>	S	16.5 ± 0.1	14.1 ± 0.9	ND	ND	51.5 ± 1.4	281.5 ± 8.3	ND	569.7 ± 1.4	0.3 ± 0.0	134.4 ± 5.3
	E	528.6 ± 0.4	228.8 ± 7.5	ND	8.7 ± 0.1	158.6 ± 3.7	477.8 ± 3.2	454.2 ± 1.2	471.2 ± 0.0	171.0 ± 2.6	252.6 ± 4.9
	M	15.0 ± 0.1	186.1 ± 6.7	ND	<LOQ	ND	5.5 ± 0.1	ND	ND	7.1 ± 0.1	32.7 ± 0.5
<i>M. dubia</i>	L	ND	<LOQ	ND	ND	247.2 ± 3.5	ND	ND	1147.8 ± 8.0	8.7 ± 0.3	375.9 ± 8.9
	P	ND	ND	6.0 ± 0.2	ND	27.7 ± 0.7	ND	ND	1010.4 ± 2.3	0.7 ± 0.0	161.9 ± 1.1
<i>O. batavia</i>	FO	54.4 ± 0.4	8628.5 ± 36.8	ND	2.4 ± 0.1	82.3 ± 2.7	30.9 ± 0.2	ND	473.7 ± 0.7	21.9 ± 0.1	687.2 ± 8.3
<i>S. sessiliflorum</i>	FW	7.1 ± 0.0	ND	ND	ND	302.0 ± 8.9	9.2 ± 0.1	ND	ND	1449.8 ± 17.0	124.0 ± 2.2
	A+S	ND	6495.1 ± 7.4	ND	0.7 ± 0.0	16.4 ± 0.3	7.3 ± 0.6	ND	6282.9 ± 38.8	4.2 ± 0.2	358.4 ± 3.5
<i>T. cacao</i>	P	1.2 ± 0.0	6055.4 ± 46.3	ND	7.9 ± 0.0	60.1 ± 0.6	24.9 ± 0.5	ND	597.6 ± 4.5	440.8 ± 2.2	343.9 ± 4.0
	A+S	<LOQ	6672.0 ± 51.1	ND	ND	9.4 ± 0.0	62.4 ± 0.8	ND	<LOQ	14.0 ± 0.3	948.0 ± 4.9
	L	29.5 ± 0.3	4128.6 ± 36.8	ND	ND	<LOQ	88.6 ± 0.5	ND	ND	ND	21.7 ± 0.1
<i>T. grandiflorum</i>	P	21.3 ± 0.1	1324.1 ± 58.5	ND	<LOQ	<LOQ	194.6 ± 2.2	ND	ND	5.5 ± 0.0	30.5 ± 0.1
	A	3.1 ± 0.2	3635.7 ± 23.0	ND	ND	33.7 ± 0.1	266.4 ± 7.7	ND	471.2 ± 0.1	7.7 ± 0.2	134.6 ± 3.3
	L	1.9 ± 0.0	1100.7 ± 15.0	ND	<LOQ	844.8 ± 0.8	128.7 ± 3.0	ND	474.7 ± 0.0	4.9 ± 0.1	1011.8 ± 1.7
	P	<LOQ	2905.7 ± 37.4	ND	ND	44.8 ± 0.1	<LOQ	ND	ND	8.4 ± 0.1	296.6 ± 0.0

^a abbreviation refers to plant part(s): A = aril, E = exocarp, FO = fruit without seed, FW = whole fruit, M = mesocarp, L = leaves, P = pericarp, S = seed; ^b ND = compound not detected; ^c <LOQ = compound presented in sample under limit of quantification.


Table 6. Concentrations of flavonoid derivatives, stilbenes and other phenolic compounds in tested plant extracts

Species	Plant part(s) ^a	Compound (ng/g DW) ^{bc}									
		apigenin-7-glucoside	luteolin-7-glucoside	naringenin-7-glucoside	quercetin-3-arabinoside	naringin	isoquercitrin	rutin	pterostilbene	resveratrol	scopoletin
<i>A. montana</i>	L	2.0 ± 0.0	22.2 ± 0.6	1.2 ± 0.1	2.6 ± 0.0	ND	1486.8 ± 21.0	8086.8 ± 92.4	ND	ND	<LOQ
<i>B. excelsa</i>	L	8.7 ± 0.1	<LOQ	2.5 ± 0.0	603.9 ± 5.7	ND	4156.2 ± 46.5	3007.1 ± 43.0	ND	1.9 ± 0.0	ND
<i>B. armeniaca</i>	P	ND	ND	11.0 ± 0.0	2.3 ± 0.0	ND	1112.7 ± 3.0	7024.2 ± 52.1	2.4 ± 0.0	0.6 ± 0.0	<LOQ
	S	ND	ND	2.5 ± 0.0	<LOQ	ND	<LOQ	8.1 ± 0.1	ND	ND	ND
<i>G. americana</i>	F	<LOQ	ND	1.5 ± 0.1	23.3 ± 0.1	28.1 ± 0.6	378.7 ± 2.0	3046.7 ± 0.3	2.5 ± 0.0	<LOQ	<LOQ
<i>I. edulis</i>	A	22.5 ± 0.4	49.6 ± 0.7	7.1 ± 0.1	2386.0 ± 37.2	ND	6241.1 ± 2.5	849.8 ± 4.5	2.5 ± 0.0	ND	<LOQ
	L	121.0 ± 1.5	416.5 ± 7.4	1.9 ± 0.1	1588.6 ± 28.0	36.8 ± 0.8	3478.6 ± 59.4	838.7 ± 6.1	ND	4.5 ± 0.1	6.4 ± 0.0
	P	35.2 ± 0.4	132.8 ± 2.2	7.9 ± 0.1	848.3 ± 9.4	ND	2892.0 ± 4.9	81.2 ± 0.8	2.4 ± 0.0	<LOQ	4.1 ± 0.1
	S	195.9 ± 2.8	310.0 ± 3.6	4.4 ± 0.1	20.2 ± 0.0	ND	458.2 ± 5.0	90.2 ± 1.4	ND	ND	ND
<i>M. flexuosa</i>	E	333.6 ± 9.5	501.5 ± 1.3	45.9 ± 0.9	70.0 ± 2.3	85.9 ± 2.5	7417.6 ± 22.2	7435.8 ± 70.8	184.3 ± 0.7	590.1 ± 13.8	ND
	M	20.8 ± 0.1	54.4 ± 0.1	30.3 ± 0.3	28.2 ± 0.6	<LOQ	5858.6 ± 80.0	3998.2 ± 106.2	5.8 ± 0.0	6.5 ± 0.1	ND
<i>M. dubia</i>	L	<LOQ	ND	11.2 ± 0.0	1392.0 ± 3.9	ND	3345.6 ± 2.5	ND	ND	1.9 ± 0.1	ND
	P	ND	ND	2.1 ± 0.1	124.0 ± 2.7	ND	170.3 ± 1.5	ND	ND	<LOQ	ND
<i>O. batava</i>	FO	68.9 ± 0.4	14.2 ± 0.1	5.0 ± 0.0	<LOQ	ND	2128.0 ± 16.5	650.6 ± 4.7	39.1 ± 0.8	907.3 ± 15.3	ND
<i>S. sessiliflorum</i>	F	26.9 ± 0.1	35.0 ± 1.0	3186.4 ± 35.1	76.6 ± 2.9	ND	4823.8 ± 5.1	3659.3 ± 87.3	ND	<LOQ	21.1 ± 0.0
<i>T. bicolor</i>	A+	ND	ND	1.6 ± 0.1	54.0 ± 1.5	ND	695.5 ± 6.1	7.3 ± 0.2	ND	8.2 ± 0.1	84.3 ± 0.7
	P	<LOQ	12.3 ± 0.3	437.3 ± 5.2	90.2 ± 1.5	198.2 ± 9.6	2064.9 ± 5.0	1936.1 ± 2.5	2.6 ± 0.8	7.5 ± 0.1	384.9 ±
<i>T. cacao</i>	A+	3.3 ± 0.0	71.3 ± 2.6	15.4 ± 0.0	3269.1 ± 85.9	<LOQ	10259.3 ± 2.6	2.4 ± 0.1	<LO	1.5 ± 0.0	<LOQ
	L	747.9 ± 4.3	1239.8 ± 2.2	5.1 ± 0.2	281.5 ± 2.1	<LOQ	917.4 ± 6.6	<LOQ	ND	<LOQ	3.2 ± 0.0
	P	69.7 ± 0.6	295.6 ± 0.7	7.6 ± 0.1	298.9 ± 5.4	<LOQ	360.1 ± 7.5	2.9 ± 0.1	ND	<LOQ	ND
<i>T. grandiflorum</i>	A	10.2 ± 0.1	29.8 ± 0.6	2.7 ± 0.0	285.1 ± 3.2	40.8 ± 1.0	1753.9 ± 17.8	44.7 ± 0.7	ND	1.1 ± 0.0	35.3 ± 0.4
	L	2.5 ± 0.1	<LOQ	<LOQ	422.3 ± 6.4	<LOQ	2474.5 ± 13.1	255.4 ± 5.8	ND	1.6 ± 0.0	82.5 ± 0.9
	P	ND	ND	7.2 ± 0.1	4184.2 ± 17.0	114.1 ± 0.1	8149.4 ± 2.4	25.6 ± 0.9	2.6 ± 0.1	0.7 ± 0.0	46.5 ± 0.3

^a abbreviation refers to plant part(s): A = aril, E = exocarp, FO = fruit without seed, FW = whole fruit, L = leaves, M = mesocarp, P = pericarp, S = seed; ^b ND = compound not detected; ^c <LOQ = compound presented in sample under limit of quantification.

Appendix C:

Tauchen J, Doskočil I, Caffi C, Lulekal E, Maršík P, Havlík J, Van Damme P, Kokoška L. In vitro antioxidant and anti-proliferative activity of Ethiopian medicinal plant extracts. *Industrial Crops and Products*. 2015;74: 671–679.



In vitro antioxidant and anti-proliferative activity of Ethiopian medicinal plant extracts



Jan Tauchen^a, Ivo Duskocil^b, Cecilia Caffi^c, Ermias Lulekal^d, Petr Marsik^e,
Jaroslav Havlik^b, Patrick Van Damme^{a,c}, Ladislav Kokoska^{a,*}

^a Department of Crop Sciences and Agroforestry, Faculty of Tropical AgriSciences, Czech University of Life Sciences Prague, Kamycka 129, 165 21 Prague 6 – Suchdol, Czech Republic

^b Department of Microbiology, Nutrition and Dietetics, Faculty of Agrobiolgy, Food and Natural Resources, Czech University of Life Sciences Prague, Kamycka 129, 165 21 Prague 6 – Suchdol, Czech Republic

^c Laboratory for Tropical and Subtropical Agriculture and Ethnobotany, Department of Plant Production, Faculty of Bio-Science Engineering, Ghent University, Coupure links 653, 9000 Ghent, Belgium

^d Department of Biology, College of Natural Sciences, Debre Berhan University, P.O. Box 445, Debre Berhan, Ethiopia

^e Laboratory of Plant Biotechnologies, Institute of Experimental Botany AS CR, v.v.i., Rozvojova 263, 165 02 Prague 6 – Lysolaje, Czech Republic

ARTICLE INFO

Article history:

Received 12 December 2014

Received in revised form 6 May 2015

Accepted 27 May 2015

Keywords:

Antioxidant

Anticarcinogenic

Plant extract

Medicinal plants

ABSTRACT

Identification and characterization of natural products with antioxidant and anti-proliferative activity has received much interest over the past few years. Ethiopia is one of the developing countries which have enormous diversity of plants and yet majority stays scientifically neglected and undiscovered. In this study, the ethanol extracts of 18 Ethiopian wild medicinal plants were investigated for their *in vitro* antioxidant and anti-proliferative potential. For this purpose DPPH (2,2-diphenyl-1-picrylhydrazyl), ORAC (oxygen radical absorbance capacity) and TPC (total phenolic content) assays together with MTT cell viability assay (performed on Hep-G2 and MRC-5) were used. Extracts of *Carissa spinarum*, *Dodonaea angustifolia*, *Jasminum abyssinicum*, *Rumex nepalensis*, *Rubus steudneri* and *Verbascum sinaiticum* exhibited the most significant results. However, it was discovered that *C. spinarum*, *J. abyssinicum* and *R. steudneri* possessed considerable toxicity against normal MRC-5 cell line. Only extracts of *D. angustifolia* and *R. nepalensis* demonstrated significant combinatory antioxidant/anti-proliferative effect, while *V. sinaiticum* showed best selective anti-proliferative activity. Since aforementioned extracts also exerted low or minimal toxicity to normal cells, we suggest these as prospective material for further development of novel plant-based agents effective against oxidative stress related diseases.

© 2015 Elsevier B.V. All rights reserved.

1. Introduction

Identification and characterization of natural products with antioxidant and anti-proliferative activity has received much interest over the past few years (Lo et al., 2002). Plants are nowadays recognized as a rich source of antioxidant compounds (e.g., simple phenolics, anthocyanins, stilbenes, flavonoids), which are used primarily in food industry (Raza and John, 2008; Brewer, 2011). It is considered that consumption of plant-based antioxidants could be connected with lowered risk of occurrence of several human diseases related to the oxidative stress, including cancer (Halliwell and Gutteridge, 2007). Moreover, plants are also providers of anti-proliferative compounds (such as podophyllotoxin, paclitaxel or

vincristine), which are able to actively inhibit growth of carcinoma cells (Dewick, 2009).

In general, common dietary plants, such as edible fruits and vegetables are primarily examined for their antioxidant activity. However, recent studies have indicated that other categories of plant material, such as medicinal plants (MPs), might possess stronger antioxidant potential than aforementioned food crops *in vitro* (Inayatullah et al., 2012; Jaberian et al., 2013). Since oxidative stress is possibly connected to development of cancer, the validation of antioxidant effect of tested material is nowadays routinely supplemented with assessment of anti-proliferative activity against various types of carcinoma cell lines (Ghali et al., 2013; De la Rosa et al., 2014; Loizzo et al., 2014). Hence, MPs are nowadays regarded as valuable material for development of food and pharmaceutical products, which are able to serve as preventive (antioxidant) and therapeutic (anti-proliferative) agents to several types of cancer and other diseases connected to oxidative stress

* Corresponding author. Tel.: +420 224382180; Fax: +420 234381829.
E-mail address: kokoska@ftz.czu.cz (L. Kokoska).

(Rao, 2012). However, in contrast to common food plants that are generally considered as safe, the practical usability of MPs for industrial purposes hugely depends on possible risk to human health such as toxicity to vital organs. Therefore, toxicological profile of newly introduced plant material should be properly described (Doeheimer et al., 2011).

MPs are generally considered as very important factor for food and health security in third world countries. However, these resources suffer from notable disregard from research and development plans (Addis et al., 2005) and moreover, are rapidly diminishing due to catastrophic destruction of natural habitats (Mengistu and Hager, 2008; Teklehaymanot and Giday, 2010). Hence economic value as well as scientific information of those plant resources is in danger of being irreversibly lost. Ethiopia is one of the developing countries where MPs are not subjected to research or development intention. In same time, this country is considered as a genetic centre for wide range of plant species and as a diversity hotspot. It is estimated, that local flora covers approximately up to 7000 vascular plant species (Hedberg et al., 2003). Despite the well-documented traditional use of medicinal plants in the region for treatment of diseases related to the oxidative stress (such as cancer, diabetes, chronic inflammatory diseases), to our best knowledge, only a very small proportion of MPs originated in Ethiopia were assessed for their antioxidant/anti-proliferative and toxicological properties (Rao et al., 2005; Eyob et al., 2008; Umer et al., 2010; Asamenew et al., 2011; Amoo et al., 2012).

In this article, we report a detailed investigation of the *in vitro* antioxidant and anti-proliferative potential of ethanol extracts of eighteen Ethiopian wild medicinal plants which are traditionally used for treatment of cancer and other diseases related to the oxidative stress. In addition, the phenolic content and toxicity of this extracts have been evaluated with aim to determine the relationship between their biological efficacy, chemical composition and safety.

2. Materials and methods

2.1. Plant material

Based on previously reported data on traditional medicinal usage for treatment of cancer and other oxidative stress-related diseases (Table 1), following plants and their botanical parts were selected for further testing: *Bersama abyssinica* (leaves and twigs), *Calpurnia aurea* (roots), *Carissa spinarum* (roots), *Clematis hirsuta* (leaves), *Clutia abyssinica* (root), *Croton macrostachyus* (leaves and twigs), *Cyathula cylindrica* (roots), *Dodonaea angustifolia* (leaves), *Embelia schimperi* (leaves and twigs; seeds/fruits), *Jasminum abyssinicum* (leaves), *Maesa lanceolata* (leaves and twigs), *Ocimum lamiifolium* (leaves), *Rubus steudneri* (leaves and twigs; roots), *Rumex nepalensis* (leaves and twigs; roots), *Thalictrum rhynchocarpum* (roots), *Verbascum sinaicum* (leaves), *Vernonia amygdalina* (flowers; leaves and twigs) and *Zehneria scabra* (leaves and twigs). Plants were collected in Ankober District (172 km northeast of the capital Addis Ababa), North Shewa Zone, Amhara Region Ethiopia, between June 2009 and May 2011. Identification of specimens was performed both in the field and at the National Herbarium of Ethiopia (ETH) using taxonomic keys and floras (Hedberg and Edwards, 1989; Edwards et al., 2000; Hedberg et al., 2003) and by comparison with voucher reference herbarium specimens. The identified voucher specimens were deposited at the National Herbarium of Ethiopia. Detailed description of tested plants (ethnobotanical data and voucher specimen numbers) are provided elsewhere (Lulekal et al., 2014a,b).

2.2. Sample preparation

15 g of air-dried plant material of each species was finely ground using Grindomix GM100 apparatus (Retsch, Germany) and extracted at room temperature in 80% ethanol using a laboratory shaker for 24 h. Because of its high efficiency in extraction of wide range of biologically active secondary metabolites and due to fact that it is conventionally used in preparation of plant-based medicinal formulations (e.g., tinctures), aqueous ethanol is generally recognized as universal solvent utilized in antioxidant and anti-proliferative assays of plant material (Schmidt et al., 2000; Huie, 2002). Extracts from each specimen were subsequently filtered and evaporated to dryness using a rotary evaporator R-200 (Büchi, Switzerland) *in vacuo* at 40 °C. Dry residues were then dissolved in 100% dimethyl sulfoxide (DMSO) to create a concentration of 51.2 mg/mL stock solution of each extract that was stored at –20 °C until tested.

2.3. Chemicals and reagents

2,2'-azobis(2-methylpropionamide) dihydrochloride (AAPH), 2,2-diphenyl-1-picrylhydrazyl (DPPH), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (trolox), fluorescein sodium salt (FL), Eagle's minimum essential medium (EMEM), fetal bovine serum, glutamine, non-essential amino acids and penicillin-streptomycin solution were obtained at Sigma–Aldrich (Prague, Czech Republic). Analytical grade quality solvents and Folin-Ciocalteu reagent were acquired at Penta (Prague, Czech Republic).

2.4. Cell culture

Human liver carcinoma cell line Hep-G2 and normal human cells fetal lung MRC-5 (ATCC, Rockville, MD, USA) were maintained in EMEM supplemented with fetal bovine serum (10%), penicillin–streptomycin solution (1%), nonessential amino acids (1%) and glutamine (4 mM and 2 mM for Hep-G2 and MRC-5, respectively). Cell cultures were incubated in 5% CO₂ atmosphere at 37 °C.

2.5. Antioxidant activity and phenolic content

2.5.1. DPPH radical-scavenging assay

Slightly modified method previously described by Sharma and Bhat (2009) was used. Initially, two-fold serial dilutions of each sample were prepared in methanol (175 µL) in 96-well microtiter plates. Subsequently, 25 µL of freshly prepared 1 mM DPPH in methanol solution was mixed with the sample in each well creating a range of concentrations from 2 to 5120 µg/mL (final volume of 200 µL) to start the radical-antioxidant reaction. The mixture was kept in the dark at laboratory temperature and absorbance was measured after 30 min at 517 nm using Infinite 200 reader (Tecan, Switzerland). Results were expressed as half maximal inhibitory concentration (µg/mL IC₅₀).

2.5.2. Oxygen radical absorbance capacity (ORAC) assay

Slightly modified method previously described by Ou et al. (2001) was used. Firstly, outer wells of black absorbance 96-well microtiter plates were filled with 200 µL of distilled water, in order to provide better thermal mass stability. Prior to the study, stock solution of AAPH radical and FL were prepared in 75 mM phosphate buffer (pH 7.0). Subsequently, 25 µL of each sample was diluted in 150 µL FL (54 nM) and incubated in 37 °C for 10 min. Reaction was started by application of 25 µL AAPH (153 mM) yielding final volume of 200 µL in each well. Extracts were tested in range

Table 1
Ethnomedicinal data on plants tested.

Scientific name	Family	Vernacular name (Amharic)	Ethnomedicinal uses
<i>Bersama abyssinica</i> Fresen.	Meliantaceae	Azimir	Treatment of diabetes (Keter and Mutiso, 2012)
<i>Calpurnia aurea</i> (Aiton) Benth.	Fabaceae	Digita	Treatment of diabetes (Giday et al., 2007; Suleman and Alemu, 2012), snakebite (Teklehaymanot et al., 2007)
<i>Carissa spinarum</i> L.	Apocynaceae	Agam	Antiarthritic activity (Hegde et al., 2010)
<i>Clematis hirsuta</i> Guill. & Perr.	Ranunculaceae	Azo hareg	Treatment of cataract (Giday et al., 2009), swelling (Teklehaymanot and Giday, 2007)
<i>Clutia abyssinica</i> Jaub. & Spach	Euphorbiaceae	Fiyeye fej	Treatment of enlarged spleen (Ramathal and Ngassapa, 2001)
<i>Croton macrostachyus</i> Hochst. ex Delile	Euphorbiaceae	Bisana	Treatment of cancer (Ochwang'i et al., 2014), snakebite (Giday et al., 2009)
<i>Cyathula cylindrica</i> Moq.	Amaranthaceae	Yedem abinet	Treatment of snakebite (Lulekal et al., 2013)
<i>Dodonaea angustifolia</i> L. f.	Sapindaceae	Kitkita	Treatment lymphatic swelling (Mesfin et al., 2009)
<i>Embelia schimperi</i> Vatke	Primulaceae	Inkoko	Treatment of swelling (Lulekal et al., 2014a,b)
<i>Jasminum abyssinicum</i> Hochst. ex DC.	Oleaceae	Abita	Treatment of snakebite (Teklehaymanot et al., 2007)
<i>Maesa lanceolata</i> Forssk.	Primulaceae	Kelewa	Treatment of snakebite (Teklehaymanot et al., 2007)
<i>Ocimum lamiiifolium</i> Hochst. ex Benth.	Lamiaceae	Dama kessie	Treatment of swelling (Lulekal et al., 2014a,b)
<i>Rubus steudneri</i> Schweinf.	Rosaceae	Injori	Treatment of stomach-ache (Giday et al., 2009)
<i>Rumex nepalensis</i> Spreng.	Polygonaceae	Lut	Treatment of rheumatism (Singh and Lal, 2008), stomach-ache (Giday et al., 2009)
<i>Thalictrum rhynchocarpum</i> Quart.-Dill. & A. Rich.	Ranunculaceae	Sire bizu	Treatment of cancer (Mugera, 1977)
<i>Verbascum sinaiticum</i> Benth.	Scrophulariaceae	Yeahya joro	Treatment of cancer (Teklehaymanot, 2009), stomach-ache (Teklehaymanot and Giday, 2007)
<i>Vernonia amygdalina</i> Delile	Asteraceae	Girawa	Treatment of cancer (Gresham et al., 2008; Kumar et al., 2011), swelling of thyroidal glands (Yirga, 2010), stomach-ache (Teklehaymanot et al., 2007)
<i>Zehneria scabra</i> (L. f.) Sond.	Cucurbitaceae	Hareg iresa	Treatment of stomach-ache (Teklehaymanot, 2009), unidentified swelling (Teklehaymanot et al., 2007)

of 3.2–64 µg/mL (final concentration). Standard calibration curves of trolox were obtained in a concentration range of 0.5–8 µg/mL (final concentration) at five concentrations levels (0.5, 1, 2, 4, 8 µg/mL). Fluorescence changes were measured in 1-min intervals for 120 min with emission and absorbance wavelengths set at 485 nm and 520 nm, respectively. Quantification of the antioxidant capacity was calculated as area under the calibration curve as proposed by Cao and Prior (1998) and was expressed as trolox equivalents (µg TE/mg extract).

2.5.3. Total phenolic content (TPC)

Total phenolic content was measured using modified method previously described by Singleton et al. (1998). Each sample in volume of 100 µL was added to 96-well microtiter plate creating range of concentrations from 21 to 341 µg/mL. Afterwards, 25 µL of pure Folin–Ciocalteu reagent was added. Plate was inserted in orbital shaker at 40 rpm for 10 min. Reaction was started by addition of 75 µL 12% Na₂CO₃ (w/v). Mixture was kept in dark at 37 °C for 2 h. Absorbance was measured at 700 nm. Nine concentration levels of gallic acid (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64 µg/mL) were used to create standard calibration curves. Results were expressed as gallic acid equivalents (µg GAE/mg extracts).

2.6. Cell viability

Modified method based on metabolization of MTT to blue formazan by mitochondrial dehydrogenases in living cells previously described by Mosmann (1983) was used. Hep-G2 and MRC-5 cells were preincubated in a 96-well plate at a density of 2.5×10^3 cells per well for 24 h in a humidified atmosphere of 5% CO₂ in air at 37 °C. After 24 h, the cells were treated with plant extracts in two-fold serial dilutions (range: 15.6–500 µg/mL) for 72 h. Thereafter, MTT reagent (1 mg/mL) in EMEM solution was added to each well and plates were incubated for additional 2 h at 37 °C. The media were then removed, and the intracellular formazan product was dissolved in 100 µL of DMSO. The absorbance was then measured at 495 nm and the percentage of viability was calculated when com-

pared to untreated control. Results were expressed as half maximal inhibitory concentration of proliferation (IC₅₀) in µg/mL concentration.

2.7. Statistical analysis

All tests were performed as three independent experiments; each carried out in triplicate. Results were expressed as mean values with standard deviations (mean ± SD). Linear correlation coefficients (*r*) between total phenolic content and antioxidant assays (DPPH and ORAC) were established using Pearson product moment correlation. Data were log-transformed to fit the specific parameters of statistical test used. Statistical analysis was performed in STATISTICA 7.1 (StatSoft Inc., USA) software.

3. Results

In this study, 18 Ethiopian medicinal plants traditionally used for treatment of oxidative stress-related diseases were assayed for *in vitro* antioxidant and anti-proliferative activity. Four of these species exhibited significant antioxidant efficacy while nine species possessed significant anti-proliferative potential. However, majority of above mentioned efficient extracts exhibited toxicity to normal cells. With regard to all observed results two extracts exhibited combinatory antioxidant and anti-proliferative effect and one species showed pronounced selective anti-proliferative activity.

3.1. Antioxidant activity and content of phenolic compounds

Complete results for antioxidant activity of tested plants extracts are summarized in Table 2. In DPPH assay, the lowest IC₅₀ values were detected for *R. nepalensis* (roots), *R. steudneri* (roots) followed by *R. nepalensis* (leaves and twigs) at values 5.7; 5.8 and 10.7 µg/mL, respectively. The moderate effect was also detected for *D. angustifolia* (22.2 µg/mL), *B. abyssinica* (26.0 µg/mL) and for *J. abyssinicum* (26.3 µg/mL). IC₅₀ of rest of the plants were in range of 32.2–2668.3 µg/mL. None of the tested plants exceeded trolox

Table 2
Antioxidant activity and total phenolic content of tested plant extracts.

Sample	Plant part(s) ^a	Antioxidant activity (mean value \pm SD ^b)		
		DPPH (IC ₅₀ ^c ; μ g/mL)	ORAC (μ g TE ^d /mg extract)	TPC (μ g GAE ^e /mg extract)
<i>B. abyssinica</i>	LT	26.0 \pm 3.9	444.3 \pm 18.5	286.4 \pm 37.2
<i>C. aurea</i>	R	799.7 \pm 70.7	331.6 \pm 30.9	72.6 \pm 17.1
<i>C. spinarum</i>	R	97.2 \pm 4.9	363.9 \pm 30.9	117.4 \pm 22.6
<i>C. hirsuta</i>	L	67.0 \pm 1.6	342.5 \pm 19.1	133.9 \pm 20.5
<i>C. abyssinica</i>	R	695.4 \pm 109.9	221.6 \pm 7.8	58.6 \pm 8.0
<i>C. macrostachyus</i>	LT	1145.7 \pm 161.2	130.8 \pm 11.4	135.2 \pm 38.9
<i>C. cylindrica</i>	R	2668.3 \pm 212.7	37.8 \pm 1.9	12.8 \pm 2.0
<i>D. angustifolia</i>	L	22.2 \pm 1.2	767.6 \pm 47.5	531.7 \pm 82.0
<i>E. schimperi</i>	LT	90.9 \pm 9.3	210.1 \pm 15.0	109.8 \pm 10.4
	S/F	210.0 \pm 21.6	107.3 \pm 4.0	60.6 \pm 6.9
<i>J. abyssinicum</i>	L	26.3 \pm 6.5	1023.7 \pm 49.5	401.3 \pm 67.8
<i>M. lanceolata</i>	LT	41.3 \pm 8.0	361.8 \pm 17.2	153.5 \pm 22.9
<i>O. lamiifolium</i>	L	45.9 \pm 6.5	567.2 \pm 28.3	156.8 \pm 25.4
<i>R. steudneri</i>	LT	58.0 \pm 6.4	1206.5 \pm 72.8	829.5 \pm 90.9
	R	5.8 \pm 1.1	1019.2 \pm 99.3	693.8 \pm 113.8
<i>R. nepalensis</i>	LT	10.7 \pm 1.7	371.1 \pm 36.6	122.6 \pm 12.4
	R	5.7 \pm 0.9	1061.4 \pm 106.4	1101.5 \pm 157.1
<i>T. rhynchocharpum</i>	R	618.1 \pm 107.8	96.3 \pm 7.0	41.1 \pm 6.3
<i>V. sinaiticum</i>	L	2015.2 \pm 173.1	565.5 \pm 24.3	22.2 \pm 5.5
<i>V. amygdalina</i>	F	32.2 \pm 7.1	665.9 \pm 98.0	193.7 \pm 27.4
	LT	39.6 \pm 8.8	609.3 \pm 38.2	191.8 \pm 38.9
<i>Z. scabra</i>	LT	93.7 \pm 14.5	372.9 \pm 31.3	133.7 \pm 10.8

^a L = leaves, LT = leaves and twigs, F = flowers, R = roots, S/F = seeds/fruits.

^b Standard deviation.

^c Half maximal inhibitory concentration.

^d Trolox equivalency.

^e Gallic acid equivalency.

antioxidant efficiency. IC₅₀ for trolox was detected at concentration of 5.8 μ g/mL.

The best results for ORAC assay were seen for *R. steudneri* (leaves and twigs), *R. nepalensis* (roots), *R. steudneri* (roots) and *J. abyssinicum* (1206.5; 1061.4; 1019.2 and 1023.7 μ g TE/mg extract, respectively). In contrast to the results of the DPPH test, these four extracts demonstrated stronger antioxidant effect than trolox. The moderate results were only seen for *D. angustifolia* (767.6 μ g TE/mg extract), whereas the rest of tested plants had ORAC values in range of 37.8–666.6 μ g TE/mg extract.

The highest contents of phenolic compounds were determined for *R. nepalensis* (roots), followed by *R. steudneri* leaves and roots, and *D. angustifolia*, with values 1101.5; 829.5; 693.8 and 531.7 μ g GAE/mg extract, respectively. The significant contents of phenolic compounds were also detected in *J. abyssinicum* (401.3 μ g GAE/mg) and *B. abyssinica* (286.4 μ g GAE/mg) extracts. Statistically significant correlation regarded as strong ($p < 0.001$) was found between TPC and both antioxidant assays used; DPPH ($r = 0.852$) and ORAC ($r = 0.798$) (Fig. 1).

3.2. Anti-proliferative activity

Complete results for anti-proliferative activity of tested plant extracts are given in Table 3. Significant anti-proliferative activity against Hep-G2 carcinoma cell lines was observed for *C. spinarum*, *M. lanceolata*, *B. abyssinica*, *E. schimperi* (leaves), *R. steudneri* (roots), *R. nepalensis* (roots), *Z. scabra* and *V. amygdalina* (flowers) whose IC₅₀ were detected at 32.8; 34.5; 35.4; 44.9; 45.5; 50.5; 57.1 and 57.8 μ g/mL, respectively. Moderate cytotoxicity was detected for *V. sinaiticum* (80.6 μ g/mL) and seeds of *E. schimperi* (81.8 μ g/mL). Rest of the extracts showed weak anti-proliferative activity (IC₅₀ range from 103.5 to 267.6 μ g/mL) or were ineffective (IC₅₀ > 500 μ g/mL). Weak positive correlation (statistically not significant at level $p = 0.05$) was detected between TPC and anti-proliferative effect towards Hep-G2 ($r = 0.389$).

Only extract of *V. sinaiticum* did not affect growth of MRC-5 cell line at the concentration 500 μ g/mL. Low or moderate toxicity

was observed for extracts of *C. cylindrica*, *C. abyssinica*, *C. aurea*, *D. angustifolia*, *C. hirsuta*, *V. amygdalina* (leaves), *R. nepalensis* (leaves), *R. steudneri* (leaves), *T. rhynchocharpum*, *R. nepalensis* (roots), *O. lamiifolium*, *J. abyssinicum* and *E. schimperi* (seeds) exhibiting IC₅₀ values in range of 119.7–426.4 μ g/mL (Table 3). The remaining species demonstrated strong toxicity with IC₅₀ ranging from 10.9 to 97.4 μ g/mL.

3.3. Antioxidant and/or anti-proliferative effectivity versus toxicity

Out of all tested plant species, combinatory antioxidant and anti-proliferative effect, together with relatively low toxicity to normal cells, was only detected for extracts of *D. angustifolia* and *R. nepalensis* (roots). By comparison of IC₅₀ (DPPH assay) and IC₅₀ (MTT assay), antioxidant potential of *D. angustifolia* and *R. nepalensis* (roots) was 5.4 \times and 10 \times stronger than observed anti-proliferative effect, respectively. Furthermore, IC₅₀ concentrations of both plants towards Hep-G2 were approximately two times lower than those for normal MRC-5 cells. Antioxidant effect of *D. angustifolia* and *R. nepalensis* (roots) is graphically illustrated in Fig. 2 (ORAC assay). Although *V. sinaiticum* did not prove to be considerable antioxidant agent, it exhibited fairly best selective cytotoxicity towards carcinoma/normal cells of all extracts tested (*V. sinaiticum* extract showed approx. 25 \times higher IC₅₀ concentration in DPPH assay than in MTT anti-proliferative test). Anti-proliferative efficacy of *V. sinaiticum* extract is shown in Fig. 3.

4. Discussion

In accordance with our study, the antioxidant efficacy of *D. angustifolia* and *R. nepalensis* was previously described *in vitro* (Gautam et al., 2010; Anusuya et al., 2012). To our best knowledge this is the first report on characterization of antioxidant properties of *J. abyssinicum* and *R. steudneri*. Secoiridoid glycosides, which are presented in *J. abyssinicum* (Gallo et al., 2005), are well known to possess considerable antioxidant potential in assays per-




Fig. 1. Linear correlation of total phenolic content with DPPH and ORAC ($r=0.852$ and $r=0.798$, respectively). Log-transformed values were used in order to fit the specific parameters of Pearson correlation.

formed *in vitro* (Dinda et al., 2009; Bi et al., 2011). However, till present moment, specific secoiridoidal compounds presented in *J. abyssinicum* (namely craigosides) have not been verified for antioxidant efficacy. Phytochemical analyses of this plant are very limited; nevertheless other *Jasminum* species were reported to contain high levels of phenolic compounds (Sulaiman et al., 2013). Moderate content of phenolic compounds was also proved for *J. abyssinicum* in this study by TPC assay. Thus, above mentioned secoiridoid structures together with phenolics could be considered as major factor affecting antioxidant activity of *J. abyssinicum* extract. Similarly as in case of *J. abyssinicum*, phytochemical information of *R. steudneri* is unavailable. However related species, *R. ulmifolius* and *R. rigidus* which are believed to be native to different parts of Africa, were found to be rich in phenolic acids flavonoids, anthocyanins, diterpenoids, carotenoids and their glycosidal derivatives (Barros et al., 2010; Nguielefack et al., 2011; Lee et al., 2012). It could be assumed,

that significant antioxidant potential of *R. steudneri* is attributed to high content of above mentioned group of chemicals. With regard to the discussion on phytochemicals responsible for antioxidant effects of above mentioned species, it is necessary to note that chemical composition and biological activity of plant extracts can significantly be affected by extraction technique and type of solvent used (Dai and Mumper, 2010). In comparison with plants used commonly as herbal medicines and spices such as Ceylon cinnamon tree (*Cinnamomum verum*) and Turmeric (*Curcuma longa*) which previously demonstrated strong antioxidant capacity in ORAC assay (1000–2000 $\mu\text{g TE/mg}$ extract) (Wojcikowski et al., 2007; Dudonné et al., 2009), the extracts of *R. steudneri*, *R. nepalensis*, *J. abyssinicum* and *D. angustifolia* exhibited results similar to above mentioned plant species. Furthermore, strong correlation between TPC and antioxidant assays (DPPH and ORAC) was previously observed for *C. verum* and *C. longa* (Wojdyło et al., 2007; Dudonné et al., 2009)

Table 3
Anti-proliferative activity and toxicity of tested plant extracts.

Sample	Plant part(s) ^a	IC ₅₀ ^b (mean ± SD ^c)/Cell line	
		HEP-G2 ^d (µg/mL)	MRC-5 ^e (µg/mL)
<i>B. abyssinica</i>	LT	35.4 ± 8.8	10.9 ± 2.3
<i>C. aurea</i>	R	>500	292.7 ± 37.6
<i>C. spinarum</i>	R	32.8 ± 5.7	97.4 ± 19.6
<i>C. hirsuta</i>	L	>500	224.6 ± 1.8
<i>C. abyssinica</i>	R	>500	355.0 ± 18.1
<i>C. macrostachyus</i>	LT	267.6 ± 1.0	27.4 ± 12.1
<i>C. cylindrica</i>	R	>500	426.4 ± 1.9
<i>D. angustifolia</i>	L	120.0 ± 10.8	225.5 ± 17.7
<i>E. schimperii</i>	LT	44.9 ± 0.1	37.0 ± 2.6
	S/F	81.8 ± 2.3	119.7 ± 10.7
<i>J. abyssinicum</i>	L	217.5 ± 10.3	122.2 ± 1.8
<i>M. lanceolata</i>	LT	34.5 ± 6.3	30.1 ± 0.2
<i>O. lamiifolium</i>	L	115.4 ± 5.0	124.1 ± 12.2
<i>R. steudneri</i>	LT	103.5 ± 8.9	183.6 ± 41.2
	R	45.5 ± 6.9	38.4 ± 1.7
<i>R. nepalensis</i>	LT	237.4 ± 8.9	184.0 ± 14.0
	R	50.5 ± 4.3	132.7 ± 5.2
<i>T. rhynchocharpum</i>	R	142.6 ± 0.4	149.0 ± 21.7
<i>V. sinaiticum</i>	L	80.6 ± 46.1	>500
<i>V. amygdalina</i>	F	57.8 ± 5.4	32.2 ± 10.1
	LT	191.5 ± 15.0	200.1 ± 30.8
<i>Z. scabra</i>	LT	57.1 ± 6.9	38.4 ± 1.7

^a L = leaves, LT = leaves and twigs, F = flowers, R = roots, S/F = seeds/fruits.

^b Half maximal inhibitory concentration of proliferation.

^c Standard deviation.

^d Human liver carcinoma cell line.

^e Normal human fetal lung cell line.

as well as for samples tested in our study. These results suggest that phenolics are the main class of compounds responsible for antioxidant effect of tested plant extracts. This finding was also previously reported for many other plant species including those with industrial interest (Qader et al., 2011; Clarke et al., 2013).

Practical usability of plants as anti-proliferative agents hugely depends on their toxicity and it is requested that these compounds should exert selective cytotoxic effect towards carcinoma and normal cells (Lindholm et al., 2002). Anti-proliferative efficacy of *V. sinaiticum* is relatively well established and our results are in accordance with cytotoxic properties of *V. sinaiticum* observed in other studies (Talib and Mahasneh, 2010). As far as we know,

this is the first report on anti-proliferative efficacy of *C. spinarum* plant extract, together with first report on selective cytotoxic effect of *V. sinaiticum* towards normal cells. *C. spinarum* was found to contain lignans, namely (–)-carinol, (–)-carissanol and (–)-nortrachelogenin, which exhibited cytotoxicity against various cancer and leukaemia cells (Sehar et al., 2011; Wangteeraprasert et al., 2012). These chemicals were therefore considered as major factor influencing anti-proliferative effect of this plant. However, *C. spinarum* also produces cardiac glycosides (including evomonoside), which previously demonstrated to be significant inhibitors of Na⁺/K⁺-ATPase, and therefore presents possible toxicological risk (Dewick, 2009; Schön et al., 1995). Most interesting results




Fig. 2. Kinetic curves of fluorescein decay induced by AAPH radical in the presence of *Dodonaea angustifolia* and *Rumex nepalensis* (roots) extracts at concentration of 1 µg/mL in comparison to positive (trolox) and negative (blank) controls (ORAC assay).




Fig. 3. Anti-proliferative effect of *Verbascum sinaiticum* extract towards hepatocellular carcinoma (Hep-G2) and normal (MRC-5) cells after 48 h exposure (MTT assay).

regarding selectivity in anti-proliferative effect towards carcinoma and normal cells was seen in *V. sinaiticum*. From compounds presented in *V. sinaiticum*, only luteolin, chrysoeriol, hydrocarpin and sinaiticin were tested for cytotoxic potential with positive effect against leukaemia P-388 cells (Afifi et al., 1993). Since these compounds belong to chemical classes of flavonoids and flavonolignans (Afifi et al., 1993; Mahmoud et al., 2007), they are regarded as non-toxic to its potential user. These constituents are therefore considered as contributory to observed selective anti-proliferative activity of *V. sinaiticum* against Hep-G2 and MRC-5 cell line. Previously, IC₅₀'s of podophyllotoxin, paclitaxel and vincristine (commonly utilized anti-cancer drugs) towards Hep-G2 carcinoma cells were assessed at concentrations around 1–2 ng/mL (Jin et al., 2010; Zhao et al., 2012; Hussain et al., 2014). As contrast to these compounds, extracts of *C. spinarum* and *V. sinaiticum* were significantly less effective anti-proliferative agents. On the other hand, in comparison to Garlic (*Allium sativum*) supplements, which are recommended to lower risk of certain types of cancer (Stan et al., 2008) and earlier demonstrated significant activity towards Hep-G2 carcinoma cell line (IC₅₀ at 330 µg/mL) (Siegers et al., 1999), extracts of *C. spinarum* and *V. sinaiticum* possessed considerably higher anti-proliferative efficacy. Even though sulphide compounds (e.g. allicin) are considered as chief constituents responsible for anticancer activity of garlic (Ariga and Seki, 2006), this plant was also found to possess moderate amounts of phenolic compounds (approx. 51 µg GAE/mg extract) (Stratil et al., 2006); i.e. at levels comparable to *C. spinarum* and *V. sinaiticum* in our study. Additionally, garlic also previously showed mild antioxidant properties in ORAC assay (Javier Moreno et al., 2006; Lim, 2015). Our data from statistical analysis (correlation between TPC and IC₅₀ for Hep-G2 cells) suggest that phenolic compounds might be partially answerable for observed anti-proliferative effect of tested plant species, which is in correspondence with above mentioned data, as well as with other studies (Yang et al., 2009).

Previously several plant-based compounds have demonstrated combinatory antioxidant and anti-proliferative effect (Znati et al., 2014). Even though antioxidant potential of *D. angustifolia* and *R. nepalensis* was previously determined (as mentioned above), to our best knowledge this is the first report on anti-proliferative efficacy of these plants. Anthraquinones and naphthalene derivatives isolated from *R. nepalensis* have previously showed both significant antioxidant activity and anti-proliferative properties towards various carcinoma cell lines *in vitro* (Gautam et al., 2010; Liang et al., 2010). It is therefore assumable that these compounds are

probably responsible for observed combinatory antioxidant and anti-proliferative effect. None of suggested active constituents were submitted to toxicity assessment; however, it could be suggested that these compounds possess selective anti-proliferative effect with mild toxicity. Clerodane diterpenoids, which are produced by *D. angustifolia* (Omota et al., 2010, 2014), have previously demonstrated considerable antioxidant efficacy and anti-proliferative activity against several carcinoma and leukaemia cell lines *in vitro* (Huang et al., 2004; Van Nguyen et al., 2009; Liu et al., 2014). Some structures belonging to clerodane diterpenoids were also found to be toxic to normal cells (Ma et al., 2012). Additionally, nephrotoxicity of *D. angustifolia* being accompanied by avascular renal necrosis was previously described in mice and ruminants (Steenkamp and Stewart, 2005). According to these findings, above mentioned compounds contribute significantly to cytotoxic and possibly even toxic activity of *D. angustifolia* extract. Examination of plant material for combinatory antioxidant/anti-proliferative potential (extracts or sole plant-derived compounds) is at present moment recognized as a novel approach (Nagahama et al., 2011). In previous study, the ethanol extract of *Berberis vulgaris*, a well-known medicinal plant traditionally used in treatment of various illnesses likely associated to oxidative stress including cancer (Abd El-Wahab et al., 2013), have demonstrated significant anti-proliferative activity towards Hep-G2 cells (IC₅₀ 106 µg/mL), as well as considerable antioxidant effect in DPPH assay (IC₅₀ approx. at 25 µg/mL) (Hanachi et al., 2006). These results were relatively comparable to activities observed for *D. angustifolia* in this study. However, *R. nepalensis* exhibited stronger effect in both assays in comparison to *B. vulgaris*. With regard to above mentioned information, we suggest that *D. angustifolia* and *R. nepalensis* might possess compounds with combinational antioxidant/anti-proliferative properties.

5. Conclusion

In summary, the current study proved *in vitro* antioxidant and anti-proliferative activity of *D. angustifolia*, *R. nepalensis* and *V. sinaiticum* extracts. Therefore these plants seem to serve as prospective material for further development of novel plant-based antioxidant and/or anti-proliferative agents. Especially antioxidant potential of *R. nepalensis* and selective anti-proliferative effect of *V. sinaiticum* deserve deeper research attention. However, detailed analysis of their chemical composition and *in vivo* antioxidant/anti-

proliferative activity should be carried out in order to verify their possible practical use.

Conflict of interest

All authors disclose that they have no financial and personal relationships with other people or organization that could inappropriately influence (bias) their work, including employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registration, and grants or other funding.

Acknowledgements

This research was supported by the Internal Grant Agency of the Czech University of Life Sciences Prague (project no. CIGA20142012 and IGA 20155012) and by the COST CZ project no. LD14070 funded by the Ministry of Education, Youth and Sports (Czech Republic). Authors are participants in the FA1005COST Action INFOGEST.

References

- Abd El-Wahab, A.E., Ghareeb, D.A., Sarhan, E.E.M., Abu-Serie, M.M., El Demellawy, M.A., 2013. *In vitro* biological assessment of berberis vulgaris and its active constituent, berberine: Antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects. *BMC Compl. Altern. Med.*, 13.
- Addis, G., Urga, K., Dikasso, D., 2005. Ethnobotanical study of edible wild plants in some selected districts of Ethiopia. *Hum. Ecol.* 33, 83–118.
- Affifi, M.S.A., Ahmed, M.M., Pezzuto, J.M., Douglas Kinghorn, A., 1993. Cytotoxic flavonolignans and flavones from verbascum sinaiticum leaves. *Phytochemistry* 34, 839–841.
- Amoo, S.O., Finnie, J.F., Van Staden, J., 2012. Acetylcholinesterase inhibition, antioxidant, antiinflammatory, antimicrobial and phytochemical properties of huernia hystrix. *Phytother. Res.* 26, 639–645.
- Anusuya, N., Gomathi, R., Manian, S., Sivaram, V., Menon, A., 2012. Evaluation of *Basella rubra* L., *Rumex nepalensis* Spreng. and *Commelina benghalensis* L. for antioxidant activity. *Int. J. Pharm. Pharm. Sci.* 4, 714–720.
- Ariga, T., Seki, T., 2006. Antithrombotic and anticancer effects of garlic-derived sulfur compounds: a review. *Biofactors* 26, 93–103.
- Asamenew, G., Bisrat, D., Mazumder, A., Asres, K., 2011. *In vitro* antimicrobial and antioxidant activities of antrone and chromone from the latex of aloe harlana reynolds. *Phytother. Res.* 25, 1756–1760.
- Barros, L., Oliveira, S., Carvalho, A.M., Ferreira, I.C.F.R., 2010. *In vitro* antioxidant properties and characterization in nutrients and phytochemicals of six medicinal plants from the portuguese folk medicine. *Ind. Crops Prod.* 32, 572–579.
- Bi, X., Li, W., Sasaki, T., Li, Q., Mitsuhata, N., Asada, Y., Zhang, Q., Koike, K., 2011. Secoiridoid glucosides and related compounds from syringa reticulata and their antioxidant activities. *Bioorg. Med. Chem. Lett.* 21, 6426–6429.
- Brewer, M.S., 2011. Natural antioxidants: sources, compounds, mechanisms of action, and potential applications. *Compr. Rev. Food Sci. Food Saf.* 10, 221–247.
- Cao, G., Prior, R.L., 1998. Measurement of oxygen radical absorbance capacity in biological samples. *Methods Enzymol.* 299, 50–62.
- Clarke, G., Ting, K.N., Wiart, C., Fry, J., 2013. High correlation of 2,2-diphenyl-1-picrylhydrazyl (dpph) radical scavenging, ferric reducing activity potential and total phenolics content indicating redundancy in use of all three assays to screen for antioxidant activity of extracts of plants from the Malaysian rainforest. *Antioxidants* 2, 1–10.
- Dai, J., Mumper, R.J., 2010. Plant phenolics: extraction, analysis and their antioxidant and anticancer properties. *Molecules* 15, 7313–7352.
- De la Rosa, L.A., Vazquez-Flores, A.A., Alvarez-Parrilla, E., Rodrigo-García, J., Medina-Campos, O.N., Ávila-Nava, A., González-Reyes, S., Pedraza-Chaverri, J., 2014. Content of major classes of polyphenolic compounds, antioxidant, antiproliferative, and cell protective activity of pecan crude extracts and their fractions. *J. Funct. Foods* 7, 219–228.
- Dewick, P.M., 2009. *Medicinal Natural Products: A Biosynthetic Approach*, 3rd ed. Wiley & Sons, Chichester, UK.
- Dinda, B., Roy Chowdhury, D., Mohanta, B.C., 2009. Naturally occurring iridoids, secoiridoids and their bioactivity. An updated review, part 3. *Chem. Pharm. Bull.* 57, 765–796.
- Doehmer, J., Weiss, G., McGregor, G.P., Appel, K., 2011. Assessment of a dry extract from milk thistle (*Silybum marianum*) for interference with human liver cytochrome-p450 activities. *Toxicol. In Vitro* 25, 21–27.
- Dudonné, S., Vitrac, X., Coutière, P., Woillez, M., Mérillon, J.-M., 2009. Comparative study of antioxidant properties and total phenolic content of 30 plant extracts of industrial interest using dpph, abts, frap, sod, and orac assays. *J. Agric. Food Chem.* 57, 1768–1774.
- Edwards, S., Tadesse, M., Demissew, S., Hedberg, I., 2000. *Flora of Ethiopia And Eritrea, Volume 2, Part 1: Magnoliaceae to Flacourtiaceae*. Uppsala University, Uppsala, Sweden.
- Eyob, S., Martinsen, B.K., Tsegaye, A., Appelgren, M., Skrede, G., 2008. Antioxidant and antimicrobial activities of extract and essential oil of korarima (*Aframomum corrorima* (Braun) P.C.M. Jansen). *Afr. J. Biotechnol.* 7, 2585–2592.
- Gallo, F.R., Palazzino, G., Federici, E., Iurilli, R., Monache, F.D., Chifundera, K., Galeffi, C., 2005. Oligomeric secoiridoid glucosides from *Jasminum abyssinicum*. *Phytochemistry* 67, 504–510.
- Gautam, R., Karkhile, K.V., Bhutani, K.K., Jachak, S.M., 2010. Anti-inflammatory, cyclooxygenase (COX)-2, COX-1 inhibitory, and free radical scavenging effects of rumex nepalensis. *Planta Med.* 76, 1564–1569.
- Chali, W., Vaudry, D., Jouenne, T., Marzouki, M.N., 2013. Assessment of cyto-protective, antiproliferative and antioxidant potential of a medicinal plant jatropha podagrica. *Ind. Crops Prod.* 44, 111–118.
- Giday, M., Asfaw, Z., Woldu, Z., 2009. Medicinal plants of the meinit ethnic group of ethiopia: an ethnobotanical study. *J. Ethnopharmacol.* 124, 513–521.
- Giday, M., Teklehaymanot, T., Anmut, A., Mekonnen, Y., 2007. Medicinal plants of the shinasha, agew-awi and amhara peoples in northwest ethiopia. *J. Ethnopharmacol.* 110, 516–525.
- Gresham, L.J., Ross, J., Izevbigie, E.B., 2008. Vernonia amygdalina: anticancer activity, authentication, and adulteration detection. *Int. J. Environ. Res. Public Health* 5, 342–348.
- Halliwell, B., Gutteridge, J.M., 2007. *Free Radicals In Biology And Medicine*, 4th ed. Oxford University Press, Oxford, UK.
- Hanachi, P., Kua, S.H., Asmah, R., Motalleb, G., Fauziah, O., 2006. Cytotoxic effect of berberis vulgaris fruit extract on the proliferation of human liver cancer line (hepg2) and its antioxidant properties. *Int. J. Cancer Res.* 2, 1–9.
- Hedberg, I., Edwards, S., 1989. *Flora Ethiopia, Volume 3: Pittosporaceae to Araliaceae*. Uppsala University, Uppsala, Sweden.
- Hedberg, I., Edwards, S., Nemomissa, S., 2003. *Flora of Ethiopia and Eritrea, Volume 4, Part 1: Apiaceae to Dipsacaceae*. Uppsala University, Uppsala, Sweden.
- Hegde, K., Issac, C., Joshi, A.B., 2010. Antiarthritic activity of carissa spinarum root extract in freund's adjuvant induced polyarthritis in rats. *Pharmacologyonline* 2, 713–718.
- Huang, D.-M., Shen, Y.-C., Wu, C., Huang, Y.-T., Kung, F.-L., Teng, C.-M., Guh, J.-H., 2004. Investigation of extrinsic and intrinsic apoptosis pathways of new clerodane diterpenoids in human prostate cancer pc-3 cells. *Eur. J. Pharmacol.* 503, 17–24.
- Huie, C.W., 2002. A review of modern sample-preparation techniques for the extraction and analysis of medicinal plants. *Anal. Bioanal. Chem.* 373, 23–30.
- Hussain, S.H., Latif, A., Cox, R.J., Simpson, T.J., Ali, M., Arfan, M., Uddin, G., 2014. Phytochemicals from the aerial parts of ligularia thomsonii and their radical scavenging activity. *Phytochem. Lett.* 7, 6–10.
- Inayatullah, S., Prenzler, P.D., Obied, H.K., Rehman, A.-U., Mirza, B., 2012. Bioprospecting traditional pakistani medicinal plants for potent antioxidants. *Food Chem.* 132, 222–229.
- Jaberian, H., Piri, K., Nazari, J., 2013. Phytochemical composition and *in vitro* antimicrobial and antioxidant activities of some medicinal plants. *Food Chem.* 136, 237–244.
- Javier Moreno, F., Corzo-Martínez, M., Dolores del Castillo, M., Villamiel, M., 2006. Changes in antioxidant activity of dehydrated onion and garlic during storage. *Food Res. Int.* 39, 891–897.
- Jin, C., Li, H., He, Y., He, M., Bai, L., Cao, Y., Song, W., Dou, K., 2010. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma *in vitro* and *in vivo*. *J. Cancer Res. Clin. Oncol.* 136, 267–274.
- Keter, L.K., Mutiso, P.C., 2012. Ethnobotanical studies of medicinal plants used by traditional health practitioners in the management of diabetes in lower eastern province, kenya. *J. Ethnopharmacol.* 139, 74–80.
- Kumar, S., Jawaid, T., Dubey, S.D., 2011. Therapeutic plants of ayurveda; a review on anticancer. *Pharmacogn. J.* 3, 1–11.
- Lee, J., Dossett, M., Finn, C.E., 2012. Rubus fruit phenolic research: the good, the bad, and the confusing. *Food Chem.* 130, 785–796.
- Liang, H.-X., Dai, H.-Q., Fu, H.-A., Dong, X.-P., Adebayo, A.H., Zhang, L.-X., Cheng, Y.-X., 2010. Bioactive compounds from rumex plants. *Phytochem. Lett.* 3, 181–184.
- Lim, T.K., 2015. *Edible Medicinal and Non Medicinal Plants: Volume 9, Modified Stems, Roots, Bulbs*. Springer Verlag, Dordrecht, Netherlands.
- Lindholm, P., Gullbo, J., Claesson, P., Goransson, U., Johansson, S., Backlund, A., Larsson, R., Bohlin, L., 2002. Selective cytotoxicity evaluation in anticancer drug screening of fractionated plant extracts. *J. Biomol. Screen.* 7, 333–340.
- Liu, C.-P., Xu, J.-B., Zhao, J.-X., Xu, C.-H., Dong, L., Ding, J., Yue, J.-M., 2014. Diterpenoids from croton laui and their cytotoxic and antimicrobial activities. *J. Nat. Prod.* 77, 1013–1020.
- Loizzo, M.R., Rashed, K., Said, A., Bonesi, M., Menichini, F., Tundis, R., 2014. Antiproliferative and antioxidant properties of alhagi maurorum boiss (leguminosae) aerial parts. *Ind. Crops Prod.* 53, 289–295.
- Lulekal, E., Asfaw, Z., Kelbessa, E., Van Damme, P., 2014a. Ethnoveterinary plants of Ankober District, North Shewa Zone, Amhara Region, Ethiopia. *J. Ethnobiol. Ethnomed.*, 10.
- Lulekal, E., Asfaw, Z., Kelbessa, E., Van Damme, P., 2013. Ethnomedicinal study of plants used for human ailments in Ankober District, North Shewa Zone, Amhara Region, Ethiopia. *J. Ethnobiol. Ethnomed.*, 9.
- Lulekal, E., Rondevaldova, J., Bernaskova, E., Cepkova, J., Asfaw, Z., Kelbessa, E., Kokoska, L., Van Damme, P., 2014b. Antimicrobial activity of traditional medicinal plants from ankober district, north shewa zone, amhara region, ethiopia. *Pharm. Biol.* 52, 614–620.

- Mahmoud, S.M., Abdel-Azim, N.S., Shahat, A.A., Ismail, S.I., Hammouda, F.M., 2007. Phytochemical and biological studies on *verbascum sinaiticum* growing in egypt. *Nat. Prod. Sci.* 13, 186–189.
- Ma, M., Jiang, Z., Ruan, J., Tan, X., Liu, J., Wang, C., Zha, X.M., Zhang, L., 2012. The furano norclerodane diterpenoid disobulbin-d induces apoptosis in normal human liver I-02 cells. *Exp. Toxicol. Pathol.* 64, 611–618.
- Mengistu, F., Hager, H., 2008. Wild edible fruit species cultural domain, informant species competence and preference in three districts of amhara region, ethiopia. *Ethnobot. Res. Appl.* 6, 487–502.
- Mesfin, F., Demissew, S., Teklehaymanot, T., 2009. An ethnobotanical study of medicinal plants in wonago woreda, snnpr, ethiopia. *J. Ethnobiol. Ethnomed.* 5, 28.
- Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immunol. Methods* 65, 55–63.
- Mugera, G.M., 1977. *Useful Drugs and Cancer Causing Chemicals in Kenya Medical and Toxic Plants (Inaugural Lecture)*. University of Nairobi, Nairobi, Kenya.
- Nagahama, K., Eto, N., Yamamori, K., Nishiyama, K., Sakakibara, Y., Iwata, T., Uchida, A., Yoshihara, I., Suiko, M., 2011. Efficient approach for simultaneous estimation of multiple health-promoting effects of foods. *J. Agric. Food Chem.* 59, 8575–8588.
- Nguelefack, T.B., Mbakam, F.H.K., Tapondjou, L.A., Watcho, P., Nguelefack-Mbuyo, E.P., Ponou, B.K., Kamanyi, A., Park, H.-J., 2011. A dimeric triterpenoid glycoside and flavonoid glycosides with free radical-scavenging activity isolated from *rubus rigidus* var. *Camerunensis*. *Arch. Pharm. Res.* 34, 543–550.
- Ochwang'i, D.O., Kimwele, C.N., Oduma, J.A., Gathumbi, P.K., Mbaria, J.M., Kiama, S.G., 2014. Medicinal plants used in treatment and management of cancer in kakamega county, Kenya. *J. Ethnopharmacol.* 151, 1040–1055.
- Omosa, L.K., Amugune, B., Ndunda, B., Milugo, T.K., Heydenreich, M., Yenesew, A., Midiwo, J.O., 2014. Antimicrobial flavonoids and diterpenoids from *dodonaea angustifolia* var. *South Afr. J. Bot.* 91, 58–62.
- Omosa, L.K., Midiwo, J.O., Derese, S., Yenesew, A., Peter, M.G., Heydenreich, M., 2010. Neo-clerodane diterpenoids from the leaf exudate of *Dodonaea angustifolia*. *Phytochem. Lett.* 3, 217–220.
- Ou, B., Hampsch-Woodill, M., Prior, R.L., 2001. Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe. *J. Agric. Food Chem.* 49, 4619–4626.
- Qader, S.W., Abdulla, M.A., Chua, L.S., Najim, N., Zain, M.M., Hamdan, S., 2011. Antioxidant, total phenolic content and cytotoxicity evaluation of selected malaysian plants. *Molecules* 16, 3433–3443.
- Ramathal, D.C., Ngassapa, O.D., 2001. Medicinal plants used by rwandese traditional healers in refugee camps in tanzania. *Pharm. Biol.* 39, 132–137.
- Rao, R.J., Kumar, U.S., Reddy, S.V., Tiwari, A.K., Rao, J.M., 2005. Antioxidants and a new germacrane sesquiterpene from *Carissa spinarum*. *Nat. Prod. Res.* 19, 763–769.
- Rao, V., 2012. Phytochemicals – A Global Perspective of Their Role in Nutrition and Health. InTech, Rijeka, Croatia.
- Raza, H., John, A., 2008. In vitro effects of tea polyphenols on redox metabolism, oxidative stress, and apoptosis in pc12 cells. *Ann. New York Acad. Sci.* 1138, 358–365.
- Schmidt, T.J., Matthiesen, U., Willuhn, G., 2000. On the stability of sesquiterpene lactones in the official arnica tincture of the *German pharmacopoeia*. *Planta Med.* 66, 678–681.
- Schön, R., Weiland, J., Megges, R., Repke, K.R.H., 1995. Differentiation between isoforms of Na⁺/K⁺-transporting atpase from human and guinea-pig cardiac muscle through use of digitalis derivatives as analytical probes. *Naunyn-schmiedeberg's Arch. Pharmacol.* 351, 282–292.
- Sehar, I., Pal, H.C., Shukla, S., Bhushan, S., Hamid, A., Gupta, B.D., Saxena, A.K., 2011. Cytotoxic evaluation and induction of mitochondria-mediated apoptosis in human leukaemia hl-60 cells by *carissa spinarum* stem isolate. *J. Pharm. Pharmacol.* 63, 1078–1090.
- Sharma, O.P., Bhat, T.K., 2009. Dpph antioxidant assay revisited. *Food Chem.* 113, 1202–1205.
- Siegers, C.-P., Steffen, B., Röbbke, A., Pentz, R., 1999. The effects of garlic preparations against human tumor cell proliferation. *Phytomedicine* 6, 7–11.
- Singh, K.N., Lal, B., 2008. Ethnomedicines used against four common ailments by the tribal communities of lahaul-spiti in western Himalaya. *J. Ethnopharmacol.* 115, 147–159.
- Singleton, V.L., Orthofer, R., Lamuela-Raventos, R.M., 1998. Analysis of total phenols and other oxidation substrates and antioxidants by means of folin-ciocalteu reagent. *Methods Enzymol.* 299, 152–178.
- Stan, S.D., Kar, S., Stoner, G.D., Singh, S.V., 2008. Bioactive food components and cancer risk reduction. *J. Cell. Biochem.* 104, 339–356.
- Steenkamp, V., Stewart, M.J., 2005. Nephrotoxicity associated with exposure to plant toxins, with particular reference to africa. *Ther. Drug Monit.* 27, 270–277.
- Stratil, P., Klejdus, B., Kubáň, V., 2006. Determination of total content of phenolic compounds and their antioxidant activity in vegetables – evaluation of spectrophotometric methods. *J. Agric. Food Chem.* 54, 607–616.
- Sulaiman, C.T., Soudha, V., Deepak, M., Balachandran, I., 2013. Comparative phytochemical studies and evaluation of radical scavenging activity in selected jasminum species. *Int. J. Pharmacognosy Phytochem. Res.* 4, 99–104.
- Suleman, S., Alemu, T., 2012. A survey on utilization of ethnomedicinal plants in nekemte town east wellega (Oromia). *Ethiopia J. Herbs, Spices Med. Plants* 18, 34–57.
- Talib, W.H., Mahasneh, A.M., 2010. Antiproliferative activity of plant extracts used against cancer in traditional medicine. *Sci. Pharm.* 78, 33–45.
- Teklehaymanot, T., 2009. Ethnobotanical study of knowledge and medicinal plants use by the people in dek island in Ethiopia. *J. Ethnopharmacol.* 124, 69–78.
- Teklehaymanot, T., Giday, M., 2010. Ethnobotanical study of wild edible plants of Kara and Kwegu semi-pastoralist people in Lower Omo River Valley, Debut Omo Zone, SNNPR, Ethiopia. *J. Ethnobiol. Ethnomed.* 6.
- Teklehaymanot, T., Giday, M., 2007. Ethnobotanical study of medicinal plants used by people in Zegie Peninsula, Northwestern Ethiopia. *J. Ethnobiol. Ethnomed.* 3.
- Teklehaymanot, T., Giday, M., Medhin, G., Mekonnen, Y., 2007. Knowledge and use of medicinal plants by people around debre libanos monastery in Ethiopia. *J. Ethnopharmacol.* 111, 271–283.
- Umer, S., Asres, K., Veeresham, C., 2010. Hepatoprotective activities of two ethiopian medicinal plants. *Pharm. Biol.* 48, 461–468.
- Van Nguyen, H., Van Pham, C., Nguyen, T.T.H., Van Tran, H., Doan, T.M.H., 2009. Novel antioxidant neo-clerodane diterpenoids from *Scutellaria barbata*. *Eur. J. Org. Chem.* 5810–5815.
- Wangteeraprasert, R., Lipipun, V., Gunaratnam, M., Neidle, S., Gibbons, S., Likhitwitayawuid, K., 2012. Bioactive compounds from *Carissa spinarum*. *Phytother. Res.* 26, 1496–1499.
- Wojcikowski, K., Stevenson, L., Leach, D., Wohlmuth, H., Gobe, G., 2007. Antioxidant capacity of 55 medicinal herbs traditionally used to treat the urinary system: a comparison using a sequential three-solvent extraction process. *J. Altern. Complement. Med.* 13, 103–109.
- Wojdyto, A., Oszmiański, J., Czemerys, R., 2007. Antioxidant activity and phenolic compounds in 32 selected herbs. *Food Chem.* 105, 940–949.
- Yang, J., Liu, R.H., Halim, L., 2009. Antioxidant and antiproliferative activities of common edible nut seeds. *LWT – Food Sci. Technol.* 42, 1–8.
- Yirga, G., 2010. Use of traditional medicinal plants by indigenous people in mekele town, capital city of tigray regional state of ethiopia. *J. Med. Plants Res.* 4, 1799–1804.
- Zhao, Y., Wang, C., Wu, Z., Fang, J., Zhu, L., 2012. Synthesis and antitumor activity of novel arolythiouraea derivatives of podophyllotoxin. *Invest. New Drugs* 30, 17–24.
- Znati, M., Ben Jannet, H., Cazaux, S., Souchard, J.P., Harzallah Skhiri, F., Bouajila, J., 2014. Antioxidant, 5-lipoxygenase inhibitory and cytotoxic activities of compounds isolated from the ferula lutea flowers. *Molecules* 19, 16959–16975.

Appendix D: Photographic documentation



Apx. D 1 Kvevri – clay vessel traditionally used in Georgia for fermentation of wine (Kakhetian winemaking method). Photograph by courtesy of David Maghradze.



Apx. D 2 Example of wine cellar with holes especially designed for kvevri insertion. Grape pomace is mashed inside the kvevri and enclosed by wooden lids, which are subsequently sealed, typically with wax. Wine is usually fermented for 3 - 5 months. Photograph by courtesy of David Maghradze.



Apx. D 3 Samples of Georgian, Central and West European wines ready to be assayed. Photograph by courtesy of Přemysl Landa.



Apx. D 4 A woman selling plants used in traditional Ethiopian medicine. Gorabela medicinal plant market, Ankober District, Ethiopia. Photograph by courtesy of Ermias Lulekal.



Apx. D 5 Back from the field. Herbarium specimens mounted on Donkey's back. Ankober District, Ethiopia. Photograph by courtesy of Ermias Lulekal.



Apx. D 6 Herbarium specimens of Ethiopian medicinal plants. From left to right: *Rumex nepalensis*, *Dodonea angustifolia* and *Verbascum sinaiticum*. Photograph by courtesy of Ermias Lulekal.



Apx. D 7 Habitus of young individual of *Inga edulis* (Guaba) at surrounding farms of Pucallpa City, Ucayali District, Peru. Photograph by courtesy of Ludvík Bortl.



Apx. D 8 Inflorescence of *I. edulis*. Photograph by courtesy of Ludvík Bortl.



Apx. D 9 Young seedlings of palm *Oenocarpus bataua* (Ungurahui). Forest nursery of Universidad Nacional Intercultural de la Amazonia (UNIA), Pucallpa City. Photograph by courtesy of Ludvík Bortl.



Apx. D 10 Habitus of mature individual of *O. bataua*. Photograph by courtesy of Ludvík Bortl.




Apx. D 11 Fruit of *O. bataua* in detail. Photograph by courtesy of Ludvík Bortl.



Apx. D 12 Local product of *O. bataua* – icecream made from fruit of this palm has been manufactured in Peru by Shambo® since 1963. Photograph by courtesy of Ludvík Bortl.



Apx. D 13 Fruit of *Annona montana* (Guanabana). Photograph by courtesy of Ludvík Bortl.



Apx. D 14 Cross-section of *A. montana* fruit. Photograph by courtesy of Ludvík Bortl.